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Abstract
Patients with chronic kidney disease (CKD) have an increased risk of cardiovascular
disease to which conventional cardiovascular risk factors and co-morbidity
contribute. Increased arterial stiffness and impaired endothelial function are common
features of CKD and recognised markers of cardiovascular risk. In recent years,
emerging cardiovascular risk factors - including inflammation, oxidative stress, and a
shift in the balance of the vasodilator nitric oxide and vasoconstrictor endothelin
systems - have become increasingly important as major contributors to increased
cardiovascular complications and may also contribute to arterial stiffness and
endothelial dysfunction in CKD.
The overall aims of the work presented within this thesis were, therefore, to
characterise the contribution of uraemia itself, and conventional and emerging
cardiovascular risk factors, to arterial stiffness and endothelial dysfunction, as
surrogates for cardiovascular risk, in a group ofCKD patients, across a wide range of
glomerular filtration rate (GFR) from normal to pre-dialysis, with relatively low co¬
morbidity. Arterial stiffness and endothelial dysfunction were measured by carotid-
femoral pulse wave velocity (CF-PWV) and flow-mediated dilatation (FMD),
respectively.
The first study aimed to assess the reproducibility for one observer with repeated
measurements (intra-observer) and for two separate observers (inter-observer) of CF-
PWV and FMD. I have shown that both inter-observer and intra-observer
measurements of CF-PWV and FMD are highly reproducible. Hence, these
techniques are therefore suitable to be incorporated into clinical studies.
The characteristics of the relationship of plasma and urinary endothelin-1 (ET-1)
concentrations to renal function were studied. In this group of CKD patients, plasma
ET-1 increased in a linear fashion, whereas fractional excretion of ET-1 increased
exponentially as renal function declined. These findings support the role of renally
derived ET-1 in renal pathophysiology.
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In the next study, I showed that arterial stiffness increases incrementally as GFR
declines whereas endothelial dysfunction is a feature only of late stage CKD (GFR <
7 •
20 ml/min/1.73m ). Age and blood pressure (BP) were the major determinants of
both. However, GFR was not an independent predictor of either CF-PWV or FMD in
this group of patients, suggesting that uraemia, on its own, is not the main driving
force in the development of vascular complications in CKD.
Therefore, I further explored the role of emerging cardiovascular risk factors to
arterial stiffness and endothelial dysfunction. Whilst, BP remains the strongest
determinant of arterial stiffness and endothelial dysfunction, inflammation and
asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, are
independent predictors of CF-PWV, and oxidative stress and plasma ET-1
independently predict FMD. Thus, the cardiovascular complications that occur in
CKD may be substantially driven by these emerging risk factors.
Then, I examined the contribution of the metabolic syndrome to arterial stiffness and
endothelial dysfunction in the same group of CKD patients. Irrespective of renal
function, CKD patients with the metabolic syndrome have increased arterial stiffness
and a trend to impaired endothelial function. Either the presence of the metabolic
syndrome or the number of risk factors for it independently predicts CF-PWV and
FMD. When risk factors for the metabolic syndrome are considered individually, BP
remains an independent determinant of both CF-PWV and FMD. Additionally, waist
circumference is also an independent predictor of CF-PWV. These findings suggest
that the metabolic syndrome or its individual risk factors maybe targets for
intervention to improve cardiovascular outcomes in all stages ofCKD.
The contributions of arterial calcification to arterial stiffness and endothelial
dysfunction were also assessed. I showed that, irrespective of renal function, CKD
patients with arterial calcification have increased arterial stiffness and a trend to
impaired endothelial function.
The findings from the observational studies presented in this thesis support the role
of emerging cardiovascular risk factors on arterial stiffness and endothelial
dysfunction in CKD. An interventional study using a peptide selective endothelin-A
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(ETa) receptor antagonist has confirmed this hypothesis. In a group ofCKD patients,
irrespective of renal function, selective ETA receptor antagonism lowered BP,
reduced proteinuria, improved arterial stiffness on top of a standard BP lowering
treatment with renin-angiotensin system blockade, and appeared to reduced arterial
stiffness independent of its effect on BP.
In summary, these studies show that in the absence of diabetes or established
cardiovascular disease, CKD patients have increased arterial stiffness and endothelial
dysfunction. Elowever, arterial stiffness and endothelial dysfunction are not predicted
by renal function. Although the conventional risk factor, BP, is the strongest
determinant of CF-PWV and FMD in CKD, the contribution of several emerging
cardiovascular risk factors on arterial stiffness and endothelial dysfunction is
observed. On the basis of these findings, chronic interventional studies, for instance




1.1 Chronic kidney disease
Chronic kidney disease (CKD) is a growing public health problem (Xue et al.,
2001). The increasing incidence of CKD is, to a large extent, being accelerated by
the global epidemic of diabetes mellitus and hypertension, as well as by the ageing
of the population (Fox et al., 2008; McClellan et al., 2003). The most widely used
definition to diagnose and stratify the stages of CKD is the National Kidney
Foundation, Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline
(Anonymous, 2002a). This guideline defines CKD according to the presence or
absence of kidney damage and level of kidney function, irrespective of the type of
kidney disease. CKD is defined as an individual with kidney damage for >3 months,
as evidenced by pathological abnormalities or markers of damage including
abnormalities in blood or urine tests or imaging test, with or without decreased
glomerular filtration rate (GFR), or an individual with GFR <60 ml/min/1.73m2 for
>3 months, with or without kidney damage (Table 1.1).
Table 1.1 Stages of CKD as defined by K/DOQI classification.
Stages Description GFR (ml/min/l.TSirf)
Stage 1 Kidney damage* with normal or increased GFR >90
Stage 2 Kidney damage* with mild reduction of GFR 60-89
Stage 3 Moderate reduction of GFR 30-59
Stage 4 Severe reduction of GFR 15-29
Stage 5 Kidney failure <15 or dialysis
Key: "Kidney damage is defined as pathologic abnormalities or markers of damage
including abnormalities in blood or urine tests or imaging studies.
In the general population with normal kidney function at baseline, the incidence of
new CKD was 9.4% in 18.5 years in the Framingham Offspring study (Fox et al.,
2004) and 7% in 9 years in the Atherosclerosis Risk in Communities study (Kurella
et al., 2005). The prevalence of CKD in large community surveys by the National
Health and Nutrition Examination Surveys (NHANES) III and IV for CKD stage 3
and 4, where kidney function was estimated by the Modification of Diet in Renal
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Disease (MDRD) formula were 4.2% and 3.7%, respectively (Coresh et al., 2005).
Another study also reported that the prevalence ofCKD stage 2 and 3 in over 10,000
adults, where kidney function was assessed by the Cockcroft & Gault (C&G)
formula was as high as 11 % (Chadban et al., 2003).
CKD leads to kidney failure or so-called end-stage renal disease (ESRD), one of the
highest cost conditions for treatment in clinical medicine. In the United Kingdom,
only -11% of all CKD patients are on renal replacement therapy but the
management of this group consumes most of the renal health care budget (Nwankwo
et al., 2005). Despite advances in dialysis and transplantation, the prognosis of
ESRD remains poor. One of the possible ways to prevent CKD patients progressing
to the advanced stages of CKD is to focus on the people with earlier stages of CKD,
and, through early diagnosis and treatment, slow the progression of their diseases to
ESRD or other adverse outcomes.
1.2 Cardiovascular disease in chronic kidney
disease
Cardiovascular disease, encompassing coronary heart disease, cerebrovascular
disease, peripheral vascular disease, and congestive heart failure, is the leading cause
of morbidity and mortality worldwide. The cardiovascular disease epidemic is
occurring despite advances in the diagnosis and treatment of this condition.
Cardiovascular disease is very common in CKD (Parfrey et al., 1999; Sarnak et al.,
2000; Stack et al., 2001). As a leading cause of mortality in the general population, it
is not surprising that cardiovascular disease is also a leading cause of death in CKD
patients. In fact, epidemiological and clinical studies have shown that cardiovascular
disease accounts for nearly 50% of all-cause mortality in dialysis patients and
cardiovascular mortality is at least 10-20 times greater in dialysis patients than in the
general population (Foley et al., 1998).
A pooled analysis of community-based studies combining data from the
Framingham Heart study and the Atherosclerosis Risk in Communities study
reported that subjects with moderate reduction of GFR (CKD stages 3 & 4) was
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associated with greater risk for cardiovascular outcomes, including myocardial
infarction, coronary heart disease, and stroke, compared to those of subjects with
normal kidney function (Weiner et al., 2004). The HOORN study showed that renal
function was inversely associated with all-cause and cardiovascular mortality in
CKD stages 2 to 5. In this study, risk of cardiovascular death was increased by -20%
for a decrease of 5 ml/min/1,73m2 of GFR, calculated by the C&G formula, after
adjustment for conventional cardiovascular risk factors and previous cardiovascular
co-morbidity (Henry et al., 2002). A recent study of-34,000 ambulatory patients has
shown a gradual increase in risk of cardiovascular mortality and decreasing GFR
(adjusted hazard ratio 1.77, 3.75, and 3.83 for CKD stages 3, 4, and 5, respectively)
(Ryan et al., 2009). In addition, it is well recognised that individuals with impaired
renal function are more likely to die from cardiovascular complications than to reach
ESRD (Culleton et al., 1999; Go et al., 2004; Shulman et al., 1989). Importantly,
because of the high prevalence of, and mortality rate from, cardiovascular disease in
CKD, it is now recommended that CKD patients are in the highest risk group for
cardiovascular disease and that CKD itself is an independent risk factor for
cardiovascular disease (Sarnak et al., 2003).
There are three major pathologic forms of cardiovascular complications in CKD. The
first is an alteration in the structure of the myocardium (left ventricular remodelling),
resulting from pressure overload secondary to hypertension and arteriosclerosis and
volume overload secondary to fluid retention, anaemia, or arteriovenous fistulae,
leading to concentric and eccentric left ventricular hypertrophy, respectively. The
second pattern is atherosclerosis and the third is arteriosclerosis which affects the
large vessels such as the aorta, leading to the development of stiff arteries.
1.3 Cardiovascular disease risk factors in
chronic kidney disease
Risk factors for cardiovascular disease in CKD can be divided into two broad
categories: conventional and emerging risk factors (Table l .2). The conventional risk
factors for cardiovascular disease are defined as those that have primarily been
described in the Framingham cohort including age, male gender, family history of
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premature cardiovascular disease, smoking, left ventricular hypertrophy,
hypertension and metabolic disorders such as hypercholesterolemia and diabetes
mellitus (Sarnak et al., 2000). Emerging risk factors are defined as risk factors not
included in the Framingham coronary risk equation and increased prevalence as
renal function declines. These include inflammation, oxidative stress, a reduction of
arterial compliance, and endothelial dysfunction (Sarnak et al., 2000).
Table 1.2 Conventional and emerging cardiovascular disease risk factors in CKD.
















Calcium & phosphorus metabolism
Decreased GFR
Endothelial dysfunction (ET-1, ADMA)




Oxidative stress (Isop, OxLDL)
Proteinuria
Uraemic toxins
Key: Table modified from (Sarnak et al., 2000). ADMA: asymmetric dimethylarginine; CRP:
C-reactive protein; ET-1: endothelin-1; GFR: glomerular filtration rate; HDL: high density
lipoprotein; Isop: isoprostane; LDL: low density lipoprotein; OxLDL: oxidised low density
lipoprotein.
CKD patients have an increased prevalence of conventional risk factors compared to
the general population (Vlagopoulos et al., 2005). For example, it has been estimated
that hypertension is present in 50-90% of dialysis patients and 70-80% of stage 1 to
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4 CKD patients. Diabetes, a leading cause of ESRD, accounts for -40% of pre-
dialysis CKD. Dyslipidaemia (increased low density lipoprotein (LDL) cholesterol
and decreased high density lipoprotein (HDL) cholesterol) was found in 50-70% of
dialysis patients. The prevalence of left ventricular hypertrophy has been reported in
up to 75% of both dialysis and non-dialysis patients. Additionally, -25% of all CKD
patients are smokers (Vlagopoulos et al., 2005).
Conventional cardiovascular risk factors are believed to dominate the scene in CKD
since most individuals who develop renal impairment usually present with a long
history of hypertension, diabetes, dyslipidaemia, smoking, or a combination of these.
However, these risk factors are not as strongly associated with subsequent
cardiovascular morbidity and mortality in advanced stage CKD and are, therefore,
insufficient to explain the high cardiovascular complications in these patients
(Ikizler, 2002). This was evidenced by applying the Framingham risk equation to
CKD patients which showed only a weak negative association between the
calculated risk and baseline renal function, suggesting that the conventional risk
factors account for some, but not all of the remarkable cardiovascular risk in CKD
(Sarnak et al, 2002).
Interestingly, evidence suggests that emerging cardiovascular risk factors become
increasingly important as major contributors to increased cardiovascular
complications in CKD as GFR declines (London et al., 2004a; Schiffrin et al., 2007;
Zoccali et al., 2003). These novel risk factors are being given emphasis not only
because they could explain the high incidence of cardiovascular events in the renal
population, but also because they may represent new targets for therapeutic
interventions. Figure 1.1 demonstrates various pathological processes that give rise
to the uraemia-related risk factors and some of the organ systems involved. Multiple
interactions between processes are illustrated. Selected emerging cardiovascular risk
factors will be described further in this chapter.
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Figure 1.1 Diagram showing various pathological processes of uraemia-related risk
factors and some of the organ systems involved.



















Key: Diagram modified from (Roberts et at., 2006), EPO: Erythropoietin; LV: left ventricular;
PTH: parathyroid hormone.
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1.4 Inflammation: C-Reactive Protein
Inflammation is an important process in the pathogenesis of atherosclerosis and its
cardiovascular complications (Ross, 1999). A number of molecules involved in the
atherosclerotic and inflammatory process can be measured as surrogates for
inflammation. These include C-reactive protein (CRP) and soluble form of adhesion
molecules, e.g. vascular cell adhesion molecule and endothelial-leucocyte adhesion
molecule. Amongst these, CRP is the most widely used marker for inflammation.
CRP is extremely sensitive, giving a very rapid response with a relatively short half-
life. In inflammatory conditions, acute phase synthesis of CRP closely reflects
disease activity. Despite the high sensitivity of CRP, it reflects only the
inflammatory state but is not disease specific.
CRP is an endogenous nonglycosylated protein of a cyclic disc of 5 identical
noncovalently-linked subunits with a molecular weight of 105,000 Da. CRP is
produced mainly by the hepatocytes in response to infection, inflammation, or tissue
damage. The formation of CRP is regulated mainly by interleukin-6 (IL-6) and, to a
lesser degree, interleukin-1 and tumour necrosis factor-oc. CRP was originally named
for its ability to precipitate somatic C-polysaccharides of pneumococci. CRP elicits
several effects on endothelial and vascular biology favouring pro-inflammatory and
pro-atherogenic phenotypes (Schwedler et al., 2006).
In the normal population, circulating CRP concentrations are very low (<1 mg/dl). In
general, CRP levels of 1-10 mg/dl are considered moderately elevated and levels of
>10 mg/dl are considered markedly elevated (van der Sande et al., 2006). Recently,
high-sensitivity assays for evaluating CRP levels (hsCRP) have been developed,
yielding the detection of circulating CRP concentrations at a very low level (0.007
mg/L) (Rifai et al., 1999). CRP is associated with increased risk for cardiovascular
disease. This was evidenced in the Women's Health Study in which cardiovascular
risk substantially increased in a linear fashion, across a range of hsCRP values from
less than 0.5 mg/L to more than 20 mg/L, even after adjustment for the Framingham
risk score (Ridker et al., 2004).
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In renal patients, inflammation is a common feature of ESRD (Stenvinkel et al.,
2005a). Elevated CRP levels have been reported in dialysis patients (Owen et al.,
1998; Spittle et al., 2001; Stenvinkel et al., 2002; Yeun et al., 2000). CRP also
independently predicts all-cause mortality in this group of patients (Spittle et al.,
2001; Yeun et al., 2000; Zimmermann et al., 1999). This is confirmed by a study
from Wanner, et al in 280 haemodialysis patients. In this study, patients in the
highest hsCRP quartile had a 2.4-fold higher risk for all-cause mortality and 1.7-fold
higher risk for cardiovascular mortality compared with those of patients in the lowest
hsCRP quartile (Wanner et al., 2002). In addition, CRP yields a substantial increase
in predictive value for all-cause and cardiovascular mortality on top of other
biomarkers such as B-type natriuretic peptide, a cardiac hormone reflecting
myocardial function, and asymmetric dimethylarginine (ADMA), an endogenous
inhibitor of nitric oxide synthase (NOS) (Mallamaci et al., 2005).
There is also evidence for the associations between elevated hsCRP and decreasing
renal function in mild renal insufficiency (Gulcan et al., 2007; Knight et al., 2004;
Romao et al., 2006; Stuveling et al., 2003; Yoshida et al., 2007). Interestingly,
hsCRP has recently been reported to incrementally increase from CKD stages 1 to 5,
suggesting that low-grade inflammation is independently associated with a declining
GFR (Romao et al., 2006). It is important to note that, although CRP may be directly
involved in the pathology of cardiovascular disease in CKD, it is usually regarded as
a risk marker rather than a causative risk factor. Factors responsible for the high CRP
concentrations in CKD patients are not fully understood. Nonetheless, co-morbidity,
life style, and genetic variations must be taken into account.
1.5 Oxidative stress
Oxidative stress is commonly described as a disturbance in the balance between
oxidant production and anti-oxidant defences (Sies, 1997). A pro-oxidant state leads
to the oxidation of macro-molecules such as lipids, carbohydrates, proteins, and
DNA, resulting in tissue injury. Atherosclerotic conditions including diabetes
mellitus, hypercholesterolaemia, and CKD are associated with increased oxidative
stress (Elimmelfarb, 2005).
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Increased production of reactive oxygen species (ROS) in the vascular wall is a
characteristic feature of atherosclerosis (Figure 1.2). ROS promote LDL oxidation,
stimulate vascular smooth muscle cell proliferation and migration, and increase
production of pro-inflammatory cytokines (Landmesser et al., 2001; Steinberg et al.,
1989).
In general, oxidants are highly reactive compounds with a very short half-life (e.g.
seconds). Lipids, proteins, carbohydrates, and nucleic acid can be modified by oxy-
radicals and appear to have a longer half-life after being modified (e.g. hours to
weeks). This long half-life makes the latter group an ultimate marker for oxidative
stress. To prevent the harmful effects of ROS, both enzymatic and non-enzymatic
anti-oxidant systems counteracting the free radicals are present (Table 1.3).
Superoxide dismutase, catalase, and glutathione peroxidase are examples of
enzymatic systems in the defence against ROS.
Figure 1.2 Reactive oxygen species generation in the cell.
Vasoconstricting substances
(angiotensin II, endothelin)
Cyclooxygenase Ion-channels - increased Ca2+
Lipoxygenase Metalloproteinases
Key: Figure modified from (Pechanova et al., 2007). eNOS: endothelial nitric oxide
synthase; NAD(P)H: nicotinamide adenine dinucleotide phosphate; NF-kB: nuclear factor
kappa-B; NO: nitric oxide; NOS: nitric oxide synthase; SOD: superoxide dismutase; ROS:
reactive oxygen species.
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Table 1.3 Examples of markers of oxidative stress and anti-oxidants.
Markers of oxidative stress Anti-oxidants
Carbohydrate oxidation Enzymatic
Advanced glycation end products Glutathione peroxidase
Lipid peroxidation Superoxide dismutase
Advanced lipid peroxidation products Non-Enzymatic
Isoprostanes Glutathione
Malonyldialdehyde Vitamin C
Oxidised low density lipoprotein Vitamin E
Protein oxidation
Advanced protein oxidation products
Oxidative stress has been identified as a significant contributor to the accelerated
vascular pathology associated with ESRD (Tetta et al., 1999). CKD patients, in
particular those who are on dialysis, are at risk of deficiencies of water-soluble
vitamins and trace elements, as a results of restricted intake, impaired absorption,
uraemia-induced alterations in metabolism and activity, as well as losses during
haemodialysis or peritoneal dialysis. Therefore, they are subjected to enhanced
oxidative stress as a result of reduced anti-oxidant defence due to a reduction of
vitamin C, vitamin E, selenium levels, and reduced activity of the glutathione
scavenging system. At the same time, their pro-oxidant activity is increased because
of ageing, diabetes co-morbidity, chronic inflammation, and bio-incompatibility of
dialysis membranes and solutions (Locatelli et al., 2003).
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1.5.1 Isoprostanes
Amongst markers for oxidative stress, isoprostanes (Isops) are an emerging family of
compounds that, currently, are one of the most reliable markers for lipid peroxidation
as recently evaluated by the National Institute of Environmental Health Science
(Kadiiska et al., 2005). First discovered by Morrow and colleagues (Morrow et al.,
1990), Isops are a group of bioactive eicosanoids derived from a non-specific free-
radical attack of arachidonic acid in the cell membrane, producing four different
series of regioisomers. These regioisomers are denoted as 5-, 8-, 12- or 15-series
compound depending on the carbon atom to which the side chain hydroxyl is
attached. Eight racemic diasteromers may be formed among each of those 4
regioisomers, giving 64 different Isops (Morrow, 2006; Taber et al., 1997). Once
Isops are generated, they are released by phospholipases, circulate as free Isops in
blood and are excreted in urine as non-metabolised or metabolised compounds
(Lynch et al., 1994; Morrow, 2005).
From all of the myriad compounds produced through free radical peroxidation of
arachidonic acid, the majority of studies have focused on the 15-series of Isop,
especially, 15-F2t-Isop or so called 8-iso-prostaglandin-F2 (8-Isop) (Lawson et al.,
1999; Morrow et al., 1999; Morrow et al., 1997). 8-Isop is a vasoconstrictor. It
stimulates mitogenesis, enhances monocyte adhesion to endothelial cells and induces
endothelial cells necrosis. All of these effects are believed to be mediated by
thromboxane A2-prostanglandin H2 receptor. 8-Isop also affects renal function by
constricting the afferent renal arteriole leading to a decreased GFR (Fukunaga et al.,
1993; Takahashi et al., 1992).
Plasma Isop concentrations are increased and correlate with the severity of
congestive heart failure (Cracowski et al., 2000) and coronary artery disease
(Vassalle et al., 2004). Urinary Isop concentrations are also elevated in patients with
pulmonary arterial hypertension (Cracowski et al., 2001), systemic sclerosis
(Cracowski et al., 2006), and coronary artery disease (Schwedhelm et al., 2004),
and are a strong independent risk marker for cardiovascular disease in patients with
coronary artery disease (Schwedhelm et al., 2004).
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Several studies have indicated that plasma Isop concentrations are increased up to 6
folds in haemodialysis patients (Handelman et al., 2001; Ikizler et al., 2002; Kim et
al., 2004; Simmons et al., 2005; Spittle et al., 2001) and are accompanied by
increased inflammation and reduced endogenous anti-oxidants such as vitamin C and
vitamin E. In these studies, the effects of haemodialysis sessions on plasma Isop
levels are not consistent. Recently, the increase in circulating Isop has also been
shown in mild renal impairment (Cottone et al., 2009). Importantly, studies have
shown progressively increased plasma Isop concentrations in CKD patients from
early stage to pre-dialysis (Cottone et al., 2009; Dounousi et al., 2006) and have
reported that Isop independently predict GFR. Data regarding the relationship of
these compounds to long-term outcomes, such as morbidity and mortality, remain to
be collected.
1.5.2 Oxidised low density lipoprotein
The current concept for the mechanisms of atherosclerotic disease processes involve
increased lipid peroxidation and formation of oxidised low density lipoprotein
(OxLDL) particles leading to an inflammatory response which is a driving force in
the development of atherosclerotic lesions (Harrison et al., 2003).
In health, the central core of an LDL molecule contains cholesterol ester and
triglyceride. The molecule is surrounded by a phospholipid monolayer, consisting
mainly of lecithin. There is one apoB-100 molecule embedded in the outer layer.
Approximately 50% of the fatty acids found in the LDL molecule are
polyunsaturated fatty acids (PUFAs), including linoleic acid, arachidonic acid, and
docosahexaenoic acid. A major role of PUFAs is to protect LDL from free radical
attack and oxidation. LDL can be oxidised by three mechanisms (Figure 1.3): in
• • 94- • •
vitro oxidation by metal ions, for example Cu ; in vivo oxidation by metal ion-
dependent lipoxygenase enzyme; and in vivo oxidation by macrophage-secreted
myleoperoxidase enzyme. NO inhibits Cu2+and macrophage-mediated oxidation of
LDL.
OxLDL has a different biochemical composition from native LDL. It is characterised
by a higher electrophoretic mobility on agarose gels and lower arachidonic and
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linoleic acid levels compared with native LDL. In vitro studies have shown that
approximately 30-40% of lysine residues in the apoB-100 moiety of OxLDL are
substituted by aldehyde. These characteristics suggested that most of the in vivo
OxLDL is generated by oxidative enzymatic activity in the arterial wall, not by the
metal ion-induced oxidation.
The main biological effect of OxLDL is to enhance the atherosclerotic process.
OxLDL induces the endothelium to express adhesion molecules for monocytes,
promoting fatty streak formation, and inducing smooth muscle cells migration
leading to an increase in fibrous plaque formation. In addition, OxLDL promotes
vasoconstriction through an inhibition ofNO production and a release of endothelin-
1 (ET-1) from the endothelium. Furthermore, OxLDL stimulates platelet adhesion
and aggregation by decreasing endothelial production of NO and increasing
prostaglandin production, enhancing endothelial dysfunction.
Higher circulating OxLDL concentrations are associated with subclinical
atherosclerosis in healthy subjects (Metso et al., 2004; Wallenfeldt et al., 2004).
Plasma levels of OxLDL are significantly elevated in patients with cardiovascular
disease (Holvoet et al., 1998a; Holvoet et al., 1998b; Suzuki et al., 2002). OxLDL
concentrations correlate with the extent of coronary artery disease in heart transplant
recipients, suggesting that OxLDL may be a marker for coronary artery disease
(Holvoet et al., 1998a). In addition, OxLDL is a good prognostic index for future
cardiovascular events in a healthy population and in patients with coronary artery
disease independent of conventional cardiovascular risk factors (Holvoet et al., 2001;
Meisinger et al., 2005).
Plasma OxLDL concentrations are increased in dialysis patients (Maggi et al., 1994;
Van Tits et al., 2003) and the concentrations gradually increase as GFR declines
(Holvoet et al., 1996). The mechanisms responsible for increasing OxLDL levels in
CKD have not been well-characterised. However, vitamin E may be an important
agent in the protection against free-radical induced oxidative damage of LDL and
biological membranes (Cristol et al., 1997; Galli et al., 1998).
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Key: NO: nitric oxide; LDL: low density lipoprotein; OxLDL: oxidised low density lipoprotein;
PUFA: polyunsaturated fatty acid.
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1.6 The metabolic syndrome
First described in 1988 by Reaven (Reaven, 1988) as Syndrome X, it is now
recognised that the metabolic syndrome is a clustering of metabolic abnormalities
and risk factors for cardiovascular disease including abdominal obesity,
hyperglycaemia, hypertension, hypertriglyceridaemia, and reduced HDL cholesterol
(Eckel et al., 2005; Grundy et al., 2004; Reaven, 1988). Several clinical criteria for
diagnosis of the metabolic syndrome have been proposed by different groups
including the National Cholesterol Education Program (NCEP) expert panel on
detection, evaluation, and treatment of high blood cholesterol in adults - the Adult
Treatment Panel III (ATP III), the World Health Organisation (WHO), and the
American Association of Clinical Endocrinologists (AACE) (Grundy et al, 2004).
These criteria share the same pathological basis of metabolic syndrome: obesity,
dyslipidaemia, and insulin resistance (Table 1.4).
In a population-based study, the metabolic syndrome, diagnosed using both NCEP
ATP III and WHO criteria, is strongly associated with markers of atherosclerosis
measured by carotid intima media thickness (IMT) and the presence of
atherosclerotic plaques in carotid and femoral arteries (Ahluwalia et al., 2006). In the
West of Scotland Coronary Prevention (WOSCOPS) study in -6,000 moderately
hypercholesterolaemic men with no history of cardiovascular disease or diabetes,
metabolic syndrome increases the risk of cardiovascular disease (hazard ratio 1.8,
95% confidence interval 1.4 - 1.3) and diabetes (hazard ratio 3.5, 95% confidence
interval 2.5 - 4.9) (Sattar et al., 2003). The increase in numbers of risk factors for the
metabolic syndrome also independently predicts cardiovascular events (Sattar et al.,
2003). Since the metabolic syndrome is highly associated with increased risks of
diabetes and cardiovascular disease, its treatment and prevention have become one of
the major public health challenges worldwide (Eckel et al., 2005).
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Table 1.4 Summary of criteria for clinical diagnosis of the metabolic syndrome.
Criteria Risk factors Defining level
NCEP - ATP III
(Diagnosis made

























Plus any two of the following:










Urinary albumin excretion rate or
albumin creatinine ratio










Table continues on the next page:
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Tables continues from the previous page:-
Criteria Risk factors Defining level
AACE Overweight / obesity as BMI >25 kg/m2
(Diagnosis Triglycerides >1.69 mmol/L
depends on HDL cholesterol
clinical Men <1.04 mmol/L
judgement Women <1.29 mmol/L
based on risk Blood pressure >130 / > 85 mmHg
factors) 2-hour post-glucose challenge >140 mg/dl
Fasting glucose 110-126 mg/dl
Other risk factors




Ethnic groups having high risk for type 2
diabetes or cardiovascular disease
Key: Adapted from (Grundy et al.} 2004). AACE: the American Association of Clinical
Endocrinologists; BMI: body mass index; HDL: high density lipoprotein; NCEP-ATP III: the
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults - Adult Treatment Panel III; WHO: World
Health Organisation.
Evidence has shown that the metabolic syndrome is prevalent in dialysis patients
with the prevalence ranges from 30% to 70% (Young et al., 2007; Zhe et al., 2008).
Recently, the metabolic syndrome, by itself, has been reported as a risk factor for
CKD (Chen et al., 2004; Hoehner et al., 2002). The risk of developing CKD and
microalbuminuria both increase progressively as the number of risk factors for the
metabolic syndrome increases. Subjects with 2, 3, 4, and 5 risk factors for the
metabolic syndrome had increased odds of 2.2, 3.4, 4.2, and 5.9, respectively, for
CKD, compared to that of those with 0 or 1 risk factor. Subjects diagnosed with the
metabolic syndrome had 2.6-fold increased odds of CKD compared to those without
the metabolic syndrome. Likewise, subjects with 2, 3, 4, and 5 risk factors for the
metabolic syndrome had increased odds of 1.2, 1.6, 2.5, and 3.2, respectively, for
microalbuminuria, compared to that of those with 0 or 1 risk factor. Subjects
diagnosed with the metabolic syndrome had 1.9-fold increased odds of




The endothelium is a single layer of cells that lines the entire vascular system. Once
thought to be inert, it is now recognised as an active organ with several important
functions. The major functions include being a barrier between blood and underlying
tissues, acting as a selective transport for essential molecules, regulating vascular
tone, and regulating haemostasis and coagulation.
Maintaining vascular tone is a crucial role of the vascular endothelium. The vascular
endothelium regulates vascular tone by producing and releasing vasoactive
substances, for example vasodilators, including nitric oxide (NO), prostacyclin, and
endothelium-derived hyperpolarising factor; and vasoconstrictors, including ET-1
and metabolites of arachidonic acid (Table 1.5). These vasoactive substances act
either on endothelial cells in an autocrine function or in a paracrine manner on other
vascular cells in order to control vascular tone (Cooke, 2000). Normally, functions of
the endothelium are generally balanced on the side of promoting vasodilatation and
inhibiting cellular proliferation. However, given that changes in environment are
induced by diseases for example hypertension or hypercholesterolaemia, the balance
can shift to vasoconstriction, thrombosis, and cell proliferation. These alterations of
endothelial function, also known as endothelial dysfunction, are recognised to have
an important role in the pathogenesis of vascular disease (Glasser et al., 1996).
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Table 1.5 A partial list of vasoactive substances produced by the endothelium.
Substances Vascular effects
Endothelium-derived hyperpolarizing factor Vasodilator
Nitric oxide Vasodilator; inhibits vascular smooth muscle
growth; anti-platelet; inhibits leucocyte
adhesion
Prostacyclin Vasodilator; inhibits vascular smooth muscle
growth; anti-platelet; inhibits leucocyte
adhesion
Angiotensin II Vasoconstrictor; induces vascular smooth
muscle growth; enhances leucocyte
adhesion
Endothelin-1 Vasoconstrictor; induces vascular smooth
muscle growth
Thromboxane A2 Vasoconstrictor; activate platelet
aggregation
Tissue plasminogen activator Thrombolytic
Plasminogen activator inhibitor -1 Inhibits thrombolysis
Von Willebrand factor Coagulation factor
Thrombomodulin Inhibits coagulation
1.7.1 The endothelial nitric oxide pathway
NO is a potent vasodilator discovered as endothelium-derived relaxing factors
(EDRF) by Furchgott and Zawadzki in 1980. Initially, it was demonstrated that the
relaxation of rabbit thoracic aorta and other blood vessels by acetylcholine (ACh)
required the presence of endothelial cells and this suggested that ACh acted on
endothelial cell muscarinic receptors to stimulate the production of EDRF leading to
the relaxation of vascular smooth muscle cells (Furchgott et al., 1980). EDRF was
later shown to be NO (Palmer et al., 1987). To date, endothelium-derived NO is the
most potent endogenous vasodilator in the body (Cooke, 2000). NO is
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biosynthesised from the substrates amino acid L-arginine (Palmer et al., 1988) which
is in blood, extracellular fluid, and also within cells (Figure 1.4).
Figure 1.4 Biosynthesis of NO from L-arginine.
Overall reaction
NOS*
L-arginine + 2 NADPH + O2 >. L-citrulline + NO + 2NADP+
Key: *Cofactors for NOS are Calmodulin/Ca2+, tetrahydrobiopterin, heam, flavin
mononucleotide, and flavin adenine dinucleotide. NADPH: nicotine adenine dinucleotide
phosphate; NO: nitric oxide; NOS: nitric oxide synthase.
Nitric oxide synthase (NOS) is the enzyme catalysing the synthesis ofNO. There are
3 isoforms of NOS: neuronal NOS (nNOS, type I), inducible NOS (iNOS, type II),
and endothelial NOS (eNOS, type III) (Papapetropoulos et al., 1999). NOS I and
NOS III are constitutively expressed in the endothelium, platelets, and some
neurones, and are calcium/calmodulin dependent whereas NOS II produces a large
amount of NO (20 times or more higher than the constitutive production) after
induction by various external stimuli for example bacterial lipopolysaccharide,
independent of calcium (Nathan et al., 1994). NOS III is located in the plasma
membrane at the region called caveolae, structures associated with the accumulation
of receptors for agents that regulate endothelial cell activity (Shaul, 2002). The most
important physiological stimulus ofNOS III is pulsatile blood flow. Normally, small
amount of NO are produced constantly by the endothelium in large- and medium-
size blood vessels to maintain blood flow by dilating the arteries. Some agonists
such as ACh and bradykinin can also activate NOS III.
Endothelial NO diffuses across the cell membrane to the cytosol of vascular smooth
muscle cells and into the lumen of the blood vessels reaching platelets. NO then
reacts with its target protein, the enzyme soluble guanylyl cyclase, leading to the
formation of cyclic guanosine monophosphate from the nucleotide guanosine
triophosphate, resulting in vasodilatation (Figure 1.5).
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Key: cGMP: cyclic guanosine monophosphate; GTP: guanosine triphosphate; L-Arg: L-
arginine; NO: nitric oxide; sGC: soluble guanylyl cyclase.
There are many factors leading to an inhibition of biological activity of NO
• • • • • 2 i
including decreased L-arginine uptake; reduction of co-factors such as Ca ,
calmodulin, BH4; inhibition of electron flow by reduced NADPH and flavins;
inhibition of NOS expression; inhibition of substrate binding to NOS such as the
endogenous inhibitor ofNOS, and increased NO scavengers.
1.7.2 Asymmetric dimethylarginine
ADMA is an endogenous competitive inhibitor of NOS (Vallance et al., 2004). In
the cardiovascular system, ADMA is produced in the heart, endothelium, and
smooth muscle cells. It is synthesised via methylation of arginine residues within the
cell by the action of protein-arginine methyltransferases (PRMT). S-
adenosylmethionine is the methyl donor in this reaction, and S-
adenosylhomocysteine is produced. Two types of PRMT were identified. PRMT
type I and II both form A^-monomethyl L-arginine (L-NMMA). ADMA is only
produced by PRMT type I and symmetric dimethylarginine (SDMA) is produced by
PRMT type II. L-NMMA and ADMA are equipotent, competitive inhibitors of all 3
isoforms of NOS, whereas SDMA has no inhibitory activity on NOS. It has been
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estimated that, per day, -300 prnol of ADMA is generated in the human body
(Achan et al., 2003).
L-NMMA and ADMA are metabolised by dimethylarginine
dimethylaminohydrolase (DDAH) enzyme to citrulline and monomethylamine or
dimethylamine, respectively. DDAH is classified into 2 types, DDAH I and II, which
differ in tissue expression. DDAH I is highly expressed in the brain and kidney
whereas DDAH II is found in the heart, placenta, and kidney (Leiper et al., 1999).
SDMA is excreted via the kidneys while ADMA is eliminated by a combination of a
renal excretion and a metabolism by DDAH (Boger et al., 2003; Vallance et al.,
2004). Brief metabolic pathways for ADMA and SDMA is summarised in Figure
1.6.
Figure 1.6 Generation and metabolism of methylarginines.
Key: ADMA: asymmetric dimethylarginine; DDAH: dimethylarginine
dimethylaminohydrolase; L-NMMA: A^-monomethyl L-arginine; NO: nitric oxide; NOS: nitric
oxide synthase; PRMT: protein arginine methyltransferases; SAH: S-adenosylhomocysteine;
SAM: S-adenosylmethionine; SDMA: symmetric dimethylarginine.
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ADMA leads to impaired endothelial function by increasing endothelial cell
adhesion and enhancing atherogenesis. Several clinical studies in non-renal patients
including patients with coronary artery disease (Lu et al., 2003; Valkonen et al.,
2001) and those with peripheral vascular disease (Mittermayer et al., 2006) have
demonstrated a strong correlation between increased plasma ADMA concentrations
and cardiovascular morbidity and mortality.
Plasma ADMA and SDMA concentrations are increased in dialysis patients
compared to healthy controls, ranging from 1.4- to 10.3-fold and 5.0- to 11.7-fold,
respectively [Vallance et al., 1992; MacAllister et al., 1996; Anderstam et al., 1997;
Kielstein et al., 1999; Schmidt et al., 1999; Cross et al., 2001; Fleck et al., 2001;
Wahbi et al., 2001; Osanai et al., 2002; Raj et al., 2002; Bergamini et al., 2004;
Martens-Lobenhoffer et al., 2004; Mochizuki et al., 2005; Morimoto et al., 2005;
Siroka et al., 2005; Yano et al., 2005; Aslam et al., 2006; Yilmaz et al., 2006]. The
increase in plasma SDMA concentrations is substantially higher than plasma ADMA
reflecting renal clearance as the main elimination process for SDMA. Most studies
have shown that plasma ADMA levels appear to be higher in haemodialysis patients
compared to patients on peritoneal dialysis. Plasma ADMA also independently
predicts all-cause mortality in dialysis patients with an increase in concentration of
plasma ADMA by 1 pmol/L leading to a 26% increase in risk of death (Zoccali et
al., 2001). In CKD patients who are not in ESRD, plasma ADMA and SDMA levels
are also significantly elevated, ranging from 1.1- to 3.4-fold and 1.4- to 8.2-fold,
respectively, compared to controls (Busch et al., 2006; Caglar et al., 2006; Fleck et
al., 2001; Kielstein et al., 2002; MacAllister et al., 1996; Marescau et al., 1997;
Nanayakkara et al., 2005; Ravani et al., 2005; Saran et al., 2003; Schmidt et al.,
2000; Tarnow et al., 2004; Wahbi et al., 2001; Yilmaz et al., 2006; Yilmaz et al.,
2007). Importantly, plasma ADMA concentrations has been shown to correlate with
GFR (r = -0.59, p < 0.01), and independently predict the progression of renal failure
(odds ratio 1.5, 95% confidence interval 1.1 - 1.9, p < 0.006) (Fliser et al., 2005).
1.7.3 The endothelial endothelin-1 pathway
The endothelins (ETs) are a family of potent vasoconstrictive peptides consisting of
21 amino acid residues. Initially, ET was isolated and identified from the medium of
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cultured porcine endothelial cells in 1988 (Yanagisawa et al., 1988). After the
discover ofET, three endogenous isoforms of ET were identified as ET-1, ET-2, and
ET-3. Each isoform contains two intra-chain disulphide bridges linking paired
cysteine amino acid residues, producing a semi-conical structure. ET-2 differs from
ET-1 by two amino acids residues while ET-3 differs by 6 amino acids (Figure 1.7).
ETs possess molecular structural homology with sarafotoxin peptides extracted from
the venom ofAtractaspis engaddensis (Kloog et al., 1988).
Figure 1.7 Structure of the three isoforms of ET.
ET-1 is the principal cardiovascular isoform of ET produced by the endothelial cells
(Inoue et al., 1989). Synthesis of ET-1 is enhanced in response to low shear stress,
turbulent blood flow, hypoxia, cytokines, angiotensin II, adrenaline, and LDL. In
contrast, high shear stress, NO, and vasodilating agents, including prostaglandins
and natriuretic peptides, suppress ET-1 production (Gray et al., 1996; Motte et al.,
2006).
ET-1 is generated within the endothelial cells via a two-step proteolytic pathway
(Gray et al., 1996) (Figure 1.8). After the transcription of a gene on chromosome 6, a
large precursor peptide of 212 amino acid residues called preproET-1 is formed.
PreproET-1 is then translated and secreted into the cytoplasm as proET-1. ProET-1
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is further processed by an enzyme, a furin-like endopeptidase, to the 38-amino-acid
precursor molecule named big ET-1. Big ET-1 is a biologically inactive intermediate
peptide and is further converted into an active ET-1 (21-amino-acid ET-1) by an
endothelin-converting enzyme (ECE) in the cytoplasm of the endothelial cells. ECE
is a family ofmetalloprotease enzymes with two main isozymes, ECE-1 and ECE-2,
of which ECE-1 is the physiologically active ECE in humans.
The endothelium releases ET-1 through both constitutive and regulated (rapid
release) pathways. The constitutive pathway is regulated mainly at the level of gene
transcription. The rapid release pathway is that ET-1 released from vesicles
originating in the Weibel-Palade bodies and the Golgi network (Barnes et al., 1998).
ET-1 abluminally released from endothelial cells acts primarily as a local autocrine
and paracrine substance rather than as an endocrine hormone. In health, low levels of
ET-1 (1-10 pmol/L) are detected in plasma, suggesting that circulating levels of ET-
1 represent an overflow of tissue-bound ET-1 and do not truly reflect the overall ET-
1 activity (Haynes et al., 1998).
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Key: ECE: endothelin-converting enzyme.
In humans, ET-1 exerts its action via two types of ET receptors, ETA and ETB
receptors. ET receptors are members of the heptahelical G-protein-coupled receptor
superfamily. ET-1 binds ETA and ETB receptors with equal affinity. By contrast, ET-
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3 has at least 100-fold less affinity for ETA receptors than ETb receptors (Davenport,
2002). In the vasculature, vascular smooth muscle cells express both ETA and ETB
receptors while the endothelial cells express mainly only ETb receptors (Molenaar et
al., 1993). Direct actions of ET-1 on ETAand ETB receptors on the vascular smooth
muscle cell are contraction, proliferation, and migration of vascular cells. On the
other hand, the effects of ET-1 via the ETB receptors on the endothelium are a
release of vasodilating compounds such as NO, leading to vascular relaxation and
anti-proliferation (Figure 1.9) (Kirkby et al., 2008). Binding of ET-1 to ETA
receptors stimulates phospholipase C to further hydrolyse phosphotidyl inositol 4, 5
biphosphate into inosital triphosphate and diacylglycerol, leading to increased
• 9_|_ • • • •
intracellular Ca and vasoconstriction. The first phase of response is rapid (2-5
seconds), followed by the second phase of sustained increase intracellular Ca2+
which may last up to 20 minutes. The effects of ET-1 binding to ETB receptors are
similar to those effects of stimulating ETA receptors via activation of phospholiphase
C. However, ETb receptor binding also activates phospholipase A2 to release
vasodilating substances such as prostaglandin (Kirkby et al., 2008; Simonson et al.,
1992). Clinical studies have demonstrated the role of ET-1 in the control of vascular
tone in healthy subjects (Haynes et al., 1994), hypertension (Cardillo et al., 1999;
Taddei et al., 1999), and CKD (Hand et al., 1999).
To date, ET receptors have been identified in many major organs including the
lungs, heart, and kidneys. In the kidneys, both ETA and ETb receptors are widely
distributed with ETb to ETA ratio = 2:1. ETA receptors are located in the glomeruli,
vasa recta and arcuate arteries, while ETb receptors are more widespread and highly
found in the collecting systems. In animal, exogenous ET-1 causes vasoconstriction
of afferent and efferent arterioles, with a greater effect on the former. In human, ET-
1 regulates renal blood flow and glomerular haemodynamics leading to a fall in total
renal blood flow and a consequence reduction of GFR. ET-1 also regulates sodium
and water homeostasis and acid-base balance (Dhaun et al., 2006; Karet et al., 1996).
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Figure 1.9 Actions of ET-1 on vascular smooth muscle cells.
Key: ET-1: endothelin-1; ETA: endothelin receptor type A; ETB: endothelin receptor type B;
NO: nitric oxide; PGI2: prostacyclin.
Clearance of ET-1 from plasma is very rapid. It occurs largely in the lungs via ETb
receptors by endocytosis and degradation of the ETB receptor-ligand complex
(Dupuis et al., 1996). The pulmonary circulation extracts -50% of the circulating
ET-1 per a single pass of blood through the lungs (Dupuis et al., 1996). The speed of
this clearance and the polarised abluminal nature of ET-1 secretion by the
endothelial cells highlight the poor predictive value of plasma ET-1 concentration as
a measure of ET-1 systhesis and the difficulty of assessing altered ET-1 activity in
disease. The kidney also plays a role in ET-1 clearance. It was shown that 10% of
circulating ET-1 is removed from the human circulation via the kidneys (Gasic et al.,
1992) either by glomerular filtration or enzymatic degradation. Neutral
endopeptidase, the enzyme located in the brush border vesicle of the proximal tubule
catabolised ET-1 and inhibition of this enzyme leads to an increase in plasma and
urinary ET-1 concentrations (Abassi et al., 1992). Renal ET-1 clearance was also
indicated by a study in rats where rats with bilateral nephrectomy had impaired
exogenous ET-1 removal (Shi et al., 1994).
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Plasma ET-1 concentrations are elevated in patients with pulmonary arterial
hypertension (Stewart et al., 1991), diabetes (Ferri et al., 1997; Schneider et al.,
2002; Takahashi el al., 1990), hypertension (Ferri et al., 1997; Goddard et al., 2000;
Shichiri et al., 1990), acute myocardial infarction (Miyauchi et al., 1991), chronic
heart failure (Lerman et al., 1992; McMurray et al., 1992), and metabolic syndrome
(Ferri et al., 1997). Plasma ET-1 concentrations are also increased in dialysis
patients (Blazy et al., 1994; Dammers et al., 2005; Demuth et al., 1998; Deray et al.,
1992; Koyama et al., 1989; Mallamaci et al., 1993; Miyauchi et al., 1991; Saito et
al., 1991; Totsune et al., 1989; Vlassopoulos et al., 1995). Circulating ET-1 is
predictive of cardiovascular remodelling presented by increased left ventricular mass
and increased common carotid artery IMT in ESRD (Demuth et al., 1998). In non-
dialysis patients, plasma ET-1 concentrations are also increased (Blazy et al., 1994;
Deray et al., 1992; Koyama et al., 1989; Mallamaci et al., 1993; Saito et al., 1991;
Vlachojannis et al., 1997). Additionally, plasma ET-1 correlates with renal function
(Blazy et al., 1994; Dammers et al., 2005; Goddard et al., 2007; Mallamaci et al.,
1993). A study has shown a progressive increase in plasma ET-1 in hypertensive
patients with GFR ranging from CKD stage 1 to pre-dialysis and also showed that
ET-1 independently predicts GFR, and is superior to inflammation (CRP) or
oxidative stress (Isop) in this respect (Cottone et al., 2009).
One mechanism proposed to be responsible for increased circulating ET-1
concentrations in CKD includes reduced ET-1 renal clearance as a consequence of
reduced GFR. However, this may not be true as evidence suggests that renal and
vascular ET-1 are two independent systems (Serneri et al., 1995). A study in rats has
shown that after systemic infusion of radiolabeled ET-1, less than 1% of
radiolabelled ET-1 is recovered in the urine (Benigni et al., 1991). This suggests that
neither glomerular filtration nor tubular secretion of plasma ET-1 account for urinary
ET-1, which is therefore assumed to be primarily of renal origin and, thus, urinary
ET-1 excretion reflects renal ET-1 production. Physiological studies in dogs and
humans have shown no difference between renal arterial and venous ET suggesting
that there is no ET clearance across the kidneys (Deray et al., 1992). This is also
supported by a study in healthy subjects which demonstrated that plasma ET-1 and
urinary ET-1 did not relate to each other, but both correlated inversely with GFR
(Goddard et al., 2007).
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1.7.4 Measurements of endothelial function
A major characteristic of endothelial dysfunction is a reduction of NO produced or
released by the endothelium (Cooke, 2000). Several methodologies have been
established to indirectly quantify the amount of NO production by assessing the
degree of vasodilatation that occurs when endothelial NO production is stimulated.
1.7.4.1 Invasive measurements of endothelial function
The gold standard clinical measure of endothelium-dependent vasomotor function is
a local intra-arterial administration, either into the forearm or coronary circulations,
using a substance that stimulates endothelial NO production such as ACh (Ludmer et
al., 1986; Newby et al., 2001). The vasodilatation can be measured as the change of
blood flow to the forearm, using venous occlusive plethysmography (Wilkinson et
al., 2001), or assessed by quantitative angiography or Doppler ultrasound in the
coronary circulations (Ludmer et al., 1986; Newby et al., 2001). An impaired
endothelium-dependent vasomotor function may be a result of either impaired
production and release of NO, increased degradation of NO, or impaired sensitivity
of the vascular smooth muscle cell to NO. Hence the endothelial-independent
vasomotor function by a NO-donor substance such as glyceryl trinitrate (GTN) or
sodium nitroprusside, is usually measured as a control (Wilkinson et al., 2001).
These methodologies have major limitations. They are invasive, expensive, time
consuming, carry with them the risks of vascular injury and have limited
applicability for large-scale studies.
1.7.4.2 Non-invasive measurements of endothelial function
Flow-mediated dilatation (FMD) is a widely used non-invasive measure of
endothelial-dependent vasomotor function of a conduit artery such as the brachial
artery (Corretti et al., 2002), using the shear stress from the flow of blood as a
physiological stimulus for NO generated vasodilatation. Impaired FMD has been
demonstrated in subjects with atherosclerosis and those with cardiovascular risk
factors (Brunner et al., 2005; Celermajer et al., 1992). In most studies, the
endothelium-independent GTN responses are reported to be preserved. This
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technique is safer and faster than invasive methods and can be applied to large
groups of patients. It can also be used to make repeated measurements over time.
Studies suggest that endothelial function assessed non-invasively in the brachial
artery correlates well with endothelial function in the coronary arteries (Anderson et
al., 1995). However, FMD is operator-dependent and results are markedly dependent
on the resolution of the ultrasound image.
Another non-invasive technique used to measure endothelial function is the
assessment of arterial pressure waveforms or pulse wave analysis (PWA) after P2
adrenoreceptor agonist administration. PWA is one of several non-invasive methods
commonly used to measure arterial stiffness (Oliver et al., 2003b). PWA has been
adapted to measure endothelial function, by giving patients a P2-adrenoreceptor
agonist, such as salbutamol, which is a NO-dependent vasodilating agent in the
peripheral circulation. When given systemically salbutamol reduces peripheral artery
wave reflection and this response is NO-dependent. This methodology was first
described in 1999 by Chowienczyk et al., where salbutamol was shown to reduce the
height of the inflection point of the digital volume pulse (Chowienczyk et al., 1999).
Subsequently, salbutamol was also shown to reduce the most relevant parameter
obtained from PWA known as augmentation index (AIx) (both central (aortic) AIx
(Wilkinson et al., 2002a) and peripheral (radial) AIx (Hayward et al., 2002)). As
with FMD, the change of the arterial waveforms that occurs with salbutamol
measured by PWA is compared to that following sublingual GTN, as a measure of
endothelium-independent vasodilatation (Wilkinson et al., 2002a). A number of
studies confirm the potential of evaluating endothelial function with this technique.
The reduction of AIx after salbutamol is impaired in patients with diabetes mellitus
(Chowienczyk et al., 1999), hypercholesterolemia (Wilkinson et al., 2002a), and
coronary artery disease (Hayward et al., 2002). This methodology is a simple, non¬
invasive technique that could be applied to large population studies and potentially
be used in clinical practice.
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1.8 Arterial stiffness
Arterial stiffening is a dynamic process involving functional and structural, including
cellular elements of the vessel walls. It is caused by fracture and fragmentation of the
elastic lamellae within the media of the vessel walls, principally in central elastic
arteries such as the aorta (O'Rourke, 1999; Zieman et al., 2005). It is an ageing
phenomenon which is accelerated by hypertension and arterial disease.
Arterial stiffening is of interest since it has been shown that it is pathologically
relevant to cardiovascular disease. Arterial stiffness is associated with a number of
conventional cardiovascular risk factors including age, gender, smoking,
hypertension, hypercholesterolaemia, and diabetes mellitus (Cockcroft et al., 1997;
Nichols, 2005; Wilkinson et al., 2000; Wilkinson et al., 2002b; Yasmin et al., 2004).
It also correlates with the severity of cardiovascular disease and is an independent
predictor for cardiovascular disease in hypertension and ESRD (Blacher et al.,
1999a; Boutouyrie, 1999; London, 2001; Safar, 2002; Sutton-Tyrrell et al., 2005). A
study has shown that survival rate is higher in patients whose blood pressure (BP)
and arterial stiffness were well controlled, compared to those with BP control only
(Guerin, 2001).
1.8.1 Arteries and arterial function
The arterial wall has three layers. The tunica externa is the outermost, composed of
connective tissue. The tunica media is a middle layer containing smooth muscle. The
tunica interna is the innermost which includes three parts: the endothelium that lines
the lumen of blood vessels; the layer of glycoprotein called the basement membrane;
and the layer of elastic fibres known as elastin. Arteries can be divided into 2 major
types: elastic and resistance arteries.
The elastic arteries, such as the aorta and the large central arteries are highly
distensible because they contain numerous layers of elastin fibres between smooth
muscle cells in the tunica media. The large elastic arteries have two main functions:
to act as conduits and as buffers. As conduit arteries, their role is to deliver blood to
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tissue and organs with minimal loss of perfusion pressure. The buffer function aims
to smooth flow pulsations from ventricular ejection to the target organs. In order to
achieve the continuous needs of peripheral tissue oxygen demand these two
functions must be balanced and performed effectively during both systole and
diastole. Large arterial functions are altered by the degenerative process that occurs
with ageing and diseases. However, it should be emphasised that the stiffening of
major arteries, particularly in hypertension and ageing, mostly affects the buffer
function (O'Rourke, 1995; Zieman et ah, 2005).
Yet, the resistance arteries, for example radial, brachial, and femoral arteries, which
are sometimes referred to as peripheral arteries, are less elastic. They have a thick
layer of smooth muscle with narrow lumina. Contraction or relaxation of this smooth
muscle has a considerable effect on the lumen of the resistance arteries, altering
blood flow to the relevant distal organs.
1.8.2 Arterial wave reflection
After being pumped from the heart, blood travels along the arteries to the peripheral
tissues and pressure waves and flow waves are produced. The behaviour and
contours of arterial pressure waves and flow waves vary in different arteries. These
changes in the pressure waveforms are because of the "reflected" pressure waves
(Nichols, 2005). Basically, by absorbing a proportion of the energy in systole and
releasing it in diastole, peripheral blood flow is smoothed and diastolic coronary
artery flow maintained. However, some pressure waves are reflected back from the
periphery because of discontinuity in calibre or elastic properties along the arterial
tree. Possible reflecting sites are branching points, areas of alteration in arterial
distensibility and high-resistance arterioles. These reflected waves summate with the
forward-going waves and produce the typical resultant waveforms (Nichols, 2005).
When the large arteries are compliant, the arterial waveform is amplified as it travels
towards the periphery (Figure 1.10, waveforms on the left). Ageing, diabetes, or
other cardiovascular diseases stiffen the arteries resulting in a reduction of the
arterial waveform amplification (Figure 1.10, waveforms on the right) (Kelly et al.,
1989; McEniery et al., 2005). These changes in the pressure waveforms caused by
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arterial stiffening negatively affect the circulation. Normally, in young adults, the
reflected wave arrives in the central artery after the closure of the aortic valve.
Therefore, it does not have any effect on central systolic pressure but it improves
coronary diastolic blood flow by augmenting diastolic pressure. In elderly
individuals with poor arterial elasticity, the reflected wave arrives earlier, occurs in
systole, augmenting systolic pressure and results in a decrease in coronary blood
flow (Figure 1.10) (Nichols, 2005).















Subject with compliant Subject with stiff large
large arteries arteries
systole diastole
Key: Figure from (Oliver et at., 2003b). Waveforms on the left: subjects with compliant large
arteries. Waveforms on the right: subjects with stiff large arteries. When the large arteries
are compliant, the initial systolic pressure wave (P0 travelling from the heart to the periphery
is responsible for the peak systolic blood pressure. Reflected pressure wave (P2) arrives at
the central aorta in the diastole, augmenting diastolic blood pressure and coronary filling. In
stiff large arteries, wave reflection occurs earlier so that systolic blood pressure is
augmented and diastolic blood pressure falls. PP: pulse pressure; AP = P2- P-i;
Augmentation index (%) = [AP/PP] x 100. More detail regarding augmentation index can be
found in Chapter 2, section 2.5.1.
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1.8.3 Measurements of arterial stiffness
The aorta is the major vessel of interest for determining arterial stiffness because it
makes the largest contribution to the arterial buffering function (Nichols, 2005).
Importantly, stiffness of the aorta, measured by aortic pulse wave velocity (PWV), is
an independent predictor of outcomes in various populations (Blacher et al., 1999a;
Boutouyrie et al., 2002; Cruickshank et al., 2002; Laurent et al., 2001). To date, a
number of invasive and non-invasive techniques have been developed for the
assessment of arterial stiffness in vivo. Invasive clinical measurements, such as 2-site
intra-arterial catheterisation for measuring PWV, are suitable for experimental
animal laboratories. These methods are not appropriate for clinical use. Non-invasive
measurements of arterial stiffness are well-established and entail measurement of
surrogate parameters which are associated with arterial stiffness. Many are
reproducible, non-invasive and relatively easily accessible to anyone without special
knowledge and without a detailed exploration of arterial mechanics. These
methodologies are in three main groups. The first group is a measure of PWV. The
second group is an assessment of arterial pressure waveforms or PWA with indices
such as AIx. The third group is a relation of changes in the diameter or an area of an
artery to distending pressure (Laurent et al., 2006; Oliver et al., 2003b).
1.8.3.1 Pulse wave velocity
PWV is the most simple, non-invasive, robust, and reproducible method for
measuring arterial stiffness. PWV is defined as the speed in which the pulse wave
travels along a measured arterial segment (Laurent et al., 2006). PWV is calculated
by dividing the distance between the two sites at which the pressure wave is being
recorded, by the time taken from the first to the second site. The proximal arterial
site is usually a common carotid artery and the distal sites are femoral artery or radial
artery (carotid-femoral PWV (CF-PWV) or carotid-radial PWV (CR-PWV)). CF-
PWV is a gold standard measure of arterial stiffness according to the current
guideline (Laurent et al., 2006). CF-PWV represents the measurement of arterial
stiffness of the aorto-iliac pathway, which is the most clinically relevant for the
assessment of arterial stiffness of the aorta since the aorta and its first branches
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(femoral arteries) are what the left ventricle 'sees' and thus are responsible for the
pathophysiological effects of arterial stiffness of the central artery.
Higher PWV reflects stiffer arteries and several conventional cardiovascular risk
factors, for instance hypertension, hypercholesterolaemia, and diabetes mellitus, are
associated with increased PWV (Nichols, 2005). However, this technique carries
some limitations. The pressure waveforms at the femoral site may be difficult to
record especially in obese patients. Additionally, the inaccuracy of the measurement
of the distance between two recording sites may affect the calculation ofPWV.
1.8.3.2 Pulse wave analysis
The parameter obtained from PWA is AIx which is defined as the ratio of the
difference of the first and second systolic pressure to the pulse pressure (see Chapter
2, section 2.5.1 for detail) (Laurent et al., 2006; Oliver et al., 2003b). It reflects the
degree to which central arterial pressure is augmented by wave reflections.
According to the current guideline, arterial pressure waveforms should be analysed
at the central level. The central AIx (CAIx) is usually estimated from either the
radial artery waveform (RAIx) using a transfer function or from the common carotid
waveform. AIx increases with age. Diseases such as hypertension and diabetes
mellitus are also associated with increased AIx (Nichols, 2005). AIx is also
influenced by PWV and other factors such as body height and heart rate (O'Rourke
et al., 1996; Yasmin et al., 1999). Importantly, comparison between AIx and aortic
PWV has shown a significant association, but a relatively low positive correlation.
This suggests that although AIx is a measurement of arterial stiffness, it is not simply
a surrogate measure of PWV (Yasmin et al., 1999). This technique is easy to
perform and highly reproducible (Wilkinson et al., 1998) but it has some limitations.
The generalised transfer function used is derived from patients with coronary heart
disease and therefore it may not be accurate for some diseases. Although, the transfer
function is not necessary when recording the waveforms at the common carotid
artery, this requires a higher degree of technical expertise.
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1.8.3.3 Arterial compliance or arterial distensibility
Local stiffness of the arteries can be measured using an ultrasound or magnetic
resonance imaging device. With these techniques, the change in pressure driving the
change in volume of the artery is measured, providing a direct measurement of
stiffness (Laurent et al., 2006; Oliver et ai, 2003b). Of the superficial arteries,
carotid stiffness is of particular interest since it is one of the most common sites for
atherosclerosis. Using the magnetic resonance imaging technique yields the ability to
measure local arterial stiffness at the aorta. However, this technique takes longer
than measuring PWV and requires a high degree of clinical expertise, therefore it is
not suitable for epidemiological studies (Laurent et al., 2006). Of note, although
carotid stiffness and CF-PWV provide similar information on the impact of ageing
on large artery stiffness in normal subjects, this is not the case for patients with
hypertension or diabetes. With diseases, the aorta stiffens more than the carotid
artery and thus aortic stiffness and carotid stiffness cannot be used interchangeably
in these patients (Laurent et al., 2006).
1.8.4 Arterial calcification and arterial stiffness in
CKD
Arterial calcification has been recognised for many years as a common complication
in CKD (Salusky et al., 2002). In fact, arterial disease in CKD patients is
characterised by extensive calcification (London et al., 2005). The precise
mechanisms responsible for this are not well understood, but arterial calcification
appears to be a similar process to bone formation. Abnormalities in mineral
metabolism and disturbances in phosphate metabolism are believed to be particularly
important determinants (Demer et al., 2008; Goodman et al., 2004). Arterial
calcification occurs in two sites: the tunica intima and tunica media. Intimal
calcification is a marker of atherosclerotic disease. Yet, medial calcification
promotes arterial stiffening, leading to left ventricular hypertrophy and reduced
coronary perfusion (Table 1.6).
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Table 1.6 Types and characteristics of vascular calcification.
Types Location and features










Type 2 diabetes mellitus,
end-stage renal disease
Key: Table modified from (Demer et al., 2008).
In ESRD, the presence of arterial calcifications is associated with increased arterial
stiffness (Sigrist et al., 2007). The extent of arterial calcifications increases with age
and the duration of dialysis (Guerin et al., 2000; Sigrist et al., 2007). In addition, the
progression of arterial calcification in a period of 12 months is an independent
predictor of survival (hazard ratio 1.03, 95% confidence interval 1.01-1.05) (Sigrist
et al., 2007). Intimal calcification, which is associated with generalised
atherosclerosis, is not specifically attributable to haemodialysis whereas medial
calcification is much more closely associated (Guerin et al., 2000). Nevertheless,
both intimal and medial calcification are associated with PWV (Guerin et al., 2000;
Haydar et al., 2004).
Abnormalities in calcium and phosphate metabolism have emerged as important
determinants of arterial calcification. Recently, attention has been focused on the
potential importance of serum fetuin-A, a potent calcification inhibitor. The absence
of fetuin-A in fetuin-A knock-out mice leads to massive extra-osseous calcification
(Schafer et al., 2003). Low circulating fetuin-A levels are associated with increased
all-cause and cardiovascular outcomes in ESRD (Ketteler et al., 2003; Stenvinkel et
al., 2005b). It is unclear whether fetuin-A levels are inversely related to arterial
stiffness markers (Hermans et al., 2006).
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1.9 Relationship between arterial stiffness and
endothelial dysfunction
Arterial stiffness and endothelial dysfunction commonly co-exist in patients with
cardiovascular disease. Conditions associated with endothelial dysfunction, such as
diabetes mellitus (Calver et al., 1992; Wilkinson et al., 2000) and
hypercholesterolemia (Chowienczyk et al., 1992; Wilkinson et al., 2002b) are
associated with increased arterial stiffness. Evidence supports a role for the
endothelium in regulating arterial stiffness by the release of vasoactive mediators
such as NO (Boutouyrie et al., 1997; Levy et al., 1990; Wilkinson et al., 2002c).
Several interventions that reduce arterial stiffness also improve endothelial function
and vice versa (Oliver et al., 2003a; Van Bortel et al., 2001).
1.10 Arterial stiffness and endothelial
dysfunction in chronic kidney disease
Increased arterial stiffness is a common feature of CKD (Guerin et al., 2008). In
ESRD, patients have reduced arterial compliance compared to the general population
of the same age and BP level (Konings et al., 2004). Indices of arterial stiffness are
substantially higher than those recorded in non-renal subjects (Benetos et al., 2002;
Blacher et al., 1999b; Konings et al., 2002; Stancanelli et al., 2007). Increases of
PWV and AIx are strong independent predictors of all-cause and cardiovascular
mortality in ESRD. Studies have shown that, for each increase of 1 m/s in PWV, the
all-cause mortality-adjusted odd ratio was 1.4 (95% confidence interval 1.2-1.6).
Likewise, for every 10% increase in AIx, the risk ratio was 1.5 (95% confidence
interval 1.2-1.9) (Blacher et al., 1999a; London, 2001). In addition, aortic PWV is an
independent predictor of survival in ESRD (Guerin, 2001).
Shinohara, et al. compared aortic PWV of CKD patients before starting
haemodialysis with that of patients on maintenance haemodialysis. The aortic PWV
was significantly higher in pre-dialysis and haemodialysis groups (9.7 and 8.9 m/s,
respectively, p < 0.01 for both), compared with 7.4 m/s in healthy controls. This
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suggests that aortic stiffening occurs in CKD before starting dialysis (Shinohara et
al., 2004). Interestingly, a study also indicated that even a mild to moderate
deterioration in renal function was associated with increased arterial stiffness. In
normotensive and hypertensive patients, those with normal serum creatinine levels
but who were in the lowest fertile of creatinine clearance (CrCl) had increased
arterial stiffness, independent of BP and other cardiovascular risk factors. The
negative association between PWV and CrCl was stronger in subjects who were
younger than 55 years old (Mourad et al., 2001). Furthermore, evidence suggests that
arterial stiffness increases correspond with the stages of CKD. In a cross-sectional
study of 102 CKD patients, Wang et al demonstrated a trend for a stepwise increase
in PWV from CKD stages 1 to 5. However, they did not find a significant difference
in the PWV between CKD stages 1 to 2 and the aged-matched control group (Wang
et al., 2005). A recent study has also confirmed the parallel decline in GFR and
arterial stiffness measured by distensibility and PWV in mild-to-moderate CKD
patients (Briet et al., 2006).
Endothelial dysfunction is evidenced in ESRD (van Guldener et al., 1998; van
Guldener et al., 1997). A prospective study in dialysis patients has demonstrated that
endothelial dysfunction measured by an invasive forearm blood flow technique is an
independent predictor of all-cause mortality (London et al., 2004b). Endothelial
dysfunction has also been found in CKD patients with mild renal insufficiency
suggesting a role for uraemia directly promoting the early development of
cardiovascular complications in CKD patients (Annuk et al., 2001; Foster et al.,
2008; MacKinnon et al., 2008; Mourad et al., 2001; Perticone et al., 2004; Stam et
al., 2006; Thambyrajah et al., 2000; Yilmaz et al., 2006).
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1.11 Relationship of emerging cardiovascular
risk factors to arterial stiffness and endothelial
dysfunction
1.11.1 C-reactive protein
A number of studies have shown associations between the circulating levels of CRP
and arterial stiffness in the general population (Kullo et al., 2005; Mattace-Raso el
al., 2004; Nagano et al., 2005; Vlachopoulos et al., 2005; Yasmin et al., 2004),
hypertension (Amar et al., 2005; Mahmud et al., 2005), familial
hypercholesterolaemia (Cheng et al., 2007), and the metabolic syndrome (Tomiyama
et al., 2005). A substudy of the regression of arterial stiffness - the controlled
doubled-blinded REASON study suggested the associations between arterial
stiffness and CRP by showing that in a group of hypertensive patients whose
baseline CRP was high (>3 mg/L), those with a greater reduction in arterial stiffness
after 12 months of antihypertensive treatment, were more likely to have a reduction
of CRP to the normal range at the end of the 12-month treatment (Amar et al., 2005).
In renal patients, the association between arterial stiffness and inflammation has been
shown in dialysis (London et al., 2003) and renal transplant patients (Verbeke et al.,
2007). A prospective study in haemodialysis patients has shown that subjects who
respond to the antihypertensive treatment had less arterial stiffness, less left
ventricular hypertrophy, and lower CRP levels compared to these of the non-
responders. The improvement of arterial stiffness and left ventricular hypertrophy in
the responder group was independently associated with CRP levels (London et al.,
2003).
With regards to endothelial dysfunction, CRP correlated with the endothelium-
dependent vasodilatory response in a forearm blood flow study in untreated
hypertensive patients (Zoccali et al., 2006). In dialysis patients, evidence has shown
associations between circulating markers of endothelial damage and increased CRP
concentrations (Bolton et al., 2001; Vaccaro et al., 2007). These effects are also
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present in patients with mild renal insufficiency (Annuk et al., 2005; Bolton et al.,
2001; Landray et al., 2004; Stam et al., 2003; Vaccaro et al., 2007). However, one
study in CKD stages 3 to 5 has shown no associations between endothelial function
and inflammation, assessed using FMD, and CRP (Annuk et al., 2005).
1.11.2 Isoprostanes
Data regarding the relationship between Isop and arterial stiffness is limited.
However, a study has reported their associations in patients with chronic fatigue
syndrome (Spence et al., 2008). Yet, several lines of evidence have shown the
relationship between both plasma and urinary Isop and endothelial dysfunction in
healthy subjects (Sarabi et al., 1999) and those with systemic sclerosis (Cracowski et
al., 2006), hypercholesterolemia (Martino et al., 2008), and coronary artery disease
(Lavi et al., 2008). The relationship between Isop and arterial stiffness and
endothelial dysfunction in renal patients remains to be investigated.
1.11.3 Oxidised low density lipoprotein
Reports concerning serum lipoproteins as related to arterial stiffness are
controversial. Some studies have found positive associations whereas some report
negative associations (Hopkins et al., 1993; Kupari et al., 1994; Spence et al., 2008;
Tomochika et al., 1996; Wilkinson et al., 2002b). Nonetheless, it has been shown
that high plasma OxLDL concentrations are associated with increased arterial
stiffness in healthy men and familial hypercholesterolaemic patients (Toikka et al.,
1999). Adjusted for age, BP, and other cardiovascular risk factors, OxLDL is the
only independent determinant of compliance of the carotid artery in healthy men
(Toikka et al., 1999). In addition, in borderline hypertensive individuals, reduced
arterial distensibility is related to increased OxLDL (Toikka et al., 2002).
Data regarding the association of OxLDL and endothelial dysfunction is limited and
unclear. Holvoet, et al. reported that OxLDL is associated with endothelial
dysfunction in CKD (Holvoet et al., 1996). Moreover, OxLDL of uraemic patients
appears to be more atherogenic since it is associated with greater monocyte-
endothelial cell adhesion (O'Byrne et al., 2001). However, Bolton, et al. found no
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relationship between OxLDL and endothelial dysfunction, measured by FMD, in
CKD patients (Bolton et al., 2001).
1.11.4 The metabolic syndrome
The metabolic syndrome and its risk factors are substantially associated with arterial
stiffness in healthy subjects (Ferreira et al., 2007; Ferreira et al., 2005; Kovaite et al.,
2007; Li et al., 2005; Nakanishi et al., 2003; van Popele et al., 2000), hypertensive
(Mule et al., 2006; Schillaci et al., 2005; Seo et al., 2005), and diabetes patients
(Martens et al., 2008; Yokoyama et al., 2007). The metabolic syndrome is an
independent predictor for arterial stiffness in many studies (Ferreira et al., 2005;
Kovaite et al., 2007; Mule et al., 2006; Schillaci et al., 2005; Yokoyama et al.,
2007). Recently, a study has shown relationships between the increase in numbers of
metabolic syndrome risk factors and arterial stiffness in peritoneal dialysis patients
(Zhe et al., 2008).
With regards to endothelial dysfunction, data is not consistent. Some studies in
healthy subjects reported that the metabolic syndrome is associated with endothelial
dysfunction (Kovaite et al., 2007; Lind, 2008) whereas others report no associations
(Mattsson et al., 2008; Wendelhag et al., 2002). In disease, the metabolic syndrome
has been shown to correlate with endothelial dysfunction in subjects with a family
history of diabetes and obesity (Ghiadoni et al., 2008) and patients with peripheral
vascular disease (Golledge et al., 2008). To date, the contribution of the metabolic
syndrome or its risk factor to arterial stiffness and endothelial dysfunction especially
in non-dialysis CKD patients is not well-investigated.
1.11.5 Asymmetric dimethylarginine
In healthy subjects, infusion ofADMA significantly decreased total cerebral infusion
and increased AIx (Kielstein et al., 2006). ADMA was associated with arterial
stiffness and was proposed to play a role in the regulation of vascular tone in young
and healthy subjects (Kals et al., 2007; Paiva et al., 2008). However, ADMA was
not an independent predictor of PWV in a large population-based study (Chirinos et
al., 2008). In CKD, an association between plasma ADMA and arterial stiffness has
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been shown in haemodialysis patients (Soveri et al., 2007). In this study,
haemodialysis sessions reduced ADMA levels and this reduction was associated
with an improvement in CAIx. More recently, plasma ADMA was reported to be
associated with arterial stiffness in patients with mild to moderate renal insufficiency
(Fujii et al., 2008).
Since ADMA reduces NO generation through the inhibition of NOS, elevated
plasma ADMA concentrations in patients with hypertension, diabetes mellitus,
congestive heart failure, and patients who are on dialysis (Abbasi et al., 2001; Boger,
2003; Vallance et al., 1992; Zoccali et al., 2001) may contribute to endothelial
dysfunction seen in these conditions (Boger, 2003; Endemann et al., 2004).
Moreover, correlations between ADMA and endothelial dysfunction have been
shown in non-dialysis proteinuric CKD patients (Yilmaz et al., 2008b), stage 1 to 5
CKD patients including those on dialysis (Yilmaz et al., 2006), and renal transplant
patients (Yilmaz et al., 2005) but not in a study in peritoneal dialysis patients
(Mittermayer et al., 2005). Plasma ADMA was an independent predictor of FMD in
some of these studies (Yilmaz et al., 2006; Yilmaz et al., 2008b).
1.11.6 Endothelin-1
An animal study has shown that infusion of exogenous ET-1 via the ovine iliac
artery increases PWV and administration of BQ123, a selective ETa receptor
antagonism, attenuates this effect, suggesting that ET-1, acting via the ETa receptor,
regulates large artery stiffness (McEniery et al., 2003). Similar findings were shown
in healthy subjects where ET-1 caused an increase in arterial stiffness which could
be blocked by concomitant administration of ETa receptor blockade (Vuurmans et
al., 2003). The effect of ET-1 on arterial stiffness was also investigated in patients
with coronary artery disease where plasma ET-1 concentrations correlated
substantially with stiffness index of the thoracic aorta, abdominal aorta, and common
iliac artery (Heintz et al., 1993). In haemodialysis patients, plasma ET-1
concentrations were associated with PWV, independent of age, BP and indices of
cardiovascular remodelling including left ventricular hypertrophy and IMT (Demuth
et al., 1998).
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ET-1 is also implicated in endothelial dysfunction seen in atherosclerotic conditions,
diabetes mellitus, and pulmonary arterial hypertension (Iglarz et al., 2007). The
proposed mechanisms of ET-1 induced endothelial dysfunction are that ET-1
decreases NO bioavailability either by diminishing NO production via an inhibition
of eNOS activity or by enhancing NO degradation via a formation of oxygen radicals
(Iglarz et al., 2007). In haemodialysis patients, plasma ET-1 concentrations inversely
correlated with endothelial function, measured using FMD, independent of age and
BP (Demuth et al., 1998). In addition, plasma ET-1 was independently related to von
Willebrand factor, a circulating marker of endothelial damage, in stage 5 CKD
patients who are not on dialysis (Dammers et al., 2005).
1.12 Hypotheses and aims
This thesis explores the degree of arterial stiffness and endothelial dysfunction in
relatively low risk CKD patients without diabetes or cardiovascular co-morbidity,
across the wide range of renal function from normal GFR to pre-dialysis, and
investigates a contribution of conventional as well as different types of emerging
cardiovascular risk factors to arterial stiffness and endothelial dysfunction in this
group of patients. Furthermore, the effects of selective ETA receptor antagonism on
arterial stiffness and endothelial dysfunction in the same group of patients are
examined.
Chapter 3 (Study 1): This study aimed to assess the reproducibility of non-invasive
measurements of arterial stiffness and endothelial function.
Hypotheses: CF-PWV and AIx, as measures of arterial stiffness, and FMD of
the brachial artery, as a measure of endothelial function, are reproducible for
one observer with repeated measurements, and for two separate observers.
Chapter 4 (Study 2): This study investigated the relationship of plasma and urinary
ET-1 concentrations to renal function in CKD patients.
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Hypotheses: As a result of reduced renal clearance and increased renal
production, plasma and urinary ET-1 concentration will increase as renal
function declines.
Chapter 5 (Study 3): This study sought to investigate the role of uraemia and
conventional cardiovascular risk factors including age, gender, smoking, high BP,
glucose, and dyslipidaemia on arterial stiffness and endothelial dysfunction in CKD
patients.
Hypotheses: As renal function declines, arterial stiffness and endothelial
dysfunction gradually increase. The increase in arterial stiffness and
endothelial dysfunction will significantly and independently relate to renal
function.
Chapter 6 (Study 4): This study assessed the contribution of inflammation,
oxidative stress, and a shift in the balance between the vasodilator (NO) and
vasoconstrictor (ET) systems to arterial stiffness and endothelial dysfunction in CKD
patients.
Hypotheses: The increase in arterial stiffness and endothelial dysfunction
seen in study 3 is also substantially explained by inflammation, oxidative
stress, and a shift in the balance of NO/ET systems (evidenced by increased
ADMA and ET-1 levels, respectively) independent of conventional
cardiovascular risk factors and renal function.
Chapter 7 (Study 5): This study assessed the prevalence of the metabolic syndrome
and the contribution of the metabolic syndrome and the risk factors for it on arterial
stiffness and endothelial dysfunction in CKD patients.
Hypothesis: The metabolic syndrome, by itself, or through its risk factors is
substantially associated to the increased arterial stiffness and endothelial
dysfunction seen in study 3, independent of conventional cardiovascular risk
factors and renal function.
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Chapter 8 (Study 6): This study assessed the prevalence of cardiovascular
calcification in CKD patients and investigated the contribution of cardiovascular
calcification to arterial stiffness and endothelial dysfunction in CKD patients.
Hypotheses: Cardiovascular calcification occurs in the early stages of CKD
and the calcification score is substantially related to arterial stiffness and
endothelial dysfunction, independent of conventional cardiovascular risk
factors and renal function.
Chapter 9 (Study 7): This study examined the effects of BQ123, a selective ETA
receptor antagonism, on arterial stiffness and endothelial function in CKD patients.
Hypotheses: Indices of arterial stiffness and endothelial dysfunction will
improve with blockade of the ET system at the ETA receptor. These effects
will be greater with ET blockade than those seen with equivalent BP
lowering using nifedipine, indicating specific beneficial effects of ET
receptor antagonism on arterial stiffness and endothelial function independent







Subjects abstained from alcohol for at least 24 hours and any caffeine-containing
products for at least 12 hours before the study. All of them were fasted for at least 8
hours before the study except for study 7 (Chapter 9) in which subjects had a light
breakfast on the morning of the study. Smoking was not permitted on the morning of
the study.
Healthy subjects in a study of the reproducibility of CF-PWV and AIx (Chapter 3)
were recruited from staff at the Clinical Research Centre and medical students at the
University of Edinburgh. They were male or female, aged 18-50 years old, with no
history of major cardiac, respiratory, neurological, diabetic, and renal disease. None
of them were on any medication.
For a study of the reproducibility of FMD (Chapter 3) and studies 2 to 6 (Chapter 4
to 8) CKD patients were recruited from the renal outpatient clinic at the Royal
Infirmary of Edinburgh. The inclusion criteria for CKD patients were: male or
female CKD patients, 18-65 years old, BP <160/100 mmHg, whether or not on anti¬
hypertensive medication. Patients with a renal transplant or on dialysis, patients with
systemic vasculitis or connective tissue disease, those with a history of established
cardiovascular disease, peripheral vascular disease, diabetes mellitus, respiratory
disease, or neurological disease, those with current alcohol abuse or those who were
pregnant, and patients treated with an organic nitrate or P-agonist were excluded.
CKD patients enrolled for study 7 (Chapter 9) were 18-70 years old with the
remainder of the inclusion criteria similar to that previously described for studies 2
to 6. For studies 2 to 6, patients continued their usual medication but omitted the
morning dose on the day of the study. Hypercholesterolaemic patients were not
excluded but they had to be established on statin medication with good cholesterol
control for at least 3 months before taking part in the study. Healthy subjects were
enrolled from the community and those who had taken any medication in the
previous 2 weeks were excluded from the studies.
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2.1.2 Study environment
All studies were performed in the Clinical Research Centre, University of
Edinburgh, in a quiet, temperature-controlled room, at 22-24°C.
Studies were approved either by a Local Research Ethics Committee or the Multi¬
centre Research Ethics Committee for Scotland. Studies were performed in
accordance with the Declaration of Helsinki of the World Medical Association. All
subjects provided their written informed consent.
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate were
recorded in duplicated using a validated oscillometric sphygmomanometer, the
Omron HEM-705CP (Omron Healthcare (UK) Ltd, Milton Keynes) (O'Brien el al.,
1996), except for the study investigating the effect of a selective ETA receptor
antagonist (BQ123) on arterial stiffness and endothelial dysfunction (Chapter 9) in
which a Dinamap Pro 100 BP monitor (GE Healthcare, Chalfont St Giles) was used
(Chang et al., 2003). Recordings were required to be within 10 mmHg of each other
(both SBP and DBP). If not, BP was repeated until two consecutive readings fulfilled
the criterion. BP was recorded on the non-dominant arm but if the patients had an
arterio-venous fistula (some of the stage 5 patients), BP was measured on the non-
fistula arm. Brachial mean arterial pressure (MAP) was calculated as MAP (mmHg)
= DBP + [(SBP-DBP) / 3]. Pulse pressure (PP) was calculated as PP (mmHg) = SBP
-DBP.
2.1.3 Research governance and ethics
2.2 Haemodynamic measurements
2.2.1 Blood pressure and heart rate
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2.2.2 Assessment of left ventricular hypertrophy
Left ventricular hypertrophy was assessed using gender-specific electrocardiogram
(ECG) criteria (Alfakih et al., 2004). Cornell criteria was used in males: left
ventricular hypertrophy present if the sum of the R-wave in lead aVL and the S-wave
in lead V3 is greater than 25 mm, and Sokolow-Lyon criteria was applied in females:
left ventricular hypertrophy presents if the QRS duration multiplied by the sum of
the S-wave in lead VI and the R-wave in lead V5 or V6 is greater than 2970.
2.3 Anthropometric measurements
Height (m) and weight (kg) were measured using a digital scale (GEC/Avery digital
scales, model number 824/890, Avery Weigh-Tronix, West Midlands, UK). Body
mass index (BMI) was calculated as: weight / [height]2 and reported in kg/m2. Waist
and hip circumference (cm) were measured on the subject in a standing position with
feet 15 cm apart. Waist circumference was measured at the midpoint between iliac
crest and lowest rib. Hip circumference was measured at the widest part between the
waist and groin. During the measurements, the tape measure was parallel to the
ground (Wahrenberg et al., 2005).
2.4 Estimation of glomerular filtration rate
CrCl, as an estimate of glomerular fdtration rate (eGFR), was calculated according to
the C&G equation (Mafham et ah, 2007). GFR (ml/min/1,73m2) = [(140- age (years)
x weight (kg) x 1.23 for male or 1.05 for female] / serum creatinine (pmol/L). The
C&G equation was selected to assess renal function in this study because it is more
accurate than the MDRD equation when used to assess mild renal insufficiency
(Froissart et al., 2005; Mafham et al., 2007). It was further corrected by body surface
area as described by Du Bois, et al (Du Bois D et al., 1916).
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2.5 Arterial stiffness measurements
The well-validated techniques of PWA and CF-PWV were used in this thesis as
surrogate measures of arterial stiffness.
2.5.1 Pulse wave analysis
Peripheral pressure waveforms were recorded from the radial artery at the wrist by
applanation tonometry using a high fidelity micromanometer (SPC-301, Millar
Instruments, Texas, USA) and the SphygmoCor apparatus (AtCor Medical Pty Ltd,
West Ryde, Australia) with SphygmoCor software version 6.3 (Figure 2.1).
Averaged peripheral and corresponding central (ascending aortic) pressure
waveforms were generated from the last 10 seconds of the radial artery recordings.
AIx was defined as: AIx (%) = [(PI - P2) / PP] x 100 (Figure 2.2).
Figure 2.1 The peripheral pressure waveform is recorded using a tonometer applied
lightly over the radial artery at the wrist.
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Figure 2.2 The central pressure waveform and the calculation of Aix.
Systolic pressure (P1)
Key: Figure from (Laurent et al., 2006). Augmentation pressure = P1 - P2. Augmentation
index = [P1-P2/ pulse pressure] x 100%. P1: late systolic peak; P2: systolic peak. In young
healthy subjects Alx is negative. Alx becomes increasingly positive in stiff arteries.
RAIx was determined from the average peripheral waveform. CAIx and CAIx
adjusted to a standard heart rate of 75 bpm (CAIx@HR75) were calculated from the
averaged central waveform which was derived from peripheral arterial pressure
waveform by a transfer function. To derive CAIx@HR75, the SphygmoCor software
adjusts CAIx at an inverse rate of 4.8% for each 10 bpm increment in HR. All PWA
measurements were made in duplicate with CAIx values within 5% of each other. If
not, further recordings were made until two consecutive readings fulfilled the
criterion. The quality control for PWA including average pulse height >100, pulse
height variation <5%, and diastolic variation <5% were followed.
2.5.2 Carotid-femoral pulse wave velocity
The SphygmoCor apparatus was also used to measure CF-PWV. During continuous
ECG monitoring, pulse wave recordings were made first at the common carotid
artery (proximal site) and then at the femoral artery (distal site) using a high fidelity
micromanometer. The software identified the foot of the pulse wave as the beginning
of the sharp systolic upstroke. The wave transit time between arterial sites was
determined in relation to the R-wave of the ECG. Surface distance between the two
recording sites was measured in mm from the suprasternal notch to the carotid
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measurement site (proximal distance) and to the femoral measurement site (distal
distance) and the distance for PWV calculation was calculated as distance travelled
(mm) = distal distance - proximal distance. CF-PWV was calculated as: CF-PWV
(m/s) = distance travelled / wave transit time. All CF-PWVs were recorded in
duplicate with values within 0.5 m/s of each other. If not, further recordings were
made until two consecutive readings fulfilled the criterion. The same quality control
for PWA was applied to the waveforms of CF-PWV.
2.6 Endothelial function measurements
2.6.1 Flow-mediated dilatation
FMD uses the shear stress from the flow of blood as a physiological stimulus for NO
generated vasodilatation. In this thesis, FMD of the brachial artery was measured.
The experimental set-up for FMD is shown in Figure 2.3.
Figure 2.3 An experimental set-up for FMD.
With individuals in a supine position and their arms out-stretched perpendicular to
the body, the brachial artery was imaged longitudinally with B-mode ultrasound
(Acuson XP 128, Siemen pic, Bracknell, UK) 5 cm above the antecubital fossa using
a linear array transducer with an imaging frequency of 11 MHz. The ultrasound
probe was held in place with a stereotactic clamp throughout the study. A segment
with clear anterior and posterior intimal interfaces between the lumen and vessel
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wall was selected as the area to be analysed for the change of the arterial diameter.
Every 3 seconds, end-diastolic frames (ECG R-wave triggered) were acquired on a
computer equipped with DT-3152 progressive scan frame grabber (Data Translation
Ltd, Basingstoke, UK) and image acquisition software (CVI Acquisition version 1.5,
Information Integrity Inc, USA).
Baseline diameter was recorded for 1 minute. To create a flow stimulus in the
brachial artery, a BP cuff, which was placed around the upper forearm, was inflated
to 50 mmHg above SBP in order to occlude blood flow into the forearm for 5
minutes. Following deflation of the cuff the artery was scanned for a further 5
minutes. The changes with endothelium-independent vasomotor function after a
sublingual administration of GTN was performed after finishing FMD. The brachial
artery was scanned at the baseline for 1 minute. 25pg of GTN (Oliver et al., 2005)
was administered sublingually and the artery was scanned for a further 5 minutes.
All the ultrasound recordings were stored on videotape. Brachial artery diameter was
calculated off-line from the stored images using semi-automated wall tracking
software (Brachial Analyzer, Medical Imaging Application, Iowa, USA). The
endothelium-dependent vasodilatation (FMD) and endothelium-independent
vasodilatation (GTN) were reported as a percentage change of the brachial artery
diameter from baseline (FMD% and GTN%).
2.6.2 A reduction of arterial wave reflection induced
by inhaled (32-adrenoreceptor agonist
Inhaled p2-adreneroreceptor agonist, salbutamol (Allen & Hanbury, Stockley Park,
UK) was administered to patients through a spacer device (Volumetric® Allen &
Hanbury, Stockley Park, UK). Two puffs (200 pg of salbutamol) were initially
placed into the spacer and were inhaled via a full inspiration. Subjects then held their
breath for 10 seconds, exhaled, and once again fully inhaled through the spacer and
held their breath for another 10 seconds. This procedure was then repeated with a
further 2 puffs. The SphygmoCor apparatus was used to measure PWA at the
peripheral site (radial artery) at 5, 10, 15, and 20 minutes of salbutamol
administration. CAIx was derived and the maximum change of CAIx from the
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baseline was compared to that following 25 pg sublingual GTN, as a measure of
endothelium-independent vasodilatation (Wilkinson et al., 2002a). The PWA
recordings for GTN were made at 3, 5, 10, 15, and 20 minutes post dose.
2.7 Assessment of arterial calcification
The presence and quantity of coronary artery calcification (CAC) was determined by
a 16-slice multi-detector computed tomography (MDCT) (Toshiba, Aquilion 16).
Imaging was applied when the patient lies supine. No contrast was used.
Tomographic imaging was preceded from the level of the lower margin of the
bifurcation of the main pulmonary artery to the diaphragm. The CAC score was
calculated using a semi-automated computer software programme (3D Vitrea
Workstation, Vital system) based on the total amount and density of the calcific
deposits found in the four branches of the coronary arteries (left main, left anterior
descending, circumflex, and right coronary artery). The final CAC score of each
patient was reported as a combination of the CAC scores of the four branches of the
coronary arteries as previously described by Agatston (Agatston et al., 1990) (Figure
2.4, Table 2.1). The radiologist who performed the test was blinded to the stages of
CKD and all of the procedures were conducted by one radiologist. This technique is
the most accurate technique available for calcium quantification and is reproducible.
It provides a quantitative evaluation of the extent of plaque burden as the
calcification of the coronary arteries closely correlates with the presence of
calcification in the aorta (Dellegrottaglie et al., 2005).
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Figure 2.4 Coronary artery calcium score calculation.
Key: Circles indicate coronary arteries. CX; circumflex artery; LAD: left anterior descending
artery; LM: left main artery; RCA: right coronary artery.
Table 2.1 An example of a coronary artery calcium score report in one subject of the
study presented in this thesis (Agatston score is the final score reported to
physician).
Name Voxel Volumefmm3) Plaque Agatston score
LM 0 0 0 0
LAD 223 163.92 2 218.6
LCX 14 10.29 3 5.9
RCA 161 118.35 7 117.9
Total 398 292.56 12 342.4
Key: LAD: left anterior descending artery; LCX; left circumflex artery; LM: left main artery;
RCA: right coronary artery; Voxel: volumetric pixel (a volume element, representing a value
on a regular grid in three dimensional space).
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2.8 Diagnosis of the metabolic syndrome
The metabolic syndrome was diagnosed using the NCEP-ATP III criteria (Table 2.2)
(Anonymous, 2002b). The diagnosis of the metabolic syndrome was made when
subjects had >3 risk factors for the metabolic syndrome. Subjects with 0-1 risk
factors for the metabolic syndrome were regarded as those without the metabolic
syndrome. Subjects with 2 risk factors for the metabolic syndrome were regarded as
those at risk of developing metabolic syndrome.
Table 2.2 The NCEP ATP III criteria for clinical diagnosis of the metabolic syndrome.
Risk factors Defining level
Blood pressure
Fasting glucose
>130 / > 85 mmHg
> 6.0 mmol/L












Key: No metabolic syndrome: subjects with 0-1 risk factor; risk for developing the metabolic
syndrome: subjects with 2 risk factors; metabolic syndrome: subjects with >3 risk factors.
2.9 Assays
2.9.1 General blood and urine samples
Blood samples were taken from subjects into the appropriate blood tubes (Sarstedt)
and analysed for full blood count, erythrocyte sedimentation rate (ESR), folate, urea,
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creatinine, sodium, potassium, bicarbonate, albumin, calcium, phosphate, glucose,
haemoglobin AiC (HbAiC), insulin, urate, total cholesterol, triglycerides, and HDL
cholesterol. These samples were analysed by the Haematology and Biochemistry
laboratories at the Western General Hospital. Plasma concentrations of parathyroid
hormone (PTH) were analysed by the Haematology and Biochemistry laboratories at
the Royal Infirmary of Edinburgh. Plasma concentrations of vitamins (vitamin A,
B1, B2, B6, C, and E) and trace elements (Zn, Cu, Se, and Mn) were analysed by the
Department of Clinical Biochemistry, Glasgow Royal Infirmary.
LDL cholesterol was calculated using Friedewald's formula (Friedewald et al.,
1972). LDL cholesterol (mmol/L) = total cholesterol - HDL cholesterol-
[triglycerides / 5]. Insulin resistance was calculated using a homeostatic model
assessment of insulin resistance (HOMA-IR) equation (Wallace et al., 2004).
HOMA-IR = [fasting plasma insulin (mU/L) x fasting plasma glucose (mmol/L)] /
22.5
Urine samples were taken in the plain tubes from subjects and a urinary dipstick was
used to analyse for blood, glucose and protein (Multistix 10 SG reagent strips for
urinalysis, Siemens Healthcare Diagnostics Inc). Urine samples were also analysed
for urinary albumin and creatinine, by the Haematology and Biochemistry
laboratories at the Western General Hospital.
2.9.2 Specific blood and urine samples
For the measurement of IL-6, ADMA, SDMA, ET-1, and big ET-1, blood samples
were collected into EDTA tubes (Sarstedt). For the measurements of hsCRP and
OxLDL blood samples were collected into plain tubes (Sarstedt). For the
measurement of 8-Isop, blood sample were collected into ice-cold EDTA tubes
(Sarstedt) containing 1 mg/ml of reduced glutathione (Mori et al., 1999). All blood
samples were centrifuged immediately at 2500g at 4°C for 20 minutes. Plasma for 8-
Isop analysis was stored in plain tubes containing 200 pg/ml of butylated hydroxy
toluene to prevent further oxidation (Mori et al., 1999) and stored at -80°C until
analysis. The remainder of the plasma and serum samples were also stored in plain
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tubes at -80°C until analysis. 20 ml aliquots of urine were collected into plain tubes
containing 2.5 ml of acetic acid for the measurement of urinary ET-1 and store at -
80°C until analysis.
For all assays, reagents and samples were brought to room temperature prior to
assay. The water used to prepare all reagents was deionised and free of trace organic
contaminants. For enzyme-linked immunosorbant assay (ELISA), all standards,
quality controls and samples were assayed in duplicate.
2.9.2.1 Plasma interleukin-6
Plasma IL-6 was quantified in the Vascular Biology Centre, Medical College of
Georgia, USA, using a commercially available sandwich ELISA (Cayman Chemical,
Ann Arbor, MI). Prior to addition to the assay, the plasma samples were diluted with
a dilution buffer (2x). Also, plasma samples and standards were purified by the
addition of a non-specific mouse immunoglobin (25 pi of the mouse serum for each
500 pi of sample or standard) in order to compensate for the effects of human anti-
mouse IgG which may be present in the samples.
100 pi of standards, quality controls, dilution buffer (= blank), and diluted samples
were added to appropriate wells of a microplate pre-coated with monoclonal
antibody specific for IL-6 which will bind any IL-6 introduced into the well. 100 pi
of an acetylcholinesterase conjugate, which binds selectively to a different epitope
on the IL-6 molecule, was then added to the well. The microplate was covered with
plastic film and incubated overnight at 25°C. After being washed 5 times with an
automatic washer, the concentration of the analyte was then determined by
measuring the enzyme activity of the acetylcholinesterase by adding 200 pi of
Ellman's reagent to each well. The product of the acetylcholinesterase-catalysed
reaction has a distinct yellow colour. The optimum assay development was detected
after 180 minutes incubation. The intensity of this colour was determined by
spectrophotometry (wavelength 405 nm) and was directly proportional to the amount
of bound conjugate which in turn was proportional to the concentration of IL-6. The
concentration of IL-6 was obtained by automatic calculations. Concentrations of
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plasma IL-6 were automatically calculated from the standard curve and multiplied by
a dilution factor of 2. The final IL-6 concentration was reported in pg/ml. The
detection limit of the assays was 1 pg/ml. The intra-assay coefficient variation was
5% and inter-assay coefficient variation was 15%.
2.9.2.2 Plasma isoprostane
Plasma 8-Isop was quantified in the Vascular Biology Centre, Medical College of
Georgia, USA. Free 8-Isop was determined by a commercially available competitive
ELISA (Cayman Chemical, Ann Arbor, MI). This method was based on the
competition between 8-Isop and 8-Isop-acetylcholinesterase conjugate (8-Isop
tracer) for a limited number of 8-Isop-specific rabbit antiserum binding sites. As the
concentration of the 8-Isop tracer was held constant while the concentration of the 8-
Isop varied, the amount of 8-Isop tracer that was able to bind to the rabbit antiserum
was inversely proportional to the concentration of 8-Isop in the well.
Samples were purified using a solid phase extraction purification method with a
recovery of more than 90% before starting ELISA. 50 pi of standards, quality
controls, dilution buffer (= blank), and diluted samples were added to appropriate
wells of a microplate pre-coated with rabbit IgG mouse monoclonal antibody. 50 pi
of 8-Isop acetylcholinesterase tracer and then 50 pi of 8-Isop antiserum were added
to each well. The microplate was incubated at 4°C for 18 hours. After being washed
5 times with an automatic washer to remove any unbound reagents, 200 pi of
Ellman's reagent which contained the substrate to acetylcholinesterase was added to
the wells. Optimum assay development was detected after 90 minutes of incubation.
The intensity of the colour, determined spectrophotometrically at 405 nm, was
proportional to the amount of 8-Isop tracer bound to the well, which was inversely
proportional to the amount of free 8-Isop present in the well during the incubation -
absorbance cc [bound 8-Isop tracer] cc 1 / [8-Isop]. The detection limit of the assays
was approximately 2 pg/ml. The intra-assay coefficient variation was 9% and inter-
assay coefficient variation was 13%.
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2.9.2.3 Plasma dimethylarginines
Plasma ADMA, and SDMA were determined in the Department of Clinical
Biochemistry at Glasgow Royal Infirmary using an optimised and fully validated
high performance liquid chromatography (HPLC) method (Blackwell et al., 2007).
Briefly, the methylarginines were extracted from plasma using solid phase extraction
on a cation exchange resin. They then underwent isocratic reverse-phase HPLC
(Waters, Watford, UK) utilising pre-column derivatisation with ortho-
phthaldialdehyde and fluorescence detection. Quantification was performed by the
method of internal standardisation using a single level calibration. The detection
limits were 0.04 pmol/L for arginine and 0.004 pmol/L for ADMA and SDMA. The
intra-assay coefficients of variation were 1.9% for ADMA and 1.6% for SDMA. The
inter-assay coefficients of variation were 2.3% for ADMA and 3.1% for SDMA.
2.9.2.4 Plasma and urinary endothelin-1
Plasma ET-1, big ET-1, and urinary ET-1 concentrations were analysed using a
standard radioimmunoassay (Peninsular Laboratories Europe, St. Helens, UK) at the
Clinical Pharmacology Unit, Centre for Cardiovascular Science, Queen Medical
Research Institute, University of Edinburgh.
The very low concentrations of ET-1 and big ET-1 in plasma preclude the direct
measurement of these peptides by radioimmunoassay. Therefore, ET-1 and big ET-1
were extracted from plasma using a sample preparation column, concentrated, and
then the subsequent extract was analysed by radioimmunoassay. The extraction
technique used was an acetic acid extraction described by Rolinski, et al which gave
approximately 89% and 91% of a recovery of ET-1 and big ET-1 from plasma,
respectively (Rolinski et al., 1994). Following the extraction, 100 pi of standards,
samples and controls were incubated overnight with the appropriate antibody. In the
following day, a known concentration of radio-labelled ET-1 or big ET-1 was added
and the tubes were incubated for further 16 hours. On the third day, the immune
complex was precipitated with Amerlex-M donkey anti-rabbit antibody (Amersham
Biosciences UK Ltd, Buckinghamshire, UK). The precipitated were counted in a
gamma counter. A standard curve was constructed and the unknown values were
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calculated from the standard curve. The detection limit was 0.25 pg/ml for ET-1 and
1 pg/ml for big ET-1. This technique had the intra- and inter-assay coefficient
variations of 6.3% and 7.2%, respectively. Urine ET-1 was determined with the same
extraction and radioimmunoassay methods as plasma ET-1.
2.9.2.5 Serum high-sensitivity C-reactive protein
Serum hsCRP was analysed by the Haematology and Biochemistry laboratories at
the Western General Hospital, using a validated latex particle enhanced
immunoturbidimetry technique (Vitros® 5, 1 FS Chemistry Systems, Ortho-Clinical
Diagnostics, Inc., New York, USA). Briefly, the reaction sequence was performed in
two steps. First, samples, standards, and quality controls were mixed with Reagent 1
containing a buffer. Then, to allow the formation of a CRP antigen-antibody
complex, anti-CRP mouse monoclonal antibodies coupled to latex microparticles
(Reagent 2) were added. The turbidity was measured spectrophotometrically at 600
nm. This technique detects CRP at the range of 0.10-15.00 mg/L. The intra- and
inter-assay variations were 2.3% and 5% respectively.
2.9.2.6 Serum oxidised low density lipoprotein
Serum OxLDL was determined in the Clinical Pharmacology Unit, Centre for
Cardiovascular Science, University of Edinburgh, using a commercially available
sandwich ELISA (Mercodia AB, Uppsala, Sweden). Serum samples were diluted
(6,56 lx) with a dilution buffer. 25 pi of standards, quality controls, dilution buffer (=
blank), and diluted samples were added to appropriate wells of a microplate pre-
coated with mouse monoclonal anti-OxLDL. 100 pi of assay buffer was then added
to each well. The microplate was incubated at 25°C, on an orbital microplate shaker
(600 rpm) for 2 hour. After being washed 6 times (0.35 ml ofwash solution per well)
with an automatic washer, 100 pi of enzyme conjugate solution (peroxidise
conjugated mouse monoclonal anti-apoB) was added to the wells and incubated at
25°C, on an orbital microplate shaker (600 rpm) for another 1 hour. Following
another washing step, 100 pi of tetramethyl benzidine (TMB) substrate solution was
added to the well and the microplate was incubated at 25°C for 15 minutes without
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shaking. The reaction was then stopped by the addition of 50 pi stop solution (0.5 M
H2SO4). The optical density was then read at 450 nm within 30 minutes. The
absorbance was proportional to the concentration of OxLDL. The concentration of
OxLDL was obtained by automatically calculating of the absorbance for the
standards versus the concentration, using cubic spline regression. The concentrations
obtained from a standard curve (mU/L) were multiplied by the dilution factor of
6,561. The final OxLDL concentrations were reported in U/L. The limit of detection
of the assays was 1 mU/L. The intra-assay coefficient variation was 7.3% and inter-
assay coefficient variation was 8.3%.
2.9.2.7 Serum fetuin-A
Serum fetuin-A was analysed in the Clinical Pharmacology Unit, Centre for
Cardiovascular Science, University of Edinburgh, using a commercially available
sandwich ELISA (BioVendor GmbH, Heidelberg, Germany). 100 pi of diluted
standards, quality controls, dilution buffer (= blank), and diluted samples were added
to appropriate wells of a microplate pre-coated with polyclonal anti-human fetuin-A
antibody. The microplate was then incubated at 25°C, on an orbital microplate
shaker (300 rpm) for 1 hour. After being washed 3 times (0.35 ml of wash solution
per well) with an automatic washer, 100 pi of polyclonal anti-human fetuin-A
antibody, conjugated with horseradish peroxidise was added to the wells and
incubated at 25°C, on an orbital microplate shaker (300 rpm) for another 1 hour
with captured fetuin-A. Following another washing step, the remaining horseradish
peroxidise conjugate was allowed to react with 100 pi of substrate solution TMB
(incubation at 25°C for 10 minutes, without shaking). The reaction was then stopped
by addition of 100 pi acidic stop solution. The absorbance of the resulting yellow
product was measured spectrophotometrically at 450 nm within 5 minutes. The
absorbance was proportional to the concentration of fetuin-A. The microplate reader
performed automatic calculations of analyte concentration. The standard curve was
constructed by plotting the mean absorbance at 450 nm of standards against a log of
the known concentration of standards. Results calculated from a standard curve were
concentrations of fetuin-A in ng/ml and these were multiplied by their respective
dilution factor of 10,000 (e.g. 21.5 ng/ml (from standard curve) x 10,000 (dilution
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factor) = 215.0 ug/ml or 0.215 g/L). The final fetuin-A concentrations were reported
in g/L. The limit of detection of the assays was 0.35 ng/ml. The intra-assay
coefficient variation was 4.8% and the inter-assay coefficient variation was 5.4%.
2.10 Drugs
2.10.1 BQ123
BQ123 (Clinalfa AG) was used as a selective ETa receptor antagonist. It is a
synthetic derivative of BE 18257B, a product of Streptomyces misakiensisis and is a
cyclic pentapeptide that is highly selective for the ETA receptor (IC50: ETA = 7.3
nM, ETb = 18 pM) (Ihara et al., 1992). Studies with radiolabeled BQ123
demonstrate that it binds competitively to the ETA receptor, achieving steady state
within 7 minutes of injection and dissociates with a half-life of 1.4 minutes (Ihara et
al., 1995). It is extracted from the circulation by the hepatic anion transport system
(Fukami et al., 1996). The dose of BQ123 infused (1000 nmol/min for 15 minutes)
was selected from previous studies as being ETA selective based on plasma BQ123
concentrations and relating these to the binding constant for the ETA receptor, as
well as by a lack of rise in plasma ET-1 concentration after its infusion (Goddard et
al., 2004b). BQ123 was dissolved in 15 ml of 0.9% physiological saline (Baxter
Healthcare Ltd) and infused intravenously at a constant rate of 1 ml/min.
2.10.2 Glyceryl trinitrate
GTN was administered sublingually for the assessment of the endothelium-
independent vasomotor function following FMD and a reduction of arterial wave
reflection after inhaled salbutamol. The dose of 25 pg was used according to the
study which showed that this dose gave a response that was comparable to that of the
higher dose (Oliver et al., 2005).
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2.10.3 Salbutamol
The salbutamol 400 |ug inhaler (Allen & Hanbury, Stockley Park, UK) was used in
the studies. Salbutamol was administered through a spacer device (Volumetric®
Allen & Hanbury, Stockley Park, UK). The dose of salbutamol was based on a
previous study by Wilkinson, et al (Wilkinson et al., 2002a).
2.10.4 Nifedipine
The calcium channel blocker, nifedipine (10 mg Adalat, Bayer; immediate release),
was obtained from the Pharmacy Department at the Western General Hospital, and
was used as an active control for the study in Chapter 9. It was administered orally.
2.10.5 Para-aminohippurate
Para-aminohippurate (PAH) sodium (Clinalfa) was used for the measurement of
renal plasma flow for studies in Chapter 9 by standard clearance techniques
(Levinsky et al., 1973). PAH is an inert and non-toxic compound that is both filtered
at the glomerulus and actively secreted by the proximal tubules, reaching the kidney
only via the blood stream. The extraction by the kidneys in a single transit is not
complete (the full criteria for a marker of renal blood flow by clearance), but about
80-90%, thus measurements are quoted as 'effective' renal plasma flow (ERPF).
This extraction is not affected by BQ123 in man (Bohm et al., 2003).
Chemical name: Sodium salt of para-amino hippuric acid
Formulation: Injection, l.lg in 5.5 ml (protect from light)
Renal Blood Flow:
Effective renal plasma flow (ERPF) was estimated, using the Fick principle, from
measurement of PAH clearance. Effective renal blood flow (ERBF) was then
calculated as:
-67-
ERBF = ERPF/ 1- haematocrit
A constant infusion technique was used for the measurement of PAH clearance. A
bolus dose in 100 ml of 5% dextrose was given over 15 minutes. This was followed
by a continuous infusion of PAH in 5% dextrose at 2 ml/min (= 120 ml/hr). The aim
was to achieve a constant plasma concentration of between 15 and 20 mg/1, at which
concentration, the above extraction ratio applied (ie. almost complete extraction).
Higher concentrations would saturate tubular transport capacity and led to
progressive reductions in clearance and extraction. Assuming a volume of
distribution of 28% of body weight for PAH (Smith, 1951), the loading dose was
calculated as:
Plasma concentration = Dose / Volume of distribution = Dose / Weight x 0.28
Thus for an 80 kg volunteer, the loading dose was 15 to 20 x (80 x 0.28) = 336 to
448 mg.
Assuming that all PAH is cleared renally from the plasma compartment, the
maintenance dose was calculated as:
Clearance = ERPF = (Infusion concentration x Infusion rate)/ plasma concentration
Using a normal ERPF value of 675 ml/min (for men), an infusion rate of 2 ml/min
and a plasma concentration of 15 to 20 mg/1, the infusion concentration was
therefore,
(675 ml/min x 15 to 20 mg/1) / 2 ml/min
= 5063 to 6750 mg/1
= 5.06 to 6.75 g/1 (=10.1 to 13.5 mg/min)
An equilibration period of 120 minutes was allowed to achieve a steady state and
thus enable venous sampling rather than arterial sampling to be employed. Previous
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work has shown that 100 minutes was sufficient to achieve a stable plasma
concentration of PAH.
In summary:
• Loading dose of PAH = 0.4 g (2ml) in 100ml of 5% dextrose over 15 min
• Maintenance infusion ofPAH = 6.6 g/1 (33ml) at an infusion rate of 2 ml/min
For subjects with a GFR >30 to <50 ml/min, the maintenance dose was reduced by a
third.
• Loading dose of PAH: 0.4 g (2ml) in 100ml of 5% dextrose over 15 min
• Maintenance infusion ofPAH: 4.4 g/1 (22ml) at an infusion rate of 2 ml/min
For subjects with a GFR <30 ml/min the maintenance dose was reduced by two
thirds.
• Loading dose ofPAH: 0.4 g (2ml) in 100ml of 5% dextrose over 15 min
• Maintenance infusion of PAH: 2.2 g/1 (11ml) at an infusion rate of 2 ml/min
2.10.6 Inulin
Inutest (Fresenius Pharma, Austria, GmbH) was used for the measurement of GFR
for studies in Chapter 9 by standard clearance techniques (Levinsky et al., 1973).
Inulin is an inert and non-toxic complex polyfructose with a molecular weight of
5,200 daltons. It is not protein bound, is freely filtered at the glomerulus, is neither
secreted nor reabsorbed within the tubules, nor metabolised within the kidney and
thus fulfils the criteria for the measurement of GFR by clearance measurements. Its
problems with solubility have been over come by the introduction of Sinistrin
(Inutest) arelated polysaccharide with identical clearance.
Chemical name: Sinistrin
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Formulation: Injection, 5g in 20 ml (25%)
Glomerular Filtration Rate (GFR)
GFR was calculated as follows:
GFR = (Urine concentration of Inutest x Urine flow rate) / Plasma concentration of
Inutest
A constant infusion technique was used for the measurement of Inutest clearance. A
bolus dose in 100 ml of 5% dextrose was given over 15 minutes. This was followed
by a continuous infusion of Inutest in 5% dextrose at 2 ml/min (= 120 ml/hr). The
aim was to achieve a constant plasma concentration of between 200-250 mg/1.
Assuming a volume of distribution of 12-18% of body weight for Inutest, (Inutest
25% Summary of product characteristics, Fresenius-GmbH, Linz) the loading dose
was calculated as:
Plasma concentration = Dose / Volume of distribution = Dose / Weight x 0.12 to
0.18
Thus for an 80 kg volunteer, the loading dose was 250 x (80 x 0.12 to 0.18) = 2400
to 3600 mg = 2.4 - 3.6 g/1
Assuming that all Inutest is cleared renally from the plasma compartment, the
maintenance dose was calculated as:
Clearance (= GFR) = (Infusion concentration x Infusion rate) / Plasma concentration
Using a normal GFR value of 100 ml/min (for men), an infusion rate of 2 ml/min
and a plasma concentration of 200-250 mg/1, the infusion concentration was thus
(100 ml/min x 200 to 250 mg/1) / 2 ml/min
= 10000 to 12500 mg/1
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= 10 - 12.5 g/1 (= 20 - 25 mg/min)
An equilibration period of 120 minutes was allowed to achieve a steady state and
thus enable venous sampling rather than arterial sampling to be employed. Previuos
work has shown that 100 minutes was sufficient to achieve a stable plasma
concentration of Inutest.
In summary
• Loading dose of inutest = 3.5 g (14ml) in 100ml 5% dextrose over 15 min
• Maintenance dose of inutest = 10 g/1 (40ml) at an infusion rate of 2 ml/min
For subjects with a GFR >30 to <50 ml/min, the maintenance dose was reduced by a
third.
• Loading dose of inutest = 3.5 g (14ml) in 100ml 5% dextrose over 15 min
• Maintenance dose of inutest: 6.7 g/1 (26.7ml) at an infusion rate of 2 ml/min
For subjects with a GFR <30 ml/min the maintenance dose was reduced by two
thirds.
• Loading dose of inutest: 3.5 g (14ml) in 100ml 5% dextrose over 15 min
• Maintenance dose of inutest: 3.3 g/1 (13.3ml) at an infusion rate of 2 ml/min
2.11 Data analysis
Descriptive statistics were presented as mean ± SD (range) unless otherwise
indicated. Microsoft Excel 2003 for Windows and SPSS version 15.0 for Windows
(SPSS Inc., Chicago, USA) were used for statistical analyses. For categorical data,
means were compared by a one-way analysis of variance (ANOVA), Kruskal-Wallis
test, the unpaired Student's t-test, and the Mann-Whitney test where appropriate.
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For Chapters 5 to 7, all data were entered into univariate analysis. This was to
explore associations of each variable in the data set separatedly. Correlation
coefficeints were calculated using the Pearson method. Significant correlations seen
with univariate analysis were presented graphically.
They were then further analysed by multivariate analysis using a stepwise linear
regression to assess how dependent variable (CF-PWV or FMD) change when
anyone of the independent variable (each of the traditional or emerging
cardiovascular risk factors or GFR entered into a regression model) is varied.
Approximately 10 independent variables were allowed to enter into one multivariate
analysis model. Therefore, data were grouped and presented in different chapter
(Chapter 5 to 7). Each chapter focuses on different aspects of emerging
cardiovascular risk factors (as independent variables) on CF-PWV and FMD (as
dependent variables) (Table 2.3). More details were described in the methodology
section of each chapter.
Table 2.3 Independent variables on focus of Chapters 5 to 7.
Chapter Independent variables on focus
Chapter 5 Traditional cardiovascular risk factors and GFR
Chapter 6 Traditional cardiovascular risk factors, GFR and emerging
cardiovascular risk factors (NO/ET-1 balance, inflammation and
oxidative stress)
Chapter 7 Traditional cardiovascular risk factors, GFR and




In order to assess the contribution of emerging cardiovascular risk factors on CF-
PWV and FMD, the first multivariate analysis model was set to comprise only the
traditional cardiovascular risk factors and GFR. Then the emerging cardiovascular
risk factors were added to the multivariate anaylsis and presented in a separate
model. The multiple coefficient of determination (r2) of each model was reported.
Multivariate analysis data were reported for both CF-PWV and FMD using standard
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regression coefficient (/? value) of independent variables. For all analyses, a p value
of < 0.5 was considered significant.
For the reproducibility test (Chapter 3), 95% limits of agreement were used to assess
the repeatability of the two measurements. This means that only 5% of the pairs of
measurements on the same subject would fall outside of the 95% limit of agreement.
Means and SDs of the differences between the two measurements were calculated
and the 95% limit of agreement was defined as mean difference ± 2SDs.
Reproducibility data was also presented graphically as plots of the difference
between the two measurements against the mean of the measurements (Bland-




Two reproducibility studies were performed and they are considered separately in
this chapter. The first study assessed the intra- and inter-observers reproducibility of
PWV and AIx determined using the SphygmoCor system. The second study
investigated the intra- and inter-observers reproducibility of the brachial artery FMD.
3.1 Reproducibility of carotid-femoral pulse
wave velocity and central augmentation index
3.1.1 Background
Arterial stiffness is highly associated with cardiovascular disease and its risk factors
(Cockcroft et al., 1997; Nichols, 2005; Wilkinson et al., 2000; Wilkinson et al.,
2002b; Yasmin et al., 2004). Therefore, measuring or monitoring arterial stiffness
may allow early identification of a subject at risk, to whom intervention might be of
most benefit (Cockcroft et al., 1997; Guerin, 2001). Two of the most widely used
non-invasive techniques for measuring arterial stiffness are PWV and AIx, assessed
using the SphymoCor system (Oliver et al., 2003b). These techniques were
previously shown to be highly reproducible (Wilkinson et al., 1998). However, prior
to applying the techniques to the series of clinical studies in this thesis, the
reproducibility of the techniques should be tested to assure the validity of the
measurements.
3.1.2 Aims and hypotheses
The aims of this study were to assess the reproducibility of CF-PWV and CAIx
determined using the PWA technique. The hypotheses were that CF-PWV and CAIx





Healthy volunteers were recruited from staff at the Clinical Research Centre and
medical students at the University of Edinburgh. The inclusion criteria were healthy
males or females, aged 18-50 years. Subjects with a history of major cardiac,
respiratory, neurological, diabetic, or renal disease were excluded. None of them
were on any medication.
3.1.3.2 Study protocol
CF-PWV and CAIx were measured using the PWA technique, after 20 minutes of
supine rest. Two observers made two measurements of each, in a random order.
First, CAIx, was measured, followed by CF-PWV. For CF-PWV, each observer
recorded a surface distance independently.
3.1.3.3 Data analyses
Values are presented as mean ± SD (range). A paired Student's /-test was used to
compare differences in the measurements between observers 1 & 2. Intra- and inter-
observer variabilities were reported as mean difference ± SD of the difference and
the reproducibility was also presented graphically as Bland-Altman plots (plots of
the difference between the two measurements against the mean of the
measurements). 95% limit of agreement (mean difference ± 2SDs of the difference)
was used to assess the reproducibility of the measurements within the graph (Bland
et al., 1986). If two measurements are reproducible, the mean difference should be
close to zero and all data should be within 2SDs of the difference.
3.1.4 Results
17 healthy subjects (male/female = 6/11), aged 28±7 years (range 21 - 40 years),
were recruited. Baseline SBP and DBP were 105+10 and 60±1 mmHg, respectively.
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3.1.4.11ntra-observer reproducibility
There were no differences between the means of the 1st & 2nd CF-PWV and CAIx
measurements for both observers (Table 3.1). The intra-observer variability for CF-
PWV was -0.2±0.5 m/s (95% limit of agreement: -1.2 to 0.9) and 0.1±0.9 m/s (95%
limit of agreement: -1.7 to 1.9) for observer 1 and observer 2, respectively. The intra-
observer variability for CAIx was 1±8 % for observer 1 (95% limit of agreement: -14
to 16) and 2+6 % for observer 2 (95% limit of agreement: -10 to 15). Bland-Altman
plots showed that most of CF-PWV and CAIx measured by both observers were
within 95% limit of agreement (Figures 3.1 A-D).
Table 3.1 CF-PWV and CAIx measured by 2 observers.
CF-PWV (m/s) CAIx (%)
Observer 1 Observer 2 Observer 1I Observer 2
1st measurement 7.9+1.1 7.6+1.0 12+13 11+13
(5.5-9.6) (5.4-8.8) (2-49) (-7-45)
2nd measurement 8.0+1.1 7.5+1.0 11+13 8+14
(5.9-9.7) (5.6-9.2) (-13-42) (-13-48)
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Figure 3.1 Bland-Altman plots presenting intra-observer reproducibility of CF-PWV
and CAIx.
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Key: Dotted lines represent the 95% limit of agreement (mean difference ± 2SDs of the
difference).
3.1.4.2 Inter-observer reproducibility
The pooled data of each observer was analysed for inter-observer reproducibility.
Overall, CF-PWV and CAIx measurements of observer 1 were higher than those of
observer 2 (Table 3.2). The inter-observer variability for CF-PWV was -0.4±0.8 m/s
(95% limit of agreement: -1.2 to 1.9). The inter-observer variability for CAIx was
3±6 % (95% limit of agreement: -9 to 14). The Bland-Altman plots showed that most
data was within 95% limit of agreement (Figures 3.2 A&B).
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Table 3.2 Pooled CF-PWV and CAlx measured by 2 observers.
CF-PWV (m/s)* CAlx (%)*
Observer 1 7.9+1.1 (5.5 - 9.7) 12+13 (-13-49)
Observer 2 7.5+1.0 (5.4 - 9.2) 9+13 (-13-48)
Key: *p < 0.01 observer 1 versus observer 2.
Figure 3.2 Bland-Altman plots presenting inter-observers reproducibility of CF-PWV
and CAlx.
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Key: Dotted lines represent the 95% limit of agreement (mean difference ± 2SDs of the
difference).
3.1.5 Discussion
Main findings: The findings indicate that CF-PWV and CAlx determined by the
PWA technique are reproducible.
The reproducibility shown in this study is in accordance with previous reports on
healthy subjects (Crilly et al., 2007; Liang et al., 1998; Papaioannou et al., 2007;
Paul et al., 2009; Siebenhofer et al., 1999; Wilkinson et al., 1998), renal patients
(Frimodt-Moller et al., 2008; Savage et al., 2002) and patients with cardiovascular
disease (Adji et al., 2006; Papaioannou et al., 2004; Paul et al., 2009; Wilkinson et
al., 1998).
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In several previous studies, reproducibility of the measurements was reported as a
coefficient of variation (CV). However, it has been demonstrated that CV can be
misleading and is, therefore, a less satisfactory method for assessing reproducibility
(Bland et al., 1986). The reproducibility reported as SD of the difference between the
paired measurements and the Bland-Altman plots which were used in this study are
more reliable (Bland et al., 1986). Table 3.3 summarises reproducibility data from
previous studies which use SD of the difference to evaluate reproducibility. From
this data, it is clear that the reproducibility of PWV in the current study is better than
others.
Of note, in this study, PWV assessed using the PWA technique proved to be more
reproducible than AIx for either the inter- or intra-observer measurements. This is in
contrast to data from a previous study in which PWV was reported to be less
reproducible than AIx (Wilkinson et al., 1998), but in keeping with recent findings
from a study in CKD patients (Frimodt-Moller et al., 2008). The higher variability of
AIx seen in this study could probably be explained by the variability in the quality of
the pressure waveforms obtained between the two observers.
Summary: PWV and AIx obtained by the PWA technique are reproducible and,
with well-trained individuals, are suitable to be incorporated into large-scale clinical
studies as simple, non-invasive measurements of arterial stiffness.
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This study: healthy subjects Observer 1: 8.0
Observer 2: 6.0
6.0
(Wilkinson et al., 1998): healthy subjects and
patients with hypertension and
hypercholesterolaemia
5.4 3.8
(Siebenhofer et al., 1999): healthy subjects
(Savage et al., 2002): CKD stages 1 - 5, dialysis,




(Papaioannou etal., 2004): patients with
cardiogenic shock and acute myocardial infarction
5.8
(Crilly et al., 2007): healthy subjects Observer 1: 2.7 2.0
Observer 2: 3.7
(Frimodt-Moller et al., 2008): CKD stages 3 - 5 Observer 1: 18.8 15.8
Observer 2: 10.6
Key: Alx: augmentation index; PWV: pulse wave velocity.
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3.2 Reproducibility of brachial artery flow-
mediated dilatation
3.2.1 Background
Endothelial dysfunction is involved in the pathogenesis of a vascular disease
(Glasser et al., 1996). Brachial artery FMD is a widely used non-invasive measure of
the endothelial-dependent vasomotor function of a conduit artery (Corretti et al.,
2002). This technique uses a shear stress from the flow of blood as a physiological
stimulus for NO generated vasodilatation. Impaired FMD is associated with
atherosclerosis and cardiovascular disease risk factors (Brunner et al., 2005;
Celermajer et al., 1992). Although FMD was shown to be reproducible in some
studies (Bots et al., 2005; Donald et al., 2006; Simova et al., 2008), the limitations
of FMD are the variability among study centres in both the procedural technique and
the analysis of an ultrasound image. Therefore, the reproducibility of FMD was
assessed to assure the validity of the measurements in the series of clinical studies
presented in this thesis.
3.2.2 Aims and hypotheses
The aim of this study was to assess the reproducibility of the brachial artery FMD in
CKD patients. The hypothesis was that FMD was reproducible for one observer with
repeated measurements, and for two separate observers.
3.2.3 Methods
3.2.3.1 Subjects
Patients were sub-recruited from a study to investigate arterial stiffness and
endothelial dysfunction in CKD. The inclusion and exclusion criteria for the patients
was fully described in Chapter 2, section 2.1.1.
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3.2.3.2 Study protocol
The brachial artery FMD was recorded after 20 minutes of supine rest. Two
observers performed FMD measurements on the same subjects but on different days.
One observer repeated FMD measurements on the same subjects 2 hours after the
first measurements were made, in order to assess intra-observer reproducibility.
3.2.3.3 Data analyses
Values are presented as mean ± SD (range). A paired Student's /-test was used to
compare the differences in the measurements between observers 1 & 2. Intra- and
inter-observer variability was reported as the mean difference ± SD of the difference
and the reproducibility was also presented graphically as the Bland-Altman plots
(plots of the difference between the two measurements against the mean of the
measurements). 95% limit of agreement (mean difference ± 2SDs of the difference)
was used to assess reproducibility of the measurements within the graph (Bland et
al., 1986). If two measurements are reproducible, the mean difference should be
close to zero and all data should be within 2SDs of the difference.
3.2.4 Results
Sixteen CKD patients (male/female = 13/3) with eGFR of 50 ± 24 ml/min/1.73m2
(range: 22 - 108 ml/min/1,73m2) were enrolled onto the study. Age was 44 ± 10
years. SBP and DBP were 118111 and 76 ± 9 mmHg, respectively.
3.2.4.11ntra-observer reproducibility
There were no differences between the means of the first and second FMD measured
by the same observer (Table 3.4). The intra-observer variability for FMD was -0.5 ±
1.4 m/s (95% limit of agreement: -3.4 to 2.3). The Bland-Altman plots showed that
data was within 95% limit of agreement (Figure 3.3).
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Table 3.4 FMD measured by observer 1 at 0 and 2 hours.
FMD (%)
1st measurement (at 0 hour) 4.5 ±3.2 (0.6-■ 12.7)
2nd measurement (at 2 hour) 5.0 ±3.3 (0.8-■ 12.8)
Figure 3.3 Bland-Altman plot presenting intra-observer reproducibility of FMD.









4 I i i i i i i i
0 2 4 6 8 10 12 14
Average
Key: Dotted lines represent the 95% limit of agreement (mean difference ± 2SDs of the
difference).
3.2.4.2 Inter-observer reproducibility
There were no differences between the FMD measured by observer 1 & 2 (Table
3.5). The inter-observer variability for FMD was -0.1 ±3.4 m/s (95% limit of
agreement: -6.8 to 6.7). The Bland-Altman plots showed that most data was within
95% limit of agreement (Figure 3.4).
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Table 3.5 FMD measured by observer 1 and 2.
FMD (%)
Observer 1 4.5±3.2 (0.6-12.7)
Observer 2 4.6±3.6 (-0.4-14.8)
Figure 3.4 Bland-Altman plot presenting inter-observer reproducibility of FMD.
Between Observers - FMD
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Key: Dotted lines represent the 95% limit of agreement (mean difference ± 2SDs of the
difference).
3.2.5 Discussion
Main findings: The findings indicate that the brachial artery FMD is a reproducible
technique to assess endothelial function in CKD patients.
Evidence has shown that the brachial artery FMD technique is a reproducible non¬
invasive technique for assessing endothelial vasomotor function. These include
studies on healthy subjects (De Roos et al., 2003; Donald et al., 2006; Donald et al.,
2008; Hardie et al., 1997; Harris et al., 2006; Liang et al., 1998; Malik et al., 2004;
Sorensen et al., 1995), overweight subjects (Harris et al., 2007), and patients with
cardiovascular disease (Simova et al., 2008). Unfortunately, most previous studies
reported their reproducibility data in CV, with a wide range of CV from very low
(1.8%) (Sorensen et al., 1995) to very high (50.3%) (De Roos et al., 2003), and that
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data, therefore, cannot be compared directly to the findings from this study.
Moreover, as discussed in section 3.1.5 of this Chapter the reproducibility presented
in SD of the difference between paired measurements and the Bland-Altman plots as
used in this study are more reliable than CV (Bland et al., 1986). Table 3.6 presents
reproducibility data from previous studies that use SD of the difference to evaluate
reproducibility. Here, the reproducibility data of the current study is comparable to
others.





This study: CKD patients 1.4 3.4
(Hardie et al., 1997): healthy subjects 2.1 2.2
(Donald ef a/., 2008): healthy subjects 1.1
(Simova et al., 2008): patients with 1.2 1.6
cardiovascular disease
Key: FMD: flow-mediated dilatation.
Summary: This study has demonstrated that FMD is a reproducible technique for
assessing endothelial vasomotor function in CKD patients and it is suitable to be





endothelin-1 in chronic kidney
disease
4.1 Introduction
The ETs are a family of peptides consisting of 21 amino acid residues first identified
in 1988 (Yanagisawa et al., 1988). ET-1 is produced both within the vascular
endothelial cells (Dhaun et al., 2006) and is the principal endogenous vasoconstrictor
among the ET family (Yanagisawa et al., 1988). Todate, it is now recognised that
vascular smooth muscle cells, macrophages, leucocytes, cardiomyocytes and
fibroblasts are all capable of ET-1 production (Kirkby et al., 2008). Direct actions of
ET-1 on vascular smooth muscle cell are contraction, proliferation, and migration of
vascular cells (Kirkby et al., 2008). Several clinical studies have demonstrated the
role of ET-1 in the control of vascular tone, at least in healthy subjects (Haynes et
al., 1994) and hypertension (Cardillo et al., 1999; Taddei et al., 1999). ET-1,
abluminally released from endothelial cells, acts primarily as a local autocrine and
paracrine substance. Thus, circulating levels of ET-1 represent an overflow of tissue-
bound ET-1. This means that plasma ET-1 concentrations are not a reliable measure
of vascular ET-1 production in the vasculature (Haynes et al., 1998).
ET-1 is also produced within the kidney. Tubular epithelial cells, mesangial cells and
podocytes are capable of ET-1 production (Kohan, 1997). Infact, the kidney contains
the highest concentration of ET-1 compared to any other organs. Importantly,
evidence suggest that vascular and renal ET-1 are two independent systems and
urinary ET-1 may represent ET-1 renal production (Benigni et al., 1991).
Clearance of ET-1 occurs largely in the lungs by endocytosis and degradation of the
ETb receptor-ligand complex (Dupuis et al., 1996). However, 10% of circulating
ET-1 is removed from the human circulation via the kidneys (Gasic et al., 1992)
either by glomerular filtration or enzymatic degradation such as neutral
endopeptidase, the enzyme located in the brush border vesicle of the proximal tubule
(Abassi et al., 1992). The renal ET-1 clearance was also indicated by a study in rats
where rats with bilateral nephrectomy had impaired exogenous ET-1 removal (Shi et
al., 1994).
In renal patients, studies have shown that plasma ET-1 concentrations are increased
in dialysis (Blazy et al., 1994; Demuth et al., 1998; Deray et al., 1992; Koyama et
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al., 1989; Mallamaci et al., 1993; Miyauchi et al., 1991; Saito et al., 1991; Totsune
et al., 1989; Vlassopoulos et al., 1995; Warrens et al., 1990) and pre-dialysis patients
(Blazy et al., 1994; Cottone et al., 2009; Dammers et al., 2005; Deray et al., 1992;
Koyama et al., 1989; Mallamaci et al., 1993; Saito et al., 1991; Vlachojannis et al.,
1997; Vlassopoulos et al., 1995; Warrens et al., 1990). Studies also showed
increased urinary ET-1 excretion in CKD (Cantaro et al., 2001; Goddard et al., 2007;
Ohta et al., 1991). In addition, some studies, but not all (Vlachojannis et al., 1997;
Warrens et al., 1990), suggest that plasma ET-1 concentrations correlate with renal
function (Blazy et al., 1994; Cottone et al., 2009; Dammers et al., 2005; Deray et al.,
1992; Goddard et al., 2007; Mallamaci et al., 1993). A recent study within the
Clinical Research Centre, University of Edinburgh, has demonstrated increases in
plasma and urinary ET-1 concentrations across a range of GFR. Interestingly, this
study also showed a rise in FeET-1 as GFR fell (Goddard et al., 2007). As
previously mentioned that vascular and renal ET-1 are two independent systems.
Assessment of a fractional excretion of ET-1 (FeET-1) would help understand this
hypothesis. FeET-1 is a measure of the amount of ET-1 that leaves the body through
urine compared to the amount of ET-1 filtered and reabsorbed by the kidney.
However, this and other studies were performed on relatively small numbers of
subjects and some were confounded by co-morbidities (Cottone et al., 2009;
Dammers et al., 2005; Deray et al., 1992; Koyama et al., 1989; Ohta et al., 1991;
Vlachojannis et al., 1997; Warrens et al., 1990).
Based on the previous work, it is worth exploring the relationships between plasma
and urinary ET-1 concentrations, FeET-1 and GFR in a larger group of CKD
patients.
4.1.1 Aims and hypotheses
The aims of this study were to investigate the relationship of plasma and urinary ET-
1 concentrations to renal function in a group of CKD patients with minimal co¬
morbidity from CKD stage 1 to pre-dialysis. The hypotheses were that, as a result of
reduced renal clearance and increased renal production, plasma and urinary ET-1




Subjects were recruited from the renal outpatients clinic at the Royal Infirmary of
Edinburgh. Subjects were categorised into 5 groups on the basis of the K/DOQI
classification (Anonymous, 2002a). The aim was to recruit around 30 subjects in
each of the CKD stages 1 to 3, and 30 subjects in stages 4 and 5 combined. Around
30 age-matched healthy volunteers were also enrolled as a control group. The
inclusion and exclusion criteria were as previously described in Chapter 2, section
2.1.1.
4.2.2 Study design and protocol
This was a prospective, cross-sectional study. Subjects refrained from alcohol for at
least 24 hours and caffeinated drinks, food and smoking for at least 12 hours before
the study. Subjects were asked to withhold their current medications on the morning
of the study. All studies were conducted in a quiet, temperature-controlled room.
Following a brief medical inquiry, the body weight and height of the subjects were
recorded. After 30 minutes of supine rest, participants underwent BP measurements.
Blood samples were then taken and urine was collected and tested for plasma and
urinary ET-1, respectively. All sample collection procedures and assays for plasma
and urinary ET-1 were performed as described in Chapter 2.
4.2.3 Data analyses
Descriptive data are given as mean ± SD. FeET-1 was calculated by the equation:
FeET-1 (%) = [(urine ET-1 / plasma ET-1) / (urine creatinine / plasma creatinine)] x
100. Means were compared by the unpaired Student's Mest and one-way ANOVA
where appropriate. Correlation coefficients were calculated using the Pearson
method. A significant level was p value < 0.05.
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4.3 Results
One hundred and forty two subjects took part in the study (115 CKD and 27 matched
non-renal controls). Causes of CKD were autosomal dominant polycystic kidney
disease (n = 26), IgA nephropathy (n = 24), reflux nephropathy (n = 11), chronic
glomerulonephritis (n = 10), noninflammatory glomerular disease (n = 8),
obstructive nephropathy (n = 5), thin basement membrane disease (n = 2), cystinuria
(n = 2), Alport disease (n =1), medullary cystic kidney (n = 1), and CKD with
unknown cause (n = 25).
The characteristics of the subjects are given in Table 4.1. Age, BMI, and BP were
comparable between CKD and non-CKD subjects. CKD patients had higher
concentrations of plasma ET-1, big ET-1, and FeET-1 than of non-CKD subjects.
There was no difference in urinary ET-1 concentrations between CKD and non-CKD
subjects.
Plasma ET-1 and plasma big ET-1 linearly correlated with eGFR (Table 4.2, Figures
4.1 A & B). FeET-1 increased exponentially as eGFR declined (Table 4.2, Figure
4.1C). These correlations hold true even after adjustment for age, SBP, DBP, gender,
total cholesterol, plasma glucose, and BMI. While plasma ET-1 and big ET-1 did not
correlate with age, SBP, DBP, and gender, FeET-1 positively correlated with SBP (r2
= 0.04, p < 0.05). Men had higher FeET-1 than women (3.0 ± 3.3 versus 2.0 ± 2.2 %,
r2= 0.03, p< 0.05).
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Table 4.1 Subject characteristics.
Non-CKD CKD
n 27 115
Age (year) 48±9 (32-64) 47±10 (23-65)
Gender: Male/Female (n) 13/14 77/38
Body mass index (kg/m2) 26±5 (18-46) 2815(19-41)
Systolic blood pressure (mmHg) 110±17 (83-152) 119115 (85-159)
Diastolic blood pressure (mmhlg) 70±10 (54-90) 74+9 (52-96)
Creatinine (mmol/L)* 78±13 (55-98) 1931164 (55-825)







Total cholesterol (mmol/L)** 4.910.8 (3.4-6.5) 4.610.7 (3.0-8.2)
Plasma ET-1 (pg/ml)* 4.611.0 (2.8-7.5) 5.5+1.1 (3.4-9.8)
Plasma big ET-1 (pg/ml)** 42±16 (25-80) 62141 (17-320)
Urinary ET-1 (pg/ml) 5.7+2.9 (1.4-11.3) 6.613.8 (0.9-36.1)
FeET-1 (%)* 1.1+0.7 (0-3.3) 3.0+3.1 (0.2-14.7)
Key: Values are mean+SD (range). *p < 0.01, **p < 0.05 for the unpaired Student's f-test.
ET-1: endothelin-1; FeET-1: fractional excretion of ET-1.
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Table 4.2 Plasma and urinary ET-1 at different eGFRs.
n
Estimated glomerular filtration rate (ml/min/1.73m )
<30 30-60 >60
Plasma ET-1 (pg/ml)* 6.1±1.2 (4.3-8.7) 5.8±1.2 (4.0-9.8) 4.9+1.0 (2.8-7.5)
Plasma big ET-1 (pg/ml)* 73±58 (24-320) 73±39 (28-188) 48±26 (17-178)
Urinary ET-1 (pg/ml) 6.8±2.4 (3.0-13.2) 7.2±5.8 (2.6-36.1) 6.1±2.8 (0.9-13.4)
FeET-1 (%)* 6.8±3.5 (1.0-14.7) 3.2±2.7 (6.0-12.7) 1.1 ±0.7 (0-4.0)
Key: *p < 0.01 for one-way ANOVA by estimated glomerular filtration rate groups. ET-1:
endothelin-1; FeET-1: fractional excretion of ET-1.
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Figure 4.1 Relationships of eGFR to plasma ET-1, big ET-1, and FeET-1.
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In a large cohort of CKD patients without dialysis or established cardiovascular co¬
morbidity, plasma ET-1 increases linearly as renal function declines, whereas FeET-
1 increases exponentially.
The finding that plasma ET-1 concentrations are increased in CKD patients is in
keeping with results from previous studies on dialysis (Blazy et al., 1994; Demuth et
al., 1998; Deray et al, 1992; Koyama et al., 1989; Mallamaci et al., 1993; Miyauchi
et al., 1991; Saito et al., 1991; Totsune et al., 1989; Vlassopoulos et al., 1995;
Warrens et al., 1990) and pre-dialysis patients (Blazy et al., 1994; Cottone et al.,
2009; Dammers et al., 2005; Deray et al., 1992; Koyama et al., 1989; Mallamaci et
al., 1993; Saito et al., 1991; Vlachojannis et al., 1997; Vlassopoulos et al., 1995;
Warrens et al., 1990). Selected previous studies in which the CKD stages were well
defined were presented in Table 4.3 and plasma ET-1 concentrations were compared
to those of this study. The levels of plasma ET-1 in the current study are comparable
to most of the studies shown in Table 4.3.
In addition, this study demonstrates a clear picture of an inverse linear correlation
between plasma ET-1 and renal function, across a wide range of GFR, in a
homogenous group of non-diabetic, low co-morbid CKD population that is
consistent with others (Blazy et al., 1994; Cottone et al., 2009; Dammers et al.,
2005; Deray et al., 1992; Goddard et al., 2007; Mallamaci et al., 1993). The
correlation between plasma ET-1 and plasma big ET-1 as well as the association
between plasma big ET-1 and GFR is consistent with a previous report (Miyauchi et
al., 1991) and could be explained by the fact that plasma big ET-1 is an intermediate
molecule in the synthesis of active ET-1 (Gray et al., 1996). These data support
increased plasma ET-1 concentration either by increased renal or extra renal ET-1
production (from increased levels of big ET-1 seen here) or reduced renal filtration
of ET-1 and thus renal clearance.
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Table 4.3 Comparing plasma ET-1 and FeET-1 with data from previous studies in pre-
dialysis CKD.
Studies Control Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Plasma ET-1 (pg/ml)
This study 4.6
(Cottone et al., 100
2009)
(Dammers et at., 1.9
2005)
(Goddard et al., 4.2
2007)
(Vlachojannis et al., 29
1997)
FeET-1 (%)
This study 1.1 1.1 3.2 6.6
(Goddard et al., 3.5 - 15.2
2007)
(Vlachojannis et al., 10.2 12.0 - - 64.0
1997)
Furthermore, this study shows an exponential rise in FeET-1 as GFR falls which is
consistent with previous reports (Table 4.3) (Goddard et al., 2007; Vlachojannis et
al., 1997). This important observation supports the view that there are two
independently acting ET systems in the systemic circulation and kidney as shown in
animal models (Benigni et al., 1991; Brooks et al., 1991; Wesson, 2001). Benigni, et
al performed isotope studies on rats and found that plasma ET-1 does not account for
urinary ET-1 (Benigni et al., 1991). Brook, et al has demonstrated that plasma ET-1
concentrations were similar between rats with chronic renal failure and control rats,
but there was an increased urinary ET-1 excretion in rats with chronic renal failure,
likely reflecting increased renal production (Brooks et al., 1991). Later, Wesson, et












1 excretion (Wesson, 2001). This data suggests that urinary ET-1 concentrations
represent renal ET-1 production. FeET-1 is theoretically a measure of the amount of
ET-1 that leaves the body through urine compared to the amount of ET-1 filtered and
reabsorbed by the kidney. Although evidence has shown that ET-1 is also cleared
renally, this is not the major route ofET-1 elimination and thus a substantial increase
in FeET-1 in a declining GFR may be more influenced by a marked increase in renal
ET-1 production (Figure 4.2).
Figure 4.2 FeET-1 versus GFR represents that increased urinary ET-1 could be a
result of a reduction in ET-1 renal clearance or an increase in ET-1 renal production.
Low GFR - urinary ET-1 tiff while plasma ET-1 f
Key: TTTT: marked increased, increased.
However, the results also show a positive correlation between BP and FeET-1 and
increasing BP as renal function declines, which may be one of the factors for
increased renal ET-1 production. Moreover, in this study, men had higher FeET-1
than women suggesting that gender may influence renal ET-1 production.
4.4.2 Limitations
As this was a cross-sectional study, the causal relationships behind the associations
described cannot be fully defined. Urinary ET-1 was measured from spot urine, and
therefore urinary ET-1 clearance cannot be calculated.
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4.4.3 Summary
In CKD patients with GFRs ranging between 8 and 154 ml/min/1.73m2, plasma ET-
1 increases in a linear fashion, whereas FeET-1 increases exponentially as GFR
declines. These findings support the view that the upregulation of renal ET-1
generation plays an important role in renal pathophysiology, and therapeutic
strategies such as ET-1 antagonists may offer benefits in CKD.
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Chapter 5
Relationships of renal function




Increased arterial stiffness, as measured by PWV, is a common feature of CKD
(Guerin et al., 2008), a recognised marker of cardiovascular risk (Blacher et al.,
1999a; Guerin et al., 2008), and an independent predictor ofmortality and survival in
dialysis patients (Blacher et al., 1999a; Guerin, 2001). The endothelium is an
important regulator of arterial stiffness (Wilkinson et al., 2004), and endothelial
dysfunction is also a common feature of CKD (Endemann et al., 2004; van Guldener
et al., 1998; van Guldener et al., 1997) and a predictor of cardiovascular disease
(Perticone et al., 2001).
Most studies of arterial stiffness and endothelial dysfunction in CKD involve dialysis
patients, or those with complex co-morbidity, including diabetes mellitus and
established cardiovascular disease, which are themselves associated with arterial
stiffening and endothelial dysfunction (Blacher et al., 1999a; Guerin, 2001; van
Guldener et al., 1998; van Guldener et al., 1997). Evidence suggests an increase in
arterial stiffness and endothelial dysfunction in the early stages of CKD with
progression as GFR falls (Thambyrajah et al., 2000; Wang et al., 2005). However,
these and other such studies again include patients with conventional cardiovascular
risk factors as well as major cardiovascular co-morbidity (Annuk et al., 2001;
Matsuda et al., 2009; Thambyrajah et al., 2000; Wang et al., 2005). Hence, the
contribution of uraemia to arterial stiffness and endothelial dysfunction in CKD
remains unclear.
5.1.1 Aims and hypotheses
The aims of this study were to investigate the relationship of arterial stiffness and
endothelial dysfunction to renal function in a group of CKD patients with minimal
co-morbidity from CKD stage 1 to pre-dialysis.
Hypotheses:
1. Arterial stiffness and endothelial dysfunction would worsen as renal function
declines.
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2. Renal function would predict arterial stiffness and endothelial dysfunction,
independent of conventional risk factors such as age and BP.
5.2 Methods
5.2.1 Subjects
Subjects were recruited from the renal outpatient clinic at the Royal Infirmary of
Edinburgh. Subjects were categorised into 5 groups on the basis of the K/DOQI
classification (Anonymous, 2002a). The aim was to recruit around 30 subjects in
each of the CKD stages 1 to 3, and 30 subjects in stages 4 and 5 combined. Around
30 age-matched healthy volunteers were also enrolled as a control group. The
inclusion and exclusion criteria were as previously described in Chapter 2, section
2.1.1.
5.2.2 Study design and protocol
The study was a prospective, cross-sectional study. Subjects refrained from alcohol
for at least 24 hours and caffeinated drinks, food and smoking for at least 12 hours
before the study. Subjects were asked to withhold their current medications on the
morning of the study. All studies were conducted in a quiet, temperature-controlled
room. After 30 minutes of supine rest, participants underwent BP measurements and
blood samples were taken. Then CAIx, CF-PWV, FMD, and PWA techniques for
measuring endothelial function were made, in that order. All techniques were
performed as described in Chapter 2, sections 2.5.1, 2.5.2, 2.6.1, and 2.6.2,
respectively.
5.2.3 End points
Primary end points were arterial stiffness measured by CF-PWV and endothelial
dysfunction measured by FMD (percentage change from baseline: FMD (%)), and
renal function as an independent determinant of CF-PWV and FMD. Secondary end
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points were arterial wave reflection measured by CAIx and endothelial dysfunction
measured by maximal changes in CAIx after salbutamol administration.
5.2.4 Data analyses
Descriptive data is given as mean ± SD. Means of the subject characteristics of all
CKD stages were compared using one-way ANOVA. Means of CF-PWV and FMD
were compared using one-way ANOVA with Bonferroni's correction for multiple
comparisons. Correlation coefficients for univariate analysis were calculated using
the Pearson method. Multivariate analysis was performed using a stepwise linear
regression. Dependent variables were CF-PWV, CAIx, and FMD. Independent
variables were age, gender, MAP, smoking status, plasma glucose, total cholesterol
and GFR. The multiple coefficient of determination (r2) of each model was reported.
Multivariate analysis data were reported for CF-PWV, CAIx and FMD using
standard regression coefficient (/? value) of independent variables. A significant level
was p value < 0.05.
5.3 Results
5.3.1 Subject characteristics
One hundred and thirty eight subjects were recruited. Causes of CKD and
medication use in the study population and characteristics of the subjects are given in
Tables 5.1 and 5.2 respectively (for full subject characteristics, see Appendix 1).
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Table 5.1 Causes of CKD and medication use in the study population.
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5



























































































Key: ACE: angiotensin converting enzyme; ADPKD: autosomal dominant polycystic kidney
disease; ARB: angiotensin receptor blocker; GN: glomerulonephritis; TBM: thin basement
membrane.
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Table 5.2 Subject characteristics.
Controls Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
n 23 28 30 30 20 7
Gender: Male/Female (n) 13/10 17/11 18/12 22/8 16/4 4/3
Smoker: Yes/No (n) 2/21 9/19 5/25 6/24 4/16 0/7
Serum creatinine (mmol/L) 78±13 77±13 102± 21 177±5 364±105 632±181
eGFR (ml/min/1.73m2) 97±19 108+17 77±9 45±9 23±4 12±3
Age (year) 47±8 43±11 49±9 51±10 45±9 51 ±12
SBP (mmHg)* 113+16 114±15 116±13 120±12 121±12 132+16
DBP (mmHg) 71±10 71±10 74±9 76±9 76±7 76±7
MAP (mmHg) 85±12 86+11 88±10 90+10 91 ±8 95±8
PP (mmHg)* 42±9 43+8 41±7 45±10 45±9 56±17
Heart rate (bpm) 58±7 63±8 62±10 60±8 58±9 63±13
BMI (kg/m2) 26±6 29±5 28±4 28±6 28±5 25±7
Plasma glucose (mmol/L) 5.0±0.5 5.0±0.5 5.0±0.6 5.1±0.4 5.1±0.5 4.8±0.7
Total cholesterol (mmol/L) 4.7±0.9 4.9±0.8 4.7±1.0 4.8±0.8 4.5±0.8 4.4±0.8
Key: *p < 0.05 for one-way ANOVA by CKD stage. BMI: body mass index; DBP: diastolic
blood pressure; eGFR: estimated glomerular filtration rate; MAP: mean arterial pressure; PP:
pulse pressure; SBP: systolic blood pressure.
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5.3.2 Relationships to renal function
SBP and PP increased as renal function declined (Table 5.2). There was an inverse
correlation between CF-PWV and eGFR (Figure 5.1 A) with an incremental increase
ofCF-PWV with increasing CKD stages (Table 5.3, Figure 5. IB). Yet, RAIx, CAIx,
and CAIx@HR75 had no relationship to eGFR (Table 5.3).
Table 5.3 Arterial stiffness and wave reflections.
Controls Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
CF-PWV (m/s)* 6.15±0.82 6.6U1.14 6.5111.04 7.29+1.96 6.98H.41 8.0011.90
RAIx (%) 74+20 72+14 79116 78120 77116 81+20
CAIx (%) 21+15 20110 25+11 24114 24112 24115
CAIx@HR75 (%) 13+14 13111 18+19 16+13 15111 19+19
Key: *p < 0.05 for one-way ANOVA. CAIx: central augmentation index; CAIx@HR75:
central augmentation index at heart rate of 75 bpm; CF-PWV: carotid-femoral pulse wave
velocity; RAIx: radial augmentation index.
Figure 5.1 Relationships of eGFR to CF-PWV.






















Key: Figure B: *p < 0.01 for stage 5 versus control, stage 1 and 2.
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In terms of FMD, baseline diameters of the brachial artery are not different across
CKD stages (Table 5.4). FMD showed a positive correlation with eGFR (Figure
5.2A). When considered by stage, FMD only fell significantly in stage 5 (Table 5.4,
Figure 5.2B). Whilst there was generally wide variability between patients in a given
CKD stage, subjects with an eGFR <20 ml/min/1.73m2 uniformly had an FMD of
<1.5% (Figure 5.2A). A receiver operating characteristic (ROC) curve was plotted to
identify the sensitivity and specificity of the GFR cut point. Although the specificity
was very high (98%), the sensitivity of this GFR cut point was poor (57%) (see
Appendix 2).
As expected, the GTN response was higher than the FMD response in all stages.
Endothelium-independent vasodilatation by GTN did not show an association with
eGFR, although the GTN response tended to be lower in stage 5 patients compared
to the other groups (Table 5.4). The change in CAIx after inhaled salbutamol and
sublingual GTN administrations had no relationship with eGFR (Table 5.4)
-106 -
Table 5.4 Endothelial function.

















PWA technique (maximal changes in CAlx after salbutamol or GTN administrations)
With salbutamol -7l9 -6±6 -7±4 -7±6 -6±9 -4±6
With GTN -13±6 -14±8 -12±4 -13±6 -13±6 -13±8
Key: *p < 0.05 for one-way ANOVA. CAlx: central augmentation index; FMD: endothelium-
dependent flow-mediated dilatation; GTN: endothelial-independent flow-mediated dilatation






































Figure 5.2 Relationships of eGFR to FMD.
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Key: Figure B: **p < 0.01 for stage 5 versus control, stages 1, 2, 3, and 4.
5.3.3 Relationships and predictors of carotid-femoral
pulse wave velocity and central augmentation index
CF-PWV correlated with RAIx, CAIx, and CAIx@HR75 (Figures 5.3 A-C). CF-
PWV also correlated with age, MAP, and plasma glucose (Figures 5.4 A-C), and
renal function (Figures 5.1 A & B), but not with gender, smoking status, total
cholesterol, or BMI. However, CAIx correlated with age, MAP, total cholesterol
(Figures 5.4 D-F), gender (r2 = 0.07, p < 0.01), and smoking status (r2 = 0.09, p <
0.01) but not with plasma glucose, BMI, or renal function.
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Figure 5.3 Correlations between CF-PWV and Alx.
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Figure 5.4 Significant positive correlations between CF-PWV & CAlx and conventional
risk factors.
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In multivariate analysis, considering renal function alongside conventional risk
factors, age and BP were the independent determinants of both CF-PWV and CAIx.
Additionally, gender and smoking status also independently predicted CAIx.
Importantly, renal function was not a predictor of either CF-PWV or CAIx (Table
5.5).
Table 5.5 Multivariate analysis of renal function and conventional cardiovascular risk
factors, as independent predictors of CF-PWV and CAIx.
CF-PWV CAIx
Age 0.06* 0.51*
Gender (male/female) -0.12 8.27*
Mean arterial pressure 0.05* 0.22**
Smoking status (yes/no) 0.07 10.04*
Glucose 0.14 -0.08
Total cholesterol -0.12 0.03
Estimated glomerular filtration rate -0.13 -0.07
r2 0.35* 0.41*
Key: The table gives standard regression coefficients ((3 values); r2: multiple coefficient of
determination; *p < 0.01; **p < 0.05.
5.3.4 Relationships and predictors of flow-mediated
dilatation
In univariate analysis, FMD correlated with MAP (Figure 5.5) and renal function
(Figures 5.2 A & B) but not with age, gender, smoking status, plasma glucose, total
cholesterol, and BMI. In multivariate analysis, with conventional risk factors and
eGFR, MAP was the only predictor of FMD (Table 5.6). The change in CAIx after
administration of f^-agonist had no relationship with FMD, renal function, or
conventional cardiovascular risk factors.
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Figure 5.5 A relationship between FMD and MAP.
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Table 5.6 Multivariate analysis of renal function and conventional cardiovascular risk




Mean arterial pressure -0.07*
Smoking status (yes/no) -0.02
Glucose -0.08
Total cholesterol 0.09
Estimated glomerular filtration rate 0.11
r2 0.07*
Key: The table gives standard regression coefficients ((3 values); r2: multiple coefficient of




In a minimally co-morbid cohort of CKD patients, arterial stiffness, measured by
CF-PWV, increases incrementally as renal function declines whereas endothelial
dysfunction, measured by FMD of the brachial artery, is a feature only of late stage
CKD. However, renal function is not an independent predictor of either CF-PWV or
FMD in this group of patients.
5.4.2 Relationships of carotid-femoral pulse wave
velocity & central augmentation index to renal
function
The finding of an inverse and graded association between CF-PWV and eGFR is in
keeping with previous data (Kawamoto et al., 2008; Kimoto et al., 2006; Matsuda et
al., 2009; Mourad et al., 2001; Ohya et al., 2006; Schillaci et al., 2006; Shinohara et
al., 2004; Stancanelli et al., 2007; Wang et al., 2005). However, those studies
included patients with dialysis, diabetes, or cardiovascular disease. Moreover, in the
current study PWV measurements are lower than in previous studies that used a
similar technique for measuring arterial stiffness (Figure 5.6, Table 5.7). The finding
that CAIx has no association with renal function is consistent with previous reports
(Lacy et al., 2006; Stancanelli et al., 2007; Takenaka et al., 2005). Again, CAIx of
this study are lower than in those studies (Table 5.7). Taken together, this likely
reflects the lack of co-morbidity in this CKD cohort, specifically chosen to minimise
confounding by conventional cardiovascular risk factors.
Of note, although PWV and CAIx were used as surrogates for arterial stiffness
(Oliver et al., 2003b), these two technique are not identical because their
determinants are different. AIx is dependent on the speed of the travelling wave
(which is regarded as PWV itself), the amplitude of the reflected wave, the reflection
point, heart rate, and ventricular contractility, whereas PWV represents intrinsic
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arterial stiffness (Oliver et al., 2003b; Yasmin et al., 1999). These differences
probably explain the discrepancy between CF-PWV and CAIx findings and the lack
of relationship between CAIx and renal function seen in the current study.













Control 12 3 4
CKD stages
□ This study OWang, et al. 2005
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Table 5.7 Comparing PWV and CAlx measurements with data from previous studies
(measurements obtained using the SphymoCor system).





(Lacy et al., 2006)




This study 21 20
(Lacy et al., 2006)
(Briet et al., 2006) 35
(Stancanelli et al., 29
2007)
Key: The values presented are the mean values.
5.4.3 Predictors of carotid-femoral pulse wave
velocity and central augmentation index
When conventional risk factors (age, gender, BP, smoking, plasma glucose, and
hypercholesterolaemia) were considered alongside renal function, age and BP, as
expected, were the strongest determinants of arterial stiffness (Guerin el al., 2008).
The finding that renal function is not a predictor for either PWV or CAlx is contrary
to several previous reports on studies including dialysis patients and CKD patients
with cardiovascular co-morbidity (Kawamoto et al., 2008; Kimoto et al., 2006;
Matsuda et al., 2009; Mourad et al., 2001; Ohya et al., 2006; Schillaci et al., 2006;


























(Briet et al., 2006; Stancanelli et al., 2007; Takenaka et al., 2005). However, in those
studies, patients with lower GFR had a higher percentage of co-morbidity which
would affect PWV and might, therefore, drive the presumed association with renal
function. Importantly, as CKD patients in this study were highly selected to have
very low comorbidity, the finding that GFR was not a predictor of PWV suggests
that uraemia per se has minimal role on enhancing cardiovascular disease in CKD.
This is contrast to the hypothesis of this study. However, this finding underscores the
importance of the well-established cardiovascular risk factor, BP, on cardiovascular
disease in CKD and emphasises the fact that all CKD patients should have tight
controlled of their BP.
Although it proved impossible to recruit a sufficient number of non-smokers to
exclude this risk factor, the results from this study suggest that smoking does not
independently contribute to CF-PWV. Despite a low number of smokers, smoking is
still an independent predictor of CAIx, in line with other studies (Polonia et al.,
2009; Rehill et al., 2006). Gender independently predicts CAIx. This could be
explained by differences of body height on wave reflections (the shorter the body
height, the higher the AIx and women are generally shorter than men) (O'Rourke et
al., 1996; Yasmin et al., 1999).
5.4.4 Relationships of flow-mediated dilatation to
renal function
The finding of endothelial dysfunction, measured by FMD, being a feature only of
late stage CKD appears to be at odds with previous studies on the early stages of
CKD (Annuk et al., 2001; Bolton et al., 2001; Caglar et al., 2008a; Caglar et al.,
2008b; Chan et al., 2006; Dogra et al., 2006; Ghiadoni et al., 2004; Perticone et al.,
2004; Thambyrajah et al., 2000; Yilmaz et al., 2006; Yilmaz et al., 2008a; Yilmaz et
al., 2007). Amongst these, three studies have measured brachial artery FMD across 5
stages of CKD and found that FMD gradually reduces as GFR falls (Figure 5.7,
Table 5.8).
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However, the results of the current study are in line with a recent report from the
Framingham Offspring cohort study in which the endothelium-dependent vasomotor
function was not different between subjects with CKD (GFR 50 ml/min/1,73m2) and
those without CKD (FMD: 2.3 versus 2.9 %, respectively) (Table 5.8) (Foster et al.,
2008). The finding that endothelial dysfunction occurs only at late stage CKD was
also confirmed by the ROC curve with the specificity of 98%. Thus, the endothelial
dysfunction seen in early stages of CKD in other studies is once again likely to be a
reflection of the co-morbidities of the subjects studied, including atherosclerotic
vascular disease (Thambyrajah et al., 2000), hypertension (Perticone et al., 2004),
diabetes mellitus (Annuk et al., 2001; Chan et al., 2006; Dogra et al., 2006), and
dialysis (Annuk et al., 2001; Caglar et al., 2008b; Dogra et al., 2006; Yilmaz et al.,
2006; Yilmaz et al., 2008a).
Figure 5.7 Comparing FMD (%) across CKD stages with data from previous studies.
Control 1 2 3 4 5
CKD stages
□ This study Q Yilmaz, et al. 2006 □ Yilmaz. et al. 2008 □ Caglar. el al. 2008
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Table 5.8 Comparing FMD (%) measurement with data from previous studies.
Studies Control Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
This study 4.9 4.6 4.7 4.0 4.2 0.7
(Yilmaz etal., 9.0 8.3 7.2 6.7 6.0 4.8
2006)
(Yilmaz et at., 9.7 8.6 7.2 6.9 6.3 5.3
2008a)
(Caglar etal., 9.0 8.4 7.3 6.8 6.1 5.0
2008b)
(Thambyrajah et 6.5 - 2.6
a/., 2000) M^
(Bolton et at., 6.4 - - 2.3
2001) < ►
(Ghiadoni et at., 6.9 - - 5.3
2004) 4 ►
(Dogra etal., 5.7 - - 3.8
2006) ^^
(Chan et at., 2006) 4.3 - - - 1.9
(Yilmaz et at., 8.9 - - 6.7 -
2007)
(Foster et at., 2.9 - - 2.3 -
2008)
(Caglar et at., 8.8 - - - 5.9
2008a)
Key: The values presented are the mean values.
The change in CAIx after inhaled (32-agonist is a novel technique for measuring
endothelial function (Hayward et al., 2002). Although the technique is relatively
easy compared to FMD, it has not been applied much in clinical research compared
to FMD. In addition, the technique has only been tested on a small number of
healthy subjects (Hayward et al., 2002; Wilkinson et al., 2002a) and in patients with
coronary artery disease (Weber et al., 2007) but not in renal patients. Our finding
that the change in CAIx after salbutamol does not correlate with FMD may imply
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that this technique might not be suitable for assessing endothelial function in
uraemic patients. However, one study has shown a higher degree of endothelial
dysfunction, assessed by this technique, in dialysis patients compared to
hypertensive patients (Covic et al., 2004).
5.4.5 Predictors of flow-mediated dilatation
Of all the risk factors studied here, BP is the only predictor of FMD. Results from
this study both confirm and contrast with previous data. In contrast to the current
findings, previous studies have shown uraemia to be an independent predictor of
endothelial dysfunction (Annuk et al., 2001; Stam et al., 2003; Yilmaz et al., 2008a).
In support of the present study is a study of stage 3 to 5 CKD patients where neither
GFR nor oxidative stress were shown to independently predict endothelial function
(Annuk et al., 2005).
Again, the finding that FMD was not determined by renal function in this low-
comorbidity cohort is contrast to the hypothesis that uraemia, on its own, would
contribute to endothelial dysfunction in CKD. In fact, uraemia has minimal role on
endothelial dysfunction unless GFR substantailly drops to the level that requires a
renal replacement therapy. As with PWV, the FMD finding indicates the importance
of a modifiable risk factor, BP, in CKD.
5.4.6 Limitations
Some of the medications taken by the patients, such as ACE inhibitors, ARBs, P-
blockers, and statins, may have had effects on both arterial stiffness and endothelial
function. However, all patients were stabilised on their therapy and did not receive
their medication on the day of the study until after measurements were made. In
addition, as this was a cross-sectional study, the causal relationships behind the




The present study shows that, in the absence of established cardiovascular disease
and diabetes, deterioration in renal function is associated with increased arterial
stiffness and endothelial dysfunction. Age and BP remain the major determinants of
both. However, when renal function and conventional cardiovascular risk factors are
considered together, renal function is not a determinant of either arterial stiffness or
endothelial dysfunction. Thus, in this relatively healthy CKD population, uraemia,
on its own, is not the main driving force of the development of vascular
complications. These complications would mainly be driven by BP or other
emerging cardiovascular risk factors. Hence, a study assessing the role of emerging
cardiovascular risk factors, such as inflammation, oxidative stress, and imbalance of




cardiovascular risk factors to
arterial stiffness and endothelial
dysfunction in chronic kidney
disease
6.1 Introduction
CKD patients have an increased risk of cardiovascular disease, with cardiovascular
mortality at least 10-20 times higher in dialysis patients than in the general
population (Foley et al., 1998). Indeed, CKD patients have a substantially higher
chance of dying from cardiovascular disease than of progressing to end-stage renal
disease (Sarnak et al., 2003). Conventional Framingham cardiovascular risk factors
including smoking, hypertension, hypercholesterolaemia, and diabetes mellitus, are
common in CKD patients. However, these only partly explain the high
cardiovascular risk. Thus, the study of emerging cardiovascular risk factors has been
an area of intense investigation (Zoccali, 2006).
Arterial stiffness and endothelial dysfunction are recognised markers of
cardiovascular risk (Blacher et al., 1999a; Guerin et al., 2008; Perticone et al., 2001).
Importantly, arterial stiffness is an independent predictor ofmortality and survival in
renal patients (Blacher et al., 1999a; Guerin AP, 2001). Emerging cardiovascular
risk factors such as inflammation, oxidative stress, and a shift in the balance of the
vasodilator NO and vasoconstrictor ET systems may contribute to arterial stiffness
and endothelial dysfunction (Gusbeth-Tatomir et al., 2007). These are all common in
a typical CKD population (Schiffrin et al., 2007; Zoccali, 2006), but are also
increased by conventional cardiovascular risk factors and by established
cardiovascular disease (Dhaun et al., 2006; Schiffrin et al., 2007). Hence, the
contribution of these emerging risk factors to arterial stiffness and endothelial
dysfunction, in CKD remains unclear.
6.1.1 Aims and hypotheses
The major findings of Chapter 5 are that arterial stiffness and endothelial dysfunction
increase as renal function declines, and these are driven by conventional
cardiovascular risk factors, such as age and BP. Based on these findings, it is worth
exploring the role of emerging cardiovascular risk factors in helping to explain the
augmented arterial stiffness and endothelial dysfunction, and high cardiovascular
risk in CKD patients.
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Thus, the aims of this study were to investigate the relationship of both conventional
and emerging cardiovascular risk factors including inflammation, oxidative stress
and markers of NO/ET activity to arterial stiffness and endothelial dysfunction in a
group of CKD patients with minimal co-morbidity from CKD stage 1 to pre-dialysis.
The prevalence of emerging cardiovascular risk factors in this group was also
assessed.
Hypotheses:
1. In this minimally co-morbid CKD group, the measured emerging risk factors
would accumulate, as renal function declined.
2. These emerging risk factors would, at least in part, independently explain the




All subjects recruited from a study investigating the relationship of arterial stiffness
and endothelial dysfunction to renal function (Chapter 5) were further enrolled on
this study.
6.2.2 Study design and protocol
This was a prospective, cross-sectional study. Subjects refrained from alcohol for at
least 24 hours and caffeinated drinks, food, and smoking for at least 12 hours before
the study. Subjects were asked to withhold their current medications on the morning
of the study. All studies were conducted in a quiet, temperature-controlled room.
After 30 minutes of supine rest, participants underwent BP measurements and then
blood samples were taken for creatinine, glucose, total cholesterol, ESR, hsCRP,
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OxLDL, IL-6, 8-IsoP, ADMA, and ET-1. After that, CF-PWV and FMD were
measured. All techniques were performed as described in Chapter 2.
6.2.3 Laboratory investigations
Serum creatinine, plasma glucose, total cholesterol, and ESR were quantified in the
hospital biochemistry laboratory. All sample collections and analyses of serum
hsCRP and OxFDE, and plasma IF-6, 8-IsoP, ADMA, and ET-1 were performed as
previously described in Chapter 2, section 2.9.2. Although not regarded as an
emerging cardiovascular risk factors, SDMA was also measured.
6.2.4 Data analyses
Descriptive data is given as mean ± SD. The means of the subject characteristics and
the emerging cardiovascular risk factors of all CKD stages were compared using
one-way ANOVA. Correlation coefficients for univariate analysis were calculated
using the Pearson method. Multivariate analysis was performed using a stepwise
linear regression. Dependent variables were CF-PWV and FMD. First, GFR and
traditional cardiovascular risk factors including age, gender, MAP, smoking status,
plasma glucose, and total cholesterol were entered into the first model. Thereafter,
emerging cardiovascular risk factors including hsCRP, IL-6, ESR, 8-Isop, OxLDL,
arginine, ADMA and ET-1 were entered into the second model. Multiple coefficient
of determination (r2) of each model was reported. Multivariate analysis data were
reported for both CF-PWV and FMD using standard regression coefficient (/? value)




A total of 138 subjects were studied. The characteristics of the studied population are
shown in Table 6.1 (for full subject characteristics, see Appendix 1). Cause of CKD
and the medication used by the patients were similar to those summarised in Table
5.1, Chapter 5.
Age was comparable between stages while MAP increased as renal function declined
but this did not reach significance. CF-PWV incrementally increased with increasing
CKD stage (r2 = 0.08, p < 0.01). FMD positively correlated with eGFR (r2 = 0.04, p
< 0.05) with those whose GFR <20 ml/min/1.73m2 having a substantial reduction of
FMD.
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Table 6.1 Subject characteristics.
Controls Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
n 23 28 30 30 20 7
Male/Female (n) 13/10 17/11 18/12 22/8 16/4 4/3
Smoker: Yes/No 2/21 9/19 5/25 6/24 4/16 0/7
(n)
Creatinine 78+13 77113 102121 17715 364+105 6321181
(mmol/L)
eGFR 97±19 108117 7719 45+9 2314 1213
(ml/min/1.73m2)
Age (year) 47±8 43+11 4919 51110 45+9 51112
MAP (mmHg) 85±12 86+11 88110 90110 9118 95+8
BMI (kg/m2) 26±6 2915 2814 28+6 2815 2517
Glucose 5.010.5 5.010.5 5.010.6 5.1+0.4 5.110.5 4.810.7
(mmol/L)
Total cholesterol 4.7±0.9 4.910.8 4.7+1.0 4.810.8 4.510.8 4.410.8
(mmol/L)
CF-PVW (m/s)* 6.15±0.82 6.6111.14 6.5111.04 7.2911.96 6.9811.41 8.00+1.90
FMD (%)** 4.9313.01 4.5612.63 4.68+2.67 4.01+2.55 4.1713.69 0.6610.54
GTN (%) 13.2615.53 10.9712.93 12.16+4.72 11.7416.27 10.74+4.31 7.5813.55
Key: *p < 0.01, **p < 0.05 for one-way ANOVA by CKD stage. BMI: body mass index; CF-
PWV: carotid-femoral pulse wave velocity; eGFR: estimated glomerular filtration rate; FMD:
flow-mediated dilatation; GTN: endothelium-independent vasodilatation response to glyceryl
trinitrate; MAP: mean arterial pressure.
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6.3.2 Relationships of emerging risk factors to renal
function
ESR, ADMA, SDMA, and ET-1 all increased as eGFR declined (r =0.11, 0.09,
0.65, 0.22, respectively, p < 0.01 for all, Table 6.2, Figures 6.1 A-D) whereas
hsCRP, IL-6, 8-Isop and OxLDL showed no relationship to renal function (Table
6.2).
Table 6.2 Circulating concentrations of variables identified as emerging
cardiovascular risk factors.
Controls Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
hsCRP (mg/L) 1 8±3.0 2.8+2.5 3.3±3.5 4.9±4.5 2.8±3.0 3.4±3.4
IL-6 (pg/ml) 8.7±8.9 9.9±10.6 11.5+11.8 12.3+12.7 6.9±6.9 6.4±5.0
ESR (mm/hr)* 7±4 9±5 14±14 18±13 18±12 26+25
8-lsop (pg/ml) 35±38 33±28 32±35 37±34 38±24 32±25
OxLDL (U/L) 54±13 52±18 55±17 57±16 51±15 53±18
Arginine (pmol/L) 79±22 72±11 75±16 72±15 77±20 76±18
ADMA (|amol/L)* 0.51±0.12 0.56±0.10 0.58±0.13 0.60±0.11 0.64±0 12 0.68±0.10
SDMA (|rmol/L)* 0.41±0.08 0.48±0.09 0.60±0.23 0.95±0.29 1.65±0.46 2.42±0.31
ET-1 (pg/ml)* 4.6±0.9 5.0±0.8 5.2±1.1 5.8±1.2 5.7±0.9 6.9±1.3
Key:*p < 0.01 for one-way ANOVA by CKD stage. ADMA: asymmetric dimethylarginine; ET-
1: endothelin-1; ESR; erythrocyte sedimentation rate; hsCRP: high-sensitivity C-reactive
protein; IL-6: interleukin-6; 8-lsop: 8-isoprostaglandin F2; OxLDL: oxidised low density
lipoprotein; SDMA: symmetric dimethylarginine.
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Figure 6.1 Relationships between eGFR and ESR, ADMA, SDMA, and ET-1.


































Additionally, in univariate analysis, age correlated positively with ESR (r2 = 0.04, p
< 0.05) and ADMA (r2 = 0.07, p < 0.01); smoking status correlated with arginine and
ET-1 (r2 = 0.03 and 0.05, respectively, p < 0.05); plasma glucose correlated with 8-
Isop (r2 = 0.03, p < 0.05); and LDL highly correlated with OxLDL (r2 = 0.32, p <
0.01) and ET-1 (r = 0.08, p < 0.01). MAP and gender showed no associations with
any emerging risk factors.
Amongst markers of inflammation, hsCRP correlated with ESR (r = 0.13, p < 0.01)
but not 1L-6. For measures of oxidative stress, 8-Isop correlated with OxLDL (r =
0.06, p < 0.01). With regards to NO/ET systems, ADMA correlated with arginine
and ET-1 (r2 = 0.19 and 0.12, respectively, p < 0.01).
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6.3.3 Relationships and predictors of carotid-femoral
pulse wave velocity
In univariate analysis, CF-PWV correlated with age, MAP, plasma glucose and
eGFR (r2 = 0.23, 0.18, 0.09, and 0.08, respectively, p < 0.01 for all), but not with
gender, smoking status, total cholesterol, or BMI. With regards to emerging risk
factors, hsCRP, ESR, and ADMA correlated with CF-PWV (Figures 6.2 A-C)
whereas IL-6, 8-Isop, OxLDL, and ET-1 did not.
When considering renal function alongside conventional risk factors, age and BP
were the independent determinants of CF-PWV (Table 6.3, Model 1). When
emerging risk factors were added to the multivariate model, age and BP remained the
major predictors ofCF-PWV but hsCRP and ADMA also predicted CF-PWV (Table
6.3, Model 2). For both multivariate models, renal function, smoking, and gender
were not predictive of PWV.
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Figure 6.2 Relationships between CF-PWV and hsCRP, ESR, and ADMA.
A r2 =0.05, p < 0.05
Serum hsCRP (mg/1)



















Table 6.3 Multivariate analysis of renal function, conventional and emerging
cardiovascular risk factors, as independent predictors of CF-PWV.
CF-PWV
Model 1 Model 2
Age 0.06* 0.05*
Gender (male/female) -0.12 -0.12
Mean arterial pressure 0.05* 0.04*
Smoking status (yes/no) 0.07 0.09
Glucose 0.14 0.10
Total cholesterol -0.12 -0.05










Key: The table gives standard regression coefficients (P values); *p < 0.01; **p < 0.05.
ADMA: asymmetric dimethylarginine; CF-PWV. carotid-femoral pulse wave velocity; ESR;
erythrocyte sedimentation rate; hsCRP: high-sensitivity C-reactive protein; OxLDL: oxidised
low density lipoprotein; r2: multiple coefficient of determination.
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6.3.4 Relationships and predictors of flow-mediated
dilatation
In univariate analysis, FMD correlated with MAP (r2 = 0.07. p < 0.01) and renal
function (r2 = 0.04, p < 0.05) but not with age, gender, smoking status, plasma
glucose, total cholesterol, and BMI. With regards to emerging cardiovascular risk
factors, FMD only correlated with plasma ET-1 (Figure 6.3) but not with markers of
inflammation, oxidative stress, or plasma ADMA.
In multivariate analysis, with conventional risk factors and eGFR, MAP was the only
predictor of FMD (Table 6.4, Model 1). When both conventional and emerging risk
factors were considered together, MAP remained a determinant of FMD but 8-Isop
and ET-1 were also independent predictors of FMD (Table 6.4, Model 2). For both
multivariate models, renal function, smoking, and gender were not predictive of
FMD.
Figure 6.3 A relationship between FMD and plasma ET-1.
r2 = 0.04, p < 0.05
Plasma ET-1 (pg/ml)
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Table 6.4 Multivariate analysis of renal function, conventional and emerging
cardiovascular risk factors, as independent predictors of FMD.
FMD
Model 3 Model 4
Age -0.06 -0.04
Gender (male/female) 0.08 0.10
Mean arterial pressure -0.07* -0.07*
Smoking status (yes/no) -0.02 0.01
Glucose -0.08 -0.08
Total cholesterol 0.09 0.09










Key: The table gives standard regression coefficients (Rvalues), *p < 0.01, **p < 0.05
ADMA: asymmetric dimethylarginine; FMD: flow-mediated dilatation; hsCRP: high-sensitivity





CKD patients without diabetes or established co-morbidity have increased arterial
stiffness and endothelial dysfunction. They also have a shift in the balance between
the NO/ET systems towards an upregulation of the vasoconstrictor ET system but
have low prevalence of inflammation and oxidative stress. Based on multivariate
analysis, amongst the conventional cardiovascular risk factors, BP is the major
determinant of arterial stiffness and endothelial dysfunction. Additionally, when
conventional and emerging cardiovascular risk factors are considered together,
hsCRP and ADMA independently predict arterial stiffness, and 8-Isop and ET-1
independently predict endothelial dysfunction.
6.4.2 Relationships of emerging risk factors to renal
function
The finding of an incremental increase of CF-PWV across CKD stages and a
reduction of FMD, especially in CKD stage 5, are in accordance with other studies
(Foster et al., 2008; Kawamoto et al., 2008; Kimoto et al., 2006; Matsuda et al.,
2009; Mourad et al., 2001; Ohya et al., 2006; Schillaci et al., 2006; Shinohara et al.,
2004; Stancanelli et al., 2007; Wang et al., 2005) (see the relationship of CF-PWV
and FMD to renal function in Chapter 5, sections 5.4.2 and 5.4.4, respectively).
In this study, neither hsCRP nor IL-6 was related to GFR. These are in contrast to
previous data (Figure 6.4, Table 6.5) (Caglar et al., 2008b; Cottone et al., 2009;
Dogra et al., 2006; Landray et al., 2004; Panichi et al., 2002; Perticone et al., 2004;
Romao et al., 2006; Shlipak et al., 2003; Stam et al., 2003) but in keeping with a
recent study in Japanese non-diabetic CKD patients (Matsuda et al., 2009). Although
the results showed that ESR increased linearly as renal function declined, this is
likely due to anaemia associated with renal impairment (Borawski et al., 2001). In
consistent with previous reports on pre-dialysis patients, none of the measures of
oxidative stress were associated with renal function (Figures 6.5 & 6.6) (Annuk et
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al., 2005; Bolton et al., 2001; Cottone et al., 2009; Dounousi et al., 2006).
Additionally, measures of inflammation and oxidative stress in the current study
were relatively low compared to other studies (Figures 6.4-6.6, Table 6.5). Taken
together, these are all in contrast to the hypothesis that inflammation and oxidative
stress are substantially increased in CKD and contribute significantly to its
accelerated vascular pathology (Himmelfarb et al., 2002; Zimmermann et al., 1999).
However, the findings of the present study suggest that uraemia is not a pro¬
inflammatory or pro-oxidant state itself, but that these features are driven largely by
co-morbidity.
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Table 6.5 Comparing circulating CRP and IL-6 with data from previous studies.
Studies Control Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
CRP (mg/L)
This study 1.8 2.8 3.3 4.9 2.8 3.4
(Dogra et al., 2006) 1.3 - - 3.9
(Dounousi et al., 2006) - 3.0 3.5 3.8 3.4
(Landray et al., 2004) 2.2 - - 3.7
(Matsuda et al., 2009) 2.0 0.9 1.8
(Panichi etal., 2002) - 3.2 4.0
►
7.9
(Shlipak etal., 2003) 4.4 - - - 5.5 -
(Stam etal., 2003) - 1.1 2.3 4.5 < —►
IL-6 (pg/ml)
This study 8.7 9.9 11.5 12.3 6.9 6.4
(Dogra etal., 2006) 1.6 - - 3.7
(Panichi et al., 2002)






Plasma ADMA, an endogenous inhibitor of NOS (Boger, 2003), and plasma ET-1
were measured as components of the NO and ET systems, respectively (Boger, 2003;
Dhaun et al., 2006). Both increased linearly as eGFR fell in accordance with the
literature (Figures 6.7, Table 6.6) (Blazy et al., 1994; Busch et al., 2006; Cottone et
al., 2009; Dammers et al., 2005; Deray et al., 1992; El-Mesallamy et al., 2008; Fleck
et al., 2001; Goddard et al., 2007; Kielstein et al., 2002; Koyama et al., 1989;
MacAllister et al., 1996; Mallamaci et al., 1993; Panichi et al., 2008; Uzun et al.,
2008; Vlachojannis et al., 1997; Vlassopoulos et al., 1995; Wahbi et al., 2001;
Warrens et al., 1990; Xiao et al., 2001; Yilmaz et al., 2006; Yilmaz et al., 2008b;
Young et al., 2009). Interestingly, the concentrations of plasma ADMA and ET-1
seen here are lower than previously published in subjects with similar levels of renal
function but added co-morbidity (Fleck et al., 2001; Koyama et al., 1989;
MacAllister et al., 1996; Saito et al., 1991; Xiao et al., 2001; Yilmaz et al., 2006;
Yilmaz et al., 2008b; Young et al., 2009), suggesting that cardiovascular co¬
morbidity may contribute significantly to endothelial dysfunction in these other
studies (Table 6.6).
There is often reciprocal upregulation of the ET system in circumstances where there
is downregulation of NO system activity (Dhaun et al., 2006). In this study, plasma
ADMA and ET-1 did, indeed, correlate highly with each other, confirming the
reciprocal relationship between the NO and ET systems. The increases in plasma
ADMA, SDMA, and ET-1 with deteriorating renal function may, in part, be due to
their reduced renal clearance (Boger, 2003; Dhaun et al., 2006), although not
excluding an increase in their synthesis.
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Table 6.6 Comparing plasma ADMA and ET-1 with data from previous studies.
Studies Control Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
ADMA (pmol/L)
This study 0.51
(Kielstein et al., 2002) 1.40
(MacAllister et al., 1996) 0.36
(Panichi et al., 2008) 0.69
(Uzun eta!., 2008) 1.05














This study 4.6 5.0 5.2
(Cottone et al., 2009) 1.6
(Dammers et al., 2005) 1.9









(Vlachojannis et al., 1997) 29 54 60
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6.4.3 Relationships and predictors of carotid-femoral
pulse wave velocity
Here, hsCRP, a marker of inflammation is associated with CF-PWV. This
relationship has been shown in several large population studies in subjects with
normal renal function (Mattace-Raso et al., 2004; Nagano el al., 2005; Yasmin et al.,
2004) and in smaller studies in haemodialysis (Haydar et al., 2004; London et al.,
2003), hypertensive (Mahmud et al., 2005), and metabolic syndrome patients
(Tomiyama et al., 2005). Of all these studies, some have also shown that hsCRP is
an independent predictor of PWV (London et al., 2003; Mahmud et al., 2005;
Matsuda et al., 2009; Mattace-Raso et al., 2004; Nagano et al., 2005; Tomiyama et
al., 2005; Yasmin et al., 2004; Yoshida et al., 2007). Our findings are in keeping
with this, suggesting that even low-grade inflammation may influence vascular
function in CKD (Stenvinkel et al., 2005a).
The current study has shown that neither 8-Isop nor OxLDL is independently
associated with CF-PWV. To date, there is no study that directly examines the
contribution of Isop or OxLDL to arterial stiffness in renal patients. However, a
study in patients with peripheral arterial disease has shown that oxidative stress,
measured by urinary Isop, was independently associated with arterial stiffness,
measured by AIx, while OxLDL had no association with AIx (Kals et al., 2008). In
contrast to this, a recent study in the elderly with diabetes and cardiovascular co¬
morbidity has shown that OxLDL independently predicted PWV (Brinkley et al.,
2009).
There is conflicting data regarding the relationship of arterial stiffness and ADMA.
Several studies showed associations in univariate analysis (Fujii et al., 2008; Kals et
al., 2007; Kielstein et al., 2006; Paiva et al., 2008; Soveri et al., 2007; Weber et al.,
2007), while some did not (Chirinos et al., 2008; Paiva et al., 2006). Here, I also
propose that plasma ADMA is an independent predictor of arterial stiffness in CKD
patients with varying GFR. This independent association has been shown in CKD
patients on dialysis (Soveri et al., 2007) and, more recently, in hypertensive patients
with renal insufficiency (Fujii et al., 2008). In contrast to the finding of this study,
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ET-1 was shown to be related to arterial stiffness (Demuth et al., 1998; Heintz et al.,
1993; Karakitsos et al., 2007; McEniery et al., 2003; Vuurmans et al., 2003). The
absence of plasma ET-1 as an independent predictor of arterial stiffness is also
contrary to other studies. However, these included patients on dialysis (Demuth et
al., 1998), those with ischaemic heart disease (Heintz et al., 1993) and diabetes
(Karakitsos et al., 2007). Thus, co-morbidity may again partly explain these
findings. Overall, our findings strongly support the contribution of ADMA and the
shift in vasodilator-vasoconstrictor balance in the development of vascular
dysfunction in CKD.
6.4.4 Relationships and predictors of flow-mediated
dilatation
In this study, BP, 8-Isop, and ET-1 were shown to be independent predictors of
endothelial function. These are in contrast to previous studies in which uraemia is an
independent predictor of endothelial dysfunction (Annuk et al., 2001; Stam et al.,
2003). A study in haemodialysis and stage 3 to 4 CKD patients (Bolton et al., 2001)
and in hypertensive patients with mild to moderate renal impairment (Zoccali et al.,
2006), inflammation independently predicts FMD. OxLDL is a predictor for FMD in
stage 1 to 5 CKD patients including those on dialysis. Nonetheless, the findings of
the current study are in accordance with the studies of stage 3 to 5 CKD patients in
which neither GFR nor OxLDL were shown to independently predict endothelial
function (Annuk et al., 2005; Bolton et al., 2001).
Our finding that ET-1 predicts FMD, again, strongly supports the contribution of the
shift in vasodilator-vasoconstrictor balance of NO/ET in CKD. Two studies have
suggested that ADMA is an independent predictor of endothelial dysfunction in non-
dialysis proteinuric patients (Yilmaz et al., 2008b) and in stage 1 to 5 CKD patients
including those on dialysis (Yilmaz et al., 2006). Of note, however, these studies
included patients with co-morbidity.
To sum up, as it was shown in Chapter 5 that uraemia has no role as a predictor of
arterial stiffness and endothelial dysfunction in this group of CKD paients with very
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low comorbidity. The finding Chapter 6 strongly confirms the impact of BP on
cardiovascular complications in CKD and, as hypothesised, further emphasises the
contribution of emerging risk factors especially inflammation and ADMA on PWV
and oxidative stress and ET-1 on FMD. Although the contribution of these emerging
risk factors on cardiovascular complications on top of traditional risk factors in the
multivariate analysis is not massive (5% increase for PWV and 0.07% increase for
FMD), these changes are of significance. As these risk factors are modifiabled it
could serve as target for interventions in cardiovascular risk and disease reduction in
CKD patients.
6.4.5 Limitations
Some of the medications taken by the patients, such as ACE inhibitors, ARBs, (3-
blockers, and statins, may have had effects on both arterial stiffness and endothelial
function. However, all patients were stabilised on their therapy and did not receive
their medications on the day of the study until after measurements had been made. In
addition, as this was a cross-sectional study, the causal relationships behind the
associations described cannot be fully defined, although they do have a sound
mechanistic basis.
6.4.6 Summary
In the absence of established cardiovascular disease and diabetes, arterial stiffness
and endothelial dysfunction increase as GFR falls. Amongst conventional risk
factors, BP determines arterial stiffness and endothelial dysfunction while renal
function is not a predictor of either. Additionally, hsCRP and ADMA are
independent predictors of arterial stiffness, and 8-Isop and ET-1 independently
predict endothelial dysfunction. Thus, the vascular complications occur in a uraemic
population may substantially be driven by inflammation, oxidative stress, and
NO/ET imbalance, instead of the uraemia itself, and measures of these could help
identify those at a higher risk of vascular disease. Interventional studies to examine
the influence of these emerging risk factors on arterial stiffness and endothelial
dysfunction, using potential therapeutic agents such as ET antagonists or
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Risk factors for the metabolic
syndrome independently predict
arterial stiffness and endothelial




The metabolic syndrome is a clustering of metabolic abnormalities and risk factors
for cardiovascular disease featuring abdominal obesity, hyperglycaemia,
hypertension, hypertriglyceridaemia, and reduced HDL cholesterol (Grundy et al.,
2004; Reaven, 1988). As the metabolic syndrome is associated with increased risks
of diabetes and cardiovascular disease (Ahluwalia et al., 2006; Sattar el al., 2003), its
treatment and prevention have become one of the major public health challenges
worldwide. The risk factors for the metabolic syndrome, either together or
individually, are also associated with arterial stiffness and endothelial dysfunction, in
health (Achimastos et al., 2007; Ferreira et al., 2007; Ferreira et al., 2005; Li et al.,
2005; Nakanishi et al., 2003; van Popele et al., 2000) and disease (Martens et al.,
2008; Mule et al., 2006; Schillaci et al., 2005; Seo et al., 2005; Stehouwer et al.,
2008; Vyssoulis et al., 2008; Yokoyama et al., 2007).
The metabolic syndrome is widely prevalent in CKD (Johnson et al., 2007) and the
metabolic syndrome is itself a risk factor for CKD (Chen et al., 2004). There is no
study directly assessing the contribution of the metabolic syndrome to arterial
stiffness and endothelial dysfunction in non-dialysis CKD patients. However, a
recent study suggests the metabolic syndrome and its risk factors do contribute to
arterial stiffness and endothelial dysfunction in dialysis patients (Zhe et al., 2008).
7.1.1 Alms and hypotheses
The major findings of Chapter 5 are that arterial stiffness and endothelial dysfunction
increase as renal function declines, and these are mainly driven by conventional
cardiovascular risk factors, such as age and BP. In Chapter 6, I have extended these
findings and showed that inflammation and the NO/ET systems also contribute to
arterial stiffness and endothelial dysfunction, and high cardiovascular risk in CKD
patients.
Based on data from Chapters 5 and 6, it is now interesting to explore the role of the
metabolic syndrome on arterial stiffness and endothelial dysfunction. The aims of the
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current study are to investigate the relationships of the metabolic syndrome and its
individual components to arterial stiffness and endothelial dysfunction in relatively
low co-morbid CKD patients across a wide range of renal function from early CKD
to pre-dialysis.
Hypotheses:
In this group of patients with minimal co-morbidity, arterial stiffness and endothelial
dysfunction would still relate to the presence of the metabolic syndrome or its




All subjects recruited from studies in Chapters 5 and 6 were further enrolled into this
study.
7.2.2 Study design and protocol
This was a prospective, cross-sectional study. Subjects refrained from alcohol for at
least 24 hours and caffeinated drinks, food, and smoking for at least 12 hours before
the study. Subjects were asked to withhold their current medications on the morning
of the study. All studies were conducted in a quiet, temperature-controlled room. On
arrival, the subject's height, weight, waist and hip circumference were measured as
described in Chapter 2. After 30 minutes of supine rest, participants underwent BP
measurements, and then blood samples were taken for creatinine, glucose,
triglycerides, and HDL cholesterol. After that, CF-PWV and FMD were measured.
All techniques were performed as described in Chapter 2.
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7.2.3 Laboratory investigations
Serum creatinine, plasma glucose, triglycerides, and HDL cholesterol were
quantified in the hospital biochemistry laboratory.
7.2.4 Diagnosis of the metabolic syndrome
The metabolic syndrome was diagnosed according to the criteria from the third
report of the National Cholesterol Education Program (NCEP) expert panel on
detection, evaluation, and treatment of high blood cholesterol in adults (Adult
Treatment Panel (ATP) III) (2002; Grundy et al., 2004). The diagnosis of the
metabolic syndrome was made when subjects had >3 risk factors for the metabolic
syndrome. Subjects with 0 - 1 and those with 2 risk factors for the metabolic
syndrome were classified as no metabolic syndrome and risk for developing
metabolic syndrome, respectively (see Table 2.2, Chapter 2, section 2.8).
7.2.5 Outcomes
Primary outcome variables were the presence of the metabolic syndrome and the
number of risk factors for the metabolic syndrome in relation to eGFR, CF-PWV,
and FMD, and the relationships of each risk factor for the metabolic syndrome (waist
circumference, SBP, DBP, glucose, triglycerides, and HDL cholesterol) to eGFR,
CF-PWV, and FMD.
7.2.6 Data analyses
Descriptive data is given as mean ± SD unless otherwise stated. The means of the
categorical data (subjects without metabolic syndrome, subjects with risk of
developing metabolic syndrome, subjects with the metabolic syndrome) were
compared by one-way ANOVA. Continuous data (risk factors for the metabolic
syndrome as 0 to 5 risk factors) were analysed by correlation coefficients for
univariate analysis using the Pearson method. Multivariate analysis was performed
using a stepwise linear regression. Dependent variables were CF-PWV and FMD.
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First, GFR and traditional cardiovascular risk factors that were not regarded as the
metabolic syndrome components including age, gender and smoking status were
entered into the first model. Thereafter, along with GFR and traditional
cardiovascular risk factors in the first model, the presence of the metabolic syndrome
(yes/no) and number of the metabolic syndrome risk factors (1 to 5 risk factors) were
entered into the second and third models, respectively. Finally, in the fourth model,
each components of the metabolic syndrome risk factors were consider individually.
Multiple coefficient of determination (r2) of each model was reported. Multivariate
analysis data were reported for both CF-PWV and FMD using standard regression
coefficient (ft value) of independent variables. A significant level was p value < 0.05.
7.3 Results
7.3.1 Subject characteristics
One hundred and fifteen CKD patients and 23 age-matched non-CKD controls were
enrolled into the study. The characteristics of the studied subjects are given in Table
7.1 (for full subject characteristics, see Appendix 1). Causes of CKD and the
medication used by the patients were similar to those summarised in Table 5.1,
Chapter 5.
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Table 7.1 Subject characteristics.
Control Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
23 28 30 30 20
eGFR






17/11 18/12 22/8 16/4




smoker (n) 2/21 9/19 5/25 6/24 4/16 0/7
Subjects without
MS (n (%)) 19(83) 17(61) 14(47) 21(70) 9(72) 3(42)
Subjects at risk






6(21) 7(23) 3(10) 6(3)
29±5 28±4 28±6 28±5
2 (29)
25±7
Key: *p < 0.01 for one-way ANOVA by CKD stage. Subjects without the metabolic
syndrome: subjects with 0 - 1 risk factor for the metabolic syndrome; subjects at risk of
developing metabolic syndrome: subjects with 2 risk factors for the metabolic syndrome;
subjects with the metabolic syndrome: subjects with >3 risk factors for the metabolic
syndrome. BMI: body mass index; eGFR: estimated glomerular filtration rate; MS: metabolic
syndrome.
Subjects were classified into 3 categories according to the number of risk factors for
the metabolic syndrome (no metabolic syndrome: subjects with 0-1 risk factor; risk
of developing metabolic syndrome: subjects with 2 risk factors; and metabolic
syndrome: subjects with >3 risk factors). 19 subjects (18%) had the metabolic
syndrome and 29 subjects (21%) were regarded as at risk of developing it. All three
categories were comparable in respect of age and eGFR (Table 7.2). As expected,
subjects with the metabolic syndrome had higher BMI, waist circumference, SBP,
DBP, glucose, triglycerides, and had lower FIDL cholesterol compared to those
without the metabolic syndrome or only at risk for developing it (Table 7.2).
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With regards to the relationship of the risk factors for the metabolic syndrome to
renal function, only SBP increased as eGFR declined (r2 = 0.11, p < 0.01). Waist
circumference, DBP, glucose, triglycerides, and HDL cholesterol showed no
relationship to renal function.
CF-PWV was higher in the metabolic syndrome group (Table 7.2, Figures 7.1 A &
C) whereas RAIx, CAIx, showed no relationship to the metabolic syndrome (Table
7.2). FMD was lower in the metabolic syndrome group (Table 7.2, Figures 7.1 B &
D) but this was not found to be significant. The endothelium-independent response
to GTN had no relationship to the metabolic syndrome (Table 7.2).
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Table 7.2 Risk factors for the metabolic syndrome, arterial stiffness and endothelial
function.












Risk factors for the metabolic syndrome
Waist circumference (cm)*
Systolic blood pressure (mmFIg)*























































Key: *p < 0.05 for one-way ANOVA by the metabolic syndrome groups. No MS: subjects with 0-1 risk
factor for the metabolic syndrome; risk for MS: subjects with 2 risk factors for the metabolic syndrome;
MS: subjects with >3 risk factors for the metabolic syndrome. CAlx: central augmentation index; CF-
PWV: carotid-femoral pulse wave velocity; eGFR: estimated glomerular filtration rate; FMD: flow-
mediated dilatation; HDL: high density lipoprotein; MS: metabolic syndrome; GTN: endothelium-




A No MS; r2= 0.06, p =
Risk for MS; r2 = 0.06, p = ns
















B No MS; r2 = 0.00,
Risk for MS; r2 = 0.04, p = ns
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Key: No MS (white circle, —fitted line): subjects without metabolic syndrome (risk factors =
0-1); Risk for MS (black square, fitted line): subjects at risk of developing metabolic
syndrome (risk factors = 2); MS (black triangle, — fitted line): subjects with metabolic
syndrome (risk factors > 3). For C & D, p values are for one-way ANOVA; eGFR: estimated
glomerular filtration rate; ns: non-significant.
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7.3.2 Relationships and predictors of carotid-femoral
pulse wave velocity
Univariate analysis was performed to assess the relationship of CF-PWV to the
number of the metabolic syndrome risk factors, each of the risk factor for the
metabolic syndrome, and related parameters which are not included in the NCEP
ATIP III criteria (eGFR, age, BMI, and waist/hip ratio). CF-PWV correlated with the
number of the metabolic syndrome risk factors (Figures 7.1 A & C). For each of the
risk factors for the metabolic syndrome, CF-PWV increased with waist
circumference, SBP, DBP (r2 = 0.10, p < 0.01), and glucose (Figures 7.2 A, C, D).
CF-PWV also increased with triglycerides and inversely correlated to HDL
cholesterol but these relationships did not reach significance. Additionally, CF-PWV
correlated with eGFR (r2 = 0.08, p < 0.01), age (r2 = 0.23, p < 0.01), and waist/hip
ratio (Figure 7.2B) but not with BMI.
In multivariate analysis, when renal function and conventional risk factors including
age, gender, and smoking status were entered into the model, renal function and age
were independent predictors of arterial stiffness (Table 7.3, Model 1). When either
the presence of the metabolic syndrome or the number of risk factors for the
metabolic syndrome a subject had were considered, both of them, together with renal
function and age, independently predicted CF-PWV (Table 7.3, Models 2 & 3).
When the individual risk factors for the metabolic syndrome were considered, renal
function was replaced by waist circumference and SBP as independent predictors of
CF-PWV (Table 7.3, Model 4).
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Figure 7.2 Correlations between CF-PWV and SBP, plasma glucose, waist
circumference, and waist/hip ratio.
A r2 = 0.09, p < 0.01 B r2 = 0.12, p < 0.01
Waist circumference (cm) Waist/hip ratio
r2 = 0.25, p < 0.01 D r2 = 0.09, p < 0.01
SBP (mmHg) Plasma glucose (mmoI/L)
Key: Male: black square; female: white circle. Figures A and B: male: — fitted line, female:
— fitted line. Figures C and D: —fitted line for total.
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Table 7.3 Multivariate analysis of renal function, conventional cardiovascular risk
factors, and risk factors for the metabolic syndrome, as independent predictors of CF-
PWV.
CF-PWV
Predictors Model 1 Model 2 Model 3 Model 4
Estimated glomerular filtration rate -0.01** -0.01** -0.01** -0.11
Age 0.06* 0.06* 0.06* 0.05*
Gender (male/female) -0.14 -0.12 -0.13 0.01
Smoking status (yes/no) 0.02 0.00 0.02 -0.02
The presence of MS (yes/no) - 0.73**
Number of MS risk factors (0 to 5) - - 0.25*
Waist circumference - - - 0.02*
Systolic blood pressure - - - 0.03*
Diastolic blood pressure - - - -0.21
Glucose - - - 0.04
Triglycerides - - - 0.06
HDL cholesterol - - -0.08
r2 0.26* 0.30* 0.31* 0.45*
Key: The table gives standard regression coefficients (/? values).*p < 0.01, **p < 0.05. CF-
PWV: carotid-femoral pulse wave velocity; HDL: high density lipoprotein; MS: metabolic
syndrome; r2: multiple coefficient of determination.
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7.3.3 Relationships and predictors of flow-mediated
dilatation
In univariate analysis, FMD correlated with eGFR (r2 = 0.04, p < 0.05) but not the
number of the metabolic syndrome risk factors (Figures 7.1 B & D), age, or BMI. In
terms of each of the risk factors for the metabolic syndrome, FMD correlated with
waist circumference, SBP, and DBP but not plasma glucose, triglycerides, and F1DL
cholesterol (Figures 7.3 A, C, D). FMD also correlated with waist/hip ratio (Figure
7.3B).
In multivariate analysis assessing renal function and conventional risk factors, eGFR
was an independent predictor of FMD (Table 7.4, Model 1). When either the
presence of the metabolic syndrome or the number of the metabolic syndrome risk
factors was added to the model, renal function still independently predicted FMD
(Table 7.4, Models 2 & 3). However, when the risk factors for the metabolic
syndrome were added individually to the model, renal function was substituted by
SBP as an independent predictor ofFMD (Table 7.4, Model 4).
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Figure 7.3 Correlations between FMD and SBP, plasma glucose, waist circumference,
and waist/hip ratio.






















r2 = 0.09, p < 0.01 D r = 0.01, p = NS
«>° o%
^ ■ t
80 100 120 140
SBP (mmHg)
3 4 5 6
Plasma glucose (mmol/L)
Key: Male: black square; female: white circle. Figures A and B: male: — fitted line, female:
— fitted line. Figures C and D: — fitted line for total.
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Table 7.4 Multivariate analysis of renal function, conventional cardiovascular risk
factors, and risk factors for the metabolic syndrome, as independent predictors of
FMD.
FMD
Predictors Model 1 Model 2 Model 3 Model 4
Estimated glomerular filtration rate 0.02** 0.02** 0.02** 0.09
Age -0.09 -0.09 -0.09 -0.05
Gender (male/female) 0.12 0.12 0.12 0.06
Smoking status (yes/no) -0.02 -0.02 -0.02 -0.03
The presence of MS (yes/no) - -0.07
Number of MS risk factors (0 to 5) - - -0.16
Waist circumference - - - -0.11
Systolic blood pressure - - -0.06*
Diastolic blood pressure - - - 0.10
Glucose - - - -0.05
Triglycerides - - - -0.06
HDL cholesterol - - - 0.09
r2 0.04** 0.04** 0.04** 0.09*
Key: The table gives standard regression coefficients (Rvalues). *p < 0.01, **p < 0.05; FMD:





In minimally co-morbid CKD patients with eGFR ranging from 8 to 154
ml/min/1.73m2,1 have previously shown in Chapter 5 that renal function is related to
an increase in arterial stiffness and endothelial dysfunction, measured by CF-PWV
and FMD, respectively. Here, I have further shown that, regardless of renal function,
CKD patients with the metabolic syndrome have higher arterial stiffness compared
to those without the metabolic syndrome. The presence of the metabolic syndrome
and the number of risk factors for it independently predict arterial stiffness.
Furthermore, when risk factors for the metabolic syndrome were added individually
into multivariate analysis, waist circumference and SBP were determinants of CF-
PWV, independent of renal function, age, gender, and smoking status.
7.4.2 Relationships and predictors of carotid-femoral
pulse wave velocity
CKD patients recruited to this study were carefully chosen to have low co-morbidity.
The prevalence of the metabolic syndrome in this CKD population is thus lower than
previously reported in dialysis (Young et al., 2007; Zhe et al., 2008), hypertensive
(Mule et al, 2006; Schillaci et al., 2005; Seo et al., 2005), and diabetic patients
(Martens et al., 2008; Yokoyama et al., 2007), but is comparable to healthy subjects
(18% versus 10 - 19%) (Achimastos et al., 2007; Ferreira et al., 2007; Ferreira et al.,
2005; Li et al., 2005). Despite this selection bias against the metabolic syndrome and
its risk factors, there is an increase in arterial stiffness in CKD patients with the
metabolic syndrome or risk factors for it, irrespective of renal function, and that
these independently predict arterial stiffness when considered alongside conventional
risk factors. This finding is in keeping with previous data from healthy subjects
(Czernichow et al., 2005; Ferreira et al., 2007; Ferreira et al., 2005; Kovaite et al.,
2007; Li et al., 2005; Nakanishi et al., 2003; van Popele et al., 2000), hypertensive
(Mule et al., 2006; Schillaci et al., 2005; Seo et al., 2005; Vyssoulis et al., 2008),
and diabetes patients (Martens et al., 2008; Yokoyama et al., 2007).
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Additionally, in this study, waist circumference predicts arterial stiffness,
independent of renal function, age, BP, and gender, in CKD patients. This finding
was previously shown only in hypertensive patients (Schillaci et al., 2005). Obesity
is associated with an increased risk of cardiovascular disease (Elsayed et al., 2008)
and with increased arterial stiffness (Orr et al., 2008). This finding supports waist
circumference, a marker of central obesity, as a better surrogate for arterial stiffness
than BMI or other cholesterol subtypes such as LDL cholesterol and triglycerides in
uraemic patients.
7.4.3 Relationships and predictors of flow-mediated
dilatation
The finding that, regardless of renal function, CKD patients with the metabolic
syndrome did not have significant impaired endothelial function was similar to data
from studies in healthy subjects (Mattsson et al., 2008; Wendelhag et al., 2002),
subjects at risk of developing diabetes mellitus (Ghiadoni et al., 2008; Scuteri et al.,
2008) and those with peripheral artery disease (Golledge et al., 2008), but not all
(Kovaite et al., 2007; Lind, 2008). In a study of -1,000 elderly subjects including
those with cardiovascular disease and diabetes where endothelial function was
measured by both the invasive forearm technique and FMD (Lind, 2008), only the
invasive forearm technique showed a reduction of endothelial function in the
metabolic syndrome group. It is recognised that the invasive forearm technique
measures endothelial function of the resistance artery while FMD measures
endothelial function of the conduit artery. Thus, it is possible that the deterioration in
endothelial function in the metabolic syndrome may occur predominantly in the
resistance artery and, hence, by using the FMD technique, endothelial dysfunction
was not detected in this study cohort. In addition, the lack of an association between
a number of risk factors for the metabolic syndrome and FMD seen here is in
contrast to a previous report in subjects at risk of developing diabetes mellitus
(Ghiadoni el al., 2008). However, it is possible that a genetic-linked to diabetes and
insulin resistance state of the subjects may confound the findings of that study.
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Of all the risk factors studied here, conventional and metabolic syndrome-related,
only SBP predicts endothelial function in the final multivariate analysis. These
results both confirm and contrast with previous data. In support of the current study,
evidence has shown that BP is an independent predictor of endothelial function
(Scuteri et al., 2008). Additionally, a study reported that the presence of the
metabolic syndrome was not a predictor of endothelial function (Kovaite et al.,
2007). By contrast, a study has shown that renal function predicts endothelial
function in CKD patients (Annuk et al., 2001). However, that study was performed
in CKD patients with diabetes in which the nature of the disease itselfmay confound
the finding and endothelial function was assessed using an invasive forearm
technique which measured endothelial dysfunction in a different vascular bed
compared to the FMD technique used in this study. The presence of the metabolic
syndrome was also shown to predict endothelial function but this was studied in
patients with peripheral arterial disease (Golledge et al., 2008).
As previously shown in Chapters 5 and 6 that uraemia does not contribute to the
increase in cardiovascular complications in CKD patients with low comorbidity. Yet,
emerging cardiovascular risk factors including inflammation, oxidative stress and the
imbalance between NO and ET-1 systems significantly contribute to these. The
findings of Chapter 7 are in keeping with the hypotheses of the study. However, the
finding that the presence of the metabolic syndrome and number of the metabolic
syndrome risk factors are predictors of PWV should be interpreted with caution as
SBP and DBP are in the criteria for a diagnosis of the metabolic syndrome.
Nonethless, this study, again, confirms the role of BP in determining cardiovascular
complications and importantly extends the type of emerging cardiovascular risk
factors that determine PWV to obesity which could be targeted as another modifiable
risk factor in reduction of cardiovascular disease in CKD.
Of note, an inverse association between DBP and CF-PWV and a positive
association between DBP and FMD seen in the multivariate analysis of this study are
surprising. However, these could be explained by an effect of pulse pressure which is
positively associated with CF-PWV and inversely related to FMD since both SBP
and DBP were entered into the analysis.
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7.4.4 Limitations
There are several criteria for the diagnosis of the metabolic syndrome (Grundy et al.,
2004). As the patients of this study are non-diabetic, we cannot use the metabolic
syndrome diagnosis criteria proposed by WHO and, therefore, the evaluation of an
effect of insulin resistance to arterial stiffness and endothelial dysfunction is limited,
and it may not be comparable with other studies using WHO criteria. Some of the
medication taken by our patients, such as ACE inhibitors, ARBs, (3-blockers, and
statins, may have had effects on both arterial stiffness and endothelial dysfunction.
However, all patients were stabilised on their therapy and did not receive their
medication on the day of the study until after measurements had been made. The low
number of smokers in this study may be responsible for the lack of expected
relationships between smoking status and arterial stiffness and endothelial
dysfunction. In addition, as this was a cross-sectional study, we cannot fully define
the causal relationships behind the associations described.
7.4.5 Summary
In summary, the present study shows that, in the absence of cardiovascular disease
and diabetes, irrespective of renal function, age, smoking status, and gender, CKD
patients with the metabolic syndrome have increased arterial stiffness compared to
those without the metabolic syndrome but there was no difference in endothelial
function. Whilst BP remains the strongest determinant of both arterial stiffness and
endothelial dysfunction, the presence of the metabolic syndrome or risk factors for it
is also an important determinant of arterial stiffness in the CKD population. As these
are not related to renal function, they provide a target for intervention to improve
cardiovascular outcomes at all stages ofCKD.
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Chapter 8
Relationships of coronary artery
calcification and fetuin-A to
arterial stiffness and endothelial
dysfunction in chronic kidney
disease
8.1 Introduction
Arterial calcification is a common pathological process in CKD (Moe et al., 2008;
Salusky et al., 2002). An increase in the calcification inducers - including
hypercalcaemia, hyperphosphataemia, elevated calcium-phosphate products,
increased PTH levels, and excessive treatment with vitamin D, - and a reduction in
the calcification inhibitors such as fetuin-A contribute to this (Moe et al., 2008).
Arterial calcification reduces aortic and arterial elasticity, leading to an impairment
of cardiovascular haemodynamics and, hence increase morbidity and mortality
(Demer et al., 2008; London et al., 2005).
Arterial calcification occurs mainly in the aorta; however, it is also present in the
coronary arteries (Dellegrottaglie et al., 2005). Coronary artery calcification (CAC)
quantified using computed tomography and presented as CAC score is commonly
used as a technique for measuring arterial calcification (Dellegrottaglie et al., 2005;
Moe et al., 2008). CAC scores are increased in ESRD (Kobayashi et al., 2008;
Kramer et al., 2005; Porter et al., 2007). Evidence suggests that the process of CAC
starts before patients reach ESRD and the extent of CAC may substantially be
related to a declining GFR (Piers et al., 2009). Additionally, CAC is associated with
arterial stiffness in ESRD (Haydar et al., 2004; Nitta et al., 2004; Schlieper et al.,
2009). A recent study also suggests the relationship between CAC and arterial
stiffness in pre-dialysis CKD (Lemos et al., 2007). Endothelial dysfunction is an
initial step in the development of atherosclerotic plaque and thus may also play a
crucial role in arterial calcification. Studies have shown the associations of
endothelial dysfunction and CAC in patients with coronary artery disease (Huang et
al., 2005; Ramadan et al., 2008) but there are no data in CKD.
Fetuin-A, a potent calcification inhibitor generated from hepatocytes, plays an
important role in the pathogenesis of arterial calcification. Circulating fetuin-A
concentrations are reduced in ESRD compared to those of healthy subjects
(Mazzaferro et al., 2007). A few studies have suggested a relationship of fetuin-A to
arterial stiffness (Hermans et al., 2006; Kuzniar et al., 2008) and endothelial
dysfunction (Caglar et al., 2007) in ESRD. Data regarding arterial stiffness and
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endothelial dysfunction in pre-dialysis CKD is limited. However, a recent study
suggests a graded decrease of fetuin-A concentrations with declining GFR (Caglar et
al., 2008b).
8.1.1 Aims and hypotheses
The aims of this study were to assess the relationships of CAC and fetuin-A to
arterial stiffness and endothelial dysfunction in a group of CKD patients with
minimal co-morbidity from CKD stage 1 to pre-dialysis.
Hypotheses:
1. In this minimally co-morbid CKD group, the presence and extent of arterial
calcification, measured using the CAC score, would increase as renal function
declined while there would be a reduction in the circulating levels of the calcification
inhibitor, fetuin-A.
2. The increase in CAC score and the reduction of fetuin-A concentrations would
independently relate to arterial stiffness, measured using CF-PWV, and endothelial
dysfunction, measured using FMD in this group of patients.
8.2 Methods
8.2.1 Subjects
From the subjects recruited for a study investigating the relationship of arterial
stiffness and endothelial dysfunction to renal function (Chapter 5), 25 subjects were
sub-recruited to this study. There were 5 subjects in each CKD stage 1 to 3 and 5
subjects in stage 4 and 5 combined. Five age-matched healthy subjects were also
recruited as a control group. The inclusion and exclusion criteria were similar to the
criteria described in Chapter 5.
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8.2.2 Study design and protocol
This was a prospective, cross-sectional study. For the measurement of CF-PWV and
FMD, subjects refrained from alcohol for at least 24 hours and caffeinated drinks,
food and smoking for at least 12 hours before the study. Subjects were asked to
withhold their current medication on the morning of the study. All CF-PWV and
FMD measurements were performed in a quiet, temperature-controlled room. After
30 minutes of supine rest, participants underwent BP measurements, and then blood
samples were taken for creatinine, glucose, total cholesterol, electrolytes, calcium,
phosphate, PTH, and fetuin-A. After that, CF-PWV and FMD were measured. All
techniques were performed as described in Chapter 2. Within a period of 1 month
after CF-PWV and FMD measurements, each subject underwent 16-slice MDCT in
order to quantify the presence and extent of CAC. The quantification of CAC score
was performed as described in Chapter 2, section 2.7 (Figure 2.2 and Table 2.1).
8.2.3 Laboratory investigations
Serum fetuin-A concentrations were determined by a commercially available ELISA
(BioVendor GmbH, Heidelberg, Germany), as previously described in Chapter 2,
section 2.9.2.7.
8.2.4 End points
The end points were the CAC score and serum fetuin-A concentrations relating to
GFR, CF-PWV, and FMD.
8.2.5 Data analyses
Descriptive data is given as mean ± SEM. The means of the subject characteristics
between controls and CKD patients, and subjects with CAC and without CAC were
compared using the unpaired Student's t test. Subjects were also divided into 4
groups according to the severity of CAC: group 1 (normal): CAC score = 0; group 2
(minimal): CAC score = 0 - 10; group 3 (mild): CAC score =11-100; and group 4
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(moderate): CAC score >100, according to the CAC cut points proposed by He, et al
(He et al., 2000). CF-PWV and FMD between 4 groups were compared by one-way
analysis of variance (ANOVA). Correlation coefficients were analysed using the
Pearson method. A significant level was p value < 0.05.
8.3 Results
8.3.1 Subject characteristics
Twenty five subjects were enrolled to the study. Table 8.1 presents the
characteristics of the control and CKD patients as a whole. For patients, the duration
of having CKD was 13+4 (range 1 - 55) years. As expected, patients had lower
eGFR. Age, gender, BP, glucose, cholesterol, BMI and calcium-phosphate related
parameters were similar between the patients and controls. The characteristics of
each CKD patient including diagnosis and medication are summarised in Table 8.2.
There were 2 patients on a vitamin D supplementation and 1 patient on calcium
acetate.
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Table 8.1 Subject characteristics.
Controls CKD patients
n 5 20
Male/Female (n) 4/1 15/5
Smoker/Non-smoker (n) 1/4 8/12
eGFR (ml/min/1.73m2)* 98±8 (76-123) 61±7 (13-108)
Age (year) 49±3 (42-57) 48±2 (29-64)
Body mass index (kg/m2) 29±4 (20-46) 29+1 (19-41)
Mean arterial pressure (mmHg) 89±6 (75-106) 88±2(74-106)
Glucose (mmol/L) 5.8±0.2 (4.9-5.8) 4.8±0.2 (2.5-5.7)
Total cholesterol (mmol/L) 5.0±0.3 (4.2-5.8) 4.5±0.1 (3.7-5.8)
Calcium (mmol/L) 2.34±0.04 (2.25-2.46) 2.36±0.03 (2.07-2.57)
Phosphate (mmol/L) 1.99±0.95 (0.97-5.80) 1.19+0.08 (0.75-2.00)
Bicarbonate (mmol/L) 26±1 (22-28) 26±1 (19-30)
Parathyroid hormone (ng/L) 66±7 (78-89) 92±21 (17-323)
Key: Data presented as mean ± SEM (range); *p < 0.01 for the unpaired Student's t test;
eGFR: estimated glomerular filtration rate.
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8.3.2 Coronary artery calcification score and fetuin-A
The overall mean CAC score was 24±14 (range 0-342). The CAC score of CKD
patients was higher than that of the controls but this did not reach significance
(25±17 (range 0-342) and 19±18 (range 0-89), respectively, p = 0.9). The overall
mean fetuin-A concentrations were 0.4±0.0 (range 0.2-0.6) g/L. CKD patients and
controls had comparable fetuin-A concentrations (0.4±0.0 (range 0.2-0.6) g/L and
0.4±0.1 (range 0.2-0.5) g/L, respectively, p = 0.9). There was no effect of gender on
the CAC score and fetuin-A.
Neither CAC score nor fetuin-A correlated with eGFR (r2 = 0.03 and 0.02,
respectively, both p > 0.05). eGFR linearly correlated with potassium, bicarbonate,
and PTH (r2 = 0.47, 0.28, 0.41, respectively, all p < 0.01) but had no relationship to
• t # 2calcium. CAC score and fetuin- A did not correlate with each other (r = 0.00, p =
0.66).
Subjects were classified as those with and without CAC (Table 8.3). Eleven subjects
(2 controls and 9 CKD patients) had CAC score >0 giving an overall prevalence of
CAC of 44%. The prevalence of CAC in the controls and CKD patients were 40%
and 45%, respectively. The mean of the CAC score in subjects with CAC was 53±31
(range 0.2-342). Fetuin-A concentrations, renal function, or calcium-phosphate
related parameters were not different between subjects with or without CAC (Table
8.3). CKD patients with CAC had CKD for a longer duration compared to patients
without CAC but this was not significant (Table 8.3). Subjects with CAC had
significantly higher CF-PWV compared to those without (Table 8.3, Figure 8.1).
However, FMD and response to GTN were lower in subjects with CAC than those
without CAC but these were not significant (Table 8.3, Figure 8.1).
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Table 8.3 Demographic data, CAC score, fetuin-A, CF-PWV, and FMD of the subjects
with and without CAC.








Duration of CKD in patients (year) 20±7 (1-55)
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10.7211.43 (3.00-20.40) 11.0510.98 (6.70-17.80)
Key: Data presented as mean 1 SEM (range); *p< 0.05 for the unpaired Student's t test; CF-
PVW: carotid femoral pulse wave velocity; eGFR: estimated glomerular filtration rate; FMD:
flow-mediated dilatation; GTN: endothelium-independent vasodilating response to glyceryl
trinitrate.
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Figure 8.1 CF-PWV and FMD in subjects with and without CAC.
□ Subjects w ithout CAC ■ Subjects w ith CAC
Key: *p < 0.05 for the unpaired Student's t test comparing subjects with and without CAC.
8.3.3 Relationships to carotid-femoral pulse wave
velocity and flow-mediated dilatation
Dividing all subjects into 4 groups according to the severity of the CAC score, CF-
PWV showed a trend of incrementally increased with the CAC score while FMD did
not (Figure 8.2). In univariate analysis, the CAC score correlated to CF-PWV (r2 =
0.18, p < 0.05) but not FMD. The CAC score also positively correlated with the
duration of CKD (r2 = 0.53, p < 0.01, Figure 8.3) but not with renal function,
calcium, phosphate, bicarbonate, PTFI, or conventional cardiovascular risk factors
including age, gender, smoking status, BP, glucose, and cholesterol. The correlation
between the CAC score and CF-PWV remains after adjusting for conventional
cardiovascular risk factors, renal function, and calcium-phosphate parameter. By
contrast, serum fetuin-A concentrations did not correlate with CF-PWV, FMD, renal
function, conventional cardiovascular risk factors, or any uraemia-related
parameters.
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(normal): CAC score = 0; group 2 (minimal): CAC score = 1-10; group 3 (mild): CAC score
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The current study shows that, irrespective of renal function, minimally co-morbid
CKD patients who develop CAC have increased arterial stiffness and a trend of
impaired endothelial function compared to those without CAC. In contrast, fetuin-A
has no relationship to arterial stiffness and endothelial dysfunction in this group of
patients.
The prevalence ofCAC in this study is lower than in previous reports in dialysis and
pre-dialysis patients (Adeney et al., 2009; Barraclough et al., 2008; Garland et al.,
2008; Lemos et al., 2007; Mazzaferro et al., 2007; Piers et al., 2009; Porter et al.,
2007; Russo et al., 2007). The extent ofCAC seen here is also very low compared to
previous data in pre-dialysis CKD with the same level of renal function (mean CAC
score 53 versus 300 to 640) (Barraclough et al., 2008; Garland et al., 2008; Piers et
al., 2009; Porter et al., 2007; Russo et al., 2007). Most of the previous studies
include patients with diabetes (Barraclough et al., 2008; Garland et al., 2008; Lemos
et al., 2007; Mazzaferro et al., 2007; Porter et al., 2007) or subjects with
cardiovascular co-morbidity (Barraclough et al., 2008; Lemos et al., 2007;
Mazzaferro et al., 2007). All of these strongly reflect the influence of dialysis,
diabetes, and cardiovascular co-morbidity on the development and progression of
atherosclerosis and support the fact that CAC is a marker of increased atherosclerosis
and cardiovascular risk.
The finding of no relationships of either CAC or fetuin-A to renal function is
consistent with recent studies in pre-dialysis CKD (Garland et al., 2008; Piers et al.,
2009) and patients with coronary artery disease (Ix et al., 2006) but is in contrast to
data in ESRD (Kobayashi et al., 2008; Kramer et al., 2005; Porter et al., 2007). A
study performed by Caglar, et al. has shown a graded decline in fetuin-A
concentrations from CKD stage 1 to 5 (Caglar et al., 2008b) which is different from
the finding of the current study. Figure 8.4 depicts fetuin-A concentration of the two
studies. As these two studies use a similar study design and technique for
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quantifying fetuin-A concentrations, the only explanation of the difference is that the
study by Caglar, et al has much larger sample size (241 subjects) compared to this
study.
Figure 8.4 Comparing fetuin-A concentrations of this study to Caglar, et al. 2008.
Controls Stage 1 Stage 2 Stage 3 Stage 4 & 5
CKD stages
□ this study H Caglar. et al. 2008
The finding that CAC is highly associated with the duration of CKD is interesting.
As this study was performed in patients with relatively low co-morbidity, this
suggests that it takes time for uraemia on its own to develop atherosclerosis. The
high prevalence of CAC seen in the literature is possible to be markedly influenced
by co-morbidity. This is also supported by results from a study in CKD stages 3 to 5
that CAC is more associated with the presence of atherosclerosis than GFR (Piers et
al., 2009). One of the mechanisms of increased arterial calcification is a shift in the
balance between calcification inducers/inhibitors towards an increased inducer side
and reduced inhibitors. Here, although the levels of calcification inducers such as
calcium-phosphate products were associated with GFR, the levels were not
significantly increased compared to the healthy control group and thus the balance
between calcification inducers/ inhibitors may not be altered.
Here, the association between the CAC score and CF-PWV is in keeping with
reports in patients with diabetes mellitus (Tsuchiya et al., 2004), those with coronary
artery disease (Mitsutake et al., 2007), middle-aged (Kullo et al., 2006) and elderly
subjects (van Popele et al., 2006). It is also consistent with data in dialysis (Haydar
et al., 2004; Nitta et al., 2004; Schlieper et al., 2009) and pre-dialysis CKD (Lemos
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et al., 2007). Additionally, in some of those studies, CAC is an independent
predictor of arterial stiffness (Haydar et al, 2004; Nitta et al., 2004). The findings
confirm the role for arterial calcification in the pathogenesis of arterial stiffening
leading to haemodynamic disturbance in CKD patients.
No association between the CAC score and FMD was found in this study which is in
contrast to previous data in patients with coronary artery disease, either symptomatic
(Huang et al., 2005) or asymptomatic (Ramadan et al., 2008) but it is in keeping
with data from a study in patients with erectile dysfunction (Kaiser et al., 2004).
Again, studies which show associations were confounded with diabetes and
cardiovascular disease which are, themselves, related to both endothelial dysfunction
and CAC.
The current study found no associations between fetuin-A and either CF-PWV or
FMD. This is in contrast to studies in dialysis (Hermans et al., 2006; Kuzniar et al.,
2008) and male subjects with normal renal function (Roos et al., 2009), which show
associations of fetuin-A to arterial stiffness, and studies in renal transplantation
(Caglar et al., 2007) and pre-dialysis (Caglar et al., 2008b) which shows
relationships of fetuin-A to endothelial dysfunction. The finding that the CAC score
was not associated with fetuin-A concentration is in contrast to the theory that fetuin-
A acts as a calcification inhibitor and its levels are reduced in accordance with
increased CAC. However, in this study, subjects have no established cardiovascular
disease and their extent of CAC seen here is also minor compared to those with co¬
morbidity. It is possible that fetuin-A would probably be more related to
cardiovascular co-morbidity and, thus, be unaltered in this group of patients.
8.4.2 Limitations
The number of subjects studied was small and thus the study may not be sufficiently
powered enough to show significant differences. At the time of starting the study,
there was no study directly looking at the relationship of the CAC score and fetuin-A
to arterial stiffness and endothelial dysfunction. Therefore, the calculation of the
appropriate sample size was not possible. The number of 5 subjects per groups was
chosen as the best fit in line with the possibility of recruiting patients when the study
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started. Some of the medication taken by the patients, such as ACE inhibitors, ARBs,
P-blockers, and statins may have had effects on both arterial stiffness and endothelial
function. However, all patients were stabilised on their therapy and did not receive
their medications on the day of the study until after measurements had been made.
Other medication such as oral calcium supplements, vitamin D supplements, and
calcium-based phosphate binders may also influence the levels of calcium/phosphate
and the extent of CAC. But the majority of the subjects studied were not taking any
of these forms of medication. In addition, because of the cross sectional design of
this study, causal relationships behind the associations described cannot be fully
defined.
8.4.3 Summary
Minimally co-morbid CKD patients have low prevalence and extent of CAC.
Irrespective of renal function, CKD patients who develop CAC have increased
arterial stiffness. Fetuin-A was not related to either arterial stiffness or endothelial





reduction in proteinuria and
arterial stiffness after acute
endothelin-A receptor
antagonism in chronic kidney
disease
9.1 Introduction
Hypertension is a frequent finding in CKD patients and its prevalence increases as
CKD progresses (Anonymous, 2002a). Despite advances in antihypertensive
treatment, the majority of CKD patients fail to reach target BP (Peralta et al., 2005).
Proteinuria is a common feature of CKD and is independently associated with an
adverse renal outcome (Jafar et al., 2003). ACE inhibitors and ARBs are anti¬
hypertensive agents which are thought to reduce proteinuria to a greater extent than
accounted for by BP lowering alone and are regarded as the main treatment for
proteinuria in CKD (Jafar et al., 2003). Yet, many CKD patients have significant
residual proteinuria despite optimal treatment (Ruggenenti et al., 2008).
CKD is strongly associated with cardiovascular disease (Parfrey et al., 1999; Sarnak
et al., 2000; Stack et al., 2001). Hypertension (McCullough et al., 2007), proteinuria
(Hillege et al., 2002), arterial stiffness (Blacher et al., 1999a) and endothelial
dysfunction (Endemann et al., 2004) are important contributors to cardiovascular
risk in CKD. It is important to search for newer treatments in CKD that will not only
lower BP and proteinuria beyond the levels achieved with standard therapies but will
also have favourable effects on arterial stiffness and endothelial function and thus
offer longer term cardiovascular and renal protection.
ET-1 is an endogenous vasoconstrictor produced within the vasculature. In CKD,
ET-1 is involved in the development and progression of renal injury. ET-1 exerts its
action via ETa and ETb receptors, with the principal effects in CKD being ETa
receptor mediated. Evidence has shown that selective ETA receptor antagonism, but
not mixed ETA/b antagonism, reduces BP, increase renal blood flow, and reduces the
effective filtration fraction (FF) in CKD patients (Goddard et al., 2004b). However,
this was a small study with only 8 subjects included and 6 of them were treated with
ACE inhibitors which may also reduce BP and confound the finding. Additionally,
ET-1 is associated with arterial stiffness and endothelial dysfunction in diabetes
(Karakitsos et al., 2007), ischaemic heart disease (Heintz et al., 1993) and dialysis
patients (Dammers et al., 2005; Demuth et al., 1998). Data regarding the effects of
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ET antagonism on arterial stiffness and endothelial dysfunction in pre-dialysis CKD
is limited.
9.1.1 Aims and hypotheses
Based on the previous work (Goddard et al., 2004b), the effects of selective ETA
antagonism, BQ123, on proteinuria, arterial stiffness and endothelial dysfunction
were studied in non-diabetic CKD patients who are not on dialysis.
Hypotheses:
1. Selective ETA antagonism would reduce proteinuria and arterial stiffness and
endothelial dysfunction.
2. These effects would be greater than those achieved with BP reduction alone.
Importantly, as the synergism between ACE inhibitors and selective ETA receptor
antagonism was previously shown (Goddard et al., 2004a). I anticipated that these
effects might occur on top of the benefits associated with standard treatment with
ACE inhibitors and/or ARBs.
9.2 Methods
9.2.1 Subjects
Twenty two patients, aged 18-70 years with stable proteinuric CKD, were recruited
into the studies. Patients who were on dialysis or with a renal transplant were
excluded. Patients with significant co-morbidity, including diabetes mellitus, heart
disease, lung disease, and peripheral vascular disease were excluded. Patients with
vasculitis and systemic inflammatory disease were also excluded to avoid other
influence on vascular reactivity. All patients were treated with ACE inhibitors and/or
ARBs. Doses of one or both drugs were titrated to the maximum tolerated. All
medication was unchanged over a 3-month period prior to the studies.
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9.2.2 Drugs
BQ123 (Clinalfa AG), a selective ETa receptor antagonist, was infused at 1000
nmol/min for 15 minutes. This dose was selected from previous studies as being ETa
selective based on plasma BQ123 concentration and relating these to the binding
constant for the ETA receptor, as well as by a lack of rise in plasma ET-1
concentration after its infusion (Goddard et al., 2004b). BQ123 was dissolved in
15ml of 0.9% physiological saline (Baxter Healthcare Ltd) and infused intravenously
at a constant rate of 1 ml/min. A saline vehicle was administered as a placebo.
Nifedipine 10 mg (Adalat, Bayer) was used as an active control and was
administered orally at the same time as BQ123 or saline was started in its respective
phase. Nifedipine was selected as an active control because of the similarity of its
antihypertensive profiles and effects on renal haemodynamics to BQ123. Moreover,
it is a clinically tolerable agent which is also used as a standard treatment in CKD
patients (de Leeuw et al., 2004).
PAH (Clinalfa) and inutest (Fresenius Pharma) for the measurements of renal plasma
flow and GFR, respectively, were dissolved in 5% dextrose (Baxter) and
administered as a bolus loading dose of 0.4g of PAH and 3.5g of inutest in 100ml of
dextrose over 15 minutes, along with a maintenance infusion of 6.6g/l of PAH and
10g/l of inutest at a rate of 2 ml/min. For subjects with a calculated GFR <50
ml/minor <30 ml/min, doses of PAH and inutest were reduced by one third and two
third, respectively (see Chapter 2, section).
9.2.3 Study design and protocol
This was a randomised, double blind, placebo-controlled study. As previous studies
with BQ123 have shown a reduction in BP in CKD patients and this BP reduction
may contribute to changes in arterial stiffness and protein reduction, nifedipine (10
mg) was used as an open-label active control in a substudy of 10 subjects. All of the
subjects attended for 2 visits, receiving placebo and BQ123 in a randomised order
with those taking part in the substudy (nifedipine, 10 mg) randomly chosen and
attended for 3 randomised visits. Each study visit was separated by at least a 7-day
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washout period to ensure complete washout of the study drugs. This washout period
was selected based on the fact that the haemodynamic changes of BQ123 return to
the baseline after 4 hours (Goddard et al., 2004b) and the half-life of nifedipine is ~2
hours. An example of a randomisation of a studied drug in one patient is given in
Figure 9.1.
Figure 9.1 An example of a randomisation of a study in one patient.
7 days
washout





For the duration of the study, subjects were asked to adhere to their usual salt intake.
All subjects abstained from alcohol, nicotine and caffeine-containing products for 24
hours. Subjects had a light breakfast before attending on each study day. All studies
were conducted in a quiet, temperature-controlled room (22-24°C) with the subject
recumbent throughout, except when voiding urine. All patients completed a 24-urine
collection for quantification of proteinuria on each study day to assess equivalent
baseline urinary protein leak between study phases. Patients continued taking their
normal medications up to and including each study day with the exception of
diuretics which they omitted that morning.
On the study day, a cannula was inserted into an antecubital vein in each arm.
Diuresis was induced by administrating 500ml of 5% dextrose intravenously over 30
minutes through the left arm cannula. Then, maintenance infusion of PAH and
inutest and 5% dextrose at 180 ml/hr continued throughout the study. After a 2-hour
equilibration period, baseline measurements were made over 1 hour. BQ123 or a
placebo was administered through the cannula on the right arm or with nifedipine
was given orally, followed by 4 hours of further measurements (Figure 9.2). BP,
cardiac output - as measured by cardiac index (CI), and heart rate were recorded
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every 15 minutes throughout the study using a well-validated non-invasive
automated technique (Thomas, 1992). Urine was collected every 60 minutes by
spontaneous voiding.
At the midpoint of each collection period, blood samples were taken from the right
antecubital cannula for PAH, inulin, sodium, and haematocrit. At 0, 30, 60, 120, and
240 minutes, additional blood samples were taken for the measurement of plasma
ET-1. CF-PWV and FMD were measured immediately before drug administration
and at 2 and 4 hours after dosing. CF-PWV and FMD measurements were performed
as described in Chapter 2.
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9.2.4 Laboratory investigations
At pre-specified time points, venous blood was collected into EDTA tubes (Sarstedt)
for the measurement of PAH, inulin, haematocrit, and plasma ET-1 and into plain
tubes (Sarstedt) for the measurement of serum sodium. Additionally, 20ml aliquots
of urine from each voiding were collected into plain tubes for the measurement of
urinary PAH, inulin, sodium, and protein.
Haematocrit was measure on whole blood using a Coulter counter. All of other blood
samples were centrifuged immediately at lOOOg at 4°C for 20 minutes. Plasma and
urine samples were then stored in plain tubes at -80°C. PAH and inulin were
determined by a HPLC method (Chan et al., 1988) and a spectrophotometry after
hydrolysis to fructose (Schreiner, 1950), respectively. Plasma and urine sodium
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concentrations were measured using an ion selective electrode. Urine protein was
measured using a colorimetric method with pyrogallol red (Watanabe et al., 1986).
Plasma ET-1 was determined by radioimmunoassay as described in Chapter 2.
9.2.5 End points
The co-primary end points were reductions in BP and proteinuria. The secondary end
points were a reduction in arterial stiffness and an improvement in endothelial
function.
9.2.6 Data analyses
BP at each time point was calculated as the mean of two recordings and was
represented by SBP, DBP, and MAP. Bioimpedence data at each time point were
calculated as the mean of 4 recordings, each the average of 15 consecutive
heartbeats. Data were corrected for body surface area to give CI (L/min/m2), for
direct comparison between subjects. Systemic vascular resistance index (SVRI) was
calculated as SVRI = MAP / CI (dynes/s/m2/cm5). Effective renal plasma flow
(ERPF) and GFR were calculated from PAH and inulin clearance, respectively.
Effective renal blood flow (ERBF) was calculated as ERBF = ERPF / (1 —
haematocrit). Effective renal vascular resistance (ERVR) was calculated as ERVR =
MAP / ERBF. FF was calculated as FF = (GFR / ERPF) x 100. Urinary protein
excretion was calculated as urinary protein x urinary flow rate. Likewise, urinary
sodium excretion was calculated as urinary sodium x urinary flow rate.
The number of subjects required to show a significant difference in BP and ERVR
was based on a previous study in CKD patients using the same dose of BQ123
(Goddard et al., 2004b). Haemodynamic and urine results are presented as mean ±
SEM change from baseline for drug and placebo and placebo corrected change from
baseline for the results of the substudy. Statistical analysis was performed on
untransformed data. Three comparisons of interest were pre-identified as placebo
versus BQ123, placebo versus nifedipine, and BQ123 versus nifedipine. Responses
were examined by repeated-measures ANOVA, and Bonferroni's correction was
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used to assess significance at specific time points. Statistical significance was taken
as p < 0.05.
9.3 Results
9.3.1 Subject characteristics
A total of 22 subjects completed the placebo and BQ123 phases of the study. Ten of
them completed the 3-phase substudy. No adverse events were observed. Individual
subject characteristics and baseline demographic data are presented in Tables 9.1 and
9.2.
Table 9.1 Subject characteristics.
Subject Diagnosis Creatinine BP ACE inhibitor ARB
(pmol/L) (mmHg)
1 IgAN 136 131/81 Ramipril 2.5mg -
2 Membranous 78 114/63 Ramipril 10mg Candesartan 4mg
3 FSGS 328 107/70 Lisinopril 40mg Valsartan 80mg
4 FSGS 154 122/79 Ramipril 10mg Candesartan 4mg
5 IgAN 131 129/67 Lisinopril 40mg Candesartan 4mg
6 IgAN 89 111/69 Ramipril 2.5mg -
7 IgAN 159 120/79 Ramipril 5mg -
8 FSGS 487 158/84 Lisinopril 20mg -
9 FSGS 266 116/68 Ramipril 10mg -
10 Membranous 90 120/69 Enalapril 40mg Losartan 50mg
11 Membranous 208 146/95 Enalapril 40mg -
Table continues on the next page:-
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12 IgAN 167 142/75 Ramipril 10mg Candesartan 32mg
13 FSGS 181 123/68 Lisinopril 40mg -
14 IgAN 118 108/67 Lisinopril 40mg Candesartan 16mg
15 FSGS 332 145/83 Ramipril 10mg Valsartan 160mg
16 IgAN 195 138/75 Lisinopril 40mg Candesartan 16mg
17 IgAN 100 142/79 Ramipril 10mg -
18 Membranous 282 142/70 Ramipril 10mg -
19 Membranous 159 133/82 Lisinopril 40mg -
20 FSGS 129 128/80 Lisinopril 40mg Valsartan 80mg
21 IgAN 158 127/76 Lisinopril 40mg Valsartan 160mg
22 FSGS 343 123/68 Ramipril 10mg Candesartan 8mg
Key: FSGS: focal segmental glomerulosclerosis; IgAN: IgA nephropathy; membranous:
membranous glomeruloropathy. Doses are total per day.
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Table 9.2 Subject baseline data for the main and substudy.
Main study Substudy
n 22 10
Male/Female (n) 20/2 10/0
Age (year) 46±3 (29-69) 45111 (29-64)
Body mass index (kg/m2) 28±1 (20-37) 3016 (21-37)
Systolic blood pressure
(mmHg)
128±3 (99-167) 12813 (108-142)
Diastolic blood pressure
(mmHg)
75±2 (63-95) 7611 (67-84)
Mean arterial pressure
(mmHg)
92±2 (80-103) 9312 (84-101)
Heart rate (bpm) 56±2 (38-75) 5712 (42-66)
SVRI (dynes/s/m2/cm5) 3360±230 (1800-5510) 35301230 (1980-5510)
Cardiac index (L/min/m2) 3.0+0.2 (1.8-4.7) 2.910.2 (1.8-4.4)
Glomerular filtration rate
(ml/min)
43±5 (12-99) 4317 (15-99)
ERBF (ml/min) 1810±233 (106-4632) 19681390 (530-4632)
ERVR (mmHg/min/ml) 11.514.4 (2.01107.8) 7.111.5(2.0-18.2)
UNaV (pEq/min) 197121 (27-392) 193128 (95-392)
Urine protein excretion
(pg/min)
15701371 (165-8616) 15201577 (109-8616)
Plasma endothelin-1 (pg/ml) 5.710.3 (3.6-10.5) 6.710.5 (3.8-8.7)
CF-PVW (m/s) 7.514.4 (5.5-12.2) 7.410.5 (5.7-10.5)
FMD (%) 4.410.6 (0.6-12.7) 4.410.9 (0.1-8.2)
Key: Values are given as mean of baseline pretreatment periods over the 2 or 3 study days ± SEM.
CF-PVW: carotid-femoral pulse wave velocity; ERBF: effective renal blood flow; ERVR: effective renal





Placebo was associated with an increased in SBP (127.6±3.3 versus 136.6±3.4
mmHg, p < 0.01), DBP (75.9±1.7 versus 79.9±2.2 mmHg, p < 0.01), and MAP
(93.1±2.1 versus 98.8±2.4 mmHg, p < 0.01) and SVRI (3360±230 versus 3670±290
2 5
dynes/s/m /cm ) from baseline to the end of the study (Figures 9.3-9.4 A & B).
BQ123 reduced SBP, DBP, MAP, and SVRI from baseline (-14.2±3.0, -6.8±0.8, -
9.2+1.2 mmHg, and -610± 100 dynes/s/m2/cm5, respectively, all p < 0.01 compared
to placebo), with the peak effects at 75 minutes after drug administration (Figures
9.3A and 9.4A). BQ123 increased CI (0.3±0.1 L/min/m2, p < 0.05 versus placebo).
There were no significant differences in the heart rate between placebo and BQ123
throughout the study (see Appendix 3 for full systemic haemodynamic data).
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Figure 9.3 Changes in MAP after ETA receptor antagonism.
A
Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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9.3.2.2 Arterial stiffness and endothelial dysfunction
Placebo increased CF-PWV (7.5±0.4 versus 7.8±0.4 m/s, p < 0.01) whereas BQ123
reduced CF-PWV (-0.8±0.1 m/s, p < 0.01 versus placebo) (Table 9.3, Figures 9.5 A
& B). There were no differences in FMD of the brachial artery between placebo and
BQ123 for the whole period of the study (Table 9.3, Figures 9.6 A & B). Placebo
and BQ123 both increased FMD from baseline but these did not reach significant
(4.4±0.6 versus 5.1±0.7 %, p - 0.08 and 4.410.5 versus 5.5+0.8 %, p = 0.06,
respectively).
Table 9.3 Changes in CF-PWV and FMD after ETA receptor antagonism and placebo in
22 subjects of the main study.
Placebo BQ123
Time from drug Ohr 2hr 4hr Ohr 2hr 4hr
CF-PWV
CF-PWV (m/s) 7.5±0.4 7.6±0.4 7.8±0.4 7.3±0.4 7.0±0.4 7.0±0.3
Absolute A CF-PWV (m/s) na 0.1 ±0.1 0.3±0.1 na -0.3+0.1 -0.4+0.1
% A CF-PWV na 1.6+1.1% 4.7+1.0% na -4.8+1.5% -5.1+1.0%
FMD
FMD (%) 4.4+0.6 4.9+0.6 5.1+0.7 4.4+0.5 4.1+0.6 5.5+0.8
Absolute A FMD (%) na 0.5+0.3 0.6+0.3 na -0.3+0.4 1.1+0.5
% A FMD na 33+20% 37+22% na 44+52% 17+11%
Key: Values are mean ± SEM; absolute A: absolute change from baseline; % A: percentage
change from baseline. CF-PWV: carotid-femoral pulse wave velocity; FMD: flow-mediated
dilatation.
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Figure 9.5 Changes in CF-PWV after ETA receptor antagonism.
A
B
Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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Figure 9.6 Changes in FMD after ETA receptor antagonism.
A
Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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9.3.2.3 Renal haemodynamics
Placebo was associated with a gradual reduction in ERBF (1810+233 versus
1454±181 ml/min, p < 0.01) and an increase in ERVR (11.5±4.4 versus 12.8+3.8
mmHg/min/ml, p < 0.05) to the study end (Table 9.4, Figures 9.7 & 9.8). By
contrast, BQ123 produced an increase in ERBF (365±104 ml/min, p < 0.01 versus
placebo, Table 9.4, Figure 9.7) and a reduction in ERVR (-3.0±0.9 mmHg/min/ml, p
< 0.01 versus placebo, Table 9.4, Figure 9.8). There were no significant changes in
GFR with either placebo or BQ123.
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Figure 9.7 Changes in effective renal blood flow after ETA receptor antagonism.
A
Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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Figure 9.8 Changes in effective renal vascular resistance after ETA receptor
antagonism.
A
Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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9.3.2.4 Urinary sodium and protein excretion
BQ123 produced a marked natriuresis with a maximum increase of 36±15 pmol/min
(p < 0.05 versus placebo, Table 9.5, Figures 9.9 A & B). There was no change in
potassium excretion. BQ123 also led to a sustained reduction in proteinuria
throughout the time course of the study with a maximum reduction of 496±141
pg/min (p < 0.01 versus placebo, Table 9.5, Figures 9.10 A & B), equivalent to a
reduction in protein leak of «30%. The size of this effect related to baseline urinary
protein excretion and was seen across all levels of GFR. Subjects with higher
baseline urinary protein excretion had a greater reduction (r2 = 0.78, p < 0.05, Figure
9.10C).
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Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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r =0.78, p< 0.05
Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline + SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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9.3.2.5 Plasma endothelin-1
There were no changes in plasma ET-1 concentrations with either placebo or BQ123
(Table 9.6, Figure 9.11).
Figure 9.11 Changes in plasma ET-1 concentrations after ETA receptor antagonism.
A
B
Key: Blue line/block: placebo; red line/block: BQ123. A presents mean percentage of
change from baseline ± SEM. B presents mean area under curve (AUC) of the percentage
of change from baseline ± SEM. *p < 0.01 versus placebo; **p < 0.05 versus placebo.
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9.3.3 Substudy with nifedipine 10mg
BQ123 and nifedipine led to a similar reduction in MAP (Figures 9.12 A-C).
Nifedipine caused an initial increase in heart rate (10 bpm from baseline) that
returned to baseline within 60 minutes. Despite the consistent change in MAP,
BQ123 reduced CF-PWV to a greater extent than did nifedipine (at 4 hours post
dose, absolute reduction in CF-PWV from baseline, -0.6±0.0 versus -0.3±0.1 m/s,
Figures 9.13 A-C). BQ123 and nifedipine had no significant effects on FMD
(Figures 9.14 A-C).
BQ123 and nifedipine also increased ERBF to a similar degree and led to a similar
level of natriuresis (at maximum, BQ123: 64+37 pmol/min; nifedipine: 37+34
pmol/min). In contrast to BQ123, nifedipine was associated with a gradual increase
in urinary protein excretion (at maximum, 190+142 pg/min, p < 0.01 versus placebo)
while BQ123 produced a consistent reduction in proteinuria (Figures 9.15 A-C). See
Appendix 4 for full results of the substudy.
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Key: Blue line: placebo; green line/block: nifedipine; red line/block: BQ123; *p < 0.01 versus
nifedipine; **p < 0.05 versus nifedipine.
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Key: Blue line: placebo; green line/block: nifedipine; red line/block: BQ123; *p < 0.01 versus
nifedipine; **p < 0.05 versus nifedipine.
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Figure 9.14 Changes in FMD after ETA receptor antagonism and nifedipine 10mg.
A
B
Key: Blue line: placebo; green line/block: nifedipine; red line/block: BQ123; *p < 0.01 versus
nifedipine; **p < 0.05 versus nifedipine.
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Selective ETA receptor antagonism reduces BP, proteinuria, and arterial stiffness in
CKD patients with varying degrees of proteinuric nephropathy. These effects are
seen on top of the maximally tolerated dose of ACE inhibitors and ARBs.
Importantly, the reductions in proteinuria and CF-PWV are greater than those seen
with nifedipine, an alternative way to achieve a similar of BP reduction.
9.4.2 Effects of BQ123 on blood pressure
The findings of this study confirm the role of ET-1 in maintaining vascular tone in
CKD, mediated mainly through the ETA receptor (Dhaun et al., 2006; Hand et al.,
1999). A few studies, using selective ETA and mixed ETA/b receptor antagonists,
have shown BP reduction with ET receptor antagonists in untreated hypertensive
patients (Krum et al., 1998; Nakov et al., 2002). Here, the reduction of BP is less
than that in a previous study in hypertensive CKD patients with a similar range of
renal function (% change from baseline in MAP -7±1 versus -13±2 %, respectively)
(Goddard et al., 2004b). The BP reduction seen in the current study confirms that ET
receptor antagonism may provide a novel strategy to lower BP to a greater extent
than existing treatments, such as renin-angiotensin blockers, in CKD patients whose
BP control is often difficult.
9.4.3 Effects of BQ123 on carotid-femoral pulse wave
velocity and flow-mediated dilatation
ETa receptor antagonism with BQ123 also reduced CF-PWV compared with
placebo. The improvement of CF-PWV seen in the current study is likely in part due
to reduction in BP caused by BQ123. However, although when the BP reduction
with BQ123 was similar to that with nifedipine, the reductions in CF-PWV were
significantly greater with BQ123. It is important to note that, although nifedipine
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caused an expected increase in heart rate, which may have a minor impact on PWV
(Lantelme et al., 2002), heart rate had returned to baseline within 60 minutes after
administration of nifedipine and before the measurement of PWV. Overall, this
result suggests that the favourable effects of ETA receptor antagonism on arterial
stiffness are independent of BP.
Epidemiological evidence suggests that PWV is an independent risk factor for
cardiovascular morbidity and mortality (Blacher et al., 1999a; Laurent et al., 2001).
In renal patients, the survival rate is better for patients whose PWV declined in
response to a BP-lowering treatment (Guerin et al., 2001). Several studies have
shown that BP lowering agents such as ACE inhibitors and ARBs could reduce
PWV independent of BP reduction. This was reported in hypertensive (Williams et
al., 2006), diabetes (Karalliedde et al., 2008), and ESRD patients (Ichihara et al.,
2005; London et al., 1996). Data from the present study suggests that ETA receptor
antagonist may reduce arterial stiffness even further in CKD patients who are already
on ACE inhibitors and/or ARBs treatment. Importantly, this reduction in arterial
stiffness from ETA receptor antagonist is BP-independent.
Although it has recently been shown that ACE inhibitors and ARBs could improve
endothelial function both in hypertension (Benndorf et al., 2007; Morimoto et al.,
2008) and proteinuric CKD (Yilmaz et al., 2007), this effect was not seen with
BQ213 in our study. In contrast to effects seen on arterial stiffness, the effects of
ETa receptor antagonism on endothelial function, measured by the brachial artery
FMD, were not striking, even though there was a trend of improvement in FMD after
BQ123. This may be explained by the fact that the effects of altering endothelial
function may take longer to develop. Moreover, this finding is in contrast to previous
data that showed an improvement in an endothelium-dependent vasodilatation in
patients with coronary artery disease (Bohm et al., 2002; Halcox et al., 2001) but is
consistent with two recent reports in patients with systemic sclerosis (Sfikakis et al.,
2007) and insulin resistance (Shemyakin et al., 2006). Instead, these two studies
have shown that endothelial function was improved by mixed ETA/b receptor
antagonists. Interestingly, in the study of coronary artery disease patients, the effects
of mixed ET^b receptor antagonists on endothelium-dependent vasodilatation occur
on top ofACE inhibitor treatment (Bohm et al., 2005).
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9.4.4 Effects of BQ123 on renal haemodynamics
BQ123 increased renal blood flow in association with a reduction in renal vascular
resistance, suggesting that ET-1 is involved in the increased renovascular tone in
CKD and its effect is mediated through ETA receptor. There were no significant
changes in GFR but a fall in FF, as seen in previous studies (Dhaun et al., 2007a;
Goddard et al., 2004b), was observed, suggesting that ET-1 induces and ETA
receptor-mediated vasoconstriction. This effect of ET-1 is likely to act efferent
arteriole but does not exclude an effect on mesangial cells and the filtration
coefficient.
9.4.5 Effects of BQ123 on urinary protein and sodium
excretion
Consistent with a reduction in FF, BQ123 produced a sustained reduction in urinary
protein excretion. Similar to the reduction in CF-PWV, the reduction in proteinuria
continued even when the BP-lowering effect of BQ123 has waned and BP has
returned to baseline, suggesting that this reduction in proteinuria was BP-
independent. Nifedipine, as a control drug, was closely matched both the decrease in
BP and the increase in renal blood flow seen with BQ123. Nifedipine acts mainly on
the afferent arteriole and therefore, as expected, it produced increases in both GFR
and proteinuria throughout the study period (see Appendix 4). As BQ123 had little
effect on GFR and substantially reduced FF and proteinuria over the same time scale
as the increase in renal blood flow, these suggests that the effects are not just
occurred on the afferent arteriole but also seen at the efferent arteriole, similar to,
and on top of, that seen with ACE inhibitors.
In the current study, across the range of GFR, the reduction in proteinuria was
related to baseline proteinuria, with subjects with a higher level of baseline urinary
protein excretion had greater reductions. This effect is similar to the effects seen with
ACE inhibitors (Jafar et al., 2003).
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A reduction in proteinuria is linked to reducing risk of CKD progression (Jafar et al.,
2003) and consequence cardiovascular disease (Tonelli et al., 2006). Despite
maximum renin-angiotensin system blockade, many proteinuric CKD patients still
have significant residual proteinuria (Ruggenenti et al., 2008). In this study, all of
the subjects were established on treatment with ACE inhibitors, with the majority
also taking ARBs. The ET and renin-angiotensin systems were known to interact
(Rossi et al., 1999), and a synergistic effect between these two systems, in terms of
systemic haemodynamics, was demonstrated in humans (Dhaun et al., 2007b;
Goddard et al., 2004a). Results of the current study suggest that ETa receptor
antagonism can produce a further reduction in proteinuria by «30% on top of that
achieved with optimal treatment with inhibitors of renin-angiotensin system. Thus, if
maintained longer term, ETa receptor antagonism should reduce both disease
progression and cardiovascularmorbidity and mortality in CKD patients.
BQ123 also produced significant natriuresis which is likely due to the increase in
renal blood flow seen with ETa receptor antagonism. In fact, nifedipine which
caused a similar change in renal haemodynamics also caused increased urinary
sodium excretion. Additionally, all of the subjects showed a net diuresis even with
placebo. Altogether these are important observations if ET receptor antagonists are
to be used in trials involving CKD patients, in whom salt and water retention is an
issue.
9.4.6 Limitations
As an acute study, the beneficial effects of ETA receptor antagonism on BP,
proteinuria, and arterial stiffness seen here have to be confirmed in a longer-term
study with a range of antihypertensive agents. The range of CKD patients enrolled
on this study is relatively homogenous, comprising pre-dialysis patients with
minimal co-morbidity. Further work is justified in other CKD populations such as
those with diabetes, vasculitis, or renal vascular disease. In addition, this is a
crossover design study, which may affect data interpretation and is not ideal for a
longer-term study in a large group of patients.
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9.4.7 Summary
ETa receptor antagonism lowers BP, reduces proteinuria, and improves arterial
stiffening on top of standard BP lowering treatment in CKD patients with a moderate
reduction of renal function. These data supports a role for selective ETA receptor
antagonism as a novel therapeutic approach in controlling hypertension and
proteinuria, and reducing arterial stiffness in CKD patients. These effects should be
confirmed in larger and longer-term studies.
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Chapter 10
Conclusions and future work
10.1 Conclusions
The series of prospective, cross-sectional studies presented in this thesis explore the
degree of arterial stiffness and endothelial dysfunction in relatively low-risk CKD
patients without diabetes or cardiovascular co-morbidity, across a wide range of
renal function from normal GFR to pre-dialysis. The contribution of conventional
and different types of emerging cardiovascular disease risk factors to arterial
stiffness and endothelial dysfunction in this group of patients was also assessed.
Additionally, an interventional study examining the effects of selective ETA receptor
antagonism on arterial stiffness and endothelial dysfunction in the same group of
patients was performed.
10.1.1 Reproducibility of carotid-femoral pulse wave
velocity, central augmentation index, and flow-
mediated dilatation
This study confirms the reproducibility of non-invasive techniques used to assess
arterial stiffness (PWV and AIx) and endothelial dysfunction (FMD).
PWV and AIx, assessed using the SphymoCor system, are two of the most widely
used non-invasive techniques for measuring arterial stiffness (Oliver et al., 2003b).
Brachial artery FMD is a widely used non-invasive measure of endothelial-
dependent vasomotor function of a conduit artery (Corretti et al., 2002). These
techniques were previously shown to be reproducible (Bots et al., 2005; Donald et
al., 2006; Simova et al., 2008; Wilkinson et al., 1998). However, these techniques
still carry some limitations. The quality of the pressure waveforms at the femoral site
or the carotid site may affect the calculation of PWV and AIx. PWV calculation can
also be affected by the inaccuracy of the measurement of the distance between the
two recording sites. Additionally, one of the most important limitations of FMD is
the variability in the analysis of an ultrasound image. These limitations could occur
either within one observer by doing repeated measurements or between two separate
observers.
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The studies in healthy subjects and CKD patients confirm that CF-PWV, AIx, and
FMD are reproducible, which is consistent with previous studies. In fact, intra- and
inter- observer reproducibility of both CF-PWV and FMD, which are the main
techniques used throughout this thesis are better than others (Donald et al., 2008;
Frimodt-Moller et al., 2008; Hardie et al., 1997; Simova et al., 2008; Wilkinson et
al., 1998), confirming the validity of the assessment of arterial stiffness and
endothelial function in this thesis. In addition, the training time for the investigators
to achieve this high level of reproducibility is within ~4 weeks.
10.1.2 Plasma endothelin-1 and fractional excretion of
endothelin-1 in chronic kidney disease
This study shows that in a large cohort of CKD patients without dialysis or
established cardiovascular co-morbidity, plasma ET-1 increases linearly as renal
function declines, whereas FeET-1 increases exponentially.
The increase in levels of plasma ET-1 in this study are comparable to previous
studies in pre-dialysis CKD (Cottone et al., 2009; Dammers et al., 2005; Goddard et
al., 2007; Vlachojannis et al., 1997). As data regarding the correlation of increased
plasma ET-1 and renal function in the literature are not consistent (Cottone et al.,
2009; Dammers et al., 2005; Goddard et al., 2007; Vlachojannis et al., 1997;
Warrens et al., 1990), this study has confirmed that plasma ET-1 has an inverse
linear correlation with GFR. The increase in plasma ET-1 concentrations seen in this
study could either be from increased renal ET-1 production or reduced renal
clearance of ET-1.
By contrast, FeET-1 exponentially increases as GFR declines, strengthening the
concept of two independent ET-1 systems in the vasculature and the kidneys
(Benigni et al., 1991; Brooks et al., 1991; Wesson, 2001). In fact, as the clearance of
circulating ET-1 is mainly through the pulmonary system, the exponential increase
of FeET-1 seen here suggests that the increased plasma ET-1 concentrations in CKD
would probably be caused by increased renal ET-1 production rather than reduced
renal clearance of ET-1. However, as the study used spot urine for the measurement
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of urinary ET-1 and the calculation of FeET-1, this should be confirmed in a
clearance study.
10.1.3 Relationships of renal function to arterial
stiffness and endothelial dysfunction in chronic
kidney disease
This study shows that in minimally co-morbid CKD patients, arterial stiffness,
measured by CF-PWV, increases incrementally as renal function declines whereas
endothelial dysfunction, measured by FMD of the brachial artery, is only a feature of
late stage CKD. However, renal function is not an independent determinant of either
CF-PWV or FMD in this group of patients.
Previous studies have shown associations between PWV and GFR in patients with
dialysis or cardiovascular co-morbidity (Briet et al., 2006; Lacy et al., 2006;
Stancanelli et al., 2007; Wang et al., 2005). This study confirms that even in
relatively 'clean' CKD patients, increased arterial stiffness still occurs but it is not
mainly driven by uraemia. The fact that FMD is only reduced in late stage CKD is
intriguing and is different from previous data (Caglar et al., 2008b; Yilmaz et al.,
2006; Yilmaz et al., 2008a). This result suggests that uraemia itself has a minor
impact on endothelial function and it takes time for uraemic patients by themselves
to develop endothelial dysfunction.
In this study, increased arterial stiffness and endothelial dysfunction are mainly
driven by age and BP. Ageing is an unavoidable physiological phenomenon. BP is a
factor that could be controlled and all CKD patients in this study have a good control
of BP. Therefore, apart from these two well known cardiovascular risk factors, there
must be some other factors which can be regarded as emerging cardiovascular risk
factors that contribute to vascular complications in CKD. One of these could be ET-1
as shown in Chapter 4 that plasma ET-1 concentrations are inversely associated with
GFR. Additionally, as a vasoconstrictor ET-1 counter balance with a vasodilating
NO. Hence, an increase in an endogenous NO inhibitor, ADMA, may be the other
risk factor. Additionally, vascular complications are highly linked to inflammation
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and oxidative stress; therefore, these two factors may be involved. The metabolic
syndrome as a cluster of metabolic abnormalities and risk factors for cardiovascular
disease and arterial calcification as a part of the pathophysiology of arterial stiffness
may also contribute. All of these are worth exploring and are assessed in the further
studies of this thesis.
10.1.4 Relationships of emerging cardiovascular risk
factors to arterial stiffness and endothelial
dysfunction in chronic kidney disease
This study shows that in CKD patients without diabetes or established co-morbidity,
BP is still the major determinant of arterial stiffness and endothelial dysfunction.
Additionally, hsCRP and ADMA also independently predict arterial stiffness, and 8-
Isop and ET-1 independently predict endothelial dysfunction.
This data confirms the finding of Chapter 5 that uraemia itself has a minor role in
increased arterial stiffness and endothelial dysfunction and BP is still the strongest
factor contributing to arterial stiffness and endothelial dysfunction in this group of
patients. This, therefore, highlights the importance of a tight BP control in CKD. As
the majority of CKD patients still fail to achieve a target BP level (Chobanian et al.,
2003; Mancia et al., 2007), this may explain the very high risk of cardiovascular
morbidity and mortality seen in the CKD population.
This study further stresses the important roles of inflammation, oxidative stress and
NO/ET imbalance as determinants of vascular complications in CKD. The measure
of these emerging risk factors, either alone or in combination may help identify
subjects with a higher risk of cardiovascular disease. These results also indicate that
interventional studies to examine the influence of these emerging risk factors on
arterial stiffness and endothelial dysfunction in CKD, using potential therapeutic
agents such as ET antagonism are of great interest.
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10.1.5 Risk factors for the metabolic syndrome
independently predict arterial stiffness and
endothelial dysfunction in chronic kidney disease
This study shows that in minimally co-morbid CKD patients, regardless of renal
function, CKD patients with the metabolic syndrome have higher arterial stiffness
compared to those without. The presence of the metabolic syndrome and the number
of risk factors for it independently determines arterial stiffness. Importantly, when
risk factors for the metabolic syndrome are considered individually, waist
circumference and SBP were independent determinants of CF-PWV.
This study, again, confirms the minimal role of uraemia on arterial stiffness and
endothelial dysfunction. This study also confirmed that metabolic syndrome, either
by itself or the number of risk factors for it, influences arterial stiffness but has a
lower impact on endothelial dysfunction. BP. as one of the risk factors for the
metabolic syndrome is, once again, the strongest determinant of arterial stiffness and
endothelial dysfunction.
Interestingly, waist circumference also independently contributes to arterial stiffness,
confirming the association of obesity and increased risk of cardiovascular morbidity
(Elsayed et al., 2008). This finding is very important because weight control, leading
to a reduction of waist circumference, is one of the modifiable risk factors that could
be performed by the patients themselves without using any medication. Evidence
suggests that risk of cardiovascular morbidity and mortality is reduced with a weight
reduction (Lavie et al., 2009).
Although not independent predictors of either arterial stiffness or endothelial
dysfunction in this study, glucose and cholesterol, as parts of the metabolic
syndrome, could still be potential risk factors to be modified. Hyperglycaemia and
dyslipidemia are linked to atherosclerosis (Kanter et al., 2007). A tight control of
them would improve the metabolic syndrome status of the patients and reduce the
number of risk factors for the metabolic syndrome, leading to a reduction of arterial
stiffness and thus cardiovascular complications.
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10.1.6 Relationships of arterial calcification to arterial
stiffness and endothelial dysfunction in chronic
kidney disease
This study shows that, irrespective of renal function, minimally co-morbid CKD
patients who develop CAC have increased arterial stiffness and a trend of impaired
endothelial function compared to those without. In contrast, fetuin-A has no
relationships to arterial stiffness and endothelial dysfunction in this group of
patients.
The prevalence and extent of CAC in this study is very low compared to previous
data (Barraclough et al., 2008; Garland et al., 2008; Piers et al., 2009; Porter et al.,
2007; Russo et al., 2007), which is consistent with the fact that these are patients
with a low-co-morbidity. Although the extent ofCAC is low, this study still suggests
the role of arterial calcification in the pathophysiology of arterial stiffness. With a
small sample size, the non-associations seen in this study have to be confirmed in a
larger study.
10.1.7 Blood pressure-independent reduction in
proteinuria and arterial stiffness after acute
endothelin-A receptor antagonism in chronic kidney
disease
This study shows that, irrespective of renal function, selective ETa receptor
antagonism reduces BP, proteinuria, and arterial stiffness in CKD patients without
diabetes or established cardiovascular co-morbidity. These effects are seen on top of
the maximally tolerated dose of ACE inhibitors and ARBs. Importantly, the
reductions in arterial stiffness are greater than those seen with nifedipine, an
alternative method of BP reduction.
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This interventional study confirms the role of ET-1 in maintaining vascular tone in
CKD and suggests that ET receptor antagonism may be a novel strategy to lower BP
in CKD patients whose BP is often difficult to control.
Importantly, this study also confirms the contribution of ET-1 system on increased
arterial stiffness as shown in Chapter 6 and suggests that this is mediated through the
ETa receptor in pre-dialysis. The reduction of arterial stiffness seen in this study is
independent of a BP reduction and occurs on top of standard hypertensive treatment
with ACE inhibitors or ARBs. Since PWV is an independent predictor for
cardiovascular morbidity and mortality (Blacher et al., 1999a; Laurent et al., 2001),
an improvement of PWV shown here provides evidence that selective ETa receptor
antagonism may be a therapeutic agent that not only controls hypertension but also
reduces arterial stiffness and thus improves cardiovascular risk in CKD.
Of course, as an acute study, these findings have to be confirmed in a longer-term
study with a wider range ofCKD patients and antihypertensive agents.
10.2 Future work
The observations in this thesis raise further questions to be answered and areas to be
explored.
10.2.1 The relationships of renal function to arterial
stiffness and endothelial dysfunction in diabetic
nephropathy
As the studies in this thesis show that, in a group of relatively low co-morbid CKD,
uraemia has a minor role in arterial stiffness and endothelial dysfunction. A study in
matched- diabetic nephropathy patients would be of interest. The hypotheses are that
the degree of arterial stiffness and endothelial dysfunction would be higher and the
starting point of developing arterial stiffness and endothelial dysfunction would be
earlier in diabetic nephropathy compared to data presented in this thesis.
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10.2.2 The relationships of emerging cardiovascular
risk factors to arterial stiffness and endothelial
dysfunction in diabetic nephropathy
Again, to elucidate the role of inflammation, oxidative stress and NO/ET imbalance,
it is important to study these risk factors in matched diabetic nephropathy. The
hypotheses are that the prevalence of inflammation, oxidative stress and NO/ET
imbalance would be higher and the associations between these risk factors and
arterial stiffness and endothelial dysfunction would be stronger than in those studied
in this thesis.
10.2.3 Modification of the metabolic syndrome risk
factors reduces arterial stiffness and endothelial
dysfunction in CKD
As shown in this thesis that the metabolic syndrome itself, the number of risk factors
for it, or its individual risk factors are independently linked to arterial stiffness and
endothelial dysfunction, it is important to investigate whether the modification of
these risk factors for the metabolic syndrome would improve arterial stiffness and
endothelial dysfunction and thus reduce cardiovascular risk in CKD. It would be
interesting to perform the studies on various groups of renal patients such as low co-
morbid CKD, diabetic nephropathy, and those on dialysis to be able to the compare
the beneficial effects.
10.2.4 The relationship of cardiovascular calcification
and the role of calcium/phosphate-binding agents to
arterial stiffness and endothelial dysfunction
Although the sample size of the study assessing the role of cardiovascular
calcification on arterial stiffness and endothelial dysfunction is relatively small, it
still shows that CAC is independently linked to arterial stiffness in CKD. This is
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worth confirming in a larger-scale study. If the relationship persists, an
interventional study with calcium/phosphate-binding agents such as selevamer on
reducing calcium load status (Chertow et al., 2002) and improving arterial stiffness
and endothelial dysfunction in pre-dialysis would be of great interest.
10.2.5 Chronic ETA receptor blockade in chronic
kidney disease
Given the reduction of proteinuria and arterial stiffness shown in the acute study of
this thesis, this needs to be confirmed in chronic studies. The attention would be
focussed on examining to the role of ETa receptor antagonism in slowing the rate of
renal progression and improving proteinuria, arterial stiffness or endothelial
dysfunction and studies should also be carried out on various CKD populations such
as patients with diabetes, vasculitis, or renal vascular disease.
-225 -
Bibliography
Abassi, Z.A., Tate, J.E., Golomb, E. & Keiser, H.R. (1992). Role of neutral
endopeptidase in the metabolism of endothelin. Hypertension, 20, 89-95.
Abbasi, F., Asagmi, T., Cooke, J.P., Lamendola, C., McLaughlin, T., Reaven,
G.M., Stuehlinger, M. & Tsao, P.S. (2001). Plasma concentrations of
asymmetric dimethylarginine are increased in patients with type 2 diabetes
mellitus. Am JCardiol, 88, 1201-3.
Achan, V., Broadhead, M., Malaki, M., Whitley, G., Leiper, J., MacAllister,
R. & Vallance, P. (2003). Asymmetric dimethylarginine causes
hypertension and cardiac dysfunction in humans and is actively metabolized
by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vase
Biol, 23, 1455-9.
Achimastos, A.D., Efstathiou, S.P., Christoforatos, T., Panagiotou, T.N.,
Stergiou, G.S. & Mountokalakis, T.D. (2007). Arterial stiffness:
determinants and relationship to the metabolic syndrome. Angiology, 58, 11-
20.
Adeney, K.L., Siscovick, D.S., Ix, J.H., Seliger, S.L., Shlipak, M.G., Jenny, N.S.
& Kestenbaum, B.R. (2009). Association of serum phosphate with vascular
and valvular calcification in moderate CKD. JAm Soc Nephrol, 20, 381-7.
Adji, A., Hirata, K. & O'Rourke, M.F. (2006). Clinical use of indices determined
non-invasively from the radial and carotid pressure waveforms. Blood Press
Monit, 11, 215-21.
Agatston, A.S., Janowitz, W.R., Hildner, F.J., Zusmer, N.R., Viamonte, M., Jr.
& Detrano, R. (1990). Quantification of coronary artery calcium using
ultrafast computed tomography. JAm Coll Cardiol, 15, 827-32.
Ahluwalia, N., Drouet, L., Ruidavets, J.B., Perret, B., Amar, J., Boccalon,
H., FIanaire-Broutin, H. & Ferrieres, J. (2006). Metabolic syndrome is
associated with markers of subclinical atherosclerosis in a French population-
based sample. Atherosclerosis, 186, 345-53.
Alfakih, K., Walters, K., Jones, T., Ridgway, J., Hall, A.S. & Sivananthan,
M. (2004). New gender-specific partition values for ECG criteria of left
ventricular hypertrophy: recalibration against cardiac MRI. Hypertension, 44,
175-9.
Amar, J., Ruidavets, J.B., Peyrieux, J.C., Mallion, J.M., Ferrieres, J., Safar,
M.E. & Chamontin, B. (2005). C-reactive protein elevation predicts pulse
pressure reduction in hypertensive subjects. Hypertension, 46, 151-5.
Anderson, T.J., Uehata, A., Gerhard, M.D., Meredith, I.T., Knab, S.,
Delagrange, D., Lieberman, E.H., Ganz, P., Creager, M.A. & Yeung,
A.C. (1995). Close relation of endothelial function in the human coronary
and peripheral circulations. JAm Coll Cardiol, 26, 1235-41.
-227 -
Annuk, M., Lind, L., Linde, T. & Fellstrom, B. (2001). Impaired endothelium-
dependent vasodilatation in renal failure in humans. Nephrol Dial
Transplant, 16, 302-6.
Annuk, M., Soveri, I., Zilmer, M., Lind, L., Hulthe, J. & Fellstrom, B. (2005).
Endothelial function, CRP and oxidative stress in chronic kidney disease. J
Nephrol, 18, 721-6.
Anonymous (2002a). K/DOQI clinical practice guidelines for chronic kidney
disease: evaluation, classification, and stratification. Am J Kidney Dis, 39,
SI-266.
Anonymous (2002b). Third Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation, 106, 3143-421.
Barnes, K., Brown, C. & Turner, A.J. (1998). Endothelin-converting enzyme:
ultrastructural localization and its recycling from the cell surface.
Hypertension, 31, 3-9.
Barraclough, K.A., Stevens, L.A., Er, L., Rosenbaum, D„ Brown, J., Tiwari,
P. & Levin, A. (2008). Coronary artery calcification scores in patients with
chronic kidney disease prior to dialysis: reliability as a trial outcome
measure. Nephrol Dial Transplant, 23, 3199-205.
Benetos, A., Adamopoulos, C., Bureau, J.M., Temmar, M., Labat, C., Bean, K.,
Thomas, F., Pannier, B., Asmar, R., Zureik, M., Safar, M. & Guize, L.
(2002). Determinants of accelerated progression of arterial stiffness in
normotensive subjects and in treated hypertensive subjects over a 6-year
period. Circulation, 105, 1202-7.
Benigni, A., Perico, N., Gaspari, F., Zoja, C., Bellizzi, L., Gabanelli, M. &
Remuzzi, G. (1991). Increased renal endothelin production in rats with
reduced renal mass. Am J Physiol, 260, F331-9.
Benndorf, R.A., Appel, D., Maas, R., Schwedhelm, E., Wenzel, U.O. & Boger,
R.H. (2007). Telmisartan improves endothelial function in patients with
essential hypertension. J Cardiovasc Pharmacol, 50, 367-71.
Blacher, J., Guerin, A.P., Pannier, B., Marchais, S.J., Safar, M.E. & London,
G.M. (1999a). Impact of aortic stiffness on survival in end-stage renal
disease. Circulation, 99, 2434-9.
Blacher, J., London, G.M., Safar, M.E. & Mourad, J.J. (1999b). Influence of
age and end-stage renal disease on the stiffness of carotid wall material in
hypertension. J Hypertens, 17, 237-44.
Blackwell, S., O'Reilly, D.S. & Talwar, D. (2007). Biological variation of
asymmetric dimethylarginine and related arginine metabolites and analytical
performance goals for their measurement in human plasma. Eur J Clin Invest,
37,364-71.
-228-
Bland, J.M. & Altman, D.G. (1986). Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet, 1, 307-10.
Blazy, I., Dechaux, M., Charbit, M., Brocart, D., Souberbielle, J.C.,
Gagnadoux, M.F., Guillot, F. & Sachs, C. (1994). Endothelin-1 in
children with chronic renal failure. Pediatr Nephrol, 8, 40-4.
Boger, R.H. (2003). The emerging role of asymmetric dimethylarginine as a novel
cardiovascular risk factor. Cardiovasc Res, 59, 824-33.
Boger, R.H. & Zoccali, C. (2003). ADMA: a novel risk factor that explains excess
cardiovascular event rate in patients with end-stage renal disease. Atheroscler
Suppl, 4, 23-8.
Bohm, F., Ahlborg, G. & Pernow, J. (2002). Endothelin-1 inhibits endothelium-
dependent vasodilatation in the human forearm: reversal by ETA receptor
blockade in patients with atherosclerosis. Clin Sci (Lond), 102, 321-7.
Bohm, F., Beltran, E. & Pernow, J. (2005). Endothelin receptor blockade
improves endothelial function in atherosclerotic patients on angiotensin
converting enzyme inhibition. J Intern Med, 257, 263-71.
Bohm, F., Pernow, J., Lindstrom, J. & Ahlborg, G. (2003). ETA receptors
mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the
splanchnic and renal circulation of healthy men. Clin Sci, 104, 143-51.
Bolton, C.H., Downs, L.G., Victory, J.G., Dwight, J.F., Tomson, C.R.,
Mackness, M.I. & plnkney, J.H. (2001). Endothelial dysfunction in chronic
renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines.
Nephrol Dial Transplant, 16, 1189-97.
Borawski, J. & Mysliwiec, M. (2001). The hematocrit-corrected erythrocyte
sedimentation rate can be useful in diagnosing inflammation in hemodialysis
patients. Nephron, 89, 381-3.
Bots, M.L., Westerink, J., Rabelink, T.J. & de Koning, E.J. (2005). Assessment
of flow-mediated vasodilatation (FMD) of the brachial artery: effects of
technical aspects of the FMD measurement on the FMD response. Eur Heart
J, 26, 363-8.
Boutouyrie, P., Bezie, Y., Lacolley, P., Challande, P., Chamiot-Clerc, P.,
Benetos, A., de la Faverie, J.F., Safar, M. & Laurent, S. (1997). In
vivo/in vitro comparison of rat abdominal aorta wall viscosity. Influence of
endothelial function. Arterioscler Thromb Vase Biol, 17, 1346-55.
Boutouyrie, P., Bussy, C., Lacolley, P., Girerd, X., Laloux, B., Laurent, S.
(1999). Association between local pulse pressure, mean blood pressure, and
large-artery remodeling. Circulation, 100, 1387-93.
Boutouyrie, P., Tropeano, A.I., Asmar, R., Gautier, I., Benetos, A., Lacolley,
P. & Laurent, S. (2002). Aortic stiffness is an independent predictor of
-229-
primary coronary events in hypertensive patients: a longitudinal study.
Hypertension, 39, 10-5.
Briet, M., Bozec, E., Laurent, S., Fassot, C., London, G.M., Jacquot, C.,
Froissart, M., Houillier, P. & Boutouyrie, P. (2006). Arterial stiffness
and enlargement in mild-to-moderate chronic kidney disease. Kidney Int, 69,
350-7.
Brinkley, T.E., Nicklas, B.J., Kanaya, A.M., Satterfield, S., Lakatta, E.G.,
Simonsick, E.M., Sutton-Tyrrell, K. & Kritchevsky, S.B. (2009).
Plasma oxidized low-density lipoprotein levels and arterial stiffness in older
adults: the health, aging, and body composition study. Hypertension, 53, 846-
52.
Brooks, D.P., Contino, L.C., Storer, B. & Ohlstein, E.H. (1991). Increased
endothelin excretion in rats with renal failure induced by partial
nephrectomy. Br J Pharmacol, 104, 987-9.
Brunner, H., Cockcroft, J.R., Deanfield, J., Donald, A., Ferrannini, E.,
Halcox, J., Kiowski, W., Luscher, T.F., Mancia, G., Natali, A., Oliver,
J.J., Pessina, A.C., Rizzoni, D., Rossi, G.P., Salvetti, A., Spieker, L.E.,
Taddei, S. & Webb, D.J. (2005). Endothelial function and dysfunction. Part
II: Association with cardiovascular risk factors and diseases. A statement by
the Working Group on Endothelins and Endothelial Factors of the European
Society of Hypertension. JHypertens, 23, 233-46.
Busch, M., Fleck, C., Wolf, G. & Stein, G. (2006). Asymmetrical (ADMA) and
symmetrical dimethylarginine (SDMA) as potential risk factors for
cardiovascular and renal outcome in chronic kidney disease - possible
candidates for paradoxical epidemiology? Amino Acids, 30, 225-32.
Caglar, K., Yilmaz, M.I., Saglam, M., Cakir, E., Acikel, C., Eyileten, T.,
Yenicesu, M., Oguz, Y., Vural, A., Carrero, J.J., Axelsson, J.,
Lindholm, B. & Stenvinkel, P. (2008a). Short-term treatment with
sevelamer increases serum fetuin-a concentration and improves endothelial
dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc
Nephrol, 3, 61-8.
Caglar, K., Yilmaz, M.I., Saglam, M., Cakir, E., Kilic, S., Eyileten, T.,
Sonmez, A., Oguz, Y., Oner, K., Ors, F., Vural, A. & Yenicesu, M.
(2007). Endothelial dysfunction and fetuin A levels before and after kidney
transplantation. Transplantation, 83, 392-7.
Caglar, K., Yilmaz, M.I., Saglam, M., Cakir, E., Kilic, S., Sonmez, A.,
Eyileten, T., Yenicesu, M., Oguz, Y., Tasar, M., Vural, A., Ikizler,
T.A., Stenvinkel, P. & Lindholm, B. (2008b). Serum fetuin-a
concentration and endothelial dysfunction in chronic kidney disease.
Nephron Clin Pract, 108, c233-40.
Caglar, K., Yilmaz, M.I., Sonmez, A., Cakir, E., Kaya, A., Acikel, C.,
Eyileten, T., Yenicesu, M., Oguz, Y., Bilgi, C., Oktenli, C., Vural, A. &
-230-
zoccali, C. (2006). ADMA, proteinuria, and insulin resistance in non-
diabetic stage I chronic kidney disease. Kidney Int, 70, 781-7.
Calver, A., Collier, J. & Vallance, P. (1992). Inhibition and stimulation of nitric
oxide synthesis in the human forearm arterial bed of patients with insulin-
dependent diabetes. JClin Invest, 90, 2548-54.
Cantaro, S., Milan Manani, S., Marcon, R., Bonfante, L., Masiero, M.,
DAngelo, A. & Calo, L. (2001). Urinary excretion of vasoactive
substances in chronic renal failure. Clin Nephrol, 55, 393-9.
Cardillo, C., Kilcoyne, C.M., Waclawiw, M., Cannon, R.O., 3rd & Panza, J.A.
(1999). Role of endothelin in the increased vascular tone of patients with
essential hypertension. Hypertension, 33, 753-8.
Celermajer, D.S., Sorensen, K.E., Gooch, V.M., Spiegelhalter, D.J., Miller,
O.I., Sullivan, I.D., Lloyd, J.K. & Deanfield, J.E. (1992). Non-invasive
detection of endothelial dysfunction in children and adults at risk of
atherosclerosis. Lancet, 340, 1111-5.
Chadban, S.J., Briganti, E.M., Kerr, P.G., Dunstan, D.W., Welborn, T.A.,
Zimmet, P.Z. & Atkins, R.C. (2003). Prevalence of kidney damage in
Australian adults: The AusDiab kidney study. JAm Soc Nephrol, 14, SI 31-8.
Chan, K., Miners, J.O. & Birkett, D.J. (1988). Direct and simultaneous high-
performance liquid chromatographic assay for the determination of p-
aminobenzoic acid and its conjugates in human urine. J Chromatogr, 426,
103-9.
Chan, W.B., Chan, N.N., Lai, C.W., So, W.Y., Lo, M.K., Lee, K.F., Chow, C.C.,
Metreweli, C. & Chan, J.C. (2006). Vascular defect beyond the
endothelium in type II diabetic patients with overt nephropathy and moderate
renal insufficiency. Kidney Int, 70, 711-6.
Chang, J.J., Rabinowitz, D. & Shea, S. (2003). Sources of variability in blood
pressure measurement using the Dinamap PRO 100 automated oscillometric
devicc. Am J Epidemiol, 158, 1218-26.
Chen, J., Muntner, P., Hamm, L.L., Jones, D.W., Batuman, V., Fonseca, V.,
Whelton, P.K. & He, J. (2004). The metabolic syndrome and chronic
kidney disease in U.S. adults. Ann Intern Med, 140, 167-74.
Cheng, H.M., Ye, Z.X., Chiou, K.R., Lin, S.J. & Charng, M.J. (2007). Vascular
stiffness in familial hypercholesterolaemia is associated with C-reactive
protein and cholesterol burden. Eur J Clin Invest, 37, 197-206.
Chertow, G.M., Burke, S.K. & Raggi, P. (2002). Sevelamer attenuates the
progression of coronary and aortic calcification in hemodialysis patients.
Kidney Int, 62, 245-52.
Chirinos, J.A., David, R., Bralley, J.A., Zea-Diaz, H., Munoz-Atahualpa, E.,
Corrales-Medina, F., Cuba-Bustinza, C., Chirinos-Pacheco, J. &
-231 -
Medina-Lezama, J. (2008). Endogenous nitric oxide synthase inhibitors,
arterial hemodynamics, and subclinical vascular disease: the PREVENCION
Study. Hypertension, 52, 1051-9.
Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo,
J.L., Jr., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., Jr. &
Roccella, E.J. (2003). Seventh report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Hypertension, 42, 1206-52.
Chowienczyk, P.J., Kelly, R.P., MacCallum, H., Millasseau, S.C.,
Andersson, T.L., Gosling, R.G., Ritter, J.M. & Anggard, E.E. (1999).
Photoplethysmographic assessment of pulse wave reflection: blunted
response to endothelium-dependent beta2-adrenergic vasodilation in type II
diabetes mellitus. JAm Coll Cardiol, 34, 2007-14.
Chowienczyk, P.J., Watts, G.F., Cockcroft, J.R. & Ritter, J.M. (1992).
Impaired endothelium-dependent vasodilation of forearm resistance vessels
in hypercholesterolaemia. Lancet, 340, 1430-2.
Cockcroft, J.R., Wilkinson, I.B. & Webb, D.J. (1997). The Trevor Howell
Lecture. Age, arterial stiffness and the endothelium. Age Ageing, 26 Suppl 4,
53-60.
Cooke, J.P. (2000). The endothelium: a new target for therapy. Vase Med, 5, 49-53.
Coresh, J., Byrd-Holt, D., Astor, B.C., Briggs, J.P., Eggers, P.W., Lacher,
D.A. & Hostetter, T.H. (2005). Chronic kidney disease awareness,
prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol,
16,180-8.
Corretti, M.C., Anderson, T.J., Benjamin, E.J., Celermajer, D., Charbonneau,
F., Creager, M.A., Deanfield, J., Drexler, H., Gerhard-Herman, M.,
Herrington, D., Vallance, P., Vita, J. & Vogel, R. (2002). Guidelines for
the ultrasound assessment of endothelial-dependent flow-mediated
vasodilation of the brachial artery: a report of the International Brachial
Artery Reactivity Task Force. JAm Coll Cardiol, 39, 257-65.
Cottone, S., Mule, G., Guarneri, M., Palermo, A., Lorito, M.C., Riccobene,
R., Arsena, R., Vaccaro, F., Vadala, A., Nardi, E., Cusimano, P. &
Cerasola, G. (2009). Endothelin-1 and F2-isoprostane relate to and predict
renal dysfunction in hypertensive patients. Nephrol Dial Transplant, 24, 497-
503.
Covic, A., Goldsmith, D.J., Gusbeth-Tatomir, P. & Covic, M. (2004).
Haemodialysis acutely improves endothelium-independent vasomotor
function without significantly influencing the endothelium-mediated
abnormal response to a beta 2-agonist. Nephrol Dial Transplant, 19, 637-43.
Cracowski, J.L., Cracowski, C., Bessard, G., Pepin, J.L., Bessard, J.,
Schwebel, C., Stanke-Labesque, F. & Pison, C. (2001). Increased lipid
-232 -
peroxidation in patients with pulmonary hypertension. Am JRespir Crit Care
Med, 164, 1038-42.
Cracowski, J.L., Kom, G.D., Salvat-Melis, M., Renversez, J.C., McCord, G.,
Boignard, A., Carpentier, P.H. & Schwedhelm, E. (2006). Postocclusive
reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane
levels in systemic sclerosis. Free Radic Biol Med, 40, 1732-7.
Cracowski, J.L., Tremel, F., Marpeau, C., Baguet, J.P., Stanke-Labesque, F.,
Mallion, J.M. & Bessard, G. (2000). Increased formation of F(2)-
isoprostanes in patients with severe heart failure. Heart, 84, 439-40.
Crilly, M., Coch, C., Clark, H., Bruce, M. & Williams, D. (2007). Repeatability
of the measurement of augmentation index in the clinical assessment of
arterial stiffness using radial applanation tonometry. Scand J Clin Lab Invest,
67,413-22.
Cristol, J.P., Bosc, J.Y., Badiou, S., Leblanc, M., Lorrho, R., Descomps, B. &
Canaud, B. (1997). Erythropoietin and oxidative stress in haemodialysis:
beneficial effects of vitamin E supplementation. Nephrol Dial Transplant,
12,2312-7.
Cruickshank, K., Riste, L., Anderson, S.G., Wright, J.S., Dunn, G. & Gosling,
R.G. (2002). Aortic pulse-wave velocity and its relationship to mortality in
diabetes and glucose intolerance: an integrated index of vascular function?
Circulation, 106, 2085-90.
Culleton, B.F., Larson, M.G., Wilson, P.W., Evans, J.C., Parfrey, P.S. &
Levy, D. (1999). Cardiovascular disease and mortality in a community-based
cohort with mild renal insufficiency. Kidney Int, 56, 2214-9.
czernichow, S., bertrais, S., blacher, J., oppert, J.M., galan, P.,
Ducimetiere, P., Hercberg, S., Safar, M. & Zureik, M. (2005). Metabolic
syndrome in relation to structure and function of large arteries: a predominant
effect of blood pressure. A report from the SU.VI.MAX. Vascular Study. Am
JHypertens, 18, 1154-60.
Dammers, R., Hoeks, A.P., Tordoir, J.H., Welten, R.J., Hamulyak, K.,
Kooman, J.P. & Kitslaar, P.J. (2005). Endothelin-1 levels and conduit
artery mechanical properties in end-stage renal disease. Blood Purif 23, 190-
5.
Davenport, A.P. (2002). International Union of Pharmacology. XXIX. Update on
endothelin receptor nomenclature. Pharmacol Rev, 54, 219-26.
De Leeuw, P.W., Ruilope, L.M., Palmer, C.R., Brown, M.J., Castaigne, A.,
Mancia, G., Rosenthal, T. & Wagener, G. (2004). Clinical significance of
renal function in hypertensive patients at high risk: results from the INSIGHT
trial. Arch Intern Med, 164, 2459-64.
De Roos, N.M., Bots, M.L., Schouten, E.G. & Katan, M.B. (2003). Within-
subject variability of flow-mediated vasodilation of the brachial artery in
-233-
healthy men and women: implications for experimental studies. Ultrasound
Med Biol, 29, 401-6.
Dellegrottaglie, S., Saran, R. & Rajagopalan, S. (2005). Vascular
calcification in patients with renal failure: culprit or innocent bystander?
Cardiol Clin, 23, 373-84.
Demer, L.L. & Tintut, Y. (2008). Vascular calcification: pathobiology of a
multifaceted disease. Circulation, 117,2938-48.
Demuth, K., Blacher, J., Guerin, A.P., Benoit, M.O., Moatti, N., Safar, M.E.
& London, G.M. (1998). Endothelin and cardiovascular remodelling in end-
stage renal disease. Nephrol Dial Transplant, 13, 375-83.
Deray, G., Carayon, A., Maistre, G., Benhmida, M., Masson, F., Barthelemy,
C., Petitclerc, T. & Jacobs, C. (1992). Endothelin in chronic renal failure.
Nephrol Dial Transplant, 7, 300-5.
Dhaun, N., Ferro, C.J., Davenport, A.P., Haynes, W.G., Goddard, J. & Webb,
D.J. (2007a). Haemodynamic and renal effects of endothelin receptor
antagonism in patients with chronic kidney disease. Nephrol Dial Transplant,
22,3228-34.
Dhaun, N., Goddard, J. & Webb, D.J. (2006). The endothelin system and its
antagonism in chronic kidney disease. JAm Soc Nephrol, 17, 943-55.
Dhaun, N., Pollock, D.M., Goddard, J. & Webb, D.J. (2007b). Selective and
mixed endothelin receptor antagonism in cardiovascular disease. Trends
Pharmacol Sci, 28, 573-9.
Dogra, G., Irish, A., Chan, D. & Watts, G. (2006). Insulin resistance,
inflammation, and blood pressure determine vascular dysfunction in CKD.
Am JKidney Dis, 48, 926-34.
Donald, A.E., Charakida, M., Cole, T.J., Friberg, P., Chowienczyk, P.J.,
Millasseau, S.C., Deanfield, J.E. & Halcox, J.P. (2006). Non-invasive
assessment of endothelial function: which technique? J Am Coll Cardiol, 48,
1846-50.
Donald, A.E., Halcox, J.P., Charakida, M., Storry, C., Wallace, S.M., Cole,
T.J., Friberg, P. & Deanfield, J.E. (2008). Methodological approaches to
optimize reproducibility and power in clinical studies of flow-mediated
dilation. JAm Coll Cardiol, 51, 1959-64.
Dounousi, E., Papavasiliou, E., Makedou, A., Ioannou, K., Katopodis, K.P.,
Tselepis, A., Siamopoulos, K.C. & Tsakiris, D. (2006). Oxidative stress is
progressively enhanced with advancing stages of CKD. Am J Kidney Dis, 48,
752-60.
Du Bois D & Du Bois E. F. (1916). A formula to estimate the approximate surface
area if height and weight be known. Arch Intern Med, 17, 863-871.
-234-
Dupuis, J., Stewart, D.J., Cernacek, P. & Gosselin, G. (1996). Human
pulmonary circulation is an important site for both clearance and production
of endothelin-1. Circulation, 94, 1578-84.
Eckel, R.H., Grundy, S.M. & Zimmet, P.Z. (2005). The metabolic syndrome.
Lancet, 365, 1415-28.
El-Mesallamy, H.O., Abdel Hamid, S.G. & Gad, M.Z. (2008). Oxidative stress
and asymmetric dimethylarginine are associated with cardiovascular
complications in hemodialysis patients: improvements by L-arginine intake.
Kidney Blood Press Res, 31, 189-95.
Elsayed, E.F., Sarnak, M.J., Tighiouart, H., Griffith, J.L., Kurth, T., Salem,
D.N., Levey, A.S. & Weiner, D.E. (2008). Waist-to-hip ratio, body mass
index, and subsequent kidney disease and death. Am JKidney Dis, 52, 29-38.
Endemann, D.H. & Schiffrin, E.L. (2004). Endothelial dysfunction. J Am Soc
Nephrol, 15, 1983-92.
Ferreira, E, Boreham, C.A., Twisk, J.W., Gallagher, A.M., Young, I.S.,
Murray, L.J. & Stehouwer, C.D. (2007). Clustering of metabolic
syndrome risk factors and arterial stiffness in young adults: the Northern
Ireland Young Hearts Project. JHypertens, 25, 1009-20.
Ferreira, I., Henry, R.M., Twisk, J.W., van Mechelen, W., Kemper, H.C. &
Stehouwer, C.D. (2005). The metabolic syndrome, cardiopulmonary fitness,
and subcutaneous trunk fat as independent determinants of arterial stiffness:
the Amsterdam Growth and Health Longitudinal Study. Arch Intern Med,
165,875-82.
Ferri, C., Bellini, C., Desideri, G., Baldoncini, R., De Siati, L. & Santucci, A.
(1997). Elevated plasma endothelin-1 levels as an additional risk factor in
non-obese essential hypertensive patients with metabolic abnormalities.
Diabetologia, 40, 100-2.
Fleck, C., Janz, A., Schweitzer, F., Karge, E., Schwertfeger, M. & Stein, G.
(2001). Serum concentrations of asymmetric (ADMA) and symmetric
(SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl, 78,
S14-8.
Fliser, D., Kronenberg, F., Kielstein, J.T., Morath, C., Bode-Boger, S.M.,
Haller, H. & Ritz, E. (2005). Asymmetric dimethylarginine and
progression of chronic kidney disease: the mild to moderate kidney disease
study. JAm Soc Nephrol, 16, 2456-61.
Foley, R.N., Parfrey, P.S. & Sarnak, M.J. (1998). Clinical epidemiology of
cardiovascular disease in chronic renal disease. Am J Kidney Dis, 32, SI 12-9.
Foster, M.C., Keyes, M.J., Larson, M.G., Vita, J.A., Mitchell, G.F., Meigs,
J.B., Vasan, R.S., Benjamin, E.J. & Fox, C.S. (2008). Relations ofmeasures
of endothelial function and kidney disease: the Framingham Heart Study. Am
J Kidney Dis, 52, 859-67.
-235-
Fox, C.S., Larson, M.G., Leip, E.P., Culleton, B., Wilson, P.W. & Levy, D.
(2004). Predictors of new-onset kidney disease in a community-based
population. JAMA, 291, 844-50.
Fox, C.S. & Muntner, P. (2008). Trends in diabetes, high cholesterol, and
hypertension in chronic kidney disease among U.S. adults: 1988-1994 to
1999-2004. Diabetes Care, 31, 1337-42.
Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. (1972). Estimation of the
concentration of low-density lipoprotein cholesterol in plasma, without use of
the preparative ultracentrifuge. Clin Chem, 18, 499-502.
Frimodt-Moller, ML, Nielsen, A.H., Kamper, A.L. & Strandgaard, S. (2008).
Reproducibility of pulse-wave analysis and pulse-wave velocity
determination in chronic kidney disease. Nephrol Dial Transplant, 23, 594-
600.
Froissart, M., Rossert, J., Jacquot, C., Paillard, M. & Houillier, P. (2005).
Predictive performance of the modification of diet in renal disease and
Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol,
16, 763-73.
Fujii, H., Takiuchi, S., Kawano, Y. & Fukagawa, M. (2008). Putative role of
asymmetric dimethylarginine in microvascular disease of kidney and heart in
hypertensive patients. Am J Hypertens, 21, 650-6.
Fukami, T., Niiyama, K., Amano, Y., Hisaka, A. & Fujino, N. (1996). Cyclic
pentapeptide endothelin A receptor antagonists with attenuated in vivo
clearance. Chem Pharmaceut Bull, 44, 609-14.
Fukunaga, M., Makita, N., Roberts, L.J., 2nd, Morrow, J.D., Takahashi, K. &
Badr, K.F. (1993). Evidence for the existence of F2-isoprostane receptors on
rat vascular smooth muscle cells. Am JPhysiol, 264, CI 619-24.
Furchgott, R.F. & Zawadzki, J.V. (1980). The obligatory role of endothelial cells
in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288,
373-6.
Galli, F., Rovidati, S., Chiarantini, L., Campus, G., Canestrari, F. &
Buoncristiani, U. (1998). Bioreactivity and biocompatibility of a vitamin
E-modified multi-layer hemodialysis filter. Kidney Int, 54, 580-9.
Garland, J.S., Holden, R.M., Groome, P.A., Lam, M., Nolan, R.L., Morton,
A.R. & Pickett, W. (2008). Prevalence and associations of coronary artery
calcification in patients with stages 3 to 5 CKD without cardiovascular
disease. Am J Kidney Dis, 52, 849-58.
Gasic, S., Wagner, O.F., Vierhapper, H., Nowotny, P. & Waldhausl, W.
(1992). Regional hemodynamic effects and clearance of endothelin-1 in
humans: renal and peripheral tissues may contribute to the overall disposal of
the peptide. J Cardiovasc Pharmacol, 19, 176-80.
-236-
Ghiadoni, L., Cupisti, A., Huang, Y., Mattei, P., Cardinal, H., Favilla, S.,
Rindi, P., Barsotti, G., Taddei, S. & Salvetti, A. (2004). Endothelial
dysfunction and oxidative stress in chronic renal failure. J Nephrol, 17, 512-
9.
Ghiadoni, L., Penno, G., Giannarelli, C., Plantinga, Y., Bernardini, M.,
Pucci, L., Miccoli, R., Taddei, S., Salvetti, A. & Del Prato, S. (2008).
Metabolic syndrome and vascular alterations in normotensive subjects at risk
of diabetes mellitus. Hypertension, 51, 440-5.
Glasser, S.P., Selwyn, A.P. & Ganz, P. (1996). Atherosclerosis: risk factors and
the vascular endothelium. Am Heart J, 131, 379-84.
Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E. & Hsu, C.Y. (2004).
Chronic kidney disease and the risks of death, cardiovascular events, and
hospitalization. NEngl JMed, 351, 1296-305.
Goddard, J., Eckhart, C., Johnston, N.R., Cumming, A.D., Rankin, A.J. &
Webb, D.J. (2004a). Endothelin A receptor antagonism and angiotensin-
converting enzyme inhibition are synergistic via an endothelin B receptor-
mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol, 15,
2601-10.
Goddard, J., Johnston, N.R., Cumming, A.D. & Webb, D.J. (2007). Fractional
urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade.
Am JPhysiol Renal Physiol, 293, F1433-8.
Goddard, J., Johnston, N.R., Hand, M.F., Cumming, A.D., Rabelink, T.J.,
Rankin, A.J. & Webb, D.J. (2004b). Endothelin-A receptor antagonism
reduces blood pressure and increases renal blood flow in hypertensive
patients with chronic renal failure: a comparison of selective and combined
endothelin receptor blockade. Circulation, 109, 1186-93.
Goddard, J. & Webb, D.J. (2000). Plasma endothelin concentrations in
hypertension. J Cardiovasc Pharmacol, 35, S25-31.
Golledge, J., Leicht, A.S., Crowther, R.G., Glanville, S., Clancy, P., Sangla,
K.S., Spinks, W.L. & Quigley, F. (2008). Determinants of endothelial
function in a cohort of patients with peripheral artery disease. Cardiology,
111,51-6.
Goodman, W.G., London, G., Amann, K., Block, G.A., Giachelli, C., Hruska,
K.A., Ketteler, M., Levin, A., Massy, Z., McCarron, D.A., Raggi, P.,
Shanahan, C.M. & Yorioka, N. (2004). Vascular calcification in chronic
kidney disease. Am J Kidney Dis, 43, 572-9.
Gray, G.A. & Webb, D.J. (1996). The endothelin system and its potential as a
therapeutic target in cardiovascular disease. Pharmacol Ther, 72, 109-48.
Grundy, S.M., Brewer, H.B., Jr., Cleeman, J.I., Smith, S.C., Jr. & Lenfant, C.
(2004). Definition of metabolic syndrome: Report of the National Heart,
-237-
Lung, and Blood Institute/American Heart Association conference on
scientific issues related to definition. Circulation, 109, 433-8.
Guerin, A., Blacher, J, Pannier, B, Marchais, SJ, Safar, ME, London, GM
(2001). Impact of aortic stiffness attenuation on survival of patients in end-
stage renal failure. Circulation, 103, 987-92.
Guerin AP, B.J., Pannier B, Marchais SJ, Safar ME, London GM (2001).
Impact of aortic stiffness attenuation on survival of patients in end-stage
renal failure. Circulation, 103, 987-92.
Guerin, A.P., Blacher, J., Pannier, B., Marchais, S.J., Safar, M.E. & London,
G.M. (2001). Impact of aortic stiffness attenuation on survival of patients in
end-stage renal failure. Circulation, 103, 987-92.
Guerin, A.P., London, G.M., Marchais, S.J. & Metivier, F. (2000). Arterial
stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial
Transplant, 15, 1014-21.
Guerin, A.P., Pannier, B., Metivier, F., Marchais, S.J. & London, G.M. (2008).
Assessment and significance of arterial stiffness in patients with chronic
kidney disease. Curr Opin Nephrol Hypertens, 17, 635-41.
Gulcan, E., Gulcan, A., Erbilen, E., Taser, F., Sahin, L., Ozbek, O. & Bicik, Z.
(2007). The predictive value of CRP levels on future severe renal disease in
overweight and obese subjects without diabetes mellitus and hypertension.
Am JMed Sci, 334, 444-51.
Gusbeth-Tatomir, P. & Covic, A. (2007). Causes and consequences of increased
arterial stiffness in chronic kidney disease patients. Kidney Blood Press Res,
30,97-107.
Halcox, J.P., Nour, K.R., Zalos, G. & Quyyumi, A.A. (2001). Coronary
vasodilation and improvement in endothelial dysfunction with endothelin
ET(A) receptor blockade. Circ Res, 89, 969-76.
Hand, M.F., Haynes, W.G. & Webb, D.J. (1999). Reduced endogenous endothelin-
1-mediated vascular tone in chronic renal failure. Kidney Int, 55, 613-20.
Handelman, G.J., Walter, M.F., Adhikarla, R., Gross, J., Dallal, G.E., Levin,
N.W. & Blumberg, J.B. (2001). Elevated plasma F2-isoprostanes in patients
on long-term hemodialysis. Kidney Int, 59, 1960-6.
Hardie, K.L., Kinlay, S., Hardy, D.B., Wlodarczyk, J., Silberberg, J.S. &
Fletcher, P.J. (1997). Reproducibility of brachial ultrasonography and flow-
mediated dilatation (FMD) for assessing endothelial function. Aust N Z J
Med, 27, 649-52.
Harris, R.A., Padilla, J., Hanlon, K.P., Rink, L.D. & Wallace, J.P. (2007).
Reproducibility of the flow-mediated dilation response to acute exercise in
overweight men. UltrasoundMed Biol, 33, 1579-85.
-238-
Harris, R.A., Padilla, J., Rink, L.D. & Wallace, J.P. (2006). Variability of flow-
mediated dilation measurements with repetitive reactive hyperemia. Vase
Med, 11, 1-6.
Harrison, D., Griendling, K.K., Landmesser, U., Hornig, B. & Drexler, H.
(2003). Role of oxidative stress in atherosclerosis. Am J Cardiol, 91, 7A-
11A.
Haydar, A.A., Covic, A., Colhoun, H., Rubens, M. & Goldsmith, D.J. (2004).
Coronary artery calcification and aortic pulse wave velocity in chronic
kidney disease patients. Kidney Int, 65, 1790-4.
Haynes, W.G. & Webb, D.J. (1994). Contribution of endogenous generation of
endothelin-1 to basal vascular tone. Lancet, 344, 852-4.
Haynes, W.G. & Webb, D.J. (1998). Endothelin as a regulator of cardiovascular
function in health and disease. JHypertens, 16, 1081-98.
Hayward, C.S., Kraidly, M., Webb, C.M. & Collins, P. (2002). Assessment of
endothelial function using peripheral waveform analysis: a clinical
application. JAm Coll Cardiol, 40, 521-8.
He, Z.X., Hedrick, T.D., Pratt, C.M., Verani, M.S., Aquino, V., Roberts, R. &
Mahmarian, J.J. (2000). Severity of coronary artery calcification by electron
beam computed tomography predicts silent myocardial ischemia.
Circulation, 101, 244-51.
Heintz, B., Dorr, R., Gillessen, T., Walkenhorst, F., Krebs, W., Hanrath, P.
& Sieberth, H.G. (1993). Do arterial endothelin 1 levels affect local arterial
stiffness? Am Heart J, 126, 987-9.
Henry, R.M., Kostense, P.J., Bos, G., Dekker, J.M., Nijpels, G., Heine, R.J.,
Bouter, L.M. & Stehouwer, C.D. (2002). Mild renal insufficiency is
associated with increased cardiovascular mortality: The Hoorn Study. Kidney
Int, 62, 1402-7.
Hermans, M.M., Brandenburg, V., Ketteler, M., Kooman, J.P., van der
Sande, F.M., Gladziwa, U., Rensma, P.L., Bartelet, K., Konings, C.J.,
Hoeks, A.P., Floege, J. & Leunissen, K.M. (2006). Study on the
relationship of serum fetuin-A concentration with aortic stiffness in patients
on dialysis. Nephrol Dial Transplant, 21, 1293-9.
Hillege, H.L., Fidler, V., Diercks, G.F., van Gilst, W.H., de Zeeuw, D., van
Veldhuisen, D.J., Gans, R.O., Janssen, W.M., Grobbee, D.E. & de Jong,
P.E. (2002). Urinary albumin excretion predicts cardiovascular and
noncardiovascular mortality in general population. Circulation, 106, 1777-
82.
Himmelfarb, J. (2005). Relevance of oxidative pathways in the pathophysiology of
chronic kidney disease. Cardiol Clin, 23, 319-30.
-239-
Himmelfarb, J., Stenvinkel, P., Ikizler, T.A. & Hakim, R.M. (2002). The
elephant in uremia: oxidant stress as a unifying concept of cardiovascular
disease in uremia. Kidney Int, 62, 1524-38.
Hoehner, C.M., Greenlund, K.J., Rith-Najarian, S., Casper, M.L. &
McClellan, W.M. (2002). Association of the insulin resistance syndrome
and microalbuminuria among nondiabetic native Americans. The Inter-Tribal
Heart Project. JAm Soc Nephrol, 13, 1626-34.
Holvoet, P., Donck, J., Landeloos, M., Brouwers, E., Luijtens, K., Arnout, J.,
Lesaffre, E., Vanrenterghem, Y. & Collen, D. (1996). Correlation
between oxidized low density lipoproteins and von Willebrand factor in
chronic renal failure. Thromb Haemost, 76, 663-9.
Holvoet, P., Mertens, A., Verhamme, P., Bogaerts, K., Beyens, G.,
Verhaeghe, R., Collen, D., Muls, E. & Van de Werf, F. (2001).
Circulating oxidized LDL is a useful marker for identifying patients with
coronary artery disease. Arterioscler Thromb Vase Biol, 21, 844-8.
Holvoet, P., Stassen, J.M., Van Cleemput, J., Collen, D. & Vanhaecke, J.
(1998a). Oxidized low density lipoproteins in patients with transplant-
associated coronary artery disease. Arterioscler Thromb Vase Biol, 18, 100-7.
Holvoet, P., Vanhaecke, J., Janssens, S., Van de Werf, F. & Collen, D.
(1998b). Oxidized LDL and malondialdehyde-modified LDL in patients with
acute coronary syndromes and stable coronary artery disease. Circulation, 98,
1487-94.
Hopkins, K.D., Lehmann, E.D., Gosling, R.G., Parker, J.R. & Sonksen, P.H.
(1993). Biochemical correlates of aortic distensibility in vivo in normal
subjects. Clin Sci (Lond), 84, 593-7.
Huang, P.H., Chen, L.C., Leu, H.B., Ding, P.Y., Chen, J.W., Wu, T.C. & Lin, S.J.
(2005). Enhanced coronary calcification determined by electron beam CT is
strongly related to endothelial dysfunction in patients with suspected
coronary artery disease. Chest, 128, 810-5.
Ichihara, A., Hayashi, M., Kaneshiro, Y., Takemitsu, T., Homma, K., Kanno,
Y., Yoshizawa, M., Furukawa, T., Takenaka, T. & Saruta, T. (2005).
Low doses of losartan and trandolapril improve arterial stiffness in
hemodialysis patients. Am JKidney Dis, 45, 866-74.
Iglarz, M. & clozel, M. (2007). Mechanisms of ET-1-induced endothelial
dysfunction. JCardiovasc Pharmacol, 50, 621-8.
ihara, M., ishikawa, k., fukuroda, T., saeki, T., funabashi, k., fukami, T.,
Suda, H. & Yano, M. (1992). In vitro biological profile of a highly potent
novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J
Cardiovasc Pharmacol, 20 Suppl 12, si 1-4.
Ihara, M., Yamanaka, R., Ohwaki, K., Ozaki, S., Fukami, T., Ishikawa, K.,
Towers, P. & Yano, M. (1995). [3HJBQ-123, a highly specific and
-240-
reversible radioligand for the endothelin ETA receptor subtype. Eur J
Pharmacol, 274, 1-6.
IKIZLER, T.A. (2002). Epidemiology of vascular disease in renal failure. BloodPurif
20,6-10.
Ikizler, T.A., Morrow, J.D., Roberts, L.J., Evanson, J.A., Becker, B., Hakim,
R.M., Shyr, Y. & Himmelfarb, J. (2002). Plasma F2-isoprostane levels are
elevated in chronic hemodialysis patients. Clin Nephrol, 58, 190-7.
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K. &
Masaki, T. (1989). The human endothelin family: three structurally and
pharmacologically distinct isopeptides predicted by three separate genes.
Proc Natl Acad Sci USA, 86, 2863-7.
Ix, J.H., Chertow, G.M., Shlipak, M.G., Brandenburg, V.M., Ketteler, M. &
Whooley, M.A. (2006). Fetuin-A and kidney function in persons with
coronary artery disease—data from the Heart and Soul Study. Nephrol Dial
Transplant, 21, 2144-51.
Jafar, T.H., Stark, P.C., Schmid, C.H., Landa, M., Maschio, G., de Jong, P.E.,
de Zeeuw, D., Shahinfar, S., Toto, R. & Levey, A.S. (2003). Progression
of chronic kidney disease: the role of blood pressure control, proteinuria, and
angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann
Intern Med, 139, 244-52.
Johnson, D.W., Armstrong, K., Campbell, S.B., Mudge, D.W., Hawley, C.M.,
Coombes, J.S., Prins, J.B. & Isbel, N.M. (2007). Metabolic syndrome in
severe chronic kidney disease: Prevalence, predictors, prognostic significance
and effects of risk factor modification. Nephrology (Carlton), 12, 391-8.
Kadiiska, M.B., Gladen, B.C., Baird, D.D., Germolec, D., Graham, L.B.,
Parker, C.E., Nyska, A., Wachsman, J.T., Ames, B.N., Basu, S., Brot,
N., Fitzgerald, G.A., Floyd, R.A., George, M., Heinecke, J.W., Hatch,
G.E., Hensley, K., Lawson, J.A., Marnett, L.J., Morrow, J.D., Murray,
D.M., Plastaras, J., Roberts, L.J., 2nd, Rokach, J., Shigenaga, M.K.,
Sohal, R.S., Sun, J., Tice, R.R., Van Thiel, D.H., Wellner, D., Walter,
P.B., Tomer, K.B., Mason, R.P. & Barrett, J.C. (2005). Biomarkers of
oxidative stress study II: are oxidation products of lipids, proteins, and DNA
markers of CC14 poisoning? Free Radic Biol Med, 38, 698-710.
Kaiser, D.R., Billups, K., Mason, C., Wetterling, R., Lundberg, J.L. & Bank,
A.J. (2004). Impaired brachial artery endothelium-dependent and -
independent vasodilation in men with erectile dysfunction and no other
clinical cardiovascular disease. JAm Coll Cardiol, 43, 179-84.
Kals, J., Kampus, P., Kals, M., Pulges, A., Teesalu, R., Zilmer, K., Kullisaar,
T., Salum, T., Eha, J. & Zilmer, M. (2008). Inflammation and oxidative
stress are associated differently with endothelial function and arterial
stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin
Lab Invest, 68, 594-601.
-241 -
Kals, J., Kampus, P., Kals, M., Teesalu, R., Zilmer, K., Pulges, A. & Zilmer,
M. (2007). Arterial elasticity is associated with endothelial vasodilatory
function and asymmetric dimethylarginine level in healthy subjects. Scand J
Clin Lab Invest, 67, 536-44.
Kanter, J.E., Johansson, F., LeBoeuf, R.C. & Bornfeldt, K.E. (2007). Do
glucose and lipids exert independent effects on atherosclerotic lesion
initiation or progression to advanced plaques? Circ Res, 100, 769-81.
Karakitsos, D., Patrianakos, A.P., Parthenakis, F.I., Malliaraki, N.,
Nikitovic, D., Kyriazis, J., Karabinis, A., Groothoff, J.W., de Groot,
E., Fourtounas, C., Daphnis, E. & Vardas, P.E. (2007). Altered proximal
aortic stiffness and endothelin plasma levels in diabetic patients with end-
stage renal disease. Asaio J, 53, 343-50.
Karalliedde, J., Smith, A., DeAngelis, L., Mirenda, V., Kandra, A., Botha, J.,
Ferber, P. & Viberti, G. (2008). Valsartan improves arterial stiffness in
type 2 diabetes independently of blood pressure lowering. Hypertension, 51,
1617-23.
Karet, F.E. & Davenport, A.P. (1996). Localization of endothelin peptides in
human kidney. Kidney lnt, 49, 382-7.
Kawamoto, R., Kohara, K., Tabara, Y. & Miki, T. (2008). An association
between metabolic syndrome and the estimated glomerular filtration rate.
Intern Med, 47, 1399-406.
Kelly, R., Hayward, C., Avolio, A. & O'Rourke, M. (1989). Noninvasive
determination of age-related changes in the human arterial pulse. Circulation,
80, 1652-9.
Ketteler, M., Bongartz, P., Westenfeld, R., Wildberger, J.E., Mahnken,
A.H., Bohm, R., Metzger, T., Wanner, C., Jahnen-Dechent, W. &
Floege, J. (2003). Association of low fetuin-A (AHSG) concentrations in
serum with cardiovascular mortality in patients on dialysis: a cross-sectional
study. Lancet, 361, 827-33.
Kielstein, J.T., Boger, R.H., Bode-Boger, S.M., Frolich, J.C., Haller, H., Ritz,
E. & Fliser, D. (2002). Marked increase of asymmetric dimethylarginine in
patients with incipient primary chronic renal disease. J Am Soc Nephrol, 13,
170-6.
Kielstein, J.T., Donnerstag, F., Gasper, S., Menne, J., Kielstein, A., Martens-
lobenhoffer, j., scalera, f., cooke, j.p., fliser, D. & bode-boger,
S.M. (2006). ADMA increases arterial stiffness and decreases cerebral blood
flow in humans. Stroke, 37, 2024-9.
Kim, K.M., Jung, B.H., Paeng, K.J., Kim, S.W. & Chung, B.C. (2004). Alteration
of plasma total F2-isoprostanes before and after hemodialysis in end-stage
renal disease patients. Prostaglandins Leukot Essent Fatty Acids, 70, 475-8.
-242-
Kimoto, E., Shoji, T., Shinohara, K., Hatsuda, S., Mori, K., Fukumoto, S.,
Koyama, H., Emoto, M., Okuno, Y. & Nishizawa, Y. (2006). Regional
arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J
Am Soc Nephrol, 17, 2245-52.
Kirkby, N.S., Hadoke, P.W., Bagnall, A.J. & Webb, D.J. (2008). The endothelin
system as a therapeutic target in cardiovascular disease: great expectations or
bleak house? Br JPharmacol, 153, 1105-19.
kloog, Y., Ambar, I., sokolovsky, M., kochva, E., wollberg, Z. & bdolah,
A. (1988). Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide
hydrolysis in rat heart and brain. Science, 242, 268-70.
Knight, E.L., Rimm, E.B., Pai, J.K., Rexrode, K.M., Cannuscio, C.C., Manson,
J.E., Stampfer, M.J. & Curhan, G.C. (2004). Kidney dysfunction,
inflammation, and coronary events: a prospective study. J Am Soc Nephrol,
15, 1897-903.
Kobayashi, S., Oka, M., Maesato, K., Ikee, R., Mano, T., Hidekazu, M. &
ohtake, T. (2008). Coronary artery calcification, ADMA, and insulin
resistance in CKD patients. Clin JAm Soc Nephrol, 3, 1289-95.
Kohan, D.E. (1997). Endothelins in the normal and diseased kidney. Am J Kidney
Dis, 29, 2-26.
Konings, C.J., Dammers, R., Rensma, P.L., Kooman, J.P., Hoeks, A.P., Kornet,
L., Gladziwa, U., van der Sande, F.M. & Leunissen, K.M. (2002).
Arterial wall properties in patients with renal failure. Am J Kidney Dis, 39,
1206-12.
Konings, C.J., Hermans, M., Kooman, J.P., Meinders, J.M., Hoeks, A.P., van
der Sande, F.M. & Leunissen, K.M. (2004). Arterial stiffness and renal
replacement therapy. Peril Dial Int, 24, 318-22.
Kovaite, M., Petrulioniene, Z., Ryliskyte, L., Badariene, J., Dzenkeviciute,
V., Cypiene, A., Laucevicius, A., Polena, S. & Gintautas, J. (2007).
Systemic assessment of arterial wall structure and function in metabolic
syndrome. Proc West Pharmacol Soc, 50, 123-30.
Koyama, H., Tabata, T., Nishzawa, Y., Inoue, T., Morii, H. & Yamaji, T.
(1989). Plasma endothelin levels in patients with uraemia. Lancet, 1, 991-2.
Kramer, H., Toto, R., Peshock, R., Cooper, R. & Victor, R. (2005). Association
between chronic kidney disease and coronary artery calcification: the Dallas
Heart Study. JAm Soc Nephrol, 16, 507-13.
Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M. & Charlon, V. (1998).
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure
in patients with essential hypertension. Bosentan Hypertension Investigators.
NEngl JMed, 338, 784-90.
-243-
Kullo, I.J., Bielak, L.F., Turner, S.T., Sheedy, P.F., 2nd & Peyser, P.A. (2006).
Aortic pulse wave velocity is associated with the presence and quantity of
coronary artery calcium: a community-based study. Hypertension, 47, 174-9.
Kullo, I.J., Seward, J.B., Bailey, K.R., Bielak, L.F., Grossardt, B.R., Sheedy,
P.F., 2nd, Peyser, P.A. & Turner, S.T. (2005). C-reactive protein is related
to arterial wave reflection and stiffness in asymptomatic subjects from the
community. Am JHypertens, 18, 1123-9.
Kupari, M., Hekali, P., Keto, P., Poutanen, V.P., Tikkanen, M.J. &
Standerstkjold-Nordenstam, C.G. (1994). Relation of aortic stiffness to
factors modifying the risk of atherosclerosis in healthy people. Arterioscler
Thromb, 14, 386-94.
Kurella, M., Lo, J.C. & Chertow, G.M. (2005). Metabolic syndrome and the risk
for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol, 16,
2134-40.
Kuzniar, J., Porazko, T. & Klinger, M. (2008). Relationship between fetuin-A
concentration, elevated levels of inflammatory markers, and arterial wall
stiffness in end-stage kidney disease. J Ren Nutr, 18, 83-6.
Lacy, P., Carr, S.J., O'Brien, D., Fentum, B., Williams, B., Paul, S.K. &
Robinson, T.G. (2006). Reduced glomerular filtration rate in pre-dialysis
non-diabetic chronic kidney disease patients is associated with impaired
baroreceptor sensitivity and reduced vascular compliance. Clin Sci (Lond),
110,101-8.
Landmesser, U. & Harrison, D.G. (2001). Oxidant stress as a marker for
cardiovascular events: Ox marks the spot. Circulation, 104, 2638-40.
Landray, M.J., Wheeler, D.C., Lip, G.Y., Newman, D.J., Blann, A.D.,
McGlynn, F.J., Ball, S., Townend, J.N. & Baigent, C. (2004).
Inflammation, endothelial dysfunction, and platelet activation in patients with
chronic kidney disease: the chronic renal impairment in Birmingham (CRIB)
study. Am J Kidney Dis, 43, 244-53.
Lantelme, P., Mestre, C., Lievre, M., Gressard, A. & Milon, H. (2002). Heart
rate: an important confounder of pulse wave velocity assessment.
Hypertension, 39, 1083-7.
Laurent, S., Boutouyrie, P., Asmar, R., Gautier, I., Laloux, B., Guize, L.,
Ducimetiere, P. & Benetos, A. (2001). Aortic stiffness is an independent
predictor of all-cause and cardiovascular mortality in hypertensive patients.
Hypertension, 37, 1236-41.
Laurent, S., Cockcroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C.,
Hayoz, D., Pannier, B., Vlachopoulos, C., Wilkinson, I. & Struijker-
Boudier, H. (2006). Expert consensus document on arterial stiffness:
methodological issues and clinical applications. Eur Heart J, 27, 2588-605.
-244 -
Lavi, S., Yang, E.H., Prasad, A., Mathew, V., Barsness, G.W., Rihal, C.S.,
Lerman, L.O. & Lerman, A. (2008). The interaction between coronary
endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in
humans. Hypertension, 51, 127-33.
Lavie, C.J., Milani, R.V. & Ventura, H.O. (2009). Obesity and cardiovascular
disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol,
53, 1925-32.
Lawson, J.A., Rokach, J. & FitzGerald, G.A. (1999). Isoprostanes: formation,
analysis and use as indices of lipid peroxidation in vivo. J Biol Chem, 274,
24441-4.
Leiper, J.M., Santa Maria, J., Chubb, A., MacAllister, R.J., Charles, I.G.,
Whitley, G.S. & Vallance, P. (1999). Identification of two human
dimethylarginine dimethylaminohydrolases with distinct tissue distributions
and homology with microbial arginine deiminases. Biochem J, 343 Pt 1, 209-
14.
Lemos, M.M., Jancikic, A.D., Sanches, F.M., Christofalo, D.M., Ajzen, S.A.,
Miname, M.H., Santos, R.D., Fachini, F.C., Carvalho, A.B., Draibe,
S.A. & Canziani, M.E. (2007). Pulse wave velocity—a useful tool for
cardiovascular surveillance in pre-dialysis patients. Nephrol Dial Transplant,
22, 3527-32.
Lerman, A., Kubo, S.H., Tschumperlin, L.K. & Burnett, J.C., Jr. (1992). Plasma
endothelin concentrations in humans with end-stage heart failure and after
heart transplantation. JAm Coll Cardiol, 20, 849-53.
Levinsky, N.G. & Levy, M. (1973). Clearance techniques. In Handbook of
Physiology, eds Orloff, J. & Berliner, R.W. pp. 103-117. Baltimore: Williams
& Wilkins Company.
Levy, B.I., Benessiano, J., Poitevin, P. & Safar, M.E. (1990). Endothelium-
dependent mechanical properties of the carotid artery in WKY and SHR.
Role of angiotensin converting enzyme inhibition. Circ Res, 66, 321-8.
Li, S., Chen, W., Srinivasan, S.R. & Berenson, G.S. (2005). Influence of
metabolic syndrome on arterial stiffness and its age-related change in young
adults: the Bogalusa Heart Study. Atherosclerosis, 180, 349-54.
Liang, Y.L., Teede, H., Kotsopoulos, D., Shiel, L., Cameron, J.D., Dart, A.M.
& McGrath, B.P. (1998). Non-invasive measurements of arterial structure
and function: repeatability, interrelationships and trial sample size. Clin Sci
(Lond), 95, 669-79.
Lind, L. (2008). Endothelium-dependent vasodilation, insulin resistance and the
metabolic syndrome in an elderly cohort: the Prospective Investigation of the
Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis, 196, 795-
802.
-245-
Locatelli, F., Canaud, B., Eckardt, K.U., Stenvinkel, P., Wanner, C. &
Zoccali, C. (2003). Oxidative stress in end-stage renal disease: an emerging
threat to patient outcome. Nephrol Dial Transplant, 18, 1272-80.
London, G., Blacher, J., Pannier, B., Guerin, A. P., Marchais, S. J., Safar, M.
E. (2001). Arterial wave reflections and survival in end-stage renal failure.
Hypertension, 38, 434-8.
London, G.M., Marchais, S.J. & Guerin, A.P. (2004a). Arterial stiffness and
function in end-stage renal disease. Adv Chronic Kidney Dis, 11, 202-9.
London, G.M., Marchais, S.J., Guerin, A.P. & Metivier, F. (2005).
Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia.
Curr Opin Nephrol Hypertens, 14, 525-31.
London, G.M., Marchais, S.J., Guerin, A.P., Metivier, F., Adda, H. & Pannier,
B. (2003). Inflammation, arteriosclerosis, and cardiovascular therapy in
hemodialysis patients. Kidney Int Suppl, S88-93.
London, G.M., Pannier, B., Agharazii, M., Guerin, A.P., Verbeke, F.H. &
Marchais, S.J. (2004b). Forearm reactive hyperemia and mortality in end-
stage renal disease. Kidney Int, 65, 700-4.
London, G.M., Pannier, B., Vicaut, E., Guerin, A.P., Marchais, S.J., Safar,
M.E. & Cuche, J.L. (1996). Antihypertensive effects and arterial
haemodynamic alterations during angiotensin converting enzyme inhibition.
JHypertens, 14, 1139-46.
Lu, T.M., Ding, Y.A., Lin, S.J., Lee, W.S. & Tai, H.C. (2003). Plasma levels of
asymmetrical dimethylarginine and adverse cardiovascular events after
percutaneous coronary intervention. Eur Heart J, 24, 1912-9.
Ludmer, P.L., Selwyn, A.P., Shook, T.L., Wayne, R.R., Mudge, G.H.,
Alexander, R.W. & Ganz, P. (1986). Paradoxical vasoconstriction induced
by acetylcholine in atherosclerotic coronary arteries. N Engl J Med, 315,
1046-51.
Lynch, S.M., Morrow, J.D., Roberts, L.J., 2nd & Frei, B. (1994). Formation of
non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and
low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest, 93,
998-1004.
MacAllister, R.J., Rambausek, M.H., Vallance, P., Williams, D., Hoffmann,
K.H. & RlTZ, E. (1996). Concentration of dimethyl-L-arginine in the plasma
of patients with end-stage renal failure. Nephrol Dial Transplant, 11, 2449-
52.
MacKinnon, B., Deighan, C.J., Ferrell, W.R., Sattar, N. & Fox, J.G. (2008).
Endothelial function in patients with proteinuric primary glomerulonephritis.
Nephron Clin Pract, 109, c40-7.
-246-
Mafham, M.M., Niculescu-Duvaz, I., Barron, J., Emberson, J.R., Dockrell,
M.E., Landray, M.J. & Baigent, C. (2007). A practical method of
measuring glomerular filtration rate by iohexol clearance using dried
capillary blood spots. Nephron Clin Pract, 106, cl04-12.
Maggi, E., Bellazzi, R., Falaschi, F., Frattoni, A., Perani, G., Finardi, G.,
Gazo, A., Nai, M., Romanini, D. & Bellomo, G. (1994). Enhanced LDL
oxidation in uremic patients: an additional mechanism for accelerated
atherosclerosis? Kidney Int, 45, 876-83.
Mafimud, A. & Feely, J. (2005). Arterial stiffness is related to systemic
inflammation in essential hypertension. Hypertension, 46, 1118-22.
Malik, J., Wichterle, D., Haas, T., Melenovsky, V., Simek, J. & Stulc, T.
(2004). Repeatability of noninvasive surrogates of endothelial function. Am J
Cardiol, 94, 693-6.
Mallamaci, F., Parlongo, S. & Zoccali, C. (1993). Influence of cardiovascular
damage and residual renal function on plasma endothelin in chronic renal
failure. Nephron, 63, 291-5.
Mallamaci, F., Tripepi, G., Cutrupi, S., Malatino, L.S. & Zoccali, C. (2005).
Prognostic value of combined use of biomarkers of inflammation, endothelial
dysfunction, and myocardiopathy in patients with ESRD. Kidney Int, 67,
2330-7.
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R.,
Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S.,
Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E., Boudier,
H.A. & Zanchetti, A. (2007). 2007 ESH-ESC Practice Guidelines for the
Management of Arterial Hypertension: ESH-ESC Task Force on the
Management of Arterial Hypertension. J Hypertens, 25, 1751-62.
Marescau, B., Nagels, G., Possemiers, I., De Broe, M.E., Becaus, I., Billiouw,
J.M., Lornoy, W. & De Deyn, P.P. (1997). Guanidino compounds in serum
and urine of nondialyzed patients with chronic renal insufficiency.
Metabolism, 46, 1024-31.
Martens, F.M., van der Graaf, Y., Dijk, J.M., Olijhoek, J.K. & Visseren, F.L.
(2008). Carotid arterial stiffness is marginally higher in the metabolic
syndrome and markedly higher in type 2 diabetes mellitus in patients with
manifestations of arterial disease. Atherosclerosis, 197, 646-53.
Martino, F., Loffredo, L., Carnevale, R., Sanguigni, V., Martino, E.,
Catasca, E., Zanoni, C., Pignatelli, P. & Violi, F. (2008). Oxidative
stress is associated with arterial dysfunction and enhanced intima-media
thickness in children with hypercholesterolemia: the potential role of
nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics, 122, e648-
55.
-247-
Matsuda, N., Takei, T., Fujiu, A., Ogawa, T. & Nitta, K. (2009). Arterial
stiffness in patients with non-diabetic chronic kidney disease (CKD). J
Atheroscler Thromb, 16, 57-62.
mattace-raso, F.U., van der cammen, T.J., van der meer, I.M., schalekamp,
M.A., Asmar, R., Hofman, A. & Witteman, J.C. (2004). C-reactive protein
and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis,
176,111-6.
Mattsson, N., Ronnemaa, T., Juonala, M., Viikari, J.S., Jokinen, E., Hutri-
Kahonen, N., Kahonen, M., Laitinen, T. & Raitakari, O.T. (2008).
Arterial structure and function in young adults with the metabolic syndrome:
the Cardiovascular Risk in Young Finns Study. Eur Heart J, 29, 784-91.
Mazzaferro, S., Pasquali, M., Pugliese, F., Barresi, G., Carbone, I.,
Francone, M., Sardella, D. & Taggi, F. (2007). Serum levels of
calcification inhibition proteins and coronary artery calcium score:
comparison between transplantation and dialysis. Am JNephrol, 27, 75-83.
McClellan, W.M., Ramirez, S.P. & Jurkovitz, C. (2003). Screening for chronic
kidney disease: unresolved issues. JAm Soc Nephrol, 14, S81-7.
McCullough, P.A., Jurkovitz, C.T., Pergola, P.E., McGill, J.B., Brown,
W.W., Collins, A.J., Chen, S.C., Li, S., Singh, A., Norris, K.C., Klag,
M.J. & Bakris, G.L. (2007). Independent components of chronic kidney
disease as a cardiovascular risk state: results from the Kidney Early
Evaluation Program (KEEP). Arch Intern Med, 167, 1122-9.
McEniery, C.M., Qasem, A., Schmitt, M., Avolio, A.P., Cockcroft, J.R. &
Wilkinson, I.B. (2003). Endothelin-1 regulates arterial pulse wave velocity
in vivo. JAm Coll Cardiol, 42, 1975-81.
McEniery, C.M., Yasmin, Hall, I.R., Qasem, A., Wilkinson, I.B. & Cockcroft,
J.R. (2005). Normal vascular aging: differential effects on wave reflection
and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial
(ACCT). JAm Coll Cardiol, 46, 1753-60.
McMurray, J.J., Ray, S.G., Abdullah, I., Dargie, H.J. & Morton, J.J. (1992).
Plasma endothelin in chronic heart failure. Circulation, 85, 1374-9.
Meisinger, C., Baumert, J., Khuseyinova, N., Loewel, H. & Koenig, W. (2005).
Plasma oxidized low-density lipoprotein, a strong predictor for acute
coronary heart disease events in apparently healthy, middle-aged men from
the general population. Circulation, 112, 651-7.
Metso, S., Loimaala, A., Mercuri, M.F., Nenonen, A., Vuori, I., Oja, P., Bond,
M.G., Laine, S., Rontu, R. & Lehtimaki, T. (2004). Circulating oxidized
low-density lipoprotein and common carotid artery intima-media thickness in
a random sample of middle-aged men. J Biomed Sci, 11, 356-61.
-248-
Mitsutake, R., Miura, S. & Saku, K. (2007). Association between coronary artery
calcification score as assessed by multi-detector row computed tomography
and upstroke time of pulse wave. Intern Med, 46, 1833-6.
Mittermayer, F., Krzyzanowska, K., Exner, M., Mlekusch, W., Amighi, J.,
Sabeti, S., Minar, E., Muller, M., Wolzt, M. & Schillinger, M. (2006).
Asymmetric dimethylarginine predicts major adverse cardiovascular events
in patients with advanced peripheral artery disease. Arterioscler Thromb Vase
Biol, 26, 2536-40.
Mittermayer, F., Schaller, G., Pleiner, J., Vychytil, A., Sunder-Plassmann,
G., Horl, W.H. & Wolzt, M. (2005). Asymmetrical dimethylarginine
plasma concentrations are related to basal nitric oxide release but not
endothelium-dependent vasodilation of resistance arteries in peritoneal
dialysis patients. JAm Soc Nephrol, 16, 1832-8.
Miyauchi, T., Sugishita, Y., Yamaguchi, I., Ajisaka, R., Tomizawa, T.,
Onizuka, M., Matsuda, M., Kono, I., Yanagisawa, M., Goto, K. & et
al. (1991). Plasma concentrations of endothelin-1 and endothelin-3 are
altered differently in various pathophysiological conditions in humans. J
Cardiovasc Pharmacol, 17 Suppl 7, S394-7.
Moe, S.M. & Chen, N.X. (2008). Mechanisms of vascular calcification in chronic
kidney disease. JAm Soc Nephrol, 19, 213-6.
Molenaar, P., O'Reilly, G., Sharkey, A., Kuc, R.E., Harding, D.P., Plumpton,
C., Gresham, G.A. & Davenport, A.P. (1993). Characterization and
localization of endothelin receptor subtypes in the human atrioventricular
conducting system and myocardium. Circ Res, 72, 526-38.
Mori, T.A., Croft, K.D., Puddey, I.B. & Beilin, L.J. (1999). An improved method
for the measurement of urinary and plasma F2-isoprostanes using gas
chromatography-mass spectrometry. Anal Biochem, 268, 117-25.
Morimoto, S., Maki, K., Aota, Y., Sakuma, T. & Iwasaka, T. (2008). Beneficial
effects of combination therapy with angiotensin II receptor blocker and
angiotensin-converting enzyme inhibitor on vascular endothelial function.
Hypertens Res, 31, 1603-10.
Morrow, J.D. (2006). The isoprostanes - unique products of arachidonate
peroxidation: their role as mediators of oxidant stress. Curr Pharm Des, 12,
895-902.
Morrow, J.D. (2005). Quantification of isoprostanes as indices of oxidant stress and
the risk of atherosclerosis in humans. Arterioscler Thromb Vase Biol, 25,
279-86.
Morrow, J.D., Chen, Y., Brame, C.J., Yang, J., Sanchez, S.C., Xu, J., Zackert,
W.E., Awad, J.A. & Roberts, L.J. (1999). The isoprostanes: unique
prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug
MetabRev, 31, 117-39.
-249 -
Morrow, J.D., Hill, K.E., Burk, R.F., Nammour, T.M., Badr, K.F. & Roberts,
L.J., 2nd (1990). A series of prostaglandin F2-like compounds are produced
in vivo in humans by a non-cyclooxygenase, free radical-catalyzed
mechanism. Proc Natl Acad Sci USA, 87, 9383-7.
Morrow, J.D. & Roberts, L.J. (1997). The isoprostanes: unique bioactive products
of lipid peroxidation. Prog Lipid Res, 36, 1-21.
Motte, S., McEntee, K. & Naeije, R. (2006). Endothelin receptor antagonists.
Pharmacol Ther, 110, 386-414.
Mourad, J.J., Pannier, B., Blacher, J., Rudnichi, A., Benetos, A., London,
G.M. & Safar, M.E. (2001). Creatinine clearance, pulse wave velocity,
carotid compliance and essential hypertension. Kidney Int, 59, 1834-41.
Mule, G., Cottone, S., Mongiovi, R., Cusimano, P., Mezzatesta, G., Seddio,
G., Volpe, V., Nardi, E., Andronico, G., Piazza, G. & Cerasola, G.
(2006). Influence of the metabolic syndrome on aortic stiffness in never
treated hypertensive patients. Nutr Metab Cardiovasc Dis, 16, 54-9.
Nagano, M., Nakamura, M., Sato, K., Tanaka, F., Segawa, T. & Hiramori, K.
(2005). Association between serum C-reactive protein levels and pulse wave
velocity: a population-based cross-sectional study in a general population.
Atherosclerosis, 180, 189-95.
Nakanishi, N., Suzuki, K. & Tatara, K. (2003). Clustered features of the
metabolic syndrome and the risk for increased aortic pulse wave velocity in
middle-aged Japanese men. Angiology, 54, 551-9.
Nakov, R., Pfarr, E. & Eberle, S. (2002). Darusentan: an effective endothelinA
receptor antagonist for treatment of hypertension. Am JHypertens, 15, 583-9.
Nanayakkara, P.W., Teerlink, T., Stehouwer, C.D., Allajar, D., Spijkerman,
A., Schalkwijk, C., ter Wee, P.M. & van Guldener, C. (2005). Plasma
asymmetric dimethylarginine (ADMA) concentration is independently
associated with carotid intima-media thickness and plasma soluble vascular
cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-
moderate renal failure. Kidney Int, 68, 2230-6.
Nathan, C. & Xie, Q.W. (1994). Nitric oxide synthases: roles, tolls, and controls.
Cell, 78, 915-8.
Newby, D.E., McLeod, A.L., Uren, N.G., Flint, L., Ludlam, C.A., Webb, D.J.,
Fox, K.A. & Boon, N.A. (2001). Impaired coronary tissue plasminogen
activator release is associated with coronary atherosclerosis and cigarette
smoking: direct link between endothelial dysfunction and atherothrombosis.
Circulation, 103, 1936-41.
Nichols, W.W., O'Rourke, M.E. (2005). McDonald's Blood Flow in Arteries:
Theretical, Experimental and Clinical Principles: Hodder Arnold.
-250-
Nitta, K., Akiba, T., Suzuki, K., Uchida, K., Ogawa, T., Majima, K.,
Watanabe, R., Aoki, T. & Nihei, H. (2004). Assessment of coronary artery
calcification in hemodialysis patients using multi-detector spiral CT scan.
Hypertens Res, 27, 527-33.
Nwankwo, E., Bello, A.K. & El Nahas, A.M. (2005). Chronic kidney disease:
stemming the global tide. Am JKidney Dis, 45, 201-8.
O'Brien, E., Mee, F., Atkins, N. & Thomas, M. (1996). Evaluation of three devices
for self-measurement of blood pressure according to the revised British
Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332,
and Nissei DS-175. Blood Press Monit, 1, 55-61.
O'Byrne, D., Devaraj, S., Islam, K.N., Collazo, R., McDonald, L., Grundy, S.
& Jialal, I. (2001). Low-density lipoprotein (LDL)-induced monocyte-
endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies
to oxidized-LDL in chronic renal failure patients on dialysis therapy.
Metabolism, 50, 207-15.
O'Rourke, M.F. (1995). Mechanical Principles in Arterial Disease. Hypertension,
26, 2-9.
O'Rourke, M.F. (1999). Wave travel and reflection in the arterial system. J
Hypertens Suppl, 17, S45-7.
O'Rourke, M.F. & Gallagher, D.E. (1996). Pulse wave analysis. J Hypertens
Suppl, 14, SI47-57.
Ohta, K., Hirata, Y., Shichiri, M., Kanno, K., Emori, T., Tomita, K. &
Marumo, F. (1991). Urinary excretion of endothelin-1 in normal subjects
and patients with renal disease. Kidney Int, 39, 307-11.
Ohya, Y., Iseki, K., Iseki, C., Miyagi, T., Kinjo, K. & Takishita, S. (2006).
Increased pulse wave velocity is associated with low creatinine clearance and
proteinuria in a screened cohort. Am J Kidney Dis, 47, 790-7.
Oliver, J.J., Bowler, A., Beudeker, Q., Cate, T. & Webb, D.J. (2005). Dose-
response relationship of sublingual nitroglycerin with brachial artery
dilatation and change in central and peripheral augmentation index. Clin
Pharmacol Ther, 77, 337-8.
Oliver, J.J. & Webb, D.J. (2003a). Noninvasive assessment of arterial stiffness and
risk of atherosclerotic events. Arterioscler Thromb Vase Biol, 23, 554-566.
Oliver, J.J. & Webb, D.J. (2003b). Noninvasive assessment of arterial stiffness and
risk of atherosclerotic events. Arterioscler Thromb Vase Biol, 23, 554-66.
Orr, J.S., Gentile, C.L., Davy, B.M. & Davy, K.P. (2008). Large artery stiffening
with weight gain in humans: role of visceral fat accumulation. Hypertension,
51, 1519-24.
-251 -
Owen, W.F. & Lowrie, E.G. (1998). C-reactive protein as an outcome predictor for
maintenance hemodialysis patients. Kidney Int, 54, 627-36.
Paiva, H., Kahonen, M., Lehtimaki, T., Raitakari, O.T., Jula, A., Viikari, J.,
Alfthan, G., Juonala, M., Laaksonen, R. & Hutri-Kahonen, N. (2008).
Asymmetric dimethylarginine (ADMA) has a role in regulating systemic
vascular tone in young healthy subjects: the cardiovascular risk in young
Finns study. Am JHypertens, 21, 873-8.
Paiva, H., Laakso, J., Kahonen, M., Turjanmaa, V., Koobi, T., Majahalme, S.,
Lehtimaki, T., Ruokonen, I. & Laaksonen, R. (2006). Asymmetric
dimethylarginine and hemodynamic regulation in middle-aged men.
Metabolism, 55, 771-7.
Palmer, R.M., Ferrige, A.G. & Moncada, S. (1987). Nitric oxide release accounts
for the biological activity of endothelium-derived relaxing factor. Nature,
327,524-6.
Palmer, R.M., Rees, D.D., Ashton, D.S. & Moncada, S. (1988). L-arginine is the
physiological precursor for the formation of nitric oxide in endothelium-
dependent relaxation. Biochem Biophys Res Commun, 153, 1251-6.
Panichi, V., Mantuano, E., Paoletti, S., Santi, S., Manca Rizza, G., Cutrupi,
S., Pizzini, P., Spoto, B., Tripepi, G. & Zoccali, C. (2008). Effect of
simvastatin on plasma asymmetric dimethylarginine concentration in patients
with chronic kidney disease. JNephrol, 21, 38-44.
Panichi, V., Migliori, M., De Pietro, S., Taccola, D., Bianchi, A.M.,
Giovannini, L., Norpoth, M., Metelli, M.R., Cristofani, R., Bertelli,
A.A., Sbragia, G., Tetta, C., Palla, R. & Colombo, R. (2002). C-reactive
protein and interleukin-6 levels are related to renal function in predialytic
chronic renal failure. Nephron, 91, 594-600.
Papaioannou, T.G., Karatzis, E.N., Karatzi, K.N., Gialafos, E.J.,
Protogerou, A.D., Stamatelopoulos, K.S., Papamichael, C.M.,
Lekakis, J.P. & Stefanadis, C.I. (2007). Hour-to-hour and week-to-week
variability and reproducibility of wave reflection indices derived by aortic
pulse wave analysis: implications for studies with repeated measurements. J
Hypertens, 25, 1678-86.
Papaioannou, T.G., Stamatelopoulos, K.S., Gialafos, E., Vlachopoulos, C.,
Karatzis, E., Nanas, J. & Lekakis, J. (2004). Monitoring of arterial
stiffness indices by applanation tonometry and pulse wave analysis:
reproducibility at low blood pressures. J Clin Monit Comput, 18, 137-44.
Papapetropoulos, A., Rudic, R.D. & Sessa, W.C. (1999). Molecular control of
nitric oxide synthases in the cardiovascular system. Cardiovasc Res, 43, 509-
20.
Parfrey, P.S. & Foley, R.N. (1999). The clinical epidemiology of cardiac disease
in chronic renal failure. JAm Soc Nephrol, 10, 1606-15.
-252-
Paul, B., Hewitson, C.L., Woodman, R.J. & Mangoni, A.A. (2009). Analysis of
short-term reproducibility of arterial vasoreactivity by pulse-wave analysis
after pharmacological challenge. Clin Exp Pharmacol Physiol, 36, 49-54.
Pechanova, O. & Simko, F. (2007). The role of nitric oxide in the maintenance of
vasoactive balance. Physiol Res, 56 Suppl 2, S7-S16.
Peralta, C.A., Hicks, L.S., Chertow, G.M., Ayanian, J.Z., Vittinghoff, E., Lin,
F. & Shlipak, M.G. (2005). Control of hypertension in adults with chronic
kidney disease in the United States. Hypertension, 45, 1119-24.
Perticone, F., Ceravolo, R., Pujia, A., Ventura, G., Iacopino, S., Scozzafava,
A., Ferraro, A., Chello, M., Mastroroberto, P., Verdecchia, P. &
Schillaci, G. (2001). Prognostic significance of endothelial dysfunction in
hypertensive patients. Circulation, 104, 191-6.
Perticone, F., Maio, R., Tripepi, G. & Zoccali, C. (2004). Endothelial dysfunction
and mild renal insufficiency in essential hypertension. Circulation, 110, 821 -
5.
Piers, L.H., Touw, H.R., Gansevoort, R., Franssen, C.F., Oudkerk, M.,
Zijlstra, F. & Tio, R.A. (2009). Relation of aortic valve and coronary artery
calcium in patients with chronic kidney disease to the stage and etiology of
the renal disease. Am J Cardiol, 103, 1473-7.
Polonia, J., Barbosa, L., Silva, J.A. & Rosas, M. (2009). Improvement of aortic
reflection wave responses 6 months after stopping smoking: a prospective
study. Blood Press Monit, 14, 69-75.
Porter, C.J., Stavroulopoulos, A., Roe, S.D., Pointon, K. & Cassidy, M.J.
(2007). Detection of coronary and peripheral artery calcification in patients
with chronic kidney disease stages 3 and 4, with and without diabetes.
Nephrol Dial Transplant, 22, 3208-13.
Ramadan, M.M., Mahfouz, E.M., Gomaa, G.F., El-Diasty, T.A., Alldawi, L.,
Ikrar, T., Limin, D., Kodama, M. & Aizawa, Y. (2008). Evaluation of
coronary calcium score by multidetector computed tomography in relation to
endothelial function and inflammatory markers in asymptomatic individuals.
CircJ, 72, 778-85.
Ravani, P., Tripepi, G., Malberti, F., Testa, S., Mallamaci, F. & Zoccali, C.
(2005). Asymmetrical dimethylarginine predicts progression to dialysis and
death in patients with chronic kidney disease: a competing risks modeling
approach. JAm Soc Nephrol, 16, 2449-55.
Reaven, G.M. (1988). Banting lecture 1988. Role of insulin resistance in human
disease. Diabetes, 2>1, 1595-607.
Rehill, N., Beck, C.R., Yeo, K.R. & Yeo, W.W. (2006). The effect of chronic
tobacco smoking on arterial stiffness. Br J Clin Pharmacol, 61, 767-73.
-253-
Ridker, P.M. & Cook, N. (2004). Clinical usefulness of very high and very low
levels of C-reactive protein across the full range of Framingham Risk Scores.
Circulation, 109, 1955-9.
Rifai, N., Tracy, R.P. & Ridker, P.M. (1999). Clinical efficacy of an automated
high-sensitivity C-reactive protein assay. Clin Chem, 45, 2136-41.
Roberts, M.A., Hare, D.L., Ratnaike, S. & Ierino, F.L. (2006). Cardiovascular
biomarkers in CKD: pathophysiology and implications for clinical
management of cardiac disease. Am J Kidney Dis, 48, 341-60.
Rolinski, B., Sadri, I., Bogner, J. & Goebel, F.D. (1994). Determination of
endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res
Exp Med (Berl), 194, 9-24.
Romao, J.E., Jr., Haiashi, A.R., Elias, R.M., Luders, C., Ferraboli, R., Castro,
M.C. & Abensur, H. (2006). Positive acute-phase inflammatory markers in
different stages of chronic kidney disease. Am JNephrol, 26, 59-66.
Roos, M., Richart, T., Kouznetsova, T., von Eynatten, M., Lutz, J., Heemann,
U., Baumann, M. & Staessen, J.A. (2009). Fetuin-A and arterial stiffness in
patients with normal kidney function. Regul Pept, 154, 39-43.
Ross, R. (1999). Atherosclerosis is an inflammatory disease. Am Heart J, 138, S419-
20.
Rossi, G.P., Sacchetto, A., Cesari, M. & Pessina, A.C. (1999). Interactions
between endothelin-1 and the renin-angiotensin-aldosterone system.
Cardiovasc Res, 43, 300-7.
Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V., Costantini, M.,
Sharma, S.K., Perna, A. & Remuzzi, G. (2008). Role of remission clinics in
the longitudinal treatment of CKD. JAm Soc Nephrol, 19, 1213-24.
Russo, D., Corrao, S., Miranda, I., Ruocco, C., Manzi, S., Elefante, R.,
Brancaccio, D., Cozzolino, M., Biondi, M.L. & Andreucci, V.E. (2007).
Progression of coronary artery calcification in predialysis patients. Am J
Nephrol, 27, 152-8.
Ryan, T.P., Fisher, S.G., Elder, J.L., Winters, P.C., Beckett, W., Tacci, J. &
Sloand, J.A. (2009). Increased cardiovascular risk associated with reduced
kidney function. Am JNephrol, 29, 620-625.
Safar, M.E., Blacher, J., Pannier, B., Guerin, AP., Marchais, S.J.,
Guyonvarc'h, P.M., London, G.M. (2002). Central pulse pressure and
mortality in end-stage renal disease. Hypertension, 39, 735-8.
Saito, Y., Kazuwa, N., Shirakami, G., Mukoyama, M., Arai, H., Hosoda, K.,
suga, S., Ogawa, Y. & Imura, H. (1991). Endothelin in patients with
chronic renal failure. J Cardiovasc Pharmacol, 17 Suppl 7, S437-9.
-254-
Salusky, I.B. & Goodman, W.G. (2002). Cardiovascular calcification in end-stage
renal disease. Nephrol Dial Transplant, 17, 336-9.
Sarabi, M., Vessby, B., Basu, S., Millgard, J. & Lind, L. (1999). Relationships
between endothelium-dependent vasodilation, serum vitamin E and plasma
isoprostane 8-iso-PGF(2alpha) levels in healthy subjects. J Vase Res, 36,
486-91.
Saran, R., Novak, J.E., Desai, A., Abdulhayoglu, E., Warren, J.S., Bustami,
R., Handelman, G.J., Barbato, D., Weitzel, W., D'Alecy, L.G. &
Rajagopalan, S. (2003). Impact of vitamin E on plasma asymmetric
dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study.
Nephrol Dial Transplant, 18, 2415-20.
Sarnak, M.J., Coronado, B.E., Greene, T., Wang, S.R., Kusek, J.W., Beck, G.J.
& Levey, A.S. (2002). Cardiovascular disease risk factors in chronic renal
insufficiency. Clin Nephrol, 57, 327-35.
Sarnak, M.J. & Levey, A.S. (2000). Cardiovascular disease and chronic renal
disease: a new paradigm. Am JKidney Dis, 35, S117-31.
Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B„
Hamm, L.L., McCullough, P.A., Kasiske, B.L., Kelepouris, E., Klag,
M.J., Parfrey, P., Pfeffer, M., Raij, L., Spinosa, D.J. & Wilson, P.W.
(2003). Kidney disease as a risk factor for development of cardiovascular
disease: a statement from the American Heart Association Councils on
Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical
Cardiology, and Epidemiology and Prevention. Circulation, 108, 2154-69.
Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O'Reilly, D.S., Haffner, S.M.,
Isles, C., Macfarlane, P.W., Packard, C.J., Cobbe, S.M. & Shepherd, J.
(2003). Metabolic syndrome with and without C-reactive protein as a
predictor of coronary heart disease and diabetes in the West of Scotland
Coronary Prevention Study. Circulation, 108, 414-9.
Savage, M.T., Ferro, C.J., Pinder, S.J. & Tomson, C.R. (2002). Reproducibility of
derived central arterial waveforms in patients with chronic renal failure. Clin
Sci (Lond), 103, 59-65.
Schafer, C., Heiss, A., Schwarz, A., Westenfeld, R., Ketteler, M., Floege, J.,
Muller-Esterl, W., Schinke, T. & Jahnen-Dechent, W. (2003). The
serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a
systemically acting inhibitor of ectopic calcification. J Clin Invest, 112, 357-
66.
Schiffrin, E.L., Lipman, M.L. & Mann, J.F. (2007). Chronic kidney disease: effects
on the cardiovascular system. Circulation, 116, 85-97.
Schillaci, G., Pirro, M., Mannarino, M.R., Pucci, G., Savarese, G., Franklin,
S.S. & Mannarino, E. (2006). Relation between renal function within the
-255-
normal range and central and peripheral arterial stiffness in hypertension.
Hypertension, 48, 616-21.
Schillaci, G., Pirro, M., Vaudo, G., Mannarino, M.R., Savarese, G., Pucci, G.,
Franklin, S.S. & Mannarino, E. (2005). Metabolic syndrome is associated
with aortic stiffness in untreated essential hypertension. Hypertension, 45,
1078-82.
Schlieper, G., Brandenburg, V., Djuric, Z., Damjanovic, T., Markovic, N.,
Schurgers, L., Kruger, T., Westenfeld, R., Ackermann, D.,
Haselhuhn, A., Dimkovic, S., Ketteler, M., Floege, J. & Dimkovic, N.
(2009). Risk factors for cardiovascular calcifications in non-diabetic
Caucasian haemodialysis patients. Kidney Blood Press Res, 32, 161-168.
Schmidt, R.J. & Baylis, C. (2000). Total nitric oxide production is low in patients
with chronic renal disease. Kidney Int, 58, 1261-6.
Schneider, J.G., Tilly, N., FIierl, T., Sommer, U., Hamann, A., Dugi, K., Leidig-
Bruckner, G. & Kasperk, C. (2002). Elevated plasma endothelin-1 levels
in diabetes mellitus. Am JHypertens, 15, 967-72.
Schreiner, G.E. (1950). Determination of inulin by means of resorcinol. Proc Soc
Exp Biol Med, 74, 117-20.
Schwedhelm, E., Bartling, A., Lenzen, H., Tsikas, D., Maas, R., Brummer, J.,
Gutzki, F.M., Berger, J., Frolich, J.C. & Boger, R.H. (2004). Urinary 8-
iso-prostaglandin F2alpha as a risk marker in patients with coronary heart
disease: a matched case-control study. Circulation, 109, 843-8.
schwedler, s.b., fllep, J.g., galle, J., wanner, C. & potempa, L.A. (2006). C-
reactive protein: a family of proteins to regulate cardiovascular function. Am
J Kidney Dis, 47, 212-22.
Scuteri, A., Tesauro, M., Rizza, S., Iantorno, M., Federici, M., Lauro, D.,
Campia, U., Turriziani, M., Fusco, A., Cocciolillo, G. & Lauro, R.
(2008). Endothelial function and arterial stiffness in normotensive
normoglycemic first-degree relatives of diabetic patients are independent of
the metabolic syndrome. Nutr Metab Cardiovasc Dis, 18, 349-56.
Seo, H.S., Kang, T.S., Park, S., Park, H.Y., Ko, Y.G., Choi, D., Jang, Y. &
Chung, N. (2005). Insulin resistance is associated with arterial stiffness in
nondiabetic hypertensives independent of metabolic status. Hypertens Res,
28,945-51.
Serneri, G.G., Modesti, P.A., Cecioni, I., Biagini, D., Migliorini, A., Costoli,
A., Colella, A., Naldoni, A. & Paoletti, P. (1995). Plasma endothelin
and renal endothelin are two distinct systems involved in volume
homeostasis. Am JPhysiol, 268, HI 829-37.
Sfikakis, P.P., Papamichael, C., Stamatelopoulos, K.S., Tousoulis, D.,
Fragiadaki, K.G., Katsichti, P., Stefanadis, C. & Mavrikakis, M.
(2007). Improvement of vascular endothelial function using the oral
-256-
endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Arthritis Rheum, 56, 1985-93.
Shaul, P.W. (2002). Regulation of endothelial nitric oxide synthase: location,
location, location. Annu Rev Physiol, 64, 749-74.
Shemyakin, A., Bohm, F., Wagner, H., Efendic, S., Bavenholm, P. & Pernow, J.
(2006). Enhanced endothelium-dependent vasodilatation by dual endothelin
receptor blockade in individuals with insulin resistance. J Cardiovasc
Pharmacol, 47, 385-90.
Shi, S.J., Rakugi, H., Higashimori, K., Jiang, B.B., Higaki, J., Mikami, H. &
Ogihara, T. (1994). Augmentation by converting enzyme inhibition of
accelerated endothelin release from rat mesenteric arteries following
nephrectomy. Biochem Biophys Res Commun, 202, 246-51.
Shichiri, M., Hirata, Y., Ando, K., Emori, T., Ohta, K., Kimoto, S., Ogura, M.,
Inoue, A. & Marumo, F. (1990). Plasma endothelin levels in hypertension
and chronic renal failure. Hypertension, 15, 493-6.
Shinohara, K., Shoji, T., Tsujimoto, Y., Kimoto, E., Tahara, H., Koyama, H.,
Emoto, M., Ishimura, E., Miki, T., Tabata, T. & Nishizawa, Y. (2004).
Arterial stiffness in predialysis patients with uremia. Kidney Int, 65, 936-43.
Shlipak, M.G., Fried, L.F., Crump, C., Bleyer, A.J., Manolio, T.A., Tracy, R.P.,
Furberg, C.D. & Psaty, B.M. (2003). Elevations of inflammatory and
procoagulant biomarkers in elderly persons with renal insufficiency.
Circulation, 107, 87-92.
Shulman, N.B., Ford, C.E., Hall, W.D., Blaufox, M.D., Simon, D., Langford,
H.G. & Schneider, K.A. (1989). Prognostic value of serum creatinine and
effect of treatment of hypertension on renal function. Results from the
hypertension detection and follow-up program. The Hypertension Detection
and Follow-up Program Cooperative Group. Hypertension, 13,180-93.
slebenhofer, A., Kemp, C., Sutton, A. & Williams, B. (1999). The
reproducibility of central aortic blood pressure measurements in healthy
subjects using applanation tonometry and sphygmocardiography. J Hum
Hypertens, 13, 625-9.
sles, H. (1997). Oxidative stress: oxidants and antioxidants. Exp Physiol, 82, 291-5.
Sigrist, M.K., Taal, M.W., Bungay, P. & McIntyre, C.W. (2007). Progressive
vascular calcification over 2 years is associated with arterial stiffening and
increased mortality in patients with stages 4 and 5 chronic kidney disease.
Clin JAm Soc Nephrol, 2, 1241-8.
Simmons, E.M., Langone, A., Sezer, M.T., Vella, J.P., Recupero, P., Morrow,
J.D., Ikizler, T.A. & Himmelfarb, J. (2005). Effect of renal transplantation
on biomarkers of inflammation and oxidative stress in end-stage renal disease
patients. Transplantation, 79, 914-9.
-257-
Simonson, M.S. & Dunn, M.J. (1992). The molecular mechanisms of
cardiovascular and renal regulation by endothelin peptides. J Lab Clin Med,
119,622-39.
Simova, I., Nossikoff, A. & Denchev, S. (2008). Interobserver and intraobserver
variability of flow-mediated vasodilatation of the brachial artery.
Echocardiography, 25, 77-83.
Smith, H.W. (1951). The kidney: structure andfunction in health and disease. New
York: Oxford University Press.
Sorensen, K.E., Celermajer, D.S., Spiegelhalter, D.J., Georgakopoulos, D.,
Robinson, J., Thomas, O. & Deanfield, J.E. (1995). Non-invasive
measurement of human endothelium dependent arterial responses: accuracy
and reproducibility. Br Heart J, 74, 247-53.
Soveri, I., Lind, L., Wikstrom, B., Zilmer, M., Zilmer, K. & Fellstrom, B.
(2007). Improvement in central arterial pressure waveform during
hemodialysis is related to a reduction in asymmetric dimethylarginine
(ADMA) levels. Nephron Clin Pract, 106, cl80-6.
Spence, V.A., Kennedy, G., Belch, J.J., Hill, A. & Khan, F. (2008). Low-grade
inflammation and arterial wave reflection in patients with chronic fatigue
syndrome. Clin Sci (Lond), 114, 561-6.
Spittle, M.A., Hoenich, N.A., Handelman, G.J., Adhikarla, R., Homel, P. &
Levin, N.W. (2001). Oxidative stress and inflammation in hemodialysis
patients. Am JKidney Dis, 38, 1408-13.
Stack, A.G. & Bloembergen, W.E. (2001). Prevalence and clinical correlates of
coronary artery disease among new dialysis patients in the United States: a
cross-sectional study. JAm Soc Nephrol, 12, 1516-23.
Stam, F., van Guldener, C., Becker, A., Dekker, J.M., Heine, R.J., Bouter,
L.M. & Stehouwer, C.D. (2006). Endothelial dysfunction contributes to
renal function-associated cardiovascular mortality in a population with mild
renal insufficiency: the Hoorn study. JAm Soc Nephrol, 17, 537-45.
Stam, F., van Guldener, C., Schalkwijk, C.G., ter Wee, P.M., Donker, A.J. &
Stehouwer, C.D. (2003). Impaired renal function is associated with markers
of endothelial dysfunction and increased inflammatory activity. Nephrol Dial
Transplant, 18, 892-8.
Stancanelli, B., Malatino, L.S., Malaponte, G., Noto, P., Giuffre, E.,
Caruso, A., Gagliano, C., Zoccolo, A.M., Puccia, G. & Castellino, P.
(2007). Pulse pressure is an independent predictor of aortic stiffness in
patients with mild to moderate chronic kidney disease. Kidney Blood Press
Res, 30, 283-8.
Stehouwer, C.D., Henry, R.M. & Ferreira, I. (2008). Arterial stiffness in diabetes
and the metabolic syndrome: a pathway to cardiovascular disease.
Diabetologia, 51, 527-39.
-258-
Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C. & Witztum, J.L.
(1989). Beyond cholesterol. Modifications of low-density lipoprotein that
increase its atherogenicity. N Engl JMed, 320, 915-24.
Stenvinkel, P. & Lindholm, B. (2005a). C-reactive protein in end-stage renal
disease: are there reasons to measure it? BloodPurif 23, 72-8.
Stenvinkel, P., Wang, K., Qureshi, A.R., Axelsson, J., Pecoits-Filho, R., Gao,
P., Barany, P., Lindholm, B., Jogestrand, T., Heimburger, O., Holmes,
C., Schalling, M. & Nordfors, L. (2005b). Low fetuin-A levels are
associated with cardiovascular death: Impact of variations in the gene
encoding fetuin. Kidney Int, 67, 2383-92.
Stenvinkel, P., Wanner, C., Metzger, T., Heimburger, O., Mallamaci, F.,
Tripepi, G., Malatino, L. & Zoccali, C. (2002). Inflammation and outcome
in end-stage renal failure: does female gender constitute a survival
advantage? Kidney Int, 62, 1791-8.
Stewart, D.J., Levy, R.D., Cernacek, P. & Langleben, D. (1991). Increased
plasma endothelin-1 in pulmonary hypertension: marker or mediator of
disease? Ann Intern Med, 114, 464-9.
Stuveling, E.M., Hillege, H.L., Bakker, S.J., Gans, R.O., De Jong, P.E. & De
Zeeuw, D. (2003). C-reactive protein is associated with renal function
abnormalities in a non-diabetic population. Kidney Int, 63, 654-61.
Sutton-Tyrrell, K., Najjar, S.S., Boudreau, R.M., Venkitachalam, L.,
Kupelian, V., Simonsick, E.M., Havlik, R., Lakatta, E.G., Spurgeon, H.,
Kritchevsky, S., Pahor, M., Bauer, D. & Newman, A. (2005). Elevated
aortic pulse wave velocity, a marker of arterial stiffness, predicts
cardiovascular events in well-functioning older adults. Circulation, 111,
3384-90.
Suzuki, T., Kohno, H., Hasegawa, A., Toshima, S., Amaki, T., Kurabayashi,
M., Nagai, R., Suzuki, T., Amaki, T., Nagai, R., Hasegawa, A., Toshima,
S., Kurabayashi, M.H., Shimada, K., Nakamura, H., Teramoto, T.,
Yamaguchi, H., Nishiyama, S., Takahashi, H., Michishita, I., Sugano,
Z. & Konoshi, K. (2002). Diagnostic implications of circulating oxidized
low density lipoprotein levels as a biochemical risk marker of coronary artery
disease. Clin Biochem, 35, 347-53.
Taber, D.F., Morrow, J.D. & Roberts, L.J., 2nd (1997). A nomenclature system
for the isoprostanes. Prostaglandins, 53, 63-7.
Taddei, S., Virdis, A., Ghiadoni, L., Sudano, I., Notari, M. & Salvetti, A.
(1999). Vasoconstriction to endogenous endothelin-1 is increased in the
peripheral circulation of patients with essential hypertension. Circulation,
100, 1680-3.
-259-
Takahashi, K., Ghatei, M.A., Lam, H.C., O'Halloran, D.J. & Bloom, S.R.
(1990). Elevated plasma endothelin in patients with diabetes mellitus.
Diabetologia, 33, 306-10.
Takahashi, K., Nammour, T.M., Fukunaga, M., Ebert, J., Morrow, J.D.,
Roberts, L.J., 2nd, Hoover, R.L. & Badr, K.F. (1992). Glomerular actions
of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha,
in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin
Invest, 90, 136-41.
Takenaka, T., Mimura, T., Kanno, Y. & Suzuki, H. (2005). Qualification of
arterial stiffness as a risk factor to the progression of chronic kidney diseases.
Am JNephrol, 25, 417-24.
Tarnow, L., Hovind, P., Teerlink, T., Stehouwer, C.D. & Parving, H.H. (2004).
Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular
morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care,
27, 765-9.
Tetta, C., Biasioli, S., Schiavon, R., Inguaggiato, P., David, S., Panichi, V. &
wratten, M.L. (1999). An overview of haemodialysis and oxidant stress.
BloodPurif, 17, 118-26.
Thambyrajah, J., Landray, M.J., McGlynn, F.J., Jones, H.J., Wheeler, D.C. &
Townend, J.N. (2000). Abnormalities of endothelial function in patients with
predialysis renal failure. Heart, 83, 205-9.
Thomas, S.H. (1992). Impedance cardiography using the Sramek-Bernstein method:
accuracy and variability at rest and during exercise. Br J Clin Pharmacol, 34,
467-76.
Toikka, J.O., Niemi, P., Ahotupa, M., Niinikoski, H., Ronnemaa, T., Viikari,
J.S., Hartiala, J.J. & Raitakari, O.T. (2002). Decreased large artery
distensibility in borderline hypertension is related to increased in vivo low-
density lipoprotein oxidation. ScandJ Clin Lab Invest, 62, 301-6.
Toikka, J.O., Niemi, P., Ahotupa, M., Niinikoski, H., Viikari, J.S., Ronnemaa,
T., Hartiala, J.J. & Raitakari, O.T. (1999). Large-artery elastic properties
in young men : relationships to serum lipoproteins and oxidized low-density
lipoproteins. Arterioscler Thromb Vase Biol, 19, 436-41.
Tomiyama, H., Koji, Y., Yambe, M., Motobe, K., Shiina, K., Gulnisa, Z.,
Yamamoto, Y. & Yamashina, A. (2005). Elevated C-reactive protein
augments increased arterial stiffness in subjects with the metabolic syndrome.
Hypertension, 45, 997-1003.
Tomochika, Y., Okuda, F., Tanaka, N., Wasaki, Y., Tokisawa, I., Aoyagi, S.,
Morikuni, C., Ono, S., Okada, K. & Matsuzaki, M. (1996). Improvement
of atherosclerosis and stiffness of the thoracic descending aorta with
cholesterol-lowering therapies in familial hypercholesterolemia. Arterioscler
Thromb Vase Biol, 16, 955-62.
-260-
Tonelli, M., Jose, P., Curhan, G., Sacks, F., Braunwald, E. & Pfeffer, M.
(2006). Proteinuria, impaired kidney function, and adverse outcomes in
people with coronary disease: analysis of a previously conducted randomised
trial. BMJ, 332, 1426.
Totsune, K., Mouri, T., Takahashi, K., Ohneda, M., Sone, M., Saito, T. &
Yoshinaga, K. (1989). Detection of immunoreactive endothelin in plasma of
hemodialysis patients. FEBS Lett, 249, 239-42.
Tsuchiya, M., Suzuki, E., Egawa, K., Nishio, Y., Maegawa, H., Inoue, S.,
Mitsunami, K., Morikawa, S., Inubushi, T. & Kashiwagi, A. (2004).
Stiffness and impaired blood flow in lower-leg arteries are associated with
severity of coronary artery calcification among asymptomatic type 2 diabetic
patients. Diabetes Care, 27, 2409-15.
Uzun, EL, Konukoglu, D., Besler, M., Erdenen, F., Sezgin, C. &
Muderrisoglu, C. (2008). The effects of renal replacement therapy on
plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein
levels. Clin Invest Med, 31, El-7.
Vaccaro, F., Mule, G., Cottone, S., Soresi, M., Giannitrapani, L., Vadala, A.,
Sparacino, V., Calabrese, S., Picone, F.P., Montalto, G. & Cerasola,
G. (2007). Circulating levels of adhesion molecules in chronic kidney disease
correlate with the stage of renal disease and with C-reactive protein. Arch
Med Res, 38, 534-8.
Valkonen, V.P., Paiva, H., Salonen, J.T., Lakka, T.A., Lehtimaki, T., Laakso,
J. & Laaksonen, R. (2001). Risk of acute coronary events and serum
concentration of asymmetrical dimethylarginine. Lancet, 358, 2127-8.
Vallance, P. & Leiper, J. (2004). Cardiovascular biology of the asymmetric
dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
Arterioscler Thromb Vase Biol, 24, 1023-30.
Vallance, P., Leone, A., Calver, A., Collier, J. & Moncada, S. (1992).
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic
renal failure. Lancet, 339, 572-5.
Van Bortel, L.M., Struijker-Boudier, H.A. & Safar, M.E. (2001). Pulse
pressure, arterial stiffness, and drug treatment of hypertension. Hypertension,
38,914-21.
Van der Sande, F.M., Kooman, J.P. & Leunissen, K.M. (2006). The predictive
value of C-reactive protein in end-stage renal disease: is it clinically
significant? Blood Purif 24, 335-41.
Van Guldener, C., Janssen, M.J., Lambert, J., Steyn, M., Donker, A.J. &
Stehouwer, C.D. (1998). Endothelium-dependent vasodilatation is impaired
in peritoneal dialysis patients. Nephrol Dial Transplant, 13, 1782-6.
Van Guldener, C., Lambert, J., Janssen, M.J., Donker, A.J. & Stehouwer, C.D.
(1997). Endothelium-dependent vasodilatation and distensibility of large
-261 -
arteries in chronic haemodialysis patients. Nephrol Dial Transplant, 12
Suppl 2, 14-8.
Van Popele, N.M., Mattace-Raso, F.U., Vliegenthart, R., Grobbee, D.E.,
Asmar, R., van der Kuip, D.A., Hofman, A., de Feijter, P.J., Oudkerk,
M. & Witteman, J.C. (2006). Aortic stiffness is associated with
atherosclerosis of the coronary arteries in older adults: the Rotterdam Study.
JHypertens, 24, 2371-6.
Van Popele, N.M., Westendorp, I.C., Bots, M.L., Reneman, R.S., Hoeks, A.P.,
Hofman, A., Grobbee, D.E. & Witteman, J.C. (2000). Variables of the
insulin resistance syndrome are associated with reduced arterial distensibility
in healthy non-diabetic middle-aged women. Diabetologia, 43, 665-72.
Van Tits, L., De Graaf, J., Hak-Lemmers, H., Bredie, S., Demacker, P.,
Holvoet, P. & Stalenhoef, A. (2003). Increased levels of low-density
lipoprotein oxidation in patients with familial hypercholesterolemia and in
end-stage renal disease patients on hemodialysis. Lab Invest, 83, 13-21.
Vassalle, C., Petrozzi, L., Botto, N., Andreassi, M.G. & Zucchelli, G.C.
(2004). Oxidative stress and its association with coronary artery disease and
different atherogenic risk factors. J Intern Med, 256, 308-15.
Verbeke, F., Van Biesen, W., Peeters, P., Van Bortel, L.M. & Vanholder,
R.C. (2007). Arterial stiffness and wave reflections in renal transplant
recipients. Nephrol Dial Transplant, 22, 3021-7.
Vlachojannis, J., Tsakas, S., Petropoulou, C. & Kurz, P. (1997). Increased
renal excretion of endothelin-1 in nephrotic patients. Nephrol Dial
Transplant, 12, 470-3.
Vlachopoulos, C., Dima, I., Aznaouridis, K., Vasiliadou, C., Ioakeimidis, N.,
Aggeli, C., Toutouza, M. & Stefanadis, C. (2005). Acute systemic
inflammation increases arterial stiffness and decreases wave reflections in
healthy individuals. Circulation, 112, 2193-200.
vlagopoulos, P.T. & Sarnak, M.J. (2005). Traditional and nontraditional
cardiovascular risk factors in chronic kidney disease. Med Clin North Am, 89,
587-611.
Vlassopoulos, D., Deray, G., Carayon, A., Maistre, G. & Jacobs, C. (1995).
Blood and peritoneal levels of endothelin in continuous ambulatory
peritoneal dialysis patients. Nephron, 69, 273-6.
Vuurmans, T.J., Boer, P. & Koomans, H.A. (2003). Effects of endothelin-1 and
endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse
wave velocity in humans. Hypertension, 41, 1253-8.
Vyssoulis, G.P., Pietri, P.G., Karpanou, E.A., Vlachopoulos, C.V., Kyvelou,
S.M., Spanos, P., Cokkinos, D.V. & Stefanadis, C.l. (2008). Differential
impact of metabolic syndrome on arterial stiffness and wave reflections:
Focus on distinct definitions. Int JCardiol.
-262 -
Wahbi,N., Dalton, R.N., Turner, C., Denton, M., Abbs, I. & Swaminathan, R.
(2001). Dimethylarginines in chronic renal failure. JClin Pathol, 54, 470-3.
Wahrenberg, H., Hertel, K., Leijonhufvud, B.M., Persson, L.G., Toft, E. &
Arner, P. (2005). Use of waist circumference to predict insulin resistance:
retrospective study. BMJ, 330, 1363-4.
Wallace, T.M., Levy, J.C. & Matthews, D.R. (2004). Use and abuse of HOMA
modeling. Diabetes Care, 27, 1487-95.
Wallenfeldt, K., Fagerberg, B., Wikstrand, J. & Hulthe, J. (2004). Oxidized
low-density lipoprotein in plasma is a prognostic marker of subclinical
atherosclerosis development in clinically healthy men. J Intern Med, 256,
413-20.
Wang, M.C., Tsai, W.C., Chen, J.Y. & Huang, J.J. (2005). Stepwise increase in
arterial stiffness corresponding with the stages of chronic kidney disease. Am
J Kidney Dis, 45, 494-501.
Wanner, C., Zimmermann, J., Schwedler, S. & Metzger, T. (2002).
Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl,
99-102.
Warrens, A.N., Cassidy, M.J., Takahashi, K., Ghatei, M.A. & Bloom, S.R.
(1990). Endothelin in renal failure. Nephrol Dial Transplant, 5, 418-22.
Watanabe, N., Kamei, S., Ohkubo, A., Yamanaka, M., Ohsawa, S., Marino, K.
& Tokuda, K. (1986). Urinary protein as measured with a pyrogallol red-
molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin
Chem, 32, 1551-4.
Weber, T., Maas, R., Auer, J., Lamm, G., Lassnig, E., Rammer, M., O'Rourke,
M.F., Boger, R.H. & Eber, B. (2007). Arterial wave reflections and
determinants of endothelial function a hypothesis based on peripheral mode
of action. Am J Hypertens, 20, 256-62.
Weiner, D.E., Tighiouart, H., Amin, M.G., Stark, P.C., MacLeod, B., Griffith,
J.L., Salem, D.N., Levey, A.S. & Sarnak, M.J. (2004). Chronic kidney
disease as a risk factor for cardiovascular disease and all-cause mortality: a
pooled analysis of community-based studies. JAm Soc Nephrol, 15, 1307-15.
Wendelhag, I., Fagerberg, B., Hulthe, J., Bokemark, L. & Wikstrand, J.
(2002). Endothelium-dependent flow-mediated vasodilatation, insulin
resistance and the metabolic syndrome in 60-year-old men. J Intern Med,
252,305-13.
Wesson, D.E. (2001). Endogenous endothelins mediate increased acidification in
remnant kidneys. JAm Soc Nephrol, 12, 1826-35.
Wilkinson, I.B., Franklin, S.S. & Cockcroft, J.R. (2004). Nitric oxide and the
regulation of large artery stiffness: from physiology to pharmacology.
Hypertension, 44, 112-6.
-263 -
Wilkinson, I.B., Fuchs, S.A., Jansen, I.M., Spratt, J.C., Murray, G.D.,
Cockcroft, J.R. & Webb, D.J. (1998). Reproducibility of pulse wave
velocity and augmentation index measured by pulse wave analysis. J
Hypertens, 16, 2079-84.
Wilkinson, I.B., Hall, I.R., MacCallum, H., Mackenzie, I.S., McEniery, C.M.,
van der Arend, B.J., Shu, Y.E., MacKay, L.S., Webb, D.J. & Cockcroft,
J.R. (2002a). Pulse-wave analysis: clinical evaluation of a noninvasive,
widely applicable method for assessing endothelial function. Arterioscler
Thromb Vase Biol, 22, 147-52.
Wilkinson, I.B., MacCallum, H., Rooijmans, D.F., Murray, G.D., Cockcroft,
J.R., McKnight, J.A. & Webb, D.J. (2000). Increased augmentation index
and systolic stress in type 1 diabetes mellitus. Qjm, 93, 441-8.
Wilkinson, I.B., Prasad, K., Hall, I.R., Thomas, A., MacCallum, H., Webb,
D.J., Frenneaux, M.P. & Cockcroft, J.R. (2002b). Increased central pulse
pressure and augmentation index in subjects with hypercholesterolemia. JAm
Coll Cardiol, 39,1005-11.
Wilkinson, I.B., Qasem, A., McEniery, C.M., Webb, D.J., Avolio, A.P. &
Cockcroft, J.R. (2002c). Nitric oxide regulates local arterial distensibility in
vivo. Circulation, 105, 213-7.
Wilkinson, I.B. & Webb, D.J. (2001). Venous occlusion plethysmography in
cardiovascular research: methodology and clinical applications. Br J Clin
Pharmacol, 52, 631-46.
Williams, B., Lacy, P.S., Thom, S.M., Cruickshank, K., Stanton, A., Collier,
D., Hughes, A.D., Thurston, H. & O'Rourke, M. (2006). Differential
impact of blood pressure-lowering drugs on central aortic pressure and
clinical outcomes: principal results of the Conduit Artery Function
Evaluation (CAFE) study. Circulation, 113, 1213-25.
Xiao, S., Wagner, L., Schmidt, R.J. & Baylis, C. (2001). Circulating endothelial
nitric oxide synthase inhibitory factor in some patients with chronic renal
disease. Kidney Int, 59, 1466-72.
Xue, J.L., Ma, J.Z., Louis, T.A. & Collins, A.J. (2001). Forecast of the number of
patients with end-stage renal disease in the United States to the year 2010. J
Am Soc Nephrol, 12, 2753-8.
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M.,
Mitsui, Y., Yazaki, Y., Goto, K. & Masaki, T. (1988). A novel potent
vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332,
411-5.
Yasmin & Brown, M.J. (1999). Similarities and differences between augmentation
index and pulse wave velocity in the assessment of arterial stiffness. QJM,
92, 595-600.
-264-
Yasmin, McEniery, C.M., Wallace, S., Mackenzie, I.S., Cockcroft, J.R. &
Wilkinson, I.B. (2004). C-reactive protein is associated with arterial
stiffness in apparently healthy individuals. Arterioscler Thromb Vase Biol,
24, 969-74.
Yeun, J.Y., Levine, R.A., Mantadilok, V. & Kaysen, G.A. (2000). C-Reactive
protein predicts all-cause and cardiovascular mortality in hemodialysis
patients. Am JKidney Dis, 35, 469-76.
Yilmaz, M.I., Saglam, M., Caglar, K., Cakir, E., Ozgurtas, T., Sonmez, A.,
Eyileten, T., Yenicesu, M., Acikel, C., Oguz, Y., Ozcan, O., Bozlar, U.,
Erbil, K., Aslan, E & Vural, A. (2005). Endothelial functions improve
with decrease in asymmetric dimethylarginine (ADMA) levels after renal
transplantation. Transplantation, 80, 1660-6.
Yilmaz, M.I., Saglam, M., Caglar, K., Cakir, E., Sonmez, A., Ozgurtas, T.,
Aydin, A., Eyileten, T., Ozcan, O., Acikel, C., Tasar, M., Genctoy, G.,
Erbil, K., Vural, A. & Zoccali, C. (2006). The determinants of endothelial
dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J
Kidney Dis, 47, 42-50.
Yilmaz, M.I., Saglam, M., Carrero, J.J., Qureshi, A.R., Caglar, K., Eyileten,
T., Sonmez, A., Cakir, E., Yenicesu, M., Lindholm, B., Stenvinkel, P. &
Axelsson, J. (2008a). Serum visfatin concentration and endothelial
dysfunction in chronic kidney disease. Nephrol Dial Transplant, 23, 959-65.
Yilmaz, M.I., Saglam, M., Sonmez, A., Caglar, K., Cakir, E., Kurt, Y.,
Eyileten, T., Tasar, M., Acikel, C., Oguz, Y., Vural, A. & Yenicesu, M.
(2007). Improving proteinuria, endothelial functions and asymmetric
dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Blood Purif, 25,327-35.
Yilmaz, M.I., Sonmez, A., Saglam, M., Qureshi, A.R., Carrero, J.J., Caglar,
K., Eyileten, T., Cakir, E., Oguz, Y., Vural, A., Yenicesu, M.,
Lindholm, B., Stenvinkel, P. & Axelsson, J. (2008b). ADMA levels
correlate with proteinuria, secondary amyloidosis, and endothelial
dysfunction. JAm Soc Nephrol, 19, 388-95.
Yokoyama, H., Kuramitsu, M., Kanno, S., Tada, J., Yokota, Y. & Kamikawa,
F. (2007). Relationship between metabolic syndrome components and
vascular properties in Japanese type 2 diabetic patients without
cardiovascular disease or nephropathy. Diabetes Res Clin Pract, 75, 200-6.
Yoshida, M., Tomiyama, H., Yamada, J., Koji, Y., Shiina, K., Nagata, M. &
Yamashina, A. (2007). Relationships among renal function loss within the
normal to mildly impaired range, arterial stiffness, inflammation, and
oxidative stress. Clin JAm Soc Nephrol, 2, 1118-24.
Young, D.O., Lund, R.J., Haynatzki, G. & Dunlay, R.W. (2007). Prevalence of
the metabolic syndrome in an incident dialysis population. Hemodial Int, 11,
86-95.
-265-
Young, J.M., Terrin, N., Wang, X., Greene, T., Beck, G.J., Kusek, J.W.,
Collins, A.J., Sarnak, M.J. & Menon, V. (2009). Asymmetric
dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J
Am Soc Nephrol.
Zhe, X.W., Zeng, J., Tian, X.K., Chen, W., Gu, Y., Cheng, L.T., Chen, H.M.,
Axelsson, J., Lindholm, B. & Wang, T. (2008). Pulse wave velocity is
associated with metabolic syndrome components in CAPD patients. Am J
Nephrol, 28, 641-6.
Zieman, S.J., Melenovsky, V. & Kass, D.A. (2005). Mechanisms,
pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vase
Biol, 25, 932-43.
zlmmermann, J., herrlinger, S., pruy, A., metzger, T. & wanner, C. (1999).
Inflammation enhances cardiovascular risk and mortality in hemodialysis
patients. Kidney Int, 55, 648-58.
Zoccali, C. (2006). Traditional and emerging cardiovascular and renal risk factors:
an epidemiologic perspective. Kidney Int, 70, 26-33.
Zoccali, C., Bode-Boger, S., Mallamaci, F., Benedetto, F., Tripepi, G.,
Malatino, L., Cataliotti, A., Bellanuova, I., Fermo, I., Frolich, J. &
Boger, R. (2001). Plasma concentration of asymmetrical dimethylarginine
and mortality in patients with end-stage renal disease: a prospective study.
Lancet, 358, 2113-7.
Zoccali, C., Maio, R., Tripepi, G., Mallamaci, F. & Perticone, F. (2006).
Inflammation as a mediator of the link between mild to moderate renal
insufficiency and endothelial dysfunction in essential hypertension. J Am Soc
Nephrol, 17, S64-8.
Zoccali, C., Mallamaci, F. & Tripepi, G. (2003). Traditional and emerging



















































































































































































































































































































































































































































































Appendix 2: ROC curve for eGFR
1 - Specificity
Area under the curve
Test result variable(s): eGFR
Asymptotic 95% Confidence
Interval
Area Standard Error (a)
Asymptotic
Significant (b) Upper Bound Lower Bound
0.268 0.070 0.000 0.131 0.405
a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5
Coordinates of the curve
Test result variable(s): eGFR
The positive actual state is FMD <1.5%
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Placebo
Time from drug (min) 0 60 120 180 240
Arterial stiffness and endothelialfunction
CF-PWV
CF-PWV (m/s) 7.5±0.4 7.7±0.4 7.7±0.4
Absolute A CF-PWV na 0.2±0.1 0.2±0.1
% A CF-PWV na 2.5±0.9 2.6±0.9
FMD
FMD (%) 3.7±0.6 4.3±0.7 4.1±0.6
Absolute A FMD na 0.6±0.2 0.4±0.2
% A FMD na 18.3±5.8 21.4±17.5
Renal haemodynamic
ERBF
ERBF (ml/min) 2112±264 1837±215 1908±233 1804±189 1726±206
Absolute A ERBF na -275±55 -204±63 -308±86 -386±70
% A ERBF na -11±1 -7±2 -9±3 -16±2
ERVR
ERVR (mniHg/min/ml) 6.3±0.9 7.1±0.9 6.8±0.8 7.0±0.9 7.9±1.0
Absolute A ERVR na 0.9±0.1 0.5±0.2 0.7±0.2 1.6±0.3
% A ERVR na 16.7±1.5 12.9±3.3 18.6±3.7 30.5±3.8
GFR
GFR (ml/min) 44±5 47±5 45±5 45±5 46±4
Absolute A GFR na 3.2±1.1 1.3±0.9 0.9±1.5 1.5±1.9
% A GFR na 7.3±2.6 4.6±2.6 2.4±3.5 6.8±4.4
FF
FF (%) 3.7±0.5 4.2±0.4 3.9±0.4 3.8±0.3 4.2±0.4
Absolute A FF na 0.5±0.1 0.3±0.1 0.1±0.3 0.7±0.2
% A FF na 21.3±6.7 14.9±8.5 16.9±10.1 30.4±11.5
Urinary sodium and protein excretion
UNaV
UNaV (mmol/min) 225±43 236±48 235±42 235±41 215±33
Absolute A UnaV na 11±10 10±15 10±24 -10±24
% A UNaV na 3±6 5±9 8±9 1±9
Proteinuria
Proteinuria (mg/min) 1320±281 1423±327 1397±318 1196±247 1201±237
Absolute A proteinuria na 103±65 77±53 -124±75 -119±72
% A proteunuria na 3±4 1±4 -9±4 -1±5
Plasma ET-1
ET-l
Plasma ET-1 (pg/ml) 6.3±0.3 6.4±0.3 5.9±0.3 5.9±0.3 6.1±0.3
Absolute A plasma ET-1 na 0.1±0.2 -0.4±0.3 -0.4±0.4 -0.2±0.5
% A plasma ET-1 na 3.0±3.6 -5.1±3.8 -4.7±6.4 1.7±7.3
Key: Values are mean±SEM; absolute A: absolute change from baseline;% A: percentage change from baseline.
CF-PWV: carotid-femoral pulse wave velocity; ERBF: effective renal blood flow; ERVR: effective renal vascular
resistance; ET-1: endothelin-1; FF: filtration fraction; FMD: flow-mediated dilatation; GFR: glomerular filtration rate;
UNaV: urinary sodium excretion.
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BQ123
Time from drug (min) 0 60 120 180 240
Arterial stiffness and endothelialfunction
CF-PWV
CF-PWV (m/s) 7.3±0.4 6.9±0.4 6.7±0.4
Absolute A CF-PWV na -0.4±0.1 -0.6±0.0
% A CF-PWV na -5.6±1.4 -8.5±0.8
FMD
FMD (%) 4.4±0.6 4.0±0.6 4.6±0.6
Absolute A FMD na -0.4±0.4 0.2±0.4
% A FMD na 107.8±77.3 4.3±10.4
Renal haemodynamic
ERBF
ERBF (ml/min) 2015±236 2162±234 2231±242 2055±233 1888±208
Absolute A ERBF na 147±47 215±100 39±49 -127±84
% A ERBF na 10±3 15±5 3±2 -4±3
ERVR
ERVR (mmHg/min/ml) 7.1±1.0 5.9±0.8 5.9±0.8 6.8±1.0 7.5±1.1
Absolute A ERVR na -1.2±0.2 -1.2±0.2 -0.2±0.1 0.4±0.2
% A ERVR na -14.5±2.2 -14.4±3.2 -3.6±2.3 7.3±3.7
GFR
GFR (ml/min) 42±4 40±3 42±4 42±4 41 ±4
Absolute A GFR na -2.2±1.5 0.0± 1.5 -0.4±1.3 -1. 1±1.4
% A GFR na -0.1 ±2.9 -0.9±3.6 -0.9±3.7 -4.0±3.1
FF
FF (%) 4.3±0.5 3.5±0.3 3.3±0.3 3.7±0.3 4.0±0.4
Absolute A FF na -0.8±0.3 -1.0±0.4 -0.6±0.3 -0.3±0.3
% A FF na -12.4±3.3 -13.5±9.5 -6.6±8.7 -1.6±9.9
Urinary sodium and protein excretion
UNaV
UNaV (mmol/min) 175±33 200±32 222±45 212±37 229±47
Absolute A UnaV na 25±9 47±17 37±11 54±23
% A UNaV na 20±8 28±11 25±10 31±10
Proteinuria
Proteinuria (mg/min) 2148±600 1696±538 1318±370 1347±398 1478±480
Absolute A proteinuria na -452±205 -830±245 -800±234 -670±210
% A proteunuria na -25±4 -34±3 -38±3 -34±4
Plasma ET-1
ET-l
Plasma ET-1 (pg/ml) 6.7±0.3 7.0±0.4 5.8±0.2 6.5±0.4 5.6±0.2
Absolute A plasma ET-1 na 0.2±0.3 -1.0±0.3 -0.2±0.4 -1.1±0.3
% A plasma ET-1 na 3.5±4.5 -10.4±4.7 -1.6±5.5 -11.3±6.5
Key: Values are mean±SEM; absolute A: absolute change from baseline;% A: percentage change from baseline
CF-PWV: carotid-femoral pulse wave velocity; ERBF: effective renai blood flow; ERVR: effective renal vascular
resistance; ET-1: endothelin-1; FF: filtration fraction; FMD: flow-mediated dilatation; GFR: glomerular filtration rate;
UNaV: urinary sodium excretion.
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Nifedipine
Time from drug (min) 0 60 120 180 240
Arterial stiffness and endothelial function
CF-PWV
CF-PWV (m/s) 7.4±0.3 7.0±0.3 7.140.3
Absolute A CF-PWV na -0.4±0.1 -0.340.1
% A CF-PWV na -4.6±1.2 -3.441.4
FMD
FMD (%) 5.1±0.7 1.6±3.1 3.140.6
Absolute A FMD na -3.540.5 -2.140.4
% A FMD na -81.2± 10.1 -26.7417.5
Renal haemodynamic
ERBF
ERBF (ml/min) 1776±240 18804262 1984±233 18514250 18934275
Absolute A ERBF na 104±61 208±81 76466 117495
% A ERBF na 4±4 17±6 744 545
ERVR
ERVR (mmHg/min/ml) 7.8±1.0 7.0±1.0 6.7±0.9 7.240.8 7.641.0
Absolute A ERVR na -0.9±0.5 -1.2±0.5 -0.740.5 -0.240.4
% A ERVR na -12.1±4.3 -13.444.9 -5.543.8 -1.644.7
GFR
GFR (ml/min) 43±5 4345 4546 5046 4746
Absolute A GFR na 0.242.3 2.841.8 7.942.2 4.441.7
% A GFR na 5.445.4 8.643.5 16.743.8 9.743.8
FF
FF (%) 4.0±0.4 4.240.4 3.940.3 4.540.4 4.440.4
Absolute A FF na 0.2±0.3 -0.140.2 0.440.2 0.440.2
% A FF na 7.1410.2 -0.4411.6 13.9410.7 9.0410.5
Urinary sodium and protein excretion
UNaV
UNaV (mmol/min) 180±27 193±45 240460 215437 207446
Absolute A UnaV na 14±23 60433 35420 27424
% A UNaV na 4±13 27415 21414 11413
Proteinuria
Proteinuria (mg/min) 1092±213 1178±237 12624237 12914279 12834287
Absolute A proteinuria na 86±73 170477 199496 1904142
% A proteunuria na 6±7 2047 26411 23411
Plasma ET-1
ET-l
Plasma ET-1 (pg/ml) 6.9±0.4 8.440.9 6.340.2 6.040.3 6.540.4
Absolute A plasma ET-1 na 1.4±1.0 -0.640.5 -1.040.4 -0.440.5
% A plasma ET-1 na 29.9±18.6 -3.245.9 -11.043.4 -2.145.4
Key: Values are mean±SEM; absolute A: absolute change from baseline;% A: percentage change from baseline.
CF-PWV: carotid-femoral pulse wave velocity; ERBF: effective renal blood flow; ERVR: effective renal vascular
resistance; ET-1: endothelin-1; FF: filtration fraction; FMD: flow-mediated dilatation; GFR: glomerular filtration rate;
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Chronic inflammation contributes to the development and progression
of chronic kidney disease (CKD). Identifying renal inflammation early
is important. There are currently no specific markers of renal inflam¬
mation. Endothelin-1 (ET-1) is implicated in the pathogenesis of
CKD. Thus, we investigated the impact of progressive renal dysfunc¬
tion and renal inflammation on plasma and urinary ET-1 concentra¬
tions. In a prospective study, plasma and urinary ET-1 were measured
in 132 subjects with CKD stages 1 to 5, and fractional excretion of
ET-1 (FeET-1) was calculated. FeET-1, serum C-reactive protein
(CRP), urinary ET-1 xreatinine ratio, and urinary albuminxreatinine
ratio were also measured in 29 healthy volunteers, 85 subjects with
different degrees of inflammatory renal disease but normal renal
function, and in 10 subjects with rheumatoid arthritis without renal
involvement (RA). In subjects with nephritis associated with systemic
lupus erythematosus (SLE), measurements were done before and after
6 mo of treatment. In subjects with CKD, plasma ET-1 increased
linearly as renal function declined, whereas FeET-1 rose exponen¬
tially. In subjects with normal renal function, FeET-1 and urinary
ET-1 xreatinine ratio were higher in SLE subjects than in other groups
(7.7 ± 2.7%, 10.0 ± 3.0 pg/p,mol, both P < 0.001), and correlated
with CRP, and significantly higher than in RA subjects (both P <
0.01) with similar CRP concentrations. In SLE patients, following
treatment, FeET-1 fell to 3.6 ± 1.4% (P < 0.01). Renal ET-1
production increases as renal function declines. In subjects with SLE,
urinary ET-1 may be a useful measure of renal inflammatory disease
activity while measured renal function is still normal.
systemic lupus erythematosus; renal inflammation; biomarker
chronic kidney disease (CKD) is common, affecting 6-11% of
the population in the developed world (23). Chronic inflam¬
mation is a major contributor to the development and progres¬
sion of CKD (21). Current treatments for inflammatory CKD
include immunosuppressive therapy, which is often associated
with significant side effects (18). Despite this, however, some
patients develop progressive renal injury resulting in end-stage
renal disease. Also, those who respond to treatment remain at
risk of further disease relapses. Identifying renal inflammatory
disease early and assessing its response to treatment remain
important clinical challenges. Measurement of renal function,
using serum creatinine for example, is often inadequate be-
Address for reprint requests and other correspondence: N. Dhaun, The Queen's
Medical Research Institute, 3rd Floor East, Rm. E3.23, 47 Little France Crescent,
Edinburgh, EH16 4TJ, United Kingdom (e-mail: bean.dhaun@ed.ac.uk).
cause substantial renal tissue damage can occur before function
is impaired to a detectable extent (15). However, serial renal
biopsies are not appropriate in clinical practice. Current disease
markers include serum C-reactive protein (CRP) and protein¬
uria. However, these lack both sensitivity and specificity for
renal inflammation. There are currently no easily assessable
clinical biomarkers specific to renal inflammation. Such mark¬
ers would not only allow early implementation of appropriate
treatments, with the hope of preventing disease progression,
but also help identify future disease relapses.
Endothelin-1 (ET-1) is a 21-amino acid peptide implicated
in the development and progression of CKD (10). It is pro¬
duced both within the vasculature and the kidney (10). ET-1 is
the most potent endogenous vasoconstrictor (39). In addition,
both within the kidney and elsewhere, ET-1 has a number of
other major effects including cell proliferation (32), inflamma¬
tion (30), and fibrosis (17). Although plasma ET-1 levels are
not a reliable measure of vascular ET-1 production, owing to
its predominantly abluminal release (40), urinary ET-1 excre¬
tion is independent of plasma ET-1 concentrations (13, 31) and
is well-correlated with renal ET-1 production (4, 38). A few
small studies showed a rise in plasma (20) and urine (26) ET-1
in severe CKD, and our group previously demonstrated in¬
creases in plasma and urinary ET-1 concentrations in eight
subjects with noninflammatory renal disease, across a range of
glomerular filtration rates (GFR) (13). However, there are no
data on how renal inflammation may alter these profiles and
hence on the utility of urinary ET-1 as a potential biomarker of
renal inflammation.
Thus, we hypothesized that, as a result of reduced clearance
and ineieased leual pioduction, lespectively, plasma and uri¬
nary ET-1 concentrations would increase as GFR declined and
that in subjects with varying degrees of inflammatory CKD,
but normal renal function, urinary ET-1 would act as a surro¬
gate measure of the underlying renal inflammation. Our main
groups of interest were thin basement membrane disease
(TBM), immunoglobulin A nephropathy (IgAN), and systemic
lupus erythematosus (SLE) with nephritis as examples of
noninflammatory, mild, and more florid inflammatory renal
diseases, respectively.
METHODS
This was a prospective, cross-sectional study approved by the
Multi-centre Research Ethics Committee for Scotland. It was per¬
formed between June 2005 and October 2007 in accordance with the
Declaration of Helsinki, and with the written informed consent of all
participants.
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Subjects. CKD subjects were recruited from the Nephrology out¬
patient clinic at the Royal Infirmary of Edinburgh. For study 1, the
inclusion criteria were male or female CKD patients, 18-65 yr old
with a blood pressure (BP) <160/100 mmHg. We excluded patients
with a renal transplant, those requiring dialysis, and patients with a
history of established cardiovascular disease, peripheral vascular dis¬
ease, diabetes mellitus, respiratory disease, and neurological disease.
Additionally, a systemic inflammatory disorder such as SLE or vas¬
culitis was a specific exclusion criterion. Age- and BP-matched
non-CKD subjects were recruited from the community.
For study 2, we included male and female subjects aged 18-70,
with hematuria and/or proteinuria of presumed glomerular origin. All
subjects had a serum creatinine and GFR in the normal range and no
history of hypertension. We excluded subjects with any significant
comorbidity. Rheumatoid arthritis (RA) subjects (as a control group
for the SLE cohort) were recruited from the Rheumatology outpatient
clinic at the Western General Hospital, Edinburgh.
Estimation of GFR. GFR was calculated using the Cockcroft and
Gault equation as an estimate of creatinine clearance: GFR = [140 —
age (yr)] X weight (kg) X (0.85 if female)/(72 X serum creatinine)
(6). GFR was further corrected by body surface area (BSA): BSA =
[71.84 X weight (kg)0425 X height (cm)0725]/l 0,000 as defined by
Du Bois and Du Bois (11).
Plasma and urine ET-1 assessment. For plasma ET-1, 10 ml of
venous blood were collected into an EDTA tube and centrifuged
immediately at 2,500 g for 20 min at 4°C. For urine ET-1, a 20-ml
aliquot of urine was collected into plain tubes with 2.5 ml of 50%
acetic acid. Samples were stored at — 80°C until analysis. After
extraction (29), ET-1 was determined by radioimmunoassay (7). The
mean recovery of ET-1, from extraction to assay, was >90% for both
plasma and urine. The intra- and interassay variations were 6.3 and
7.2%, respectively. The cross-reactivity of the antibody was 100%
with ET-1, 7% for both ET-2 and ET-3, and 10% with big ET-1.
Study protocol. Subjects refrained from alcohol for at least 24 h and
caffeinated drinks, food, and smoking for at least 12 h before the
study. All studies were conducted in a quiet, temperature-controlled
room. Following a brief medical inquiry to confirm suitability for the
study, body weight and height of the participants were recorded. After
30 min of supine rest, BP and heart rate were recorded, with an
appropriate sized cuff, using a validated oscillometric sphygmoma¬
nometer, the Omron HEM-705CP (25). Following this, blood was
taken for analysis and urine was collected and tested for presence of
blood and/or protein.
Data and statistical analysis. Data were stored and analyzed in
Microsoft Excel (version 11.3.7, Microsoft). Fractional excretion of
ET-1 (FeET-1) was calculated by [(urine ET-l/plasma ET-1 X plasma
creatinine/urine creatinine) X 100]%. The D'Agostino and Pearson
omnibus test was used to evaluate the distribution characteristic of the
data. Means were compared by one-way ANOVA, Kruskal-Wallis
test, unpaired Student's t-test, and Mann-Whitney U-test where ap¬
propriate. Correlation coefficients were calculated using the Pearson
method. To measure the sensitivity and specificity for FeET-1 at
different values, a conventional receiver-operator curve (ROC) curve
was generated using subjects with IgAN and microhematuria as
controls. The area under curve was calculated to ascertain the quality
of FeET-1 as a biomarker. An area of 0.5 is no better than expected
by chance, whereas a value of 1.0 signifies a perfect biomarker. A
significant level was P value £ 0.05. Descriptive data are given as
means ± SD.
RESULTS
Study 1. One hundred forty two subjects were enrolled into
this study (115 CKD and 27 matched non-CKD subjects).
CKD diagnoses were autosomal dominant polycystic kidney
disease (n = 26), IgAN (rt = 24), reflux nephropathy (n = 11),
chronic glomerulonephritis (n = 10), noninflammatory glo¬
merular disease (n = 8), obstructive nephropathy (n = 5),
TBM (n = 2), cystinuria (n = 2), Alport disease (n = 1), and
medullary cystic kidney disease (n = 1). Twenty-five CKD
subjects had no known cause for their renal disease. GFR
ranged from 8 to 154 ml-min-1* 1.73 m2. Baseline character¬
istics of all study subjects are shown in Table 1.
There was a negative linear correlation between GFR and
plasma ET-1 (Table 2 and Fig. 1A, r2 = 0.22, P < 0.001).
FeET-1 increased exponentially as GFR declined (Table 2 and
Fig. IB, r2 = 0.47, P < 0.001). Whereas plasma ET-1 did not
correlate with BP, there was a positive correlation between BP
and FeET-1 (r2 = 0.04, P < 0.05). Similarly, although there
was no impact of gender on plasma ET-1 (r = —0.08, P =
0.346), FeET-1 was higher in males than in females (3.0 ± 3.3
vs. 2.0 ± 2.2%, r = —0.167, P < 0.05). There was no
relationship between GFR and serum CRP, consistent with our
subjects comprising of a noninflammatory cohort of CKD
patients.
Study 2. One hundred fourteen subjects took part in study 2:
healthy volunteers (HV; n — 29), TBM (n = 8), IgAN (n =
22), microscopic hematuria of presumed glomerular origin
(MH; n — 35), SLE with nephritis (n = 10), and RA (n — 10).
All subjects with TBM, IgAN, and lupus nephritis had biopsy-
proven renal diagnoses. Of those with SLE, four had type IV
Table I. Demographic data for non-CKD and CKD subjects in study 1
Non-CKD Subjects (n — 27) CKD Subjects (n = 115) P Value
Age, yr 48±9 (32-64) 47 ± 10 (23-65) ns
Sex, malc/fcmalc 13/14 77/38 —
BMI, kg/m2 26±5 (18^16) 28±5 (19^11) ns
SBP, mmHg 110± 17 (83-152) 119± 15 (85-159) ns
DBP, mmHg 70± 10 (54-90) 74±9 (52-96) ns
Creatinine*, mg/dl 0.88 it 0.15 (0.62-1.11) 2.20± 1.86 (0.62-9.33) P < 0.001
eGFR, ml -min-1 • 1.73 m~2 94± 18 (68-131) 63 ±35 (8-154) P < 0.001
Cholesterol!, mg/dl 193 ±31 (131-255) 178 ± 35 (116-317) P < 0.05
CRP, mg/1 2±3 (0-12) 4±4 (0-15) P < 0.05
Plasma ET-1, pg/ml 4.6± 1.0 (2.8-7.5) 5.5 + 1.1 (3.4-9.8) P < 0.001
FeET-1, % 1.1 ±0.7 (0-3.0) 3.0±3.1 (0.2-14.7) P < 0.01
ACR, mg/mmol 0.5±0.8 (0-3.3) 48.6±(0-428) P < 0.001
Values are means ± SD (range). BMI, body mass index; FeET-1, fractional excretion of ET-1; SBP, systolic blood pressure; DBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; ACR, albumin:creatinine ratio; ns, not significant. *To convert to p.mol/1, multiply by 88.4.
tTo convert to mmol/1. multiply by 0.0259.
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<30 ml-min"1*!!!"2 ml-min"1*™"2 >60 ml-min"1-m"2 P Value
Plasma ET-1 pg/ml 6.1 ± 1.2 (4.3-8.7) 5.8±1.2 (4.0-9.8) 4.9±1.0 (2.8-7.5) <0.001
FeET-1 % 6.8±3.5 (1.0-14.7) 3.2±2.7 (6.0-12.7) 1.1 ±0.7 (0-4.0) <0.001
Values are means ± SD (range).
lupus nephritis on renal biopsy, two type V, and four both types
IV and V (37). These subjects were studied before, and 6 mo
after, the start of treatment. This comprised of oral pred¬
nisolone for all 10 subjects, with 6 additionally receiving
mycophenolate mofetil as a steroid-sparing agent, and the
remaining 4 subjects receiving cyclophosphamide. All subjects
in study 2 had normal renal function with GFR ranging from 61
to 153 ml-min 1 • 1.73 m~. A cohort of subjects with RA was
included as a control group for those with lupus nephritis as
having a similar degree of systemic inflammation, as measured
by serum CRP, but no evidence of renal disease as shown by
a clear urinalysis and GFR >60 mTmin_1-1.73 m~2. Subject
characteristics are shown in Table 3.
All groups of subjects had similar plasma ET-1 concentra¬
tions (Fig. 2A; HV: 5.3 ± 1.8, TBM: 4.4 ± 0.8, IgAN: 5.1 ±
1.0, MH: 4.5 ± 0.7, SLE: 4.7 ± 0.9, RA: 4.6 ± 0.9 pg/ml).
However, both FeET-1 and urinary ET-1:creatinine ratio were
significantly higher in lupus nephritis subjects compared with
eGFR (ml/min/1.73 m2)
eGFR (ml/min/1.73 m2)
Fig. 1. Scatter plots for estimated glomerular filtration rate (eGFR;
ml-min"1-1.73 m2) and plasma endothelin-1 (ET-1; pg/ml; A), r2 = 0.22, P <
0.001, and fractional urinary excretion of ET-1 (FeET-1; %; B), r2 = 0.47, P <
0.001.
HV and all other renal groups (Fig. 2, C and D; SLE:FeET-l
7.7 ± 2.1%, urinary ET-l:creatinine ratio 10.0 ± 3.0 pg/p,mol,
P < 0.05 vs. TBM and P < 0.001 vs. HV, IgAN, and MH, for
both). Both FeET-1 and urinary ET-l:creatinine ratio were
similar between HV, TBM, IgAN, and MH.
CRP concentrations followed a similar pattern (Fig. 2B\
SLE: 63 ± 15 mg/1, P < 0.001 vs. HV and other renal
subjects). Despite similar CRP concentrations to subjects with
RA (Fig. 2B; RA: 61 ±16 mg/1), subjects with lupus nephritis
had a significantly higher FeET-1 and urinary ET-l:creatinine
ratio (Fig. 2, C and D\ SLE vs. RA: FeET-1 7.7 ± 2.7 vs. 3.7 ±
2.1%, urinary ET-1:creatinine ratio 10.0 ± 3.0 vs. 2.1 ± 1.3
pg/pmol, P < 0.01 for both). RA subjects also had higher
urinary ET-1 creatinine ratio (P < 0.05) and FeET-1 (P <
0.01) than HV and subjects with MH and IgAN. There was no
relationship between degree of proteinuria and FeET-1, urinary
ET-1 creatinine ratio, or CRP.
For FeET-1, the area under the ROC was 1.0 (curve not
shown). Table 4 lists the derived sensitivities and specificities
at different cutoff values for FeET-1. A value above 2.7% in
renal patients yielded good sensitivity and specificity for the
detection of SLE.
For subjects with SLE and nephritis, FeET-1 fell signifi¬
cantly following treatment (Fig. 3; 7.7 ± 2.7 vs. 3.6 ± 1.4%,
P < 0.01). Effects of treatment on other disease markers are
shown in Table 5.
DISCUSSION
Consistent with our previous findings in a limited number of
subjects (8 CKD and 8 healthy controls) (13), we now dem¬
onstrated in a large cohort of subjects that plasma ET-1
increases linearly as GFR declines, whereas FeET-1 shows an
exponential rise. We also showed for the first time that urinary
ET-1 concentrations are raised in patients with systemic in¬
flammatory disease and active renal involvement (but not
systemic inflammatory disease without renal involvement),
even when GFR is normal, whereas there is little impact of
inflammation on plasma ET-1. Finally, urinary ET-1 concen¬
trations fall following successful disease treatment. Thus, uri¬
nary ET-1 may be a useful marker of renal inflammation in the
early stages of inflammatory renal disease, before renal func¬
tion is affected, and may help direct treatment in these condi¬
tions.
Previous studies showed increased plasma ET-1 concentra¬
tions in predialysis (8, 20) and dialysis-requiring (9, 20) CKD
patients. Our results are in keeping with these studies. How¬
ever, we also demonstrated that plasma ET-1 increases linearly
as renal function declines, across a wide range of GFRs and in
a relatively homogeneous, noninflammatory CKD population.
This is likely to be largely due to reduced renal filtration of
ET-1 and thus renal clearance from the circulation. Impor-
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Table 3. Demographic data for study 2 subjects
HV (n = 29) TBM (n = 8) IgAN (n = 22) MH (n = 35) SLE (n = 10) RA (n = 10)
Age, yr 46± 10 (32-64) 42± 11 (26-60) 41 ±11 (24-59) 45± 13 (22-64) 40± 14 (26-60) 44±8 (29-56)
Sex (male/female) 12/17 3/5 17/5 14/21 4/6 3/7
BMI kg/m2 25±4 (18-34) 26±5 (19-31) 27±4 (22-36) 28±5 (21 -39) 26±5 (19-29) 25±4 (20-33)
SBP mmllg 119± 18 (84-152) 115± 10 (101 —124) 117±9 (106- 132) 121 ± 14 (8 — 156) 124+17 (96-151) 131 ± 13 (109— 149)
DBP mmHg 73± 10 (59-93) 76±5 (67-81) 74 ±8 (62-96) 78± 11 (57-111) 77 ±11 (63-87) 76±8 (63-87)
Creatinine" mg/dl 0.87±0.14 (0.62-1.05) 0.83±0.11 (0.68-0.98) 1.04±0.26 (0.55-1.30) 0.92±0.18 (0.55-1.33) 0.94±0.24 (0.67-1.43) 0.92±0.10 (0.81 -1.14)
eGFR ml-min"1 • 1.73 m-2 94 ± 16 (62- 130) 102± 13 (74— 115) 97 ±26 (61 - 153) 97 ±25 (68-130) 97±27 (61-142) 89 ±19 (61-132)
Cholesterol mg/dl 193±35 (147-282) 205 ±42 (127-228) 178 ±27 (139-228) 201 ±42 (124-340) 189 ±31 (143-236) 193± 19 (166-232)
CRP mg/l 1 ±2 (0-10) 1 ±2 (0—6) 2±2 (0— 10) 3±4 (0- 14) 63it 15 (45-87) 61 ± 16 (38-91)
ACR mg/mmol 0.6±1.0 (0-3.6) 1.6±2.3 (0-6.6) 26.9±46.0 (0-173.5) 2.3±3.5 (0-15.2) 27.8±27.0 (4.3-89.3) 1.1 ±0.8 (0-2.6)
Values are means ± SD (range). HV, healthy volunteers; TBM, subjects with thin basement membrane disease; IgAN, immunoglobulin A nephropathy; MH,
microhematuria of presumed glomerular origin; SLE, systemic lupus erythematosus with nephritis; RA, rheumatoid arthritis. For CRP, P < 0.001 for SLE vs.
all renal groups. For ACR, P < 0.05 for TBM vs. SLE, P < 0.01 for HV vs. IgAN and for MH vs. SLE, P < 0.001 for HV vs. SLE, and p < 0.05 for RA
vs. SLE. aTo convert to p.mol/1, multiply by 8S.4. To convert to mmol/1, multiply by 0.0259.
tantly, we also showed an exponential rise in FeET-1 as GFR
declines. It is well established that a number of renal cell types
are able to synthesize ET-1 (10, 19, 33) and that ET-1 is an
important regulator of renal function in CKD (10, 14). It has
been shown in animal models that plasma ET-1 does not
account for urinary ET-1 (4) and that renal cortical interstitial
ET-1 levels correlate with urinary ET-1 excretion (38). These
data support the view that urinary ET-1 concentrations reflect
renal ET-1 production in CKD. Our finding of an exponential
increase in FeET-1 as GFR declines is consistent with this
evidence. Our results also show a positive correlation between
BP and FeET-1 and increasing BP, as GFR falls, may well be
one of the stimuli for renal ET-1 production. Furthermore, men
had a higher FeET-1 than women suggesting that gender may
influence renal ET-1 production and so explain the gender bias
of some renal diseases. ET-1 is proinflammatory and its up-
regulation in CKD may contribute to disease progression (10).
Thus, antagonizing the effects of ET-1 may offer therapeutic
benefits in patients with CKD, and this is supported by pre¬
clinical and clinical data (1,5, 14).
The results of our study suggest that urinary ET-1 is a useful
marker of active renal inflammation in patients with lupus
nephritis and normal renal function. Urinary ET-1 levels in
subjects with TBM disease, a noninflammatory condition, and
in those with IgAN nephropathy, associated with mild renal
inflammation, were no different to those in HV. These findings
are consistent with renal ET-1 production being driven by more
florid inflammatory renal disease as is seen in lupus nephritis.
In this study, we used spot urine samples, as are collected
routinely in the clinic, rather than timed urine collections
making the data more widely clinically applicable. Although a
urinary biomarker of disease activity would be ideal, being
noninvasive and readily available, our results show an overlap
in urinary ETicreatinine ratios between different renal groups.
However, our sample size is small and it will be important to
see whether the same holds true in a larger cohort of subjects.
Interestingly, the lack of overlap between FeET-1 levels in
subjects with active lupus nephritis and levels in HV and those
with other renal diagnoses does support its use as a discrimi¬
natory test in the clinical management of lupus nephritis.
Fig. 2. Plasma ET-1 (pg/ml; A), serum C-reac-
tive protein (CRP; mg/l; B), FeET-1 (%; O, and
urinary ET-l:creatinine ratio (pg/p,mol; D) in
healthy volunteers (HV) and subjects with thin
basement membrane disease (TBM), immuno¬
globulin A nephropathy (IgAN), microhematuria
of presumed glomerular origin (MH), systemic
lupus erythematosus with nephritis (SLE), and
rheumatoid arthritis (RA). A-D: horizontal black
bars show mean value. B: ***p < 0.001 for SLE
vs. all groups except RA, for which P = not
significant (ns). C and D: *P < 0.05 for SLE vs.
TBM. ***p < 0.001 for SLE vs. all other groups,
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Table 4. FeET-1 test characteristics for renal subjects at
different cutoff values
Cutoff for FeET-1, % Sensitivity 95% CI Specificity 95% CI
>2.08 1.00 0.69-1.00 0.96 0.85-0.99
>2.70 1.00 0.69-1.00 0.98 0.88-1.00
>3.96 1.00 0.69-1.00 1.00 0.92-1.00
>4.96 0.90 0.56-1.00 1.00 0.92-1.00
CI, confidence interval.
Consistent with this is the area under the ROC of 1.0. Although
calculation of FeET-1 requires both a blood and urine sample,
it should still be feasible in most renal clinics. This would be
of particular help in the assessment of renal disease activity
because involvement of different organs in SLE is variable.
Thus, in the group of patients who present to the renal clinic
with an active urinary sediment but in the presence of normal
renal function, an elevated urinary ET-1 level may help iden¬
tify those who have more active inflammatory renal disease,
such as lupus nephritis. It is important to note that we used the
Cockcroft and Gault equation as our estimate of GFR. Al¬
though imperfect as this will not detect more subtle loss of
renal function, in particular renal reserve, its use is preferable
























Fig. 3. FeET-l (%; A) and albumin:creatinine ratio (ACR; B) in patients with
SLE with nephritis pre- and posttreatment. *P < 0.05 and ***P < 0.001.
Table 5. CRP, ACR, dsDNA, and complement levels
in subjects with lupus nephritis pre- and posttreatment
Pretreatment (n = 10) Posttreatment in = 10) P Value
CRP, rng/1 63 ±15 5±3 P < 0.001
ACR, mg/mmol 27.8±27.0 19.1 ±18.6 P < 0.05
dsDNA (0-15 iu/ml) 102 ±86 92 ±93 P < 0.05
Complement, g/1
C3 (0.73-1.4) 0.73±0.20 0.78 ± 0.11 P = ns
C4 (0.12-0.3) 0.13 ±0.06 0.17±0.03 P < 0.05
Values are means ± SD. Normal ranges for double-strand DNA (dsDNA)
and complement are shown in brackets.
FeET-1 and CRP were both significantly elevated in subjects
with lupus nephritis compared with HV and subjects with other
renal diagnoses. Thus, one may argue that it is the systemic
inflammation in lupus nephritis that is driving the increase in
renal ET-1 production. However, when we compared urinary
ET-1 concentrations in subjects with newly diagnosed and
untreated RA, with a similar degree of systemic inflammation
as reflected by a similar CRP, but with no evidence of renal
involvement, FeET-1 was significantly higher in those with
lupus nephritis. These data suggest that the increase in urinary
ET-1 in lupus nephritis is predominantly in response to the
renal inflammation. As the current study had limited numbers,
we are unable to comment on the relationship between histo¬
logical class of lupus nephritis and renal ET-1 production, but
this is an area of ongoing study. Interestingly, although sub¬
jects with RA had a lower FeET-1 than those with lupus
nephritis, they had a greater FeET-1 than HV and those with
other renal diagnoses suggesting that systemic inflammation
may, in part, contribute to renal ET-1 production. Indeed,
previous studies suggest that inflammatory mediators stimulate
ET-1 production (34, 42).
The current clinical study was designed to look at a prese¬
lected group of patients: those referred to the renal clinic on the
basis of an abnormal urinalysis (hematuria ± proteinuria) but
in the presence of normal renal function. Our active control
group ideally needed to comprise of subjects with a similar
degree of systemic inflammation to those with lupus nephritis
but with no evidence of renal disease. We chose patients with
RA as they commonly present to the rheumatology clinic. They
often have evidence of systemic inflammation but it is uncom¬
mon for the kidney to be involved (28), especially at the outset
of disease. Although one may argue subjects with untreated
SLE without nephritis may have been a better choice of
control, these patients have variable CRP levels (2, 16) despite
other evidence of systemic inflammation (12, 22), and their
degree of inflammation is considerably less when not associ¬
ated with nephritis. Clearly, comparing urinary ET-l:creatinine
ratio and FeET-1 in those with SLE in the presence and
absence of nephritis would be of some interest and an area of
future study.
One problem in the management of lupus nephritis is as¬
sessing the response to immunosuppressive treatment as well
as the early detection of relapse. A rising serum creatinine may
be due to active disease or progressive renal scarring. How¬
ever, serial renal biopsies are not without risk, making a
simpler test desirable. The data from the current study show a
significant fall in FeET-1 in subjects with lupus nephritis
following successful treatment. At 6 mo, all subjects were in
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clinical disease remission as defined by an improvement in
symptoms and a fall in GRP. Importantly, all subjects showed
a fall in FeET-1. By contrast, some (6 of 10), but not all,
showed a resolution of their microscopic hematuria, and/or
reduction in proteinuria (7 of 10). Other immunological mark¬
ers of disease activity (double-strand DNA and complement
levels) also showed variable changes. Thus, these data suggest
that a fall in urinary ET-1 may be a useful additional marker of
response to therapy. Whether monitoring urinary ET-1 levels
may be useful in detecting patients who do not respond to
therapy remains unclear. As a limitation, we recognize that the
heterogeneity in treatment given may impact on the data and
this should be studied further. Furthermore, none of the 10
patients relapsed within the 6-mo period and it remains spec¬
ulative whether urinary ET-1 levels would rise before clinical
relapse and this should also be the focus of larger studies.
It is important to consider whether renal impairment or
significant proteinuria would affect the utility of urinary ET-1
as a biomarker of renal inflammation. The results of study 1
demonstrate that in patients with noninflammatory CKD
FeET-1 only begins to increase at a GFR of —60 ml/min. All
of the subjects with lupus nephritis in study 2 had better renal
function than this. It would be of great interest to see whether
FeET-1 levels were higher in subjects with severe enough
inflammatory renal disease to cause deterioration in GFR (<60
ml/min), such as in those with small vessel vasculitis, than in
subjects with similar GFRs but noninflammatory CKD, and
whether levels remained higher in those without active inflam¬
mation. With regard to proteinuria, our data show no relation¬
ship between urinary ET-1 concentrations and degree of pro¬
teinuria. This is in contrast to others who showed both mi¬
croalbuminuria (35) and nephrotic range proteinuria (36)
associated with urinary ET-1 albeit in different cohorts of
patients. Certainly, both in vitro (24) and in vivo (3) experi¬
ments showed that proteinuria may stimulate renal ET-1 pro¬
duction and this was associated with damage to the podocyte.
All our subjects had low-grade proteinuria and whether higher
degrees would relate to urinary ET-1 and whether alterations in
podocyte function contribute to the development of lupus
nephritis remain unclear and should be another area for further
study.
Our data add to the existing and expanding literature on
urinary biomarkers of inflammatory renal disease, in particular
relating to lupus nephritis (41). In a recent study by Pitashny et
al. (27), urinary lipocalin-2 levels were found to be higher in
subjects with SLE in the presence of nephritis than in its
absence. However, there was significant overlap in lipocalin-2
levels between the two groups, the population studied included
a majority of Hispanics and African-Americans, and the re¬
sponse to disease treatment was not assessed.
In conclusion, in the current study we found that urinary
ET-1 may act as a useful marker of active renal inflammation
in lupus nephritis and provide additional clinically relevant
information about disease activity to that given by established
markers. Further study is needed to investigate whether rising
urinary ET-1 concentrations are useful in identifying patients
who do not respond to therapy or predicting a relapse, and
whether different therapies may have variable effects on uri¬
nary ET-1. Furthermore, studying patients with other inflam¬
matory renal diseases such as those with small vessel vasculitis
would be of great interest.
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Endothelin-Kidney Disease
Blood Pressure-Independent Reduction in Proteinuria and
Arterial Stiffness After Acute Endothelin-A Receptor
Antagonism in Chronic Kidney Disease
Neeraj Dhaun, Iain M. Maclntyre, Vanessa Melville, Pajaree Lilitkarntakul, Neil R. Johnston,
Jane Goddard, David J. Webb
Abstract—Endothelin 1 is implicated in the development and progression of chronic kidney disease and associated
cardiovascular disease. We, therefore, studied the effects of selective endothelin-A receptor antagonism with BQ-123
on key independent surrogate markers of cardiovascular risk (blood pressure, proteinuria and renal hemodynamics,
arterial stiffness, and endothelial function) in patients with nondiabetic chronic kidney disease. In a double-blind,
randomized crossover study, 22 subjects with proteinuric chronic kidney disease received, on 2 separate occasions,
placebo or BQ-123. Ten of these subjects also received nifedipine (10 mg) as an active control for the antihypertensive
effect of BQ-123. Blood pressure, pulse wave velocity, flow-mediated dilation, renal blood flow, and glomerular
filtration rate were monitored after drug dosing. BQ-123 reduced blood pressure (mean arterial pressure: —7±1%;
PCO.OOl versus placebo) and increased renal blood flow (17±4%; P<0.01 versus placebo). Glomerular filtration rate
remained unchanged. Proteinuria (—26±4%; P<0.01 versus placebo) and pulse wave velocity (—5±1%; P<0.001
versus placebo) fell after BQ-123, but flow-mediated dilation did not change. Nifedipine matched the blood pressure and
renal blood flow changes seen with BQ-123. Nevertheless, BQ-123 reduced proteinuria (—38±3% versus 26±11%;
P<0.001) and pulse wave velocity (—9±1% versus —3±1%; P<0.001) to a greater extent than nifedipine. Selective
endothelin-A receptor antagonism reduced blood pressure, proteinuria, and arterial stiffness on top of standard treatment
in renal patients. Furthermore, these studies suggest that the reduction in proteinuria and arterial stiffness is partly
independent of blood pressure. If maintained longer term, selective endothelin-A receptor antagonism may confer
cardiovascular and renal benefits in patients with chronic kidney disease. (Hypertension. 2009;54:113-119.)
Key Words: endothelin ■ blood pressure ■ arterial stiffness ■ proteinuria ■ chronic kidney disease
Chronic kidney disease (CKD) is common, affecting 6%t 11 % of the population in the developed world.1
Hypertension is a frequent finding in patients with CKD,2 and
its prevalence increases as CKD progresses.3 Despite treat¬
ment with multiple antihypertensive agents, the majority of
CKD patients fail to reach target blood pressure (BP).4
Proteinuria is a common feature of CKD and is independently
associated with an adverse renal outcome.5 Current treat¬
ments for proteinuria focus on BP reduction,5 ideally using
angiotensin-converting enzyme (ACE) inhibitors6 and angio¬
tensin receptor blockers,7 both of which are thought to reduce
proteinuria to a greater extent than accounted for by BP-
lowering alone.5 Nevertheless, many CKD patients have
significant residual proteinuria despite optimal treatment.8
CKD is also strongly associated with incident cardiovas¬
cular disease (CVD).9 Hypertension10 and proteinuria11 make
an important contribution to CVD risk in CKD, as do arterial
stiffness12 and endothelial dysfunction.13 Thus, there remains
an unmet need for newer treatments in CKD that will not only
lower BP and proteinuria beyond the levels achieved with
standard therapies but will also have favorable effects on
arterial stiffness and endothelial dysfunction and so offer
longer term cardiovascular and renal protection.
Endothelin (ET) 1 is the most potent endogenous vasocon¬
strictor produced within the vasculature. It is implicated in
both the development and progression of CKD.14 The effects
of ET-1 are mediated via 2 receptors, the ETA and ETB
receptors, with the major pathological effects in CKD being
ETA receptor mediated.14 However, there are currently few
human studies.1516 ET-1 also contributes to arterial stiffness17
and endothelial dysfunction18 in patients with CVD; however,
there are no similar studies in CKD patients.
Our group has shown previously that selective ETA recep¬
tor antagonism, but not mixed ETA/B antagonism, reduces BP,
increases renal blood flow, and reduces the effective filtration
fraction in patients with CKD.15 However, this was a small
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study (n=8) where only 2 of the subjects had overt protein¬
uria (>300 mg/d), and only 6 were treated with an ACE
inhibitor. Thus, based on this work, we hypothesized that, in
patients with nondiabetic proteinuric CKD, selective ETA
receptor antagonism would reduce proteinuria and arterial
stiffness and improve endothelial dysfunction and that these
effects would be greater than those achieved with BP reduc¬
tion alone. Because we have previously demonstrated a
synergism between ACE inhibitors and selective ETA recep¬
tor antagonism in health,19 we anticipated that these effects
might be evident on top of standard treatment with ACE
inhibitors and/or angiotensin receptor blockers.
Methods
Subjects
This was a randomized, double-blind, placebo-controlled study
(please also see the online data supplement available at http://
hyper.ahajoumals.org). Because previous studies with BQ-123 have
shown a reduction in BP in CKD patients, and because BP reduction
may contribute to changes in arterial stiffness, protein excretion, and
natriuresis, nifedipine was used as an open-label active control in a
substudy. All of the subjects attended for 2 visits, receiving placebo
and BQ-123 in a randomized order, with those taking part in the
substudy (nifedipine, 10 mg) randomly chosen and attending for 3
randomized visits. Because previous studies with the same dose of
BQ-123 have demonstrated that hemodynamic changes return to
baseline after 4 hours,15 and the half-life of nifedipine is =2 hours,
each visit was separated by &7 days to ensure complete washout of
the study drugs.
Twenty-two patients with stable proteinuric CKD were recruited
into the studies, which were performed between May 2006 and
December 2007 in the University of Edinburgh Clinical Research
Centre with the approval of the local research ethics committee and
the written informed consent of each subject. The investigations
conformed to the principles outlined in the Declaration of Helsinki.
Drugs
BQ-123 (Clinalfa AG), a selective ETA receptor antagonist, was
infused at 1000 nmol/min for 15 minutes. This dose was selected
from previous studies as being ETA selective based on plasma
BQ-123 concentrations and relating these to the binding constant for
the ETA receptor, as well as by a lack of rise in plasma ET-1
concentration after its infusion.15 The drug was dissolved in physi¬
ological saline (15 mL of 0.9%, Baxter Healthcare Ltd) and infused
IV at a constant rate of 1 mL/min. Saline vehicle was administered
as a placebo.
Nifedipine (10 mg; Adalat, Bayer) was used as an active control
and administered orally at the same time that BQ-123 or saline was
started in its respective phase. Our choice of active control agent was
based, most importantly, on the need for the drug to match the
antihypertensive profile of BQ-123, to produce a similar change in
renal hemodynamics, and to be a clinically tolerable agent that is also
a standard treatment in CKD patients.20 Although we investigated
other agents, nifedipine was the only drug to fulfill all of these
criteria.
Para-aminohippurate sodium (PAH; Clinalfa) and inutest (Frese-
nius Pharma) were dissolved in 5% dextrose (Baxter) and adminis¬
tered as a bolus loading dose of 0.4 g of PAH and 3.5 g of inutest in
100 mL of dextrose over 15 minutes, along with a maintenance
infusion of 6.6 g/L of PAH and 10 g/L of inutest at a rate of 2
mL/min. For subjects with a calculated glomerular filtration rate
(GFR) <50 mL/min or <30 mL/min, doses of PAH and inutest were
reduced by one third and two thirds, respectively.
Assays
At prespecified time points, venous blood was collected into EDTA
tubes (Sarstedt) for the measurement of PAH, inulin, hematocrit, and
plasma ET-1 and into plain tubes (Sarstedt) for the measurement of
serum sodium. In addition, 20-mL aliquots of urine from each
voiding were collected into plain tubes for the measurement of
urinary PAH, inulin, sodium, and protein.
Hematocrit was measured on whole blood using a Coulter counter.
All of the other blood samples were centrifuged immediately at
lOOOg at 4°C for 20 minutes, and plasma and urine were stored in
plain tubes at — 80°C. Inulin was determined by spectrophotometry
after hydrolysis to fructose21 and PAH by high-performance liquid
chromatography.22 Plasma and urine sodium concentrations were
measured by using an ion selective electrode and urine protein by
using a colorimetric method with pyrogallol red.23 After extraction,
ET-1 was determined by radioimmunoassay.24
Assessment of Arterial Stiffness and
Endothelial Function
Pulse wave velocity (PWV) was used as a measure of arterial
stiffness,25 using the SphygmoCor system (SphygmoCor Mx version
6.31, AtCor Medical), in which a high-fidelity micromanometer
(SPC-301, Millar Instruments) was used to determine carotid-
femoral PWV. Flow-mediated dilation (FMD) was used to assess
endothelium-dependent vasomotor function.26 We did not use glyc¬
eryl trinitrate as a measure of endothelium-independent vasomotor
function to avoid interference with responses to study drugs. FMD
was quantified both as the peak change from baseline and as the area
under the curve of the change from baseline in brachial artery
diameter after 5 minutes of forearm ischemia.
Study Protocol
On each study day, a cannula was inserted into an antecubital vein in
each arm (please also see the data supplement). Diuresis was induced
by administering 500 mL of 5% dextrose IV over 30 minutes through
the left arm cannula. Thereafter, maintenance infusions of PAH and
inutest and 5% dextrose at 180 mL/h continued throughout the study.
After a 2-hour equilibration period, baseline measurements were
made over 1 hour. Drug or placebo was then administered through
the right antecubital cannula or with nifedipine given orally, fol¬
lowed by 4 hours of further measurement. BP, cardiac output (as
measured by cardiac index [CI]), and heart rate were recorded
throughout the study by well-validated noninvasive automated tech¬
niques27-28 every 15 minutes, and urine was collected every 60
minutes by spontaneous voiding.
At the midpoint of each collection period, blood was sampled
from the right antecubital cannula for PAH, inulin, sodium, and
hematocrit. At 0, 30, 60, 120, and 240 minutes, additional samples
were taken for the measurement of plasma ET-1. PWV and FMD
were measured immediately before drug and again at 2 and 4 hours
after dosing.
Data Analysis
Data were stored and analyzed in Microsoft Excel (version 11.3.7,
Microsoft Ltd). BP at each time point was calculated as the mean of
2 recordings and was represented by systolic BP, diastolic BP, and
mean arterial pressure (MAP; diastolic BP+1/3 pulse pressure).
Bioimpedance data at each time point were calculated as the mean of
4 recordings, each the average of 15 consecutive heartbeats. Data
were corrected for body surface area to give CI, for direct compar¬
ison between subjects. Systemic vascular resistance index (SVRI)
was calculated by dividing MAP by CI and was expressed in dynes
per second per meter squared per centimeter5. GFR and effective
renal plasma flow were calculated from inulin and PAH clearances,
respectively. Effective renal blood flow (ERBF) was calculated by
dividing the effective renal plasma flow by (1-hematocrit) and
effective renal vascular resistance (ERVR) by dividing MAP by
ERBF. Urinary protein and sodium excretion (UNaV) were calcu¬
lated as (urinary proteinXurinary flow rate) and (urinary
sodiumXurinary flow rate), respectively.
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Table. Baseline Data for Main Study and Substudy
Parameter Main Study Substudy
Systolic BP, mm Hg

















128±3 (99 to 167) 128±3 (108 to 142)
75±2 (63 to 95) 76±1(67 to 84)
92±2 (80 to 103) 93±2 (84 to 101)
3360± 230 (1800 to 5510) 3530 ± 230 (1980 to 5510)
3.0±0.2 (1.8 to 4.7)
56±2 (38 to 75)
7.5+0.4 (5.5 to 12.2)
4.4±0.6 (0.6 to 12.7)
1810±233 (106 to 4632)
11,5±4.4 (2.0 to 107.8)
43±5 (12 to 99)
2.9±0.2 (1.8 to 4.4)
57±2 (42 to 66)
7.4±0.5 (5.7 to 10.5)
4.4±0,9 (0.1 to 8.2)
1968 ±390 (530 to 4632)
7.1 ±1.5 (2.0 to 18.2)
43±7 (15 to 99)
197 ± 21 (27 to 392) 193± 28 (95 to 392)
1570± 371 (165 to 8616) 1520± 577 (109 to 8616)
5.7±0.3 (3.6 to 10.5) 6.7±0.5 (3.8 to 8.7)
Values are given as means of baseline pretreatment periods over the 2 or 3
study days±SEM (range).
Statistical Analysis
The number of subjects required to show a significant difference in
BP and ERVR was based on previous data in CKD patients using the
same dose of BQ123.'5 The coprimary end points were reductions in
BP and proteinuria, with the secondary end points being a reduction
in arterial stiffness and improvement in endothelial function. Base¬
line hemodynamic data were calculated as the mean of the 2 time
points that immediately preceded administration of the study drug.
For urine data, only 1 baseline measurement was used immediately
before drug dosing. Hemodynamic and urine results are expressed as
mean±SEM change from baseline for drug and placebo and placebo-
corrected change from baseline for substudy results. Statistical
analysis was performed on untransformed data. Three comparisons
of interest were preidentified as placebo versus BQ-123, placebo
versus nifedipine, and BQ-123 versus nifedipine. Responses were
examined by repeated-measures ANOVA, and Bonferroni's correc¬
tion was used to assess significance at specific time points. Statistical
significance was taken at the 5% level.
Results
All 22 of the CKD patients completed the placebo and
BQ-123 phases of the study without adverse events. All of the
subjects had similar baseline urinary protein leaks on each
study day. Patient diagnoses were IgA nephropathy (n=9),
membranous glomerulopathy (n=5), and focal segmental
glomerulosclerosis (n=8). For individual subject characteris¬
tics and overall demographic data, please see Tables SI and
S2. Subject baseline parameters are shown in the Table.
Main Study
Systemic Hemodynamics
Placebo was associated with increases in systolic BP (127.6±3.3
versus 136.6±3.4 mmHg; PCO.OOl), diastolic BP (75.9±1.7
versus 79.9±2.2 mmHg; PCO.OOl), MAP (93.1 ±2.1 versus
98.8±2.4 mmHg; PCO.OOl), and SVRI (3360±230 versus
3670±290 dyne/s per m2 per cm5; PC0.05) from baseline to
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Figure 1. Systemic hemodynamics and arterial stiffness after
ETA receptor antagonism. Values are given as mean percentage
of change from baseline±SEM (left) and mean area under curve
(AUC) of the percentage of change from baseline±SEM (right).
Black line/block, placebo; gray line/block, BQ-123. ±P<0.05 vs
placebo, fP<0-01 vs placebo, *Pc0.001 vs placebo (ANOVA
plus Bonferroni correction for significance at specific time
points).
systolic BP (—14.2±3.0 mmHg; PCO.OOl versus placebo),
diastolic BP f—6.8±0.8 mmHg; PCO.OOl versus placebo),
MAP (—9.2± 1.2 mm Hg; PCO.OOl versus placebo), and SVRI
(—610± 100 dyne/s per m2/cm5; PCO.OOl versus placebo), with
the peak effects at 75 minutes after drug administration. BQ-123
also increased CI (0.3±0.1 L/min per m2; PC0.05 versus
placebo). There were no significant differences in the heart rate
between placebo and BQ-123 throughout the time course of the
study.
Arterial Stiffness and Endothelial Function
Although PWV increased after placebo (7.5±0.4 versus
7.8±0.4 m/s; PC0.001), BQ-123 was associated with a
significant fall in PWV (—0.8±0.1 m/s; PCO.OOl versus
placebo; Figure 1C). With regard to endothelial function,
there were no differences in brachial artery FMD response
between BQ-123 (4.4±Q.5% versus 5.5±0.8%; P=0.056)
and placebo (4.4±0.6% versus 5.1 ±0.7%; P=0.082).
Renal Hemodynamics
Administration of placebo was associated with a gradual
reduction in ERBF (1810±233 versus 1454± 181 mL/min;
PCO.OOl) and an increase in ERVR (11.5±4.4 versus
12.8±3.8 mm Hg/min per mL; PC0.05) to the study end
(Figure 2A and 2B). In contrast, BQ-123 produced a striking
increase in ERBF (365±104 mL/min; PC0.01 versus pla¬
cebo) and a reduction in ERVR (—3.0±0.9 mm Hg/min per
mL; PC0.01 versus placebo). There were no significant
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Figure 2. Renal hemodynamics and UNaV after ETA receptor
antagonism. RBF indicates renal blood flow; RVR, renal vascular
resistance; UNaV, sodium clearance. Legend as for Figure 1.
changes in GFRs with either placebo or BQ-123 (maximal
change from baseline: 2% for placebo and 3% for BQ-123).
Urinary Sodium and Protein Excretion
Placebo had little effect on UNaV, whereas BQ-123 produced a
marked natriuresis with a maximum increase of 36±15 pmoV
min (P<0.05 versus placebo; Figures 2C and 3). There was no
change in potassium excretion.
Although placebo had little effect on urinary protein
excretion, BQ-123 led to a sustained reduction in proteinuria
throughout the time course of the study. This reduction at its
maximum equated to —496 ±141 pg/min (P<0.01 versus
placebo), a reduction in protein leak of s»30%. The size of
this effect related to baseline urinary protein excretion, with
subjects with higher baseline proteinuria achieving a greater
reduction (^=0.78; P<0.05). This effect was seen across all
levels of GFR.
Plasma ET-1
There were no changes in plasma ET-1 concentrations with
either drug or placebo.
Substudy: Nifedipine (10 mg)
Ten of the 22 subjects took part in a fully randomized 3-way
crossover substudy, which included placebo, BQ-123, and
nifedipine. Subject baseline parameters are shown in Table 1.
All 10 of the subjects completed the 3 phases of the substudy
without adverse events.
BQ-123 and nifedipine produced a similar reduction in
MAP (please see Figure SI). Nifedipine caused an initial
increase in heart rate (mean increase of 10 bpm from
baseline) that returned to baseline by 60 minutes. Despite the
consistent change in MAP, BQ-123 reduced arterial stiffness
to a greater extent than did nifedipine (PWV: —0.6±0.0
versus —0.3±0.1 m/s; P<0.001; please see Figure SI).
BQ-123 and nifedipine also increased ERBF to a similar
degree (please see Figure S1) and produced a similar natri¬
uresis (at maximum, BQ-123: 64±37 /umol/min; nifedipine:
37±34 /nmol/min). By contrast to BQ-123, nifedipine was
associated with a gradual increase in urinary protein excretion
(at maximum: 190±142 p,g/min; P<0.01 versus placebo;
please see Figure SI), whereas BQ123 produced a consistent
reduction in proteinuria.
Discussion
We have demonstrated that selective ETA receptor antago¬
nism reduces BP, proteinuria, and arterial stiffness in patients
with varying degrees of proteinuric nephropathy and that
these effects are seen on top of maximally tolerated treatment
with ACE inhibitors and angiotensin receptor blockers. Im¬
portantly, the reductions in proteinuria and arterial stiffness
are greater than those found with an alternative method of BP
reduction. These findings suggest a potential role for ETA
receptor antagonism in conferring longer-term cardiovascular
and renal benefits in patients with CKD.
The current study confirms the importance of ET-1, acting
through the ETA receptor, in maintaining the increased
vascular tone seen in CKD. There are only 2 studies of the
longer-term antihypertensive effects of ET receptor antago¬
nism. These suggest that both selective ETA29 and mixed
ETa/b antagonists30 are effective at reducing BP, but neither
240
Time from drug (min)
5 i
E 0








Protein Excretion Baseline proteinuria (mg/min)
0.78, p< 0.05
Figure 3. Protein excretion after ETA receptor antagonism. Values are given as mean percentage of change from baseline±SEM (left),
and mean area under curve (AUC) of the percentage of change from baseline±SEM (right). Black line/block, placebo; gray line/block,
BQ-123. +P<0.05 vs placebo, tP<0.01 vs placebo, *P<0.001 vs placebo (ANOVA plus Bonferroni correction for significance at spe¬
cific time points). B, Effect of baseline protein excretion on maximal proteinuria reduction (milligrams per minute) with BQ-123 (r2=0.78;
P<0.05). This remains significant (r2=0.29; P<0.05) when the 2 outliers are removed.
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study included patients with CKD. Furthermore, both studied
untreated hypertensive patients. Our current data suggest that,
at least in patients with CKD, where BP control is often
difficult, ET receptor antagonism may provide a novel
strategy to lower BP to a greater extent than that achieved
with existing treatments.
BQ-123 also significantly reduced PWV compared with
placebo. This is likely to be attributed largely to the reduction
in BP seen with BQ-123.25 However, PWV continued to fall
at the end of the study, even when BP had returned to
baseline. Furthermore, when the antihypertensive effect of
BQ-123 was matched with nifedipine, the reduction in arterial
stiffness was significantly greater with BQ-123. Although
nifedipine did cause an expected increase in heart rate, which
may have a minor impact on PWV,31 this had returned to
baseline within an hour of the study start and before the
measurement of PWV. These observations suggest that the
effects of ETa receptor antagonism on arterial stiffness seen
here are not accounted for by changes in BP alone and should
be confirmed in longer-term studies with a range of BP-
lowering agents.
There are a few clinical trials demonstrating that differen¬
tial lowering of PWV with medical treatment results in
different cardiovascular or renal outcomes,32-33 but the impor¬
tance of such studies is underscored by epidemiological data
suggesting that PWV is an independent risk factor for CVD
morbidity and mortality.12-34 Karalliedde et al35 recently
showed a BP-independent reduction in PWV with valsartan
compared with amlodipine in patients with type 2 diabetes
mellitus and proteinuria. Our current data suggest that ETA
receptor antagonism may reduce arterial stiffness even further
in patients already established on blockers of the renin-an¬
giotensin system and, similarly, in a BP-independent manner.
However, the effects of ETA receptor antagonism on endo¬
thelial function, as assessed by FMD, were less impressive,
although there was a trend toward improvement. It may well
be that these effects take longer to develop.
ETa receptor antagonism increased renal blood flow in
association with a reduction in renal vascular resistance,
suggesting that ET-1, acting through ETA receptors, is in¬
volved in the increased renovascular tone seen in CKD. We
observed no significant changes in GFR, but we did, as in
previous studies,15-36 see a fall in the filtration fraction (—7%
at maximum; data not shown), suggesting that ET-1 induces
an ETa receptor-mediated vasoconstriction, preferentially
affecting the efferent arterioles, although not excluding an
effect on mesangial cells and the filtration coefficient. Con¬
sistent with a reduction in filtration fraction, BQ-123 pro¬
duced a sustained reduction in urinary protein excretion that
was only beginning to slow at the end of the study. As with
the reduction in arterial stiffness, the reduction in proteinuria
continued even when the antihypertensive effect of BQ-123
had waned and BP had returned to baseline, suggesting a
BP-independent effect. Our control drug, nifedipine, closely
matched both the decrease in BP and the increase in renal
blood flow seen with BQ-123. Nifedipine acts predominantly
at the afferent arteriole, and, so, as expected, it produced
steady increases in both GFR (7 mL/min at maximum; data
not shown) and proteinuria throughout the study period.
Because BQ-123 had little effect on GFR and substantially
reduced filtration fraction and proteinuria over the same time
scale as the increase in renal blood flow, these findings are
consistent with an action not just at the afferent arteriole but
with potential preferential dilation at the efferent arteriole,
similar to, and on top of, that seen with ACE inhibitors.
Although the acute effects on proteinuria described here
are likely to be largely explained by systemic and renal
hemodynamic changes, it is important to consider other
longer-term targets for selective ETA receptor antagonism,
eg, the podocyte, which has been implicated in the develop¬
ment of proteinuria.37 Indeed, a recent study by Wenzel et al16
showed a reduction in macroalbuminuria in subjects with
diabetic nephropathy after 12-week dosing with the ET
receptor antagonist avosentan. Interestingly, the authors ob¬
served no change in BP, supporting a BP-independent mech¬
anism for the proteinuria reduction seen.
In the current study, the reduction in proteinuria was
related to baseline proteinuria, with subjects with a higher
level of baseline proteinuria achieving greater reductions.
This effect was seen across the range of GFRs. This is similar
to the effects seen with ACE inhibitors.5 Proteinuria reduction
is important both for reducing risk of CKD progression5 and
for consequent CVD.38 Despite maximum achievable renin-
angiotensin system blockade, many patients with proteinuric
CKD have significant residual proteinuria.8 Importantly, in
this study, all of the subjects were established on treatment
with ACE inhibitors, with the majority also taking angioten¬
sin receptor blockers. The ET and renin-angiotensin systems
are known to interact,39 and a synergistic effect, in terms of
systemic hemodynamics, has been demonstrated between
ETa receptor antagonism and both ACE inhibition19 and
angiotensin II type 1 receptor antagonism40 in humans. Our
data suggest that ETA receptor antagonism can produce a further
reduction in proteinuria of —30% on top of that achieved with
optimal treatment with inhibitors of the renin-angiotensin sys¬
tem. If maintained longer term, this should reduce both CKD
progression and CVD morbidity and mortality.
BQ-123 produced a significant natriuresis. This is likely to
be mainly attributable to the increase in renal blood flow seen
with ETa receptor antagonism. Indeed, nifedipine, which
caused a similar change in renal hemodynamics, also caused
natriuresis. In addition, all of the subjects showed a net
diuresis, even with placebo. These are important observations
if ET receptor antagonists are to be used in trials involving
CKD patients, in whom salt and water retention is an issue.
As a limitation, ours is an acute study, and it will be
important to confirm that these effects are maintained longer
term, as they are in patients with essential hypertension and
pulmonary arterial hypertension.41 Indeed, the acute studies
in these areas predicted the beneficial chronic effects. In
addition, we studied a relatively homogeneous CKD popula¬
tion, and further work is needed in a broader population of
patients with CKD, including those with diabetes mellitus,
vasculitis, and renal vascular disease. Finally, the crossover
study design may affect data interpretation and is not ideal for
longer-term studies in a larger cohort of subjects.
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Perspectives
The current data support a role for selective ETA receptor
antagonism as a novel and worthwhile therapeutic target in
CKD to lower BP, arterial stiffness, and proteinuria on top of
standard treatment, and on this basis, larger and longer-term
studies in both diabetic and nondiabetic CKD are justified.
Furthermore, with the availability now of both selective ETA
and mixed ETA/B receptor antagonists, a comparison of their
renal effects would be of great interest. Indeed, whereas in
pulmonary arterial hypertension the studies to date suggest
both selective ETA antagonism and mixed ETA/B antagonism
to be of benefit, the current data support selective ETA
receptor antagonism over mixed blockade in CKD. There
have been no major studies as yet in subjects on maximal
renin-angiotensin system blockade, across a wide range of
GFRs, or looking at natriuresis. Additional studies taking
these clinically relevant factors into consideration are now
needed. Furthermore, the effects of longer-term treatment on
renal hemodynamics remain unclear.
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Supplementary methods
Subjects
Patients with significant co-morbidity, including diabetes mellitus, heart or lung disease, and peripheral
vascular disease were excluded. All patients were treated with ACE inhibitors and/or ARBs for their
proteinuria. Explicitly, doses of one or both of drugs were titrated to the maximum tolerated, dependent
on BP, renal function, serum potassium levels and side effects. All medications were unchanged over
the 3 months preceding the studies. To enhance homogeneity and avoid other influences on vascular
reactivity, patients with vasculitis, other systemic inflammatory disease, polycystic kidney disease,
nephrotic syndrome, or obstructive uropathy were excluded.
Study protocol
For the duration of the study, subjects were asked to adhere to their usual salt intake. All subjects
abstained from alcohol, nicotine and caffeine-containing products for 24 hours, and had a light breakfast
before attending on each study day. All studies were performed in a quiet, temperature-controlled room
at 22 to 24°C with the subject recumbent throughout, except when voiding urine. All patients completed
a 24-hour urine collection for quantification of proteinuria on each study day to assess equivalent
baseline urinary protein leak between study phases. Patients continued taking their normal medications
up to and including each study day with the exception of diuretics, which they omitted that morning.
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Supplemental table / figure legends
Table SI: Individual subject characeristics. To convert to pmol/l, multiply by 88.4. Doses are total per
day. IgAN: immunoglobulin A nephropathy; FSGS: focal & segmental glomerulosclerosis;
Membranous: membranous glomerulopathy; EPO: erythropoietin.
Table S2: Subject demographic data for main and sub-study. Values are mean ± SEM (range). To
convert to pmol/1, multiply by 88.4. trTo convert to mmol/1, multiply by 0.0259.
Figure SI: Systemic and renal hemodynamics, arterial stiffness and protein excretion after ETa receptor
antagonism and nifedipine lOmg. MAP: mean arterial pressure; RBF: renal blood flow; PWV: pulse
wave velocity. Values are given as mean placebo-corrected % change from baseline ± SEM (left) and
mean area under curve of placebo-corrected % change from baseline ± SEM (right). Green line/block,
nifedipine; red line/block, BQ-123. +p < 0.05 vs. nifedipine, tp < 0.01 vs. nifedipine, *p < 0.001 vs.
nifedipine (ANOVA plus Bonferroni correction for significance at specific time points).
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Table SI: Individual subject characteristics
g Diagnosis Creatinine Proteinuria BP
2 (mg/dl)* (g/d)
ACE inhibitor ARB Other drugs
1 IgAN 1.54 3.30 131/81 Ramipril 2.5mg














5 IgAN 1.48 2.28 129/67 Lisinopril 40mg Candesartan
4mg
Atorvastatin 20mg
6 IgAN 1.01 0.38 111/64 Ramipril 2.5mg
7 IgAN 1.80 0.60 120/79 Ramipril 5mg




















10 Membranous 1.02 0.69 120/69 Enalapril 40mg Losartan
50mg
Amlodipine 5mg
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108/67 Lisinopril 40mg Candesartan
16mg
145/83 Ramipril lOmg Valsartan
160mg





128/80 Lisinopril 40mg Valsartan
80mg
i
127/76 Lisinopril 40mg Valsartan
160mg





















To convert to pmol/I, multiply by 88.4.
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Table S2: Subject demographic data for main and sub-study
Demographic Main study Sub-study
Age, y 46 ± 3 (29 - 69) 45 ± 11 (29 — 64)
2
Body mass index, kg/m 28 ± 1 (20-37) 30 ±6 (21-37)
SBP, mmHg 128 ± 3 (107 — 158) 131 ±3 (108- 145)
DBP, mmHg 75 ± 2 (63 - 95) 75 ± 2 (67 - 83)
MAP, mmHg
2
93 ±2 (75 - 118) 93 ±2 (84- 101)
Creatinine*, mg/dl 2.16 ±0.33 (0.88-5.51) 2.26 ± 1.00 (1.13 -3.88)
Cholesterol, mg/dl 170 ± 8 (127-228) 166 ±35 (127-228)
Urinary sodium excretion, mEq/24h 163 ± 18 (39-300) 174 ±75 (39-300)
Urinary protein excretion, g/24h 2.7 ±0.7 (0.4-8.7) 2.9 ±2.8 (0.4-8.0)
To convert to pmol/1, multiply by 88.4. fTo convert to mmol/1, multiply by 0.0259.
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Time from drug (min)
Figure S1. Systemic and renal hemodynamics, arterial stiffness and protein excretion
after ETA receptor antagonism and nifedipine 10mg
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